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Lifelong haematopoiesis depends critically on a small population of bone marrow 
resident haematopoietic stem cells (HSCs), which possess unique self-renewal 
capacity and multilineage differentiation potential, ultimately replenishing all blood 
lineages. In view of these properties, HSC transplantation (HSCT) is an effective 
treatment for a wide range of bone marrow disorders. However, owing to the rarity of 
HSCs in adult haematopoiesis, and our inability to effectively expand HSCs in vitro, 
the clinical need for HSCT vastly exceeds HSC availability.  
 
Acute myeloid leukaemia (AML) is an aggressive clonal disorder of haematopoietic 
stem and progenitor cells (HSPCs), in which the acquisition of mutations by HSPCs 
results in a block in their myeloid differentiation, and the generation of self-renewing 
leukaemic stem cells (LSCs). LSCs initiate and propagate the disease, and given that 
they are treatment-resistant, often fuel disease relapses. The two major challenges in 
the field of haematopoiesis currently, are therefore to expand HSCs for 
transplantation, and to identify novel therapeutic targets to eliminate LSCs.  
 
In the last decade, epitranscriptomics has developed as a novel layer of regulation of 
gene expression. RNA N6-methyladenosine (m6A) is the most abundant internal 
mRNA modification. m6A is installed on mRNA by methyltransferase complexes 
known as writers and removed by demethylases defined as erasers. The m6A 
modification is recognised by reader proteins, including those belonging to the YTH 
domain family (YTHDF1, YTHDF2, YTHDF3, YTHDC1, YTHDC2). While writers and 
erasers have been implicated in several cancers, including AML, the roles of m6A 
readers in normal and malignant haematopoiesis remains unexplored. 
 
This thesis describes the study of the YTHDF2 m6A reader in normal haematopoiesis 
and AML. Using the Vav-iCre system to conditionally delete Ythdf2 from the 
haematopoietic system of mice, we observed a significant increase in the number of 
haematopoietic stem and progenitor cells (HSPCs) compared to controls. In primary 
and secondary long-term competitive transplantation assays, Ythdf2-deficient HSCs 
reconstituted multilineage haematopoiesis and showed an increased capacity to 
rapidly repopulate the myeloid lineage. Furthermore, bone marrow analysis 4 months 
after transplantation revealed an increased contribution of Ythdf2-deficient cells to the 
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HSPC compartments of transplanted mice compared to controls. To study the role of 
Ythdf2 in AML, we compared the ability of Ythdf2-deficient and control pre-LSCs to 
generate leukaemia in a murine retroviral AML model. We showed that constitutive 
(Vav-iCre) and inducible (Mx1-Cre) genetic deletion of Ythdf2 severely compromises 
the development and propagation of leukaemia driven by a range of oncogenes, 
including Meis1/Hoxa9, Mll-AF9, PML-RARA and MOZ-TIF2. Mechanistically, we 
showed that loss of Ythdf2 inhibits degradation of multiple m6A-modified transcripts, 
including Tnfrsf2, whose upregulation sensitizes Ythdf2-deficient LSCs to TNF-
induced apoptosis.  
 
In summary, we demonstrated that inhibition of Ythdf2 specifically compromises LSC 
development and propagation, but simultaneously expands HSCs and enhances their 
myeloid reconstitution upon transplantation. We therefore propose YTHDF2 as a 




Lay summary  
 
In healthy humans, blood is produced throughout life from a rare population of bone 
marrow stem cells. These cells can be used to treat a variety of diseases, but are 
currently in very short supply. Acute myeloid leukaemia is an aggressive cancer of 
white blood cells, with a poor long-term survival owing to frequent recurrence of 
disease after treatment. The research of our group is therefore aimed towards these 
two major areas; identifying new strategies for the expansion of blood stem cells, and 
finding ways to eliminate cancer cells in acute myeloid leukaemia.  
 
In an attempt to answer these questions, we have focused on a novel area of 
research, which studies how RNA is processed and broken down. RNA is a code 
which allows genes to be translated into proteins, ultimately guiding all biological 
processes. However, it is now known that certain modifications, for example 
methylation, can determine how well and how long RNA functions for. For example, 
YTHDF2 is a protein which recognises methylated RNA and targets it for breakdown 
in the cell. In the course of my PhD, I have studied the role of YTHDF2 in normal 
blood formation, and also in acute myeloid leukaemia.       
 
Using a mouse model, I showed high levels of YTHDF2 in the cells which give rise to 
the blood system. I also showed that deletion of the gene Ythdf2 specifically within 
the blood system results in an expansion of the primitive, founder bone marrow stem 
cells. Finally, I showed that Ythdf2-deficient cells generate leukaemia in mice with a 
significant delay compared to control cells, indicating that YTHDF2 is required for 
leukaemia development.  
 
Overall, the results summarised in this thesis show that YTHDF2 inhibition might allow 
us to expand the cells which generate blood, and simultaneously eliminate those 
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The term ‘haematopoiesis’, originating from the Greek words ‘haima’ (blood) and 
‘poiēsis’ (to make something) refers to the production of all cellular components of 
blood. Haematopoiesis depends critically on a relatively rare population of bone 
marrow resident haematopoietic stem cells (HSCs) which possess unique self-
renewal ability and multilineage differentiation potential, ultimately replenishing all 
blood lineages (Orkin and Zon 2008).  
 
1.1.1 The haematopoietic hierarchy 
The classical model of haematopoiesis is a stepwise hierarchy, in which multipotent 
HSCs reside at the apex and generate oligopotent progenitors, which in turn give rise 
to lineage committed unipotent progenitors, and finally mature blood cells. However, 
it is now widely accepted that this classical model is an oversimplification, prompting 
several recent revisions to the haematopoietic hierarchy (Zhang, Gao et al. 2018).  
The existence of the haematopoietic stem cell, and the hierarchical organisation of 
haematopoiesis, was first proposed by Maximov, in 1909. In the 1950s, researchers 
showed that injection of allogeneic bone marrow (BM) into guinea pigs and mice was 
able to rescue them from the effects of lethal irradiation (Jacobson, Simmons et al. 
1951, Lorenz, Congdon et al. 1952). In 1960s the in vivo colony forming unit spleen 
(CFU-S) assay was used to demonstrate that single haematopoietic precursors were 
capable of multilineage differentiation potential (Till and McCulloch 1961, Becker, 
McCulloch et al. 1963, Wu, Till et al. 1967). In 1980s, cell surface markers were 
identified for the isolation of murine HSCs, after which transplantation of these cells 
was shown to reconstitute all blood lineages. This was followed by the sequential 
characterisation of HSCs and their progenies (Spangrude, Heimfeld et al. 1988, 
Kondo, Weissman et al. 1997, Akashi, Traver et al. 2000) to generate the classical 
haematopoietic hierarchy, with revisions as required when new cell types were 
identified (Adolfsson, Månsson et al. 2005, Wilson, Laurenti et al. 2008). 
Until recently, two classes of HSCs were defined; long-term HSCs (LT-HSCs) capable 
of permanently reconstituting the haematopoietic system following lethal irradiation, 
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but rare and quiescent under stable conditions, and short term-HSCs (ST-HSCs), 
capable of rapidly differentiating to multipotent progenitors (MPPs) and reconstituting 
the haematopoietic system for 8-12 weeks following irradiation (Morrison, Wandycz 
et al. 1997, Yang, Bryder et al. 2005). 
In the classical model of haematopoiesis (Figure 1.1.1A), LT-HSCs sit above ST-
HSCs at the apex of the hierarchy. HSCs give rise to MPPs, which generate common 
myeloid progenitors (CMPs) or common lymphoid progenitors (CLPs). CLPs generate 
lymphocytes, whilst CMPs give rise to megakaryocyte/erythroid progenitors (MEPs), 
or granulocyte/macrophage progenitors (GMPs). MEPs generate megakaryocytes 
and erythrocytes, whereas GMPs generate granulocytes, macrophages, and dendritic 
cells (Akashi, Traver et al. 2000). 
In the last decade, several developments have altered our understanding of 
haematopoiesis. Firstly, the advent of single cell genomic, transcriptomic and 
proteomic technologies has revealed marked heterogeneity in HSCs, a population of 
cells previously considered homogeneous based on their cell surface marker 
expression. For example, a subset of HSCs has been shown to express Hdc, which 
encodes histidine decarboxylase, and this population has been shown to have a bias 
towards myeloid differentiation in vivo (Chen, Deng et al. 2017). Similarly, differential 
expression of the SLAM markers CD150 and CD229 has been shown to separate 
HSCs with varying lineage potential; CD150high (myeloid bias), CD150low (lymphoid 
bias), CD229 negative (myeloid bias), and CD229 positive (lymphoid bias) (Beerman, 
Bhattacharya et al. 2010, Oguro, Ding et al. 2013).  
Secondly, novel lineage tracing strategies have revealed clonal relationships between 
haematopoietic cells, demonstrating that lineage segregation is derived principally 
from HSCs, and occurs in a continuous fashion, rather than the stepwise model of 
classical haematopoiesis. It has been shown that megakaryocytes can develop 
directly from HSCs, bypassing intermediate differentiation stages (Notta, Zandi et al. 
2016). Accordingly, high expression of the megakaryocyte marker von Willebrand 
factor has been identified in HSCs (Månsson, Hultquist et al. 2007), and these cells 
have been shown to depend on thrombopoietin, a cytokine essential for 
megakaryocytic development (de Sauvage, Carver-Moore et al. 1996, Sanjuan-Pla, 
Macaulay et al. 2013).  
 27 
Thirdly, several new cell types have been identified prompting modification of the 
haematopoietic hierarchy. In addition to LT-HSCs and ST-HSCs, intermediate-term 
HSCs (IT-HSCs) have been identified with a self-renewal capacity midway between 
the two (Benveniste, Frelin et al. 2010). Furthermore, several sub-classes of MPPs 
have been identified (MPP1-4), with MPP1 cells having a similar role to that of ST-
HSCs, and MPP2, MPP3 and MPP4 working in parallel directly downstream, with 
MPP2 and MPP3 predominantly generating CMPs (Wilson, Laurenti et al. 2008, 
Pietras, Reynaud et al. 2015). Finally, lymphoid-primed multipotent progenitors 
(LMPPs) have been described as a subpopulation of HSCs with high expression of 
Flt3, and a cell surface marker profile similar to that of MPP4 cells (Adolfsson, Borge 
et al. 2001, Adolfsson, Månsson et al. 2005, Forsberg, Serwold et al. 2006, Boyer, 
Schroeder et al. 2011). The revised haematopoietic hierarchy includes IT-HSCs and 
the four subpopulations of MPPs (Figure 1.1.1B).  
 
Finally, significant plasticity has been demonstrated in the haematopoietic system in 
recent years, particularly in response to stress. In 2014, Sun et al. used a novel 
transposon tagging system for in situ labelling and clonal tracking of haematopoietic 
stem cells in mice, to demonstrate that in the steady state, haematopoiesis is 
maintained by a large number of long-lived progenitors, rather than a small number 
of multipotent HSC (Sun, Ramos et al. 2014). In 2015, Busch et al. reported HSC 
lineage tracing and outputs from a mouse model with inducible genetic labelling of 
primitive Tie2+ HSCs (Busch, Klapproth et al. 2015). Consistent with the findings of 
Sun et al., Busch reported that steady state haematopoiesis is dependent on ST-
HSCs, rather than LT-HSCs, but also concluded that long-term (>1 year), the ST-
HSC compartment does require continuous input from LT-HSCs (estimate of 150 
HSCs feeding in per day). Busch et al. also showed however, that under conditions 
of haematopoietic stress, for example 5-fluorouracil (5-FU) treatment, LT-HSCs can 
enter the cell cycle and proliferate rapidly to facilitate haematopoietic reconstitution 





Figure 1.1.1 Classical and revised representations of the haematopoietic 
hierarchy. (A) Classical haematopoietic hierarchy, with LT-HSCs and ST-HSCs 
giving rise to MPPs, and then diverging to CMP or CLP progenitors. Subsequently, 
CLPs give rise directly to lymphoid cells, whereas CMPs generate MEPs and GMPs. 
MEPs generate megakaryocytes and erythrocytes, whilst GMPs generate 
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granulocytes, macrophages and dendritic cells. (B) Revised haematopoietic 
hierarchy, with the addition of IT-HSCs, MPP subclasses 1-4, and LMPPs. Adapted 
from ‘Haematopoietic Hierarchy - An Updated Roadmap’ (Zhang, Gao et al. 2018). 
 
The advent of single cell RNA sequencing (scRNA-Seq) was a turning point in our 
understanding of the haematopoietic hierarchy. Prior to this, haematopoietic research 
had long focused on single cells, through colony forming assays in vitro, and single 
cell transplantation as the gold standard assay for HSCs in vivo. However, molecular 
techniques such as bulk RNA-Seq, were compromised by an inability to detect 
specific gene expression changes occurring at a single cell level, which is of particular 
importance in a heterogeneous cell population. The advent of scRNA-Seq has 
allowed us to study molecular heterogeneity in a systematic fashion across the entire 
haematopoietic system (Laurenti and Göttgens 2018). Whilst this rapidly expanded 
knowledge (Velten, Haas et al. 2017, Hay, Ferchen et al. 2018, Zheng, Papalexi et al. 
2018), it also generated new controversies. For example, a scRNA-Seq study by 
Velten et al. suggested that unilineage-restricted cells emerge directly from a 
‘continuum of low-primed undifferentiated HSPCs’ (Velten, Haas et al. 2017). In 
contrast, more recent scRNA-Seq studies together with assays of chromatin stability 
have supported a structured hierarchy (Buenrostro, Corces et al. 2018, Pellin, 
Loperfido et al. 2019), including lineage directed stem cell precursors in mice 
(Sanjuan-Pla, Macaulay et al. 2013, Carrelha, Meng et al. 2018), the presence of 
sequential lymphoid progenitors in humans (Karamitros, Stoilova et al. 2018), and a 
previously unidentified basophil haematopoietic branchpoint (Pellin, Loperfido et al. 
2019).   
 
The concept of HSC heterogeneity has come not only from scRNA-Seq, but also from 
functional studies. For example, Knapp et al. performed serial transplantation assays 
of single human cord blood cells and showed that it is possible to prospectively isolate 
a population of human cord blood cells (CD33+CD34+CD38-CD45RA-CD90+CD49F+) 
with serially transplantable but wide-ranging cell outputs (Knapp, Hammond et al. 
2018). By measuring mitogenic response, DNA methylation, 40-protein content and 
transcriptional profile at the single cell level, they were able to demonstrate 
heterogeneity both within and across cell populations (Knapp, Hammond et al. 2018). 
Another example is the work by Yamamoto et al., who combined a single cell 
transplantation system and marker mice to demonstrate the existence of myeloid 
restricted progenitors with long term repopulating capacity (MyRPs) in the 
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phenotypically defined HSC compartment (Yamamoto, Morita et al. 2013). They 
showed that these MyRPs are lineage committed to megakaryocytes, 
megakaryocyte-erythroid cells, or common myeloid cells (MkRPs, MERPs, or 
CMRPs, respectively). When these authors combined their single cell transplantation 
assays with paired daughter cell assays, they showed that HSCs can undergo 
symmetric division to generate two daughter HSCs, or asymmetric division to yield 
HSC-MkRP or HSC-CMRP pairs. These direct differentiation pathways were 
described as ‘myeloid bypass’ pathways, potentially essential for fast responses to 
ablation stress (Yamamoto, Morita et al. 2013). 
 
1.1.2 Immunophenotypic characterisation of murine HSCs and progenitor cells 
 
Our understanding of the haematopoietic hierarchy has expanded significantly in the 
last 30 years thanks to the immunophenotypic characterisation of murine 
haematopoietic stem and progenitor cells (HSPCs). In 1988, Weissman’s group 
showed that a population of haematopoietic cells with ST-HSC activity could be 
isolated from BM based on the expression of stem cell antigen-1 (Sca-1), low 
expression of Thy1.1, and a lack of expression of lineage markers (Spangrude, 
Heimfeld et al. 1988). Subsequent work by the same group showed that this lineage 
negative (Lin-), Sca-1+, Thy1.1 low population also contained LT-HSCs (Uchida and 
Weissman 1992). However, a major disadvantage of the staining technique was that 
Thy1.1 is not expressed in all strains of mice, critically not in C57/BL6 mice, which are 
used widely for haematopoietic transplantation studies (Spangrude and Brooks 
1992).  
 
In 1992, Ikuta et al. showed that 5-10% of all BM cells express the stem cell growth 
factor receptor CD117, also referred to as c-Kit (Ikuta and Weissman 1992). The same 
year, Okada et al. showed that by combining c-Kit and stem cell antigen-1 (Sca-1) 
staining, a population of HSPCs could be isolated from the lineage negative fraction 
of BM (Lin- Sca-1+ c-Kit+ cells, LSK cells) (Okada, Nakauchi et al. 1992). LSK staining 
thus provided a valuable tool for HSPC isolation, which is still widely used.  
Further characterisation of the HSPC compartment was reported in 2001 and 2005, 
through the staining of LSK cells with antibodies against CD34 and Flt3. These 
studies showed that LT-HSCs reside within the double negative CD34- Flt3- fraction 
of LSK cells, and subsequently acquire these markers during the process of 
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differentiation, with ST-HSCs expressing CD34 (LSK CD34+ Flt3-), and LMPPs 
expressing both CD34 and Flt3 (LSK CD34+Flt3+) (Adolfsson, Borge et al. 2001, 
Yang, Bryder et al. 2005).  
An alternative approach for isolation of HSCs is through staining with vital dyes, for 
example the mitochondrial binding dye rhodamine 123 (Rh123) or DNA-binding dye 
Hoescht 33342 (Ho 33342) (Goodell, Brose et al. 1996). Upon staining, HSCs retain 
very little of these dyes, owing to the high expression of drug efflux pumps in these 
cells. More typically however, Ho 33342 staining is used to detect a ‘side population 
of cells’ based on dual wavelength emission. Unfortunately, this method can be 
affected by slight changes in technique and is not as sensitive for HSCs as CD34/Flt3 
staining.  
 
Another approach for defining the HSPC compartment is through SLAM staining. 
SLAM proteins are a family of cell surface glycoproteins in the immunoglobulin 
superfamily. Kiel et al. showed that a combination of CD150, CD48 and CD224 
staining can identify LT-HSC (LSK CD150+CD224-CD48-), MPPs (LSK CD150-
CD224+CD48-), HPC-1 (CD150-CD224+CD48+) and HPC-2 (LSK 
CD150+CD224+CD48+) from murine BM (Kiel, Yilmaz et al. 2005). Kim et al. showed 
that the same combination of markers can be used to isolate HSPC compartments 
from foetal liver (Kim, He et al. 2006). In contrast to CD34/Flt3 staining, SLAM staining 
is not significantly affected by age, or transplantation (Yilmaz, Kiel et al. 2006). 
Recently, Oguro et al. showed that the combination of CD150, CD48, CD224 and 
CD229 can be used to identify 7 functionally distinct haematopoietic populations, 
including HSCs, MPPs and restricted progenitors, in a functional hierarchy which 
displays stepwise reductions in cell cycle quiescence, differentiation potential, and 
self renewal (Oguro, Ding et al. 2013).  
 
The markers currently used to define the murine haematopoietic hierarchy are shown 
in Figure 1.1.2. Staining for CD34 and Flt3 or SLAM CD150 and CD48 is used most 
commonly to define HSPC populations within the LSK compartment (Guitart, 
Subramani et al. 2013, Takubo, Nagamatsu et al. 2013, Vukovic, Sepulveda et al. 
2016, Guitart, Panagopoulou et al. 2017, Paris, Morgan et al. 2019). More 
differentiated progenitors can be identified and isolated based on additional cell 
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surface markers, such as CD16/32, CD41, CD105, and CD127 (Pronk, Rossi et al. 
2007, Kent, Copley et al. 2009, Morita, Ema et al. 2010). 
 
Human long term HSCs have been phenotypically defined as Lin-CD34+CD38-
CD45RA-CD90+RholoCD49F+, whilst human MPPs have been defined as 
CD34+CD38-CD45RA-CD90- CD49F- (Majeti, Park et al. 2007, Notta, Doulatov et al. 
2011). Further discussion of HSCs in this thesis will focus predominantly on murine 




Figure 1.1.2 Cell surface markers used for the immunophenotypic 
characterisation of murine haematopoietic stem and progenitor cells. Figure 
adapted from Doulatov et al. 2012 (Doulatov, Notta et al. 2012).  
 
It is important to note that characterising HSCs on the basis of cell surface expression 
cannot be considered synonymous with functional studies, which are discussed in the 
next section.  
 
1.1.3 Functional characterisation of murine HSCs and progenitor cells 
 
Colony forming cell (CFC) assays are used as an in vitro measure of haematopoietic 
progenitor cells in a given population. These assays are carried out using semi-solid 
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agar, or commercially available methylcellulose preparations. Colonies are scored 12 
days after plating, and are largely lineage restricted, although the most immature 
(multipotent) do contain a mixture of granulocytes, macrophages, erythrocytes and 
sometimes megakaryocytes (Miller and Lai 2005).  
 
The colony forming unit-spleen (CFU-S) assay measures the ability of transplanted 
haematopoietic cells to rescue an irradiated recipient mouse by colonisation of 
ablated haematopoietic tissue. Within 2 weeks of transplantation, CFU-S cells seed 
into the spleen and generate colonies of differentiating haematopoietic cells. 
Macroscopically visible colonies can thus be counted to give a CFU-S assay result 
(Till 1964). Importantly, this assay measures early engrafting cells, typically ST-HSCs, 
or downstream progenitors. To accurately evaluate LT-HSCs, the gold standard long-
term repopulating assay should be used.  
 
The most common form of long-term repopulating assay is the competitive 
transplantation assay, in which the HSC potential of a given sample is measured 
against that of an established source (typically whole bone marrow of congenic wild 
type mice) (Harrison 1980). A variation of this assay involves the successive dilution 
of the test sample compared with the known source (limiting dilution assay), so as to 
establish HSC frequency (Taswell 1981, Szilvassy, Lansdorp et al. 1989, Szilvassy, 
Humphries et al. 1990).  
 
1.1.4 Developmental origins of the haematopoietic system 
Multiple waves of haematopoiesis take place during development (Orkin and Zon 
2008). In mammals, the initial transient waves of haematopoiesis occur in the yolk 
sac, through haematopoietic differentiation of mesodermal cells. The first and most 
primitive of these waves generates mainly large nucleated erythrocytes, which 
provide oxygen carrying capacity to support the needs of the growing embryo. 
Megakaryocytes and macrophages are also generated, which contribute to tissue 
remodelling in the embryo (Silver and Palis 1997, Palis, Robertson et al. 1999, Tober, 
Koniski et al. 2007). The second wave (‘pro-definitive’ wave) follows shortly 
afterwards, consisting of erythromyeloid and lymphoid progenitors. There is now 
substantial evidence that these erythromyeloid progenitors give rise to lifelong tissue 
resident macrophages at many sites throughout the body, including the brain 
(Ginhoux, Greter et al. 2010), and possibly the liver and lung (Ginhoux and Guilliams 
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2016, Perdiguero and Geissmann 2016). The third wave of haematopoiesis occurs 
within the embryo itself, and produces the first definitive HSCs (dHSCs), i.e. HSCs 
capable of permanently reconstituting the haematopoietic system of an irradiated 
recipient. These dHSCs first appear in the ventral wall of the dorsal aorta (Müller, 
Medvinsky et al. 1994, De Bruijn, Ma et al. 2002) in an area known as the aorta-
gonad-mesonephros (AGM) region, which is capable of autonomous production of 
dHSCs, as shown in explant cultures (Medvinsky and Dzierzak 1996). AGM dHSCs 
go on to seed multiple organs throughout the embryo, including the foetal liver, 
spleen, thymus and BM.  
The origin of HSCs is an area of significant debate, in particular the relationship 
between primitive and definitive haematopoiesis. In both cases, there exists a close 
relationship between vascular and haematopoietic cells. The presence of yolk sac 
blood islands - clusters of haematopoietic precursor cells surrounded by angioblasts 
– first suggested that haematopoietic and endothelial cells might share a common 
precursor cell. Consistent with this, recent studies in bH1eGFP transgenic mouse 
embryos (reporter mice for embryonic globin) have shown that primitive erythroblasts 
emerge from haemogenic endothelial cells (Stefanska, Batta et al. 2017) or 
‘haemogenic angioblasts’ (Lacaud and Kouskoff 2017). Similarly, definitive 
haematopoiesis in the AGM of the embryo has been shown to occur through a 
process of endothelial to haematopoietic transition (EHT) (Jaffredo, Gautier et al. 
1998). Studies by North et al. have shown that expression of the haematopoietic 
transcription factor Runx1 in haemogenic endothelial cells is essential for EHT to take 
place (North, Gu et al. 1999, North, De Bruijn et al. 2002).  
A schematic for murine haematopoiesis during development is shown in Figure 1.1.4. 
In mice, primitive haematopoiesis starts around E7.5, whilst definitive haematopoiesis 
begins around E10.5. At this time, and for several days afterwards, HSCs are also 
found in the mouse placenta, although their contribution to lifelong haematopoiesis is 
uncertain (Gekas, Dieterlen-Lièvre et al. 2005, Ottersbach and Dzierzak 2005). By 
E12.5, dHSCs from the AGM have migrated to the foetal liver, and this has become 
the major site of foetal haematopoiesis (Morrison, Hemmati et al. 1995, Kumaravelu, 
Hook et al. 2002). Subsequently, haematopoiesis also takes place in the spleen, 
thymus and ultimately the BM (from E18.5). Postnatally and for the remainder of life, 
the BM is the major site of haematopoiesis (Zanjani, Ascensao et al. 1993, Clapp, 
Freie et al. 1995).  
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It has recently been shown that the definitive haematopoietic program is repressed in 
early embryogenesis through epigenetic silencing, and that reversal of this repression 
can elicit multipotency in otherwise lineage restricted haematopoietic progenitors (Vo, 
Kinney et al. 2018). In this study, the authors investigated the role of EZH1, which 
mediates methylation on histone H3 lysine 27 (Shen, Liu et al. 2008). They showed 
that reduced expression of EZH1 enhances multi-lymphoid output from human 
pluripotent stem cells, whilst Ezh1 deficiency in mouse embryos results in 
precocious emergence of functional dHSCs in vivo (Vo, Kinney et al. 2018).  
 
 
Figure 1.1.4 Sites of haematopoiesis during mouse development. Mesoderm 
formation (around E6.5) is followed by development of yolk sac blood islands (E7.5) 
which are responsible for primitive haematopoiesis. Definitive haematopoiesis begins 
with the emergence of HSCs in the AGM region (E10.5) and continues in the foetal 
liver (from E14.5), and subsequently in the BM (from E18.5 in the foetus, and then 
postnatally into adulthood). Adapted from Baron et al. 2012 (Baron, Isern et al. 2012).    
1.1.5 Properties of HSCs 
HSCs are defined by their capacity for both self-renewal and multilineage 
differentiation. By this definition, every time that an HSC divides, at least one of its 
daughter cells must become an HSC itself. Symmetric division results in expansion 
of the HSC pool, for example in cases of haematopoietic stress, such as 
transplantation or after haematopoietic injury. In contrast, asymmetric division 
maintains the HSC pool and multilineage differentiation under steady-state conditions 
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(Blank, Karlsson et al. 2008). The unique properties of HSCs make it possible for one 
HSC to reconstitute an entire haematopoietic system. As a result, HSC 
transplantation (HSCT) is a highly valued treatment modality for a range of bone 
marrow pathologies (Copelan 2006).   
 
 
Figure 1.1.5 Haematopoietic stem cell fates. Taken from Blank et al. 2008 (Blank, 
Karlsson et al. 2008).  
 
Strict regulation of HSC fate choices (Figure 1.1.5) is essential for the orderly 
maintenance of normal haematopoiesis, the ability to respond to episodes of 
haematopoietic stress, and the avoidance of leukaemic transformation. As in other 
organ systems, HSC fates are determined by a complex interplay of external stimuli 
(regulated by the HSC niche, see section 1.1.6) and intracellular regulatory programs 
(see section 1.1.7).  
 
1.1.6 The HSC niche  
The concept of the HSC niche was first introduced in a seminal paper by R. Schofield 
in 1978 (Schofield 1978), referring to the cellular, vascular and neural regulatory unit 
which maintains and directs HSC self-renewal and differentiation. The adult HSC 
Efficient isolation of human HSCs has pr ven more difficult,
primarily as a consequence of lack of appropriate in vivo assays.
As of today, the rhodaminelow fraction of the Lin!CD34"CD38!
population of human cord blood (CB), containing putative HSCs
at a frequency of 1 in 30 cells, provides the most stringent
isolation of human HSCs.12 Populations containing putative
human HSCs can be functionally analyzed in nonobese diabetic/
severe combined immune deficient (NOD/SCID) mouse strains.13
SCID repopulating cells (SRCs) represent the most primitive
hematopoietic population assessable, but NOD/SCID assays are
hampered by the generally low engraftment of human cells and
the difficulty in keeping NOD/SCID mice for long-term analy-
ses. This predicament can be overcome by serial NOD/SCID
transplantations, allowing for analysis of even more primitive
populations. However, such assay keep HSCs under constant
stress, which is why caution should be taken when interpreting
obtained data.
Regulation of hematopoietic stem cells, a
dynamic state of balance
To meet the need of a variety of situations, ranging from normal
homeostasis to acute blood loss or infection, hematopoiesis must be
rapidly yet meticulously controlled. Whether regarded as stochastic
mainly regulating probabilities or deterministic providing more
precise instructions, both intrinsic and extrinsic signals undoubt-
edly participate in the regulation of HSCs.1,14-16 Through reduction-
















Figure 1. HSC fate decisions. During or after cell division, the 2 daughter cells of an HSC are faced with several options, or fate decisions. These include the possibility to
remain a HSC (the process of self-renewal), which can be either symmetric or asymmetric in its nature, to commit along the path of differentiation or to go through apoptosis. In
addition, the option to move to other anatomic sites in or outside the BM (migration) can be regarded as a fate decision, which is particularly important during specific stages of
ontogeny when HSCs seed the fetal liver or later the BM.
SIGNALING PATHWAYS AND STEM CELL FATE 493BLOOD, 15 JANUARY 2008 ! VOLUME 111, NUMBER 2
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bone marrow niche is known to comprise a mixture of cell types, including osteoblasts, 
macrophages, megakaryocytes, endothelial cells, sympathetic nervous system cells, 
perivascular and perisinusoidal mesenchymal stromal/stem cells (Boulais and 
Frenette 2015). Complex cellular interactions are therefore likely to be involved in 
regulating HSC fate decisions (Wohrer, Knapp et al. 2014).  
The localisation of HSCs with the BM niche remains an area of intense debate, 
beyond the scope of this summary (Morrison and Scadden 2014). Whilst there is a 
significant body of evidence to suggest that HSCs reside in a perivascular niche, 
supported by perivascular stromal cells and endothelial cells (Kobayashi, Butler et al. 
2010, Ding, Saunders et al. 2012, Ding and Morrison 2013, Greenbaum, Hsu et al. 
2013, Poulos, Guo et al. 2013), there is debate as to whether HSCs are localised 
primarily around sinusoids (Kiel, Yilmaz et al. 2005, Kiel, Radice et al. 2007, Nombela-
Arrieta, Pivarnik et al. 2013), or near bone surfaces (Kunisaki, Bruns et al. 2013). An 
alternative explanation, that HSCs are uniformly distributed within the BM space, was 
recently published by a group which used catulin and KIT expression to identify HSCs 
in optically cleared BM (Acar, Kocherlakota et al. 2015).  
Various BM cell types have been implicated in the regulation of HSCs within the niche. 
Early studies implicated an important role for osteoblasts, given their (then believed) 
co-localisation with HSCs in the endosteal region, as well as the decrease in 
lymphoid, erythroid and myeloid progenitors following conditional osteoblastic 
ablation (Visnjic, Kalajzic et al. 2004). Conversely, increasing the number of 
osteoblasts through enforced parathyroid hormone signalling, or through inactivation 
of bone morphogenic protein receptor type IA resulted in HSC expansion (Zhang, Niu 
et al. 2003). However, attempts to uncover a mechanism for the regulation of HSPCs 
by osteoblasts were unsuccessful, including studies of two critical cytokines known to 
be non-cell-autonomously required for HSC maintenance, CXC-chemokine ligand 12 
(CXCL12) and stem cell factor (SCF). Conditional ablation of these cytokines in 
osteoblastic cells did not significantly affect HSCs (Ding, Saunders et al. 2012, Ding 
and Morrison 2013, Greenbaum, Hsu et al. 2013).  Since then, 3D imaging studies 
have shown that HSCs do not significantly associate with osteoblasts in BM (Kunisaki, 
Bruns et al. 2013), and it is now believed that mature osteoblasts do not significantly 
regulate HSCs within the BM niche, but that immature osteo-lineage cells do regulate 
haematopoietic lymphoid progenitor cells.    
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Perivascular cells have been shown to play an important role in regulating HSC 
functions in the BM, specifically mesenchymal stem cells (MSCs), a stromal stem cell 
population capable of differentiation into bone, fat or cartilage.  MSCs have been 
shown to organise niche structures capable of supporting HSCs in vitro and in vivo 
(Frenette, Pinho et al. 2013), within the BM and also in ectopic locations such as the 
renal capsule (Chan, Chen et al. 2009). Mesenchymal stem and progenitor cells 
(MSPCs) have been shown to express high levels of factors involved in HSC 
regulation, including CXCL12, SCF, ANGPT1, OPN and VCAM1 (Pinho and Frenette 
2019). In this context, MSCs (enriched in a population of cells expressing GFP from 
regulatory elements of the Nes promoter) have been reported as the cell type 
responsible for potentiating sympathetic nervous system induced HSC mobilisation 
by CXCL12 (Méndez-Ferrer, Michurina et al. 2010).  
Other cells involved in regulation of the HSC niche include endothelial cells, HSC 
descendants (macrophages, T regulatory cells, megakaryocytes) and adipocytes. 
Endothelial cells have been shown to regulate the HSC niche through the production 
of factors such as Notch ligands, CXCL12, SCF and pleiotrophin, and by promoting 
haematopoietic injury following regeneration (Pinho and Frenette 2019). Under stable 
conditions, megakaryocytes are responsible for maintaining HSC quiescence, 
through secretion of cell cycle regulators thrombopoietin, TGFβ1 and CXCL4 (Bruns, 
Lucas et al. 2014, Nakamura-Ishizu, Takubo et al. 2014, Zhao, Perry et al. 2014). In 
response to haematopoietic stress however, megakaryocytes secrete FGF1 and 
downregulate TGFβ1, resulting in expansion of the HSC pool (Zhao, Perry et al. 
2014).  






Figure 1.1.6 The adult BM HSC niche. Figure taken from Pinho et al. 2019 (Pinho 
and Frenette 2019). 
 
1.1.7 Haematopoietic transcription factors 
 
Intracellular decision making is strongly influenced by the co-ordinated action of 
transcriptional regulatory networks, which are composed of transcription factors (TFs) 
and the gene regulatory DNA sequences they bind to.  
 
TFs can act as dominant or negative regulators of haematopoiesis. Historically, the 
chicken model developed by Graf et al. facilitated many of the discoveries which 
underlie our current understanding of haematopoiesis. In this system, multipotent 
progenitor cells from chickens are transformed with retrovirus containing myb and ets 
oncogenes. Forced expression of the transcription factor GATA1 in these cells 
induces reprogramming to erythroid, eosinophil, or thromboblast (chicken 
megakaryocyte) lineages (Kulessa, Frampton et al. 1995). On the other hand, forced 
expression of PU.1 induces myeloid differentiation (Nerlov and Graf 1998), whilst the 
combination PU.1, GATA1 and C/EBP  induces eosinophilic differentiation (Nerlov, 
McNagny et al. 1998). The concentration of TFs was also shown to be important, for 
example low GATA1 expression resulted in eosinophilic differentiation, whilst high 
GATA1 expression induced erythroid and megakaryocytic differentiation (Kulessa, 
Frampton et al. 1995). Concentration dependent haematopoietic TF effects have also 
been demonstrated in the mouse, where a decrease in GATA1 concentration 
Adipocytes. In humans, ageing accelerates BM adiposity, 
which is especially apparent in long bones where hae-
matopoietic sites are progressively replaced by fatty 
yellow marrow with reduced haematopoietic activity36. 
Adiponectin (ADIPOQ), an adipocyte- secreted protein, 
impairs the proliferation of haematopoietic progeni-
tors in vitro122. Furthermore, adipocyte- rich marrow 
(such as in the vertebrae of the mouse tail) contains 
fewer HSPCs than does adipocyt - poor marrow (such 
as that in the thoracic vertebrae). In the A- ZIP/F1 
‘fatless’ mouse, BM engraftment by HSCs is acceler-
ated123. In addition, the BM recovers more quickly after 
transplantation or chemotherapy when mice are treated 
with a peroxisome proliferator- activated receptor γ 
(PPARγ) antagonist, which inhibits adipogenesis123,124. 
These results suggest that adipocytes are negative 
regulators of HSC function; however, alterations in 
MSPCs may also indirectly contribute to this result. 
A novel MSC population (CD45−CD31−SCA1+CD24+) 
that is regulated by diet and ageing and can give rise to 
osteochondrogenic and adipogenic precursors, has been 
identified125. Consistent with the negative influence of 
adipocytes, co- transplantation of adipogenic precursors 
in an intratibial injection model inhibits HSPC engraft-
ment and bone fracture healing in a manner mediated by 
the negative regulator dipeptidyl peptidase 4 (REF.124). By 
contrast, adipocyte progenitors derived from Adipoq–
CreER- labelled cells transiently support the regeneration 
of HSCs by producing SCF126. Further studies are needed 
to clarify the mechanisms of adipolineage- cell regulation 
of the HSC niche, particularly at steady state.
Neural regulation. Innervation in the skeletal system 
has been suggested to regulate haematopoiesis in the 
bone and BM49,98,127. Whereas parasympathetic nerves 
only innervate the bone and do not fully penetrate 
the marrow52,128, sympathetic nerves50,51 and sensory 
nerves51,129 innervate both the bone and BM. Sympathetic 
fibres release the neurotransmitter noradrenaline, which 
signals through adrenergic receptors. HSPC mobiliza-
tion out of the marrow to peripheral organs depends 
on an intact gradient of CXCL12. Granulocyte colony- 
stimulating factor (G- CSF) decreases the steepness of the 
gradient by selectively reducing CXCL12 levels in BM, 
leading to rapid HSPC gress from t e BM77,130. The SNS 


























































Fig. 3 | The adult bone marrow HSC niche in homeostasis. Schematic representation of the adult bone marrow 
haematopoietic stem cell (HSC) niche in homeostasis, showing various cell types and niche factors that directly or 
indirectly regulate HSC activity. Emerging evidence highlights the vasculature and associated stromal cells, such as 
periarteriolar nestin (Nes)–GFPhigh cells, neural–glial antigen 2 (NG2)-positive cells, myosin heavy chain 11 (MYH11)- 
positive cells, perisinusoidal Nes–GFPlow cells, CXC- chemokine ligand 12 (CXCL12)-abundant reticular (CAR) cells and 
leptin receptor (LEPR)-positive cells, as key regulators of HSC maintenance. Sympathetic nervous system (SNS) nerves 
regulate HSC mobilization, and nonmyelinating Schwann cells may contribute to HSC quiescence. Osteoblasts have been 
implicated in HSC regulation, but the precise molecular signals have not been clearly elucidated; however, they may have 
a role in regulating lymphoid progenitors. Adipocytes may negatively affect HSC maintenance. Haematopoietic cells, such 
as macrophages, neutrophils, regulatory T (Treg) cells and megakaryocytes, are examples of HSC- derived progeny that can 
feed back and contribute to HSC maintenance or mobilization. Regional localization of HSC subsets has shown that 
platelet- biased or myeloid- biased von Willebrand (Vwf)–GFP+ HSCs and Vwf–GFP− HSCs may be located in and regulated 
by separate bone marrow niches containing megakaryocytes and arterioles, respectively. DARC, duffy antigen receptor for 
chemokines; IL-7 , interleukin-7; OPN, osteopontin; OSM, oncostatin M; SCF, stem cell factor ; TGFβ, transforming growth 
factor- β; TNF, tumour necrosis factor.
Engraftment
The process by which donor 
haematopoietic stem c lls 
persist in the host, generate 
mature progeny and 
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interferes with the maturation of erythroid cells (McDevitt, Shivdasani et al. 1997). 
Whilst the aforementioned TFs act in a dominant positive way to regulate 
haematopoiesis, others exert negative effects, for example Pax5 is required for B cell 
commitment and differentiation, and in the absence of Pax5, progenitors fail to restrict 
their lineage choice (Nutt, Heavey et al. 1999).  
 
Whilst these studies clearly demonstrate the importance of TFs in regulation of 
haematopoiesis, the in vivo situation is significantly more complex. Recent work has 
therefore focused on defining more complex haematopoietic regulatory network 
models, with the aid of genome-wide technologies, and advanced computational 
analyses (Sive and Göttgens 2014). For example, Wilson et al. evaluated ten key 
regulators of HSPCs (Scl, Lyl1, Lmo2, Gata2, Runx1, Meis1, Pu.1, Erg, Fli-1, Gfi1b) 
in a murine multipotent progenitor cell line, and identified a previously unrecognized 
interaction between seven TFs (Scl, Lyl1, Lmo2, Gata2, Runx1, Erg and Fli1) (Wilson, 
Foster et al. 2010).  
 
A summary of major haematopoietic transcription factors and their functions is 
provided in Table 1.1.7.  
 
Transcription Factor Role in haematopoiesis 
Stem Cell Leukaemia 
(SCL) 
A basic helix-loop-helix (bHLH) TF which is required for specification of 
haematopoiesis during development, adult HSC survival and 
quiescence, and terminal maturation of erythroid, megakaryocyte, and 
mast cell lineages (Porcher, Chagraoui et al. 2017).  
Runt-related 
transcription factor 1 
(RUNX1) 
First identified as a critical regulator of haematopoiesis (Okuda, Van 
Deursen et al. 1996, Wang, Stacy et al. 1996). RUNX1 is a core binding 
factor required for the emergence of HSCs in the yolk sac, and 




MLL has a critical role in foetal and adult HSC self-renewal (McMahon, 
Hiew et al. 2007), and is a common translocation partner in leukaemia 
(Hess 2004). MLL encodes a SET-domain containing a histone 
methyltransferase region, which is shown to be active in chromatin 
remodelling, activating Hox genes (Milne, Briggs et al. 2002). 
Lim only domain 2 
(LMO2) 
Member of the large zinc-finger protein LMO family (Kadrmas and 
Beckerle 2004). Required for definitive haematopoiesis, and commitment 
to the erythroid lineage (Yamada, Warren et al. 1998). 
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Globin transcription 
factor 2 (GATA2) 
Member of the GATA family of zinc-finger TFs, essential for foetal and 
adult haematopoiesis, with a broad expression across all haematopoietic 
cells (Tsai, Keller et al. 1994). Involved in the production and expansion 
of HSCs in the AGM, and the proliferation of HSCs in the BM (Ling, 
Ottersbach et al. 2004).  
Purine-rich sequence 1 
(PU.1) 
An ETS-family TF that functions in myeloid and B lymphoid lineage 
differentiation (Laslo, Spooner et al. 2006, Gupta, Gurudutta et al. 2009). 
Also binds RNA and may modulate pre-mRNA splicing (Guillouf, Gallais 
et al. 2006).  
Homeobox A9 (HOXA9) Member of the HOX family of homeobox genes, best recognised for their 
role in axial patterning (Krumlauf 1994). HOXA9 is highly expressed in 
HSPCs, and its expression decreases with differentiation (Sauvageau, 
Lansdorp et al. 1994, Pineault, Helgason et al. 2002). 
Myeloid ecotropic viral 
integration site 1  
(MEIS1) 
Member of the TALE (three amino acid loop extension) family of 
homeodomain transcription factors (Moskow, Bullrich et al. 1995). 
Regulates growth and differentiation during vertebrate development 
(Moens and Selleri 2006). Highly expressed in the primitive 
compartment, and downregulated in differentiated cells (Pineault, 
Helgason et al. 2002). 
Leucine zipper CCAAT-
enhancer binding 
protein a (C/EPBa) 
Essential TF for neutrophilic differentiation and for the development of 
acute myeloid leukaemia (AML) (Avellino and Delwel 2017).  
 
 
Table 1.1.7 Haematopoietic transcription factors. 
 
Notably, more than half of all haematopoietic transcription factors identified to date 
were discovered first as chromosomal translocation partners in the context of 
leukaemia. Clearly therefore, the excessive cell proliferation and differentiation block 
which characterises this malignancy is not a non-specific effect but involves the 
disruption of critical pathways of haematopoietic transcriptional control.  
 
1.1.8 HSC expansion ex vivo 
 
HSCT can provide a new haematopoietic system and restore blood cell production in 
recipients (Osawa, Hanada et al. 1996, Copelan 2006, Notta, Doulatov et al. 2011).  
As such, HSCT is a valuable treatment modality for a variety of disorders, including 
cancers, bone marrow failure syndromes, and also in gene therapy settings (Copelan 
2006). However, human HSCs are rare, only constituting around 0.01% of adult BM 
(Seita and Weissman 2010), and this limits the clinical application of HSCT therapy. 
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The outcome of HSCT is directly correlated with the number of HSCs transplanted. 
For HSCT to be successful, approximately 3-4 x 106/kg of recipient bodyweight HSCs 
are required (Al-Anazi 2012, Remberger, Törlén et al. 2015). Efficient expansion of 
HSCs ex-vivo, from human BM or umbilical cord blood, is therefore a key area of 
research. 
 
Several advancements have been made in this area over the past decade. The 
advent of high throughput screening libraries of low molecular weight compound 
libraries has revealed promising new chemical compounds for ex-vivo HSC 
expansion. For example, Boitano et al. screened 100 000 small molecules and 
identified a purine derivative, StemRegenin 1 (SR1), capable of promoting a 50-fold 
ex vivo expansion of human cord blood-derived CD34+ cells. SR1 has been showed 
to antagonise the aryl hydrocarbon receptor (AHR). A recent clinical trial using SR1 
expanded HSCs (treated for 15 days ex-vivo) showed better engraftment and earlier 
recovery of recipient neutrophil and platelet counts compared to control HSCs. 
Similarly, Fares et al. screened a library of 5280 low molecular weight compounds 
and 300 analogues to identify a pyrimidoindole derivative UM171, which induces HSC 
expansion in an AHR-independent manner, and is more effective at doing so with 
primitive human CD34+CD45RA cells compared with SR1 (Fares, Chagraoui et al. 
2014).  
 
Another approach for ex-vivo HSC expansion has focused on engineering an 
appropriate ex-vivo HSC niche, through provision of cytokines, extracellular matrix 
components, and structural 3D architectures. For example, co-culturing human 
CD34+ cord blood cells with mesenchymal stromal cells resulted in a 30-fold 
expansion of CD34+ cells, and subsequently faster neutrophil engraftment times in 
transplanted recipients, compared to those who received control CD34+ cells (De 
Lima, McNiece et al. 2012).   
 
There is also growing evidence that targeting HSC metabolic pathways and 
endoplasmic reticulum (ER) stress pathways might potentiate improved HSC 
expansion ex-vivo. For example, it is known that FL HSCs undergo very rapid 
expansion in vivo, without showing ER stress (Sigurdsson, Takei et al. 2016). With 
this is mind, it is interesting that chemical chaperones capable of reducing ER stress, 
for example tauroursodeoxycholic acid (TUDCA) have been shown to support the 
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engraftment of HSCs following transplantation (Miharada, Sigurdsson et al. 2014). In 
terms of metabolic pathways, treatment of murine LSK cells with alexidine 
dihydrochloride (which inhibits mitochondrial phosphatase Ptpmt1 and can shift 
mitochondrial aerobic metabolism to glycolysis) was shown to triple the 
transplantation efficiency in a competitive transplant setting relative to control cells 
(Liu, Zheng et al. 2015). Active mitophagy also seems to be a mechanism for inducing 
HSC self-renewal, as opposed to differentiation (Ito, Turcotte et al. 2016).  
 
Most recently, a study by Wilkinson et al. reported long term ex-vivo HSC expansion 
using a defined, albumin-free culture system. They identified a synergistic 
combination of thrombopoietin and low levels of fibronectin and stem cell factor to 
induce HSC self-renewal, and replaced serum albumin in the culture system with 
polyvinyl alcohol, to reduce biological contaminants. Using this approach, the authors 
showed between 236- and 899-fold expansions of functional HSCs over 1 month 
(Wilkinson, Ishida et al. 2019).  
 
In spite of these, and many other, significant advances in the field of ex-vivo HSC 
expansion, much work remains to bring HSC availability in line with HSCT demand. 
Of particular importance will be to determine the relative contributions of stem cell 
intrinsic and niche factors in HSC self-renewal, as well as the role of hypoxia and 




The term ‘leukaemia’, originating from the Greek words ‘leukos’ (white) and ‘haima’ 
(blood) refers to a malignant proliferation of immature white blood cells. The condition 
typically originates in the bone marrow, and proceeds to involve the peripheral blood 
and extramedullary organs. Leukaemias are broadly divided into four main types, 
depending on the cell type of origin and its state of differentiation; acute myeloid (or 
myelogenous) leukaemia (AML), chronic myeloid (or myelogenous) leukaemia (CML), 
acute lymphocytic (or lymphoblastic) leukaemia (ALL), and chronic lymphocytic 
leukaemia (CLL). Polycythaemia vera and essential thrombocythaemia also fall under 
the umbrella classification of myeloid leukaemia. AML itself may arise de novo or may 
be preceded by a myelodysplastic phase (myelodysplastic syndrome, MDS). A 
schematic overview of these leukaemia subtypes is illustrated in Figure 1.2. The work 
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presented in this thesis focused on AML, as this is the commonest leukaemia affecting 





Figure 1.2 Schematic overview of the main types of leukaemia. AML can arise de 
novo, or from a pre-existing myelodysplastic syndrome. On rare occasions, AML 
develops from myeloproliferative neoplasia.  Adapted from ‘Acute Myeloid 
Leukaemia’ (Khwaja, Bjorkholm et al. 2016).  
 
1.2.1 Acute myeloid leukaemia (AML) 
 
AML is an aggressive malignant disorder of haematopoietic stem and progenitor cells, 
characterised by a clonal expansion of poorly differentiated myeloid precursor cells at 
the expense of normal haematopoiesis.  
 
1.2.2 Epidemiology of AML 
 
AML is the commonest form of leukaemia in adults, accounting for 80% of cases in 
this group (Yamamoto and Goodman 2008). In contrast, AML only accounts for about 
20% of leukaemia cases in paediatric patients (Puumala, Ross et al. 2013). Although 
AML can affect any age group, it is most common in older people, with the median 
age of diagnosis around 70 years (Bennett, Catovsky et al. 1976, Juliusson, Antunovic 
et al. 2009). The incidence of AML increases gradually from the age of 40-50 years, 
and more steeply from the age of 60 years, as shown by Cancer Research UK data 
(Figure 1.2.2). In the western world, AML is slightly more common in males compared 
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with females, with a male to female ratio of 1.1 to 1.3, increasing to 1.8 at 80-84 years 
of age (Dores, Devesa et al. 2012) (Figure 1.2.2). People who have received 
cytotoxic chemotherapy or radiation therapy for a primary malignancy are at a greater 
risk for subsequent AML development, as are those with myelodysplastic conditions. 
Treatment with alkylating agents (chlorambucil, cyclophosphamide, melphalan) or 
topoisomerase II inhibitors (for example, etoposide, mitoxantrone, anthracyclines) is 
especially linked to development of therapy-related AML (Bueso-Ramos, Kanagal-
Shamanna et al. 2015). In addition, AML is known to have a strong ethnic component, 
with Asian Americans having a significantly lower lifetime risk compared with white 
Americans, regardless of birth place (Pang, Cook et al. 2002). Finally, certain 
inherited disorders are associated with a high risk of AML, including Down syndrome, 
Fanconi anaemia, Bloom syndrome, ataxia-telangiectasia, Diamond-Blackfan 





Figure 1.2.2 UK incidence of AML by sex and age, for the period from 2010 to 
2015. Figure adapted from Cancer Research UK incidence statistics (Cancer 
Research UK [online], http://www.cancerresearchuk.org/health-professional/ cancer-
statistics/statistics-by-cancer-type/leukaemia- aml/incidence (accessed June 2019)). 
1.2.3 Classification of AML 
 
A variety of classification systems have been used historically for AML. In the 1970s, 
AML was classified according to the French American British (FAB) system (Bennett, 
Catovsky et al. 1976). This system initially defined six major AML subtypes (M1-M6, 
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see Table 1.2.3A) based on cell morphology and the use of a-naphthyl acetate 
esterase (ANAE) to discriminate monoblasts from myeloblasts (Bennett, Catovsky et 
al. 1976).  Later, immunological markers were used to define two additional AML 
subtypes; acute myeloblastic leukaemia with minimal differentiation (AML-M0) (Lee, 
Pollak et al. 1987) and acute megakaryocytic leukaemia (AML-M7) (see Table 
1.2.3A). In 2001, the WHO issued a replacement classification system for 
haematological malignancy, incorporating cytogenetic and molecular analysis results 
for more accurate sub-grouping of the diseases (Vardiman, Harris et al. 2002). 
Updates to the WHO classification system were published in 2008 (Vardiman, Thiele 
et al. 2009), and 2016 (Arber, Orazi et al. 2016), to take into account the expanding 
knowledge in the area of cancer genomics. The most recent classification system, 
from 2016, is summarised in Table 1.2.3B.  
 
FAB subtype Name 
M0 Acute myeloblastic leukaemia with minimal differentiation 
M1 Acute myeloblastic leukaemia without maturation 
M2 Acute myeloblastic leukaemia with maturation 
M3 Promyelocytic leukaemia 
M4 Acute myelomonocytic leukaemia 
M5 Acute monocytic leukaemia 
M6 Acute erythroid leukaemia 
M7 Acute megakaryocytic leukaemia 
 
Table 1.2.3A Summary of the FAB classification of AML  
 
Acute myeloid leukaemia and related neoplasms 
AML with recurrent genetic abnormalities 
• AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 
• AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11 
• APL with PML-RARA 
• AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A 
• AML with t(6;9)(p23;q34.1);DEK-NUP214 
• AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM 
• AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1  
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• Provisional entity: AML with BCR-ABL1 
• AML with mutated NPM1 
• AML with biallelic mutations of CEBPA 
• Provisional entity: AML with mutated RUNX1 
AML with myelodysplasia-related changes 
Therapy related myeloid neoplasms 
AML not otherwise specified (NOS) 
• AML with minimal differentiation  
• AML without maturation  
• AML with maturation  
• Acute myelomonocytic leukaemia  
• Acute monoblastic/monocytic leukaemia  
• Pure erythroid leukaemia  
• Acute megakaryoblastic leukaemia  
• Acute basophilic leukaemia  
• Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid proliferations related to Down syndrome 
• Transient abnormal myelopoiesis (TAM) 
• Myeloid leukaemia associated with Down syndrome 
Table 1.2.3B Summary of the WHO classification of AML. Adapted from ‘The 2016 
revision to the World Health Organization classification of myeloid neoplasms and 
acute leukemia’ (Arber, Orazi et al. 2016).  
1.2.4 Pathophysiology of AML 
 
AML results from the malignant transformation of a haematopoietic stem cell, or a 
primitive haematopoietic progenitor cell which has re-acquired stem cell properties, 
generating a leukaemic stem cell (LSC). This leukaemic stem cell divides to generate 
leukaemic progenitor cells, which acquire additional mutations, leading to the 
characteristic karyotypic and molecular heterogeneity of AML. Critically, leukaemic 
stem cells are both rare and quiescent, making them relatively resistant to the 
standard therapies used to eliminate bulk cancer cells. As a result, they may survive 





Figure 1.2.4 Leukaemic stem cells propagate AML and are difficult to eradicate. 
HSPCs (within dashed box) acquire mutations to generate LSCs, which give rise to 
the bulk of cancer cells. LSCs are rare and quiescent, therefore relatively resistant to 
standard therapies. Residual LSCs therefore fuel AML relapse upon cessation of 
treatment.  
 
Approximately half of all human AML patients have gross structural cytogenetic 
abnormalities, including balanced translocations and chromosomal gains or losses 
(Byrd, Mrózek et al. 2002). These cytogenic abnormalities are well established as 
causal genetic events in AML, and strongly influence disease course as well as 
treatment response. In addition, almost all AML patients are found to have at least 
one oncogenic driver mutation, whilst two or more oncogenic drivers are identified in 
at least 86% of cases (Papaemmanuil, Gerstung et al. 2016). The commonest 
cytogenetic abnormalities and oncogenic mutations in AML are discussed in further 
detail in sections 1.2.5 and 1.2.6 respectively.  
 
Work conducted in mouse models has shown a ‘two hit’ model for AML, whereby a 
single gene mutation is insufficient to cause leukaemia in isolation, instead initial and 
secondary mutations are required (Kelly and Gilliland 2002, Papaemmanuil, Gerstung 
et al. 2016). This is supported by the observation that the risk of AML increases with 
age (Short, Rytting et al. 2018), in line with the acquisition of mutations by 
haematopoietic stem and progenitor cells. Studies of clinically healthy humans have 
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shown that clonal haematopoiesis (defined as clonal expansion of HSCs harbouring 
mutations) increases with age, with a sharp rise in incidence between the ages of 50 
and 65 years (Jaiswal, Fontanillas et al. 2014, Score, Chase et al. 2015). Mutations 
in genes that encode epigenetic modifiers, DNMT3A, TET2, ASXL1 and IDH1/2 are 
frequently identified in elderly people with clonal haematopoiesis and carry an 
increased risk of haematopoietic malignancy (Jaiswal, Fontanillas et al. 2014, Xie, Lu 
et al. 2014). However, given that these mutations are consistently identified within the 
founding AML clone, and are almost never found in isolation (Papaemmanuil, 
Gerstung et al. 2016), it seems likely that they require additional, co-operating 
mutations in order to initiate leukaemia.  
 
1.2.5 Cytogenetics of AML 
 
Cytogenetic abnormalities are known to be the most important independent 
prognostic factor in AML (Mrózek, Marcucci et al. 2012, Estey 2013) and are present 
in approximately half of all AML patients (Byrd, Mrózek et al. 2002). Although over 
740 recurrent balanced aberrations have been identified in AML (Mitelman, 
Johansson et al. 2002), four translocations occur most frequently, namely PML-
RARA, AML1-ETO, CBFb-MYH11 and MLL-fusions. These common onco-fusions 
are discussed in further detail below, as are the critical downstream effectors of MLL-
fusions, Meis1 and Hoxa9, and the oncogenic fusion MOZ-TIF2.  
 
1.2.5.1 t(15;17) PML-RARA 
PML-RARA is a fusion oncogene present in more than 95% of human acute 
promyelocytic leukaemia (APL; FAB-M3) cases, and in 10% of total human AML 
cases (Martens and Stunnenberg 2010). PML-RARA is the product of a t(15;17) 
chromosomal translocation, which fuses the promyelocytic leukaemia gene (PML) to 
the gene encoding retinoic acid receptor α (RARA) (de Thé, Chomienne et al. 1990). 
The resulting PML-RARα fusion impairs the normal function of RARα in neutrophil 
differentiation, and ultimately induces APL.  
1.2.5.2 t(8;21) AML1-ETO 
The AML1-ETO fusion is present in approximately 10% of AML cases (Martens and 
Stunnenberg 2010). The fusion protein is formed of the conserved runt homology 
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domain (rhd) from the critical haematopoietic transcription factor RUNX1 (formerly 
termed AML1, encoded on chromosome 21), joined to the majority of the ETO 
repressor protein (encoded on chromosome 8). AML1-ETO retains the ability to bind 
DNA sequences through the rhd of RUNX1, and to recruit transcriptional corepressors 
through ETO, therefore acting as a transcriptional repressor of RUNX1 target genes. 
More recently, additional roles for AML1-ETO have been documented in AML, namely 
increased HSC/MPP self-renewal through activation of the Wnt and Notch signalling 
pathways, and inhibition of lineage commitment through interaction with the 
haematopoietic transcription factors, GATA-1, PU.1, C/EBPa and E2A (Elagib and 
Goldfarb 2007).  
1.2.5.3 Inv(16) CBFb-MYH11  
The CBFb-MYH11 fusion is present in approximately 8% of AML cases (Martens and 
Stunnenberg 2010). This fusion protein results from the pericentric inversion of 
chromosome 16, thereby fusing core binding factor b (CBFb) to the C-terminal coiled-
coil region of a smooth muscle myosin heavy chain (MYH11) (Liu, Tarle et al. 1993). 
In normal haematopoiesis, CBFb binds to RUNX1, forming the core binding factor 
(CBF), an essential transcription factor for haematopoiesis and myeloid 
differentiation. The CBFb-MYH11 fusion disrupts the binding of CBFB to RUNX1, 
leading to repression of CBF-target genes, and ultimately a block in differentiation 
(Lutterbach, Hou et al. 1999). Expression of CBFb-MYH11 in isolation is insufficient 
to generate leukaemia, and co-operating mutations are required for leukaemic 
transformation (Castilla, Garrett et al. 1999).  
1.2.5.4 MLL-fusions 
The Mixed Lineage Leukaemia gene (MLL) on chromosome 11q23 is the human 
homologue of Drosophila melanogaster trithorax, and is a frequent target for 
chromosomal translocations in human acute leukaemias of both lymphoblastic and 
myeloid varieties. MLL, which encodes a histone methyltransferase (Milne, Briggs et 
al. 2002, Nakamura, Mori et al. 2002), is involved in the regulation of homeotic genes 
during embryonic development (Benjamin, Hess et al. 1995) and is also required for 
the development and maintenance of normal haematopoiesis (Yagi, Deguchi et al. 
1998, Ernst, Mabon et al. 2004, Jude, Climer et al. 2007). MLL translocations are 
present in more than 70% of infant leukaemias (either lymphoblastic or myeloid), 10% 
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of adult leukaemias (myeloid), and also occur following therapy with topoisomerase II 
inhibitors for other malignancies (Muntean and Hess 2012). Overall, MLL 
rearrangements are present in approximately 10% of human leukaemias, and are 
often associated with a poor prognosis (Krivtsov and Armstrong 2007). In MLL-
rearranged leukaemias, the N terminal of MLL is fused to one of over 60 fusion 
partners. The most common translocation in AML is t(9;11), which encodes the 
oncogenic fusion protein MLL-AF9, and is typically associated with the FAB-M4 or M5 
subtypes of human AML (Swansbury, Slater et al. 1998).  
1.2.5.5 Meis1/Hoxa9 
 
Homeobox A9 (HOXA9) belongs to the HOX family of homeobox genes, best 
recognised for their role in axial patterning (Krumlauf 1994). HOXA9 is highly 
expressed in HSCs and primitive haematopoietic progenitors, and its expression 
decreases with differentiation (Sauvageau, Lansdorp et al. 1994, Pineault, Helgason 
et al. 2002). HOXA9 is frequently upregulated in human AML samples, particularly 
when MLL fusions are present, and is associated with a negative prognosis (Golub, 
Slonim et al. 1999, Kawagoe, Humphries et al. 1999, Lawrence, Rozenfeld et al. 
1999). In a cancer classification study based on gene microarrays, an attempt to 
identify genes linked with clinical outcome highlighted HOXA9 from amongst 6817 
genes as the single most highly correlated gene overexpressed in patients with 
treatment failure (Golub, Slonim et al. 1999).  
 
MEIS1 belongs to the TALE (three amino acid loop extension) family of 
homeodomain transcription factors (Moskow, Bullrich et al. 1995). Like HOXA9, 
MEIS1 is known to play an important role in regulating growth and differentiation 
during vertebrate development (Moens and Selleri 2006). Furthermore, MEIS1 
expression mirrors that of HOXA9 during haematopoiesis, with high levels of 
expression in early progenitors and progressive downregulation during differentiation 
(Pineault, Helgason et al. 2002). In the context of AML, both Meis1 and Hoxa9 are 
directly upregulated by MLL-fusion proteins (Milne, Briggs et al. 2002, Zeisig, Milne 
et al. 2004), and are also highly expressed in non MLL-rearranged leukaemias, where 
they carry a negative prognosis (Lawrence, Rozenfeld et al. 1999). Meis1 is reported 
to be an essential and rate-limiting regulator of MLL leukemia stem cell potential 
(Wong, Iwasaki et al. 2007), and is also an important and well-established co-factor 




The MOZ-TIF2 fusion is associated with AML with inv(8)(p11q13) (Carapeti, Aguiar 
et al. 1999), and is a less common oncogenic fusion in human AML, accounting for 
fewer than 1% of cases (Martens and Stunnenberg 2010). MOZ (monocytic 
leukaemia zinc finger) is a MYST family histone acetyltransferase (HAT), which was 
first cloned as a fusion partner of CBP as a consequence of t(8;16)(p11;p13) 
associated with the FAB M4/M5 subtype of AML (Borrow, Stanton et al. 1996). TIF2 
is a member of the p160 nuclear receptor transcriptional coactivator family (Glass, 
Rose et al. 1997), which stimulates gene expression by facilitating the assembly of 
basal transcription factors into a stable preinitiation complex (Klein-Hitpass, Tsai et 
al. 1990). MOZ-TIF2 was first identified by Carapeti et al., who reported that this fusion 
retains the histone acetyltransferase homology domains of both proteins and also the 
CBP binding domain of TIF2 (Carapeti, Aguiar et al. 1998, Carapeti, Aguiar et al. 
1999). 
1.2.6 Molecular abnormalities of AML 
 
Approximately 48% of primary AML patients present with no gross structural 
chromosomal changes (Byrd, Mrózek et al. 2002). These cytogenetically normal AML 
(CN-AML) cases are the result of gene mutations and altered gene expression, driving 
changes in the proliferation and differentiation of HSPCs. The advent of high 
throughput next generation sequencing technologies has fuelled a rapid expansion in 
our understanding of the AML genomic landscape and has highlighted the marked 
heterogeneity and complexity that exists there (Network 2013, Metzeler, Herold et al. 
2016, Papaemmanuil, Gerstung et al. 2016). In 2013, the Cancer Genome Atlas 
Research Network published a comprehensive analysis of the genetic abnormalities 
(genomic, transcriptomic and epigenomic) from 200 adult AML patients. In this study, 
whole genome sequencing of 50 patients and exome sequencing of 150 patients 
revealed more than 2,000 different mutated genes, of which 23 were defined as 
frequently mutated genes. On average there were 13 gene mutations per sample, 5 
of those in frequently mutated genes. Only 3 genes were mutated in >25% of patients; 
FMS-related tyrosine kinase 3 (FLT3), nucleophosmin 1 (NPM1) and DNA 
methyltransferase 3A (DNMT3A) (Network 2013). FLT3, NPM1 and DNMT3A were 
also reported as the most frequently mutated genes (occurring in 39%, 33% and 31% 
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of patients respectively) in a 2016 paper by Metzeler et al. who sequenced 68 
recurrently mutated genes in a cohort of 664 adult AML patients (Figure 1.2.6) 
(Metzeler, Herold et al. 2016). In the same year, Pappermuil et al. reported the results 
of cytogenetic analysis, and sequencing of 111 cancer genes, from 1540 AML 
patients enrolled in three high intensity treatment trials (Papaemmanuil, Gerstung et 
al. 2016). This study identified 5234 driver mutations across 76 genes or genomic 
regions, with at least one driver mutation identified in 96% of AML patients, and at 
least 2 found in 86% AML patients. Importantly, the large sample size of this study 
meant that the authors were able to use allele fractions of point mutations to infer 
clonal relationships. In this way, they showed that mutations in genes encoding 
epigenetic modifiers (DNMT3A, TET2, ASXL1, IDH1 and IDH2) are often acquired 
early in the course of the disease and require additional mutations to induce 
leukaemia (Papaemmanuil, Gerstung et al. 2016). Our expanding understanding of 
AML gene mutations, and their implications for prognosis and treatment, has resulted 
in the amendment of the WHO classification system (Arber, Orazi et al. 2016), and 
the introduction of molecular screening as a routine component of AML classification 
at the time of diagnosis.  
 
The cooperating mutations in AML can be categorized into functional groups reflecting 
distinct cellular activities. Broad categories of mutations are those affecting 1) 
transcription factors regulating stem cell self-renewal and differentiation, 2) cell 
signalling pathways regulating cell proliferation and survival and 3) epigenetic 
modifiers regulating gene expression. More recently, the importance of cohesin 
complex and spliceosome mutations has also become apparent (Papaemmanuil, 
Gerstung et al. 2016). For example, splicesome mutations including SRSF2, SF3B1, 
U2AF1 and ZRSR2 are now regarded as pathognomic for AML secondary to MDS 
(Cazzola, Della Porta et al. 2013). Similarly, somatic cohesion complex mutations, 
including STAG2, TAD21 and SMC3 have been identified in approximately 20% of 
high risk MDS and secondary AML, and are associated with an adverse prognosis 
(Thota, Viny et al. 2014).   
 





Figure 1.2.6 Driver gene mutations in AML. Adapted from ‘Spectrum and 
prognostic relevance of driver gene mutations in acute myeloid leukaemia’ (Metzeler, 





Gene and Category Prevalence Description Prognosis 
Nucleophosmin 1 (NPM1) 25-30% of AML 
Female bias 
Expression of NPM1 protein in the 
cytoplasm instead of the nucleus, causing 
myeloid proliferation and leukaemogenesis. 
Associated with monocytic AML morphology. 
Favourable 
DNA Methyltransferase 3A 
(DNMT3A) 
• Epigenetic modification 
18-22% of AML 
34% of CN-AML 
DNMT3A mutations are identified frequently 
in clonal haematopoiesis, and as 
preleukaemic mutations. May persist during 
remission.  
Adverse 
FMS-like Tyrosine Kinase 
3 (FLT3)  
• Proliferation 
20% of AML 
30-45% of CN-
AML 
Internal tandem duplications (ITDs) in the 
juxta membrane domain, or mutations in the 
second tyrosine kinase domain (TKD), 
causing constitutive activation of FLT3 and 




(IDH) 1 and 2 
• Epigenetic modification 
15-20% AML 
25-30% CN-AML 
Gain of function mutations, replacing 
physiological IDH enzyme function with the 





2 (TET2)  
• Epigenetic modification 
and differentiation 
9-23% AML Loss of function mutations. Commoner in 
older patients. Mutually exclusive with IDH1, 
IDH2 and WT1 mutations.   






5-13% AML More common in older patients and 
secondary AML.  
Adverse 
CCAAT Enhancer Binding 
Protein α (CEBPA) 
• Differentiation and 
stem cell self-renewal 
6-10% AML 
15-19% CN-AML 
Critical transcription factor controlling gene 
expression during haematopoiesis. Biallelic 
mutations (usually N terminal plus C 







Additional Sex Comb-Like 
(ASXL1) 
• Epigenetic modification 
5-11% AML Loss of function mutations, commoner in 
older patients and secondary AML.   
Adverse 
Mixed Lineage Leukaemia 
(MLL) 
• Differentiation and 
stem cell self-renewal  
11% CN-AML Partial in tandem duplications associated 
with a poorer prognosis. 
Adverse 
Tumour Protein p53 (TP53) 
• Tumour suppression 
8-14% AML Occurs in AML with a complex karyotype, 
rare in the absence of chromosomal 
deletions. Associated with chemoresistance. 
More common in older patients and 
secondary AML.  
Very adverse 
Receptor Tyrosine Kinase 
(c-Kit) 
<5% AML Constitutive activation and aberrant 





22-29% in AML 
with t(8;21) or 
inv(16) 
NRAS and KRAS 
• Proliferation 
12% AML (NRAS) 
5% AML (KRAS)  
Missense mutations affecting membrane 
localisation. Aberrant downstream signalling.  
None 
Wilms Tumour 1 (WT1) 
• Epigenetic modification 
and differentiation 
7% AML Predominantly normal karyotype. Mutually 
exclusive with IDH1, IDH2 and TET2 
mutations.   
Adverse 
 
Table 1.2.6 Recurrent gene mutations in AML. Combined data from Khwaja et al., 
Saultz et al., and Short et al. (Khwaja, Bjorkholm et al. 2016, Saultz and Garzon 2016, 
Short, Rytting et al. 2018). 
 
1.2.7 Clinical presentation of AML 
 
AML patients present with signs reflecting the accumulation of malignant and poorly 
differentiated myeloid cells in the BM, peripheral blood, and occasionally also other 
organs. Non-specific symptoms are common, including a decreased appetite, weight 
loss, fatigue and fever. Signs of BM failure are frequently present, specifically 
thrombocytopenia causing bleeding tendencies, anaemia, and infection. 
Lymphadenopathy (enlarged lymph nodes) and hepatosplenomegaly (enlargement 
of the liver and spleen) may be present (Khwaja, Bjorkholm et al. 2016). In rare AML 
patients, hyperleukocytosis, which is defined as a leukocyte count of > 100 x 109 
WBC/l, can lead to capillary occlusion, and potentially multi-organ failure and death 
(Röllig and Ehninger 2015). Another infrequent complication of AML is spontaneous 
tumour lysis syndrome, which can occur in patients with a high tumour burden, 
particularly upon initiation of treatment (Montesinos, Lorenzo et al. 2008).   
 
1.2.8 Diagnosis of AML 
 
Diagnosis of AML requires the identification of at least 20% myeloid blast cells 
(myeloblasts, monoblasts, megakaryoblasts) during examination of the BM (samples 
obtained by aspirate and/or core biopsy) or peripheral blood (Döhner, Estey et al. 
2010). Notable exceptions to this rule are isolated extramedullary AML (myeloid 
sarcoma), or the presence of recurrent karyotypic or molecular abnormalities which 
are pathognomic for AML, i.e., t(8;21), inv(16) and t(15;17) (Vardiman, Thiele et al. 
2009). Immunophenotyping of patient samples by flow cytometry confirms the myeloid 
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origin of the malignancy and facilitates further categorisation of AML subtype. Positive 
myeloperoxidase staining, or the documentation of Auer rods (azurophilic cytoplasmic 
inclusion bodies seen commonly in APL, acute myelomonocytic leukaemia, and the 
majority of AML with t(8;21)), are also consistent with a myeloid malignancy (De 
Kouchkovsky and Abdul-Hay 2016). Following a diagnosis of AML, cytogenetic 
analysis (through karyotyping and fluorescent in situ hybridisation, FISH), and 
screening for commonly identified gene mutations and rearrangements are carried 
out, to facilitate accurate AML classification. This information is used to provide 




Immunophenotyping is used for lineage specification (differentiation of AML from 
ALL), and for sub-classification of AML subtypes in a 2-step approach, as outlined in 
Table 1.2.8.1. AML can be confirmed if myeloblasts are positive for at least 2 of the 
following myeloid markers; MPO, CD13, CD33, CDw65 and CD117, with MPO being 
the most specific (Bene, Castoldi et al. 1995). Notably, lymphoid antigens are 
detected in around 25% of AML patient samples, with T cell marker CD7 reported in 
10-30% of cases, and B cell marker CD19 reported in 3% of cases.  
 
Step 1: Lineage specification 
B lineage CD19, cyCD22 and cyCD79a 
T lineage cyCD3, CD2 and CD7 
Myeloid lineage MPO, CD13, CD33 and CDw65 
Progenitor cell antigens CD34, TdT, HLA-DR, CD10 and 
CD117 
Step 2: Subtype specification in myeloid leukaemia 
Monocytic CD14, CD11b, CD4 
Erythroid CD71, CD36, CD235a 
Megakaryoblastic CD41a, CD61 
Granulocytic CD65, (CD15)  
 
Table 1.2.8.1 Two step immunophenotyping process for AML. Cy, cytoplasmic; 
HLA-DR, human leukocyte antigen-antigen D related; MPO, myeloperoxidase; TdT, 
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terminal deoxynucleotidyltransferase. Adapted from ‘Acute Myeloid Leukaemia’ 
(Khwaja, Bjorkholm et al. 2016). 
 
1.2.9 Treatment of AML 
 
The treatment for AML has changed little in the last 40 years. However, since 2017 
several new drugs have been introduced, building on an increased understanding 
about the genomic landscape of AML, and the rationale for targeted and specific 
therapies. Nevertheless, the core of therapy remains the same currently; cytarabine 
and an anthracycline for induction, followed by consolidation chemotherapy with 
cytarabine, or haematopoietic stem cell transplantation (HSCT) (Short, Rytting et al. 
2018). The intensity of the regime is chosen based on the patient’s ability to tolerate 
treatment. Where possible, high intensity induction therapy is administered, with 7 
days of cytarabine at 100-200 mg/m2 intravenously plus 3 days of an anthracycline 
i.e. daunorubicin or idarubicin (Short, Rytting et al. 2018). With this treatment, 
‘complete morphological remission’ (see 1.2.10 for discussion) is reported in 60-85% 
of patients under the age of 60 years, and in 40-60% of patients 60 years of age and 
above (Döhner, Weisdorf et al. 2015). Assuming complete remission is achieved with 
induction therapy, the next choice is whether to follow this up with consolidation 
chemotherapy, or proceed directly to HSCT, which carries a greater risk of treatment 
related mortality, but reduces the risk of relapse in high risk AML disease (Schlenk 
2014). Consolidation chemotherapy is generally recommended at first remission for 
AML patients with favourable risk disease. Standard of care is a cytarabine-based 
regimen, 1.5-3 g/m2 (dose depending on AML subtype) every 12 hours for 3 days per 
cycle, with 4 cycles administered in total (Short, Rytting et al. 2018). In general, HSCT 
is recommended at the first remission where the risk of relapse is considered to 
exceed 35% i.e. in high risk cases, and in some intermediate risk cases. Allogeneic 
HSCT benefits AML patients via a two-part mechanism; leukaemic cells are targeted 
first by the high-dose cytotoxic pre-conditioning regimen, and then by engrafted donor 
T cells, which exert an important ‘graft versus host leukaemia’ effect (Gupta, Tallman 
et al. 2011).  
 
In recent years, several new drugs have been introduced for the treatment of AML, to 
complement or replace standard cytarabine - anthracycline therapy, depending on 
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patient factors and the molecular and cytogenetic features of their disease. These 
various therapies, and the rationale for their use, are summarised in Table 1.2.9.  
 
Therapy Mechanism Usage References 
Gemtuzumab 
ozogamicin 
Anti-CD33 antibody drug 
conjugate that carries 
calicheamicin, a potent DNA 
damaging toxin.  
Beneficial effect in most AML 
subgroups, particularly those with high 
CD33 expression, and in patients with 
favourable/intermediate risk disease. 
Used in combination with standard 
therapy (particularly effective in 
paediatric leukaemia), or as a single 
agent in patients unable to tolerate 
standard therapy.  
(Godwin, Gale et 
al. 2017) 
FLT3 inhibitors Midostaurin is an oral 
multitargeted kinase inhibitor. 
Further examples include 
Sorafenib, Quizartinib, 
Crenolanib. 
Midostaurin significantly improves 
survival in AML patients with FLT3 
ITD or FLT3 kinase domain mutations 
(51.4 versus 44.3% 4-year overall 
survival when used in combination 
with standard therapy). 
(Stone, 




Enasidenib is an oral selective 
inhibitor of mutant IDH2, which 
induces blast cell 
differentiation. 
Suitable for AML patients with IDH2 
mutations (10-20% AML cases). 
Overall response rate of around 40%, 
complete remission of 20%, median 
survival time 9.3 months.  
(Stein, DiNardo 
et al. 2017) 
Clofarabine Second generation purine 
nucleoside analogue. 
Single agent or as combination 
therapy, overall response rates 
around 40%. Well tolerated addition to 
low dose cytarabine in patients not 
suitable for high intensity treatment. 
(Kantarjian, Erba 
et al. 2009, 
Burnett, Russell 
et al. 2013) 
Hypomethylating 
agents 
Inhibition of DNA methylation, 
resulting in re-expression of 
tumour suppressor genes. 
Examples include azacytidine 
and decitabine.   
Used in MDS and AML. Response 
rates of 20-30%. Well tolerated 
addition to low dose cytarabine in 
patients not suitable for high intensity 
treatment. 
(Kantarjian, 
Thomas et al. 
2012, Dombret, 
Seymour et al. 
2015) 
All-trans-retinoic 
acid (ATRA) and 
arsenic trioxide 
(ATO) 
Induce differentiation of 
promyelocytes into 
neutrophils. 
Used in APL. Should be administered 
immediately, decreases risk of 
bleeding diathesis and death.  
(Lo-Coco, 
Avvisati et al. 
2013) 
 
Table 1.2.9 Novel therapies for AML, additional to cytarabine / anthracycline 
treatment.   
 
Several novel therapies are currently in development for AML, offering new hope to 
patients with high risk or relapsed disease, or those unfit for standard therapy. For 
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example, reversible inhibitors of the major nuclear export receptor chromosome 
region maintenance 1 (CRM1) (which mediates export and inactivation of tumour 
suppressors including p53, RB1, p21, p73, FOXO1), have shown strong anti-
leukaemic effects in pre-clinical studies (Ranganathan, Yu et al. 2012, Etchin, Sun et 
al. 2013). Other drugs under investigation for treatment of AML include STAT3 small 
molecule inhibitors, monoclonal antibodies against CD123, bromodomain and extra 
terminal protein inhibitors, B-cell lymphoma 2 (BCL-2) inhibitors, checkpoint inhibitors 
e.g. anti-CTLA4 and anti-PD1 monoclonal antibodies, and novel chimeric antigen 
receptor T cell therapies that target epitopes highly expressed on AML blasts (Gill, 
Tasian et al. 2014, Grosso, Hess et al. 2015). 
 
1.2.10 Prognosis of AML 
 
In 2010, the European Leukaemia Net (ELN) classification scheme was created in an 
attempt to standardise risk stratification in adult AML patients by combining details of 
cytogenetic and molecular abnormalities (Döhner, Estey et al. 2010, Mrózek, 
Marcucci et al. 2012). Using this scheme, patients were divided into 1 of 4 groups 
favourable, intermediate 1, intermediate 2 and adverse (see Table 1.2.10). 
 
Genetic group Subsets 
Favourable t(8;21)(q22;q22); RUNX1-RUNX1T1 
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
Mutated NPM1 without FLT3-ITD (normal karyotype) 
Mutated CEBPA (normal karyotype) 
Intermediate I Mutated NPM1 and FLT3-ITD (normal karyotype) 
Wild-type NPM1 and FLT3-ITD (normal karyotype) 
Wild-type NPM1 without FLT3-ITD (normal karyotype) 
Intermediate II t(9;11)(p22;q23); MLLT3-MLL 
Cytogenetic abnormalities not classified as favourable or adverse 
Adverse inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
t(6;9)(p23;q34); DEK-NUP214 
t(v;11)(v;q23); MLL rearranged 
−5 or del(5q); −7; abnl(17p); complex karyotype 
 
Table 1.2.10 Risk stratification in AML (Döhner, Estey et al. 2010). 
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Morphological complete remission of AML is defined as fewer than 5% of blasts on a 
BM aspirate sample with marrow spicules and with a count of at least 200 nucleated 
cells, alongside an absolute neutrophil count of > 1000/µl and a PLT count of ³ 
100,000/µl. There should also be no blasts with Auer rods, and no persistence of 
extramedullary disease (Cheson, Bennett et al. 2003). However, with the advent of 
next generation high throughput sequencing methods, it has become increasingly 
clear that morphological complete remission fails to detect minimal residual disease, 
which can subsequently serve as a foundation for leukaemic relapse (Chen, Xie et al. 
2015). Prognostic information is therefore likely to change significantly as methods 
for detection of minimal residual disease become mainstream, for example 
multiparameter flow cytometry, and quantitative real-time PCR (Kern, Haferlach et al. 
2008). At present, with standard cytarabine/anthracycline chemotherapy, long term 
survival for patients with AML is achieved in only 35-40% of those younger than 60 
years of age. The prognosis for patients of 60 years and above is even poorer, with a 
long-term survival of only 10-15% (Döhner, Estey et al. 2017). The reason for the 
inferior prognosis in older patients is twofold, they are less likely to tolerate intensive 
chemotherapy (Podoltsev, Stahl et al. 2017), and they are more likely to have higher 
risk disease, with less favourable cytogenetic and molecular characteristics (Lindsley, 
Mar et al. 2015, Creutzig, Zimmermann et al. 2016). In contrast, the prognosis for 
paediatric AML is more favourable, with cure rates approaching 70% (Kolb and 
Meshinchi 2015).  
 
1.3 Epitranscriptomics as a novel layer of regulation of gene expression 
 
Genomic, transcriptomic and epigenomic pathways controlling AML have been 
recognised for many years, and continue to be well studied (1.2.5 and 1.2.6). 
However, in the last decade, the field of epitranscriptomics has emerged as a novel 
layer of regulation of gene expression, with significant effects on normal and 
malignant stem cell biology. With the advent of next generation and high throughput 
sequencing technologies, and liquid chromatography/mass spectroscopy techniques, 
the extent of these modifications and their biological significance is becoming 
increasingly apparent.  
 
1.3.1 RNA modifications 
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Over 170 RNA modifications have been identified to date. These modifications are 
listed and regularly updated in the comprehensive MODOMICS database (Boccaletto, 
Machnicka et al. 2017). Through the addition of polar, charged, aliphatic or aromatic 
moieties, these modifications affect the functions of the four basic ribonucleotide 
residues of RNA; adenine (A), uracil (U), guanine (G) and cytosine (C), providing a 
post transcriptional layer of regulation for gene expression. Compared to 
transcriptional regulation of mRNA, regulatory pathways at the post transcriptional 
level have the advantage of providing fine-tuned and localised control, which can be 
rapidly adapted to changing circumstances.  
 
In the process of protein synthesis, messenger RNA (mRNA) is translated into protein 
through the combined actions of transfer RNA (tRNA) and ribosomal RNA (rRNA), 
which associates with specific proteins to form ribosomes. The most abundant cellular 
RNA is rRNA, whereas the most extensively modified is tRNA (Pan 2018). Common 
rRNA modifications include 2’-O-methylation (Nm) of the ribose and isomeration of 
uridine to pseudouridine (y), and these typically occur adjacent to functionally 
important sites (Sloan, Warda et al. 2017). Modifications of tRNA are highly diverse, 
and include 5-methylcytosine (m5C), N1-methyladenosine (m1A), pseudouridine (y), 
5-methyluridine (m5U), 1-methylguanosine (m1G), 7-methylguanosine (m7G), inosine 
(I), and also more complex multistep modifications such as 5-methoxycarbonyl-
methyl-2-thiouridine (mcm5s2U) (Pan 2018).  
 
The 5’ cap and 3’ poly(A) tail are well characterised modifications of mRNA, and both 
contribute to transcript stability, nuclear export and translation initiation (Sachs 1990, 
Ghosh and Lima 2010). The mRNA 5’ cap also assists polyadenylation, and pre-
mRNA splicing. In addition to the 5’cap and 3’ poly(A) tail, a number of internal mRNA 
modifications have also been identified (Figure 1.3.1), the best characterised of which 





Figure 1.3.1 Common chemical modifications in eukaryotic mRNA transcripts. 
Nm (2’-O-methylation); m5C (5-methylcytosine); m1A (N1-methyladenosine); y 
(pseudouridine); hm5C (5-hydroxymethylcytosine), m6A (N6-methyladenosine). Figure 
taken from Roundtree et al. (Roundtree, Evans et al. 2017).  
 
1.3.1.1 2’-O-methylation (Nm) 
 
2’-O-methylation (Nm) is a co- or post-transcriptional modification of RNA in which a 
methyl group (CH3) is added to the 2’ hydroxyl (OH) of the ribose moiety. This 
abundant and highly conserved modification is found at multiple sites on tRNA, rRNA, 
mRNA and small non-coding RNAs (ncRNAs). Amongst other roles, Nm modification 
can affect structure and RNA/protein interactions of RNA (Dimitrova, Teysset et al. 
2019).   
 
1.3.1.2 5-methylcytosine (m5C) and 5-hydroxymethylcytosine (hm5C) 
 
Methylation at the 5 position of cytosine in mRNA was first identified more than 40 
years ago (Desrosiers, Friderici et al. 1974, Dubin and Taylor 1975), but it was only 
recently, with the advent of bisulfide m5C sequencing, that the abundance and extent 
of this modification in mRNA and ncRNA became apparent (Squires, Patel et al. 
2012). Recent work has shown that m5C is recognised by the mRNA export adaptor 
protein ALYREF, suggesting that it plays a role in the nuclear export of m5C-modified 
transcripts (Yang, Yang et al. 2017). 5-hydroxymethylcytosine (hm5C) is the oxidation 
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product of m5C, catalysed by the ten-eleven translocation (TET) family of enzymes 
(Fu, Guerrero et al. 2014).  
 
1.3.1.3 N1-Methyladenosine (m1A) 
 
Methylation at the N1 position of adenosine (m1A) occurs in mammalian mRNA at low 
levels, with m1A/A ratios ranging from 0.015% to 0.16% in cells and tissues 
(Dominissini, Nachtergaele et al. 2016). Nevertheless, because m1A occurs at the 
Watson Crick interface it generates a positively charged base and can therefore 
markedly affect RNA secondary structure (Dominissini, Nachtergaele et al. 2016, Li, 
Xiong et al. 2016). m1A is enriched around translation initiation start sites in coding 
transcripts and is thought to function primarily in translation, and RNA-RNA 
interactions (Dominissini, Nachtergaele et al. 2016, Li, Xiong et al. 2016). To date, 
two AlkB family proteins have been found to demethylate m1A; ALKBH3 (Li, Xiong et 
al. 2016) and ALKBH1 (Liu, Clark et al. 2016). Levels of m1A are dynamic, changing 
in response to nutrient starvation and heat shock (Dominissini, Nachtergaele et al. 
2016, Li, Xiong et al. 2016).  
 
1.3.1.4 Pseudouridine (y) 
 
Pseudouridine (y), isomerisation of the uridine base, was the first RNA modification 
discovered (Cohn and Volkin 1951) and was quickly established as an abundant 
component of rRNA and tRNA (Cohn 1960). In the last 5 years, sequencing 
technologies including PseudoU-Seq and y-Seq have facilitated transcriptome-wide 
quantitative mapping of pseudouridine, revealing hundreds of y-modified human 
mRNAs (Carlile, Rojas-Duran et al. 2014, Schwartz, Bernstein et al. 2014). 
Furthermore, quantitative mass spectroscopy analysis has shown that y is much 
more prevalent in mammalian mRNA than previously thought, occurring at a y/U ratio 
of 0.2-0.6% (Li, Zhu et al. 2015). Pseudouridylation, which is catalysed by 
pseudouridine synthases, alters RNA secondary structure due to improved base 
stacking (Davis 1995), and has been shown to affect many cellular processes 
including translation efficiency, splicing, telomere maintenance and regulation of gene 
expression (Mochizuki, He et al. 2004, Carlile, Rojas-Duran et al. 2014, Schwartz, 
Bernstein et al. 2014). In addition, pseudouridylation of any of the three translation 
termination codons (all of which contain a uridine at the first position) has been shown 
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to prevent translation termination in a process termed stop codon read through 
(Karijolich and Yu 2011, Fernández, Ng et al. 2013).   
 
1.3.1.5 N6-methyladenosine (m6A) 
 
Methylation at the N6 position of adenosine (m6A) is the most prevalent internal 
modification on eukaryotic mRNA and has been identified in the transcripts of over 
7000 human genes (Meyer, Saletore et al. 2012, Dominissini, Moshitch-Moshkovitz 
et al. 2013). m6A was first discovered in 1974 (Desrosiers, Friderici et al. 1974, Perry 
and Kelley 1974), but received limited attention until the discovery of the demethylase 
enzymes FTO (Jia, Fu et al. 2011) and ALKBH5 (Zheng, Dahl et al. 2013), which 
indicated that the modification was reversible, and might therefore act in a regulatory 
role. Around the same time, the development of high throughput sequencing 
technologies provided transcriptome-wide maps of modification sites on mRNA, long 
non-coding RNAs, and later also small nucleolar RNAs (snoRNAs) (Meyer, Saletore 
et al. 2012, Dominissini, Moshitch-Moshkovitz et al. 2013), revealing the prevalence 
of m6A, and prompting studies of its functional significance. 
 
The ratio of m6A to A in total cellular RNA is reported to be around 0.1-0.5% 
(Desrosiers, Friderici et al. 1974, Dubin and Taylor 1975, Jia, Fu et al. 2011, Zheng, 
Dahl et al. 2013). N6-methyladenosine marks are preferentially located near stop 
codons and 3′ untranslated regions (Meyer, Saletore et al. 2012, Dominissini, Moshitch-
Moshkovitz et al. 2013), and occur in the consensus motifs G(m6A)C (70%) or A 
(m6A)C (30%) (Wei and Moss 1977).  
 
We now know that m6A plays a fundamental role in key biological processes, and that 
aberrations in m6A regulators drive a wide range of pathologies, including cancer. The 
regulation of m6A, and its role in health and disease is discussed below.  
 
1.3.2 m6A regulators 
 
m6A methylation is installed by methyltransferase complexes (writers) and removed 






Figure 1.3.2 m6A writers, erasers and readers. m6A writers: m6A is predominantly 
installed on mRNA in the consensus sequence RR(m6A)CH (R = A or G; H = A, C or 
U) by a methyltransferase complex with a METTL3-METTL14 core, and associated 
adaptor proteins including WTAP, VIRMA, ZC3H13, HAKAI, RBM15/15B. METTL16 
is a recently identified m6A writer, which installs m6A in the consensus sequence 
UAC(m6A)GAGAA on transcript MAT2A. m6A erasers: m6A is removed by either of 
the two demethylases, FTO or ALKBH5. m6A readers: m6A modified mRNA is bound 
by 3 classes of reader proteins a) YTH family proteins, which bind via a well-defined 
YTH domain b) HNRNPC/G and HNRNPA2B1, which bind following a ‘structural 
switch’ of RNA, which is initiated by m6A modification c) RNA binding proteins 
IGF2BP1-3 and FMR1, which bind via an unknown mechanism.  
1.3.2.1 m6A writers 
 
m6A is installed on mRNA co-transcriptionally by a methyltransferase writer complex. 
At the core of this complex is methyltransferase 3 (METTL3), which is the catalytically 
active subunit (Bokar, Shambaugh et al. 1997), bound to methyltransferase 14 
(METTL14), which facilitates RNA binding (Wang, Doxtader et al. 2016, Wang, Feng 
et al. 2016). The METTL3-METTL14 core is associated with several additional 
proteins, including WTAP, VIRMA, ZC3H13, HAKAI and RBM15/15B.  The function 
of the METTL3-METTL14 writer complex proteins is summarised in Table 1.3.2.1.  
 
Subunit Role References 
METTL3 Catalytic subunit (Bokar, Shambaugh et al. 
1997) 
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METTL14 Critical to support METTL3 structurally and for recognition of 
RNA substrates but weak methyltransferase activity itself 
(Liu, Yue et al. 2014, Wang, 
Doxtader et al. 2016, Wang, 
Feng et al. 2016) 
WTAP METTL3/14 localisation and substrate recruitment (Ping, Sun et al. 2014) 
VIRMA Mediates preferential mRNA methylation in 3′UTR and near 
stop codon 
(Yue, Liu et al. 2018) 
ZC3H13 Facilitates nuclear localisation of the writer complex (Wen, Lv et al. 2018) 
HAKAI Interacts with core components to facilitate m6A methylation (Horiuchi, Kawamura et al. 




Associate with METTL3-WTAP, facilitating binding to certain 
mRNAs and XIST 
(Patil, Chen et al. 2016) 
 
Table 1.3.2.1 Components of the m6A writer complex and their functions.  
 
The METT3-METTL14-WTAP complex is predominantly localised in the nucleus 
(Bokar, Shambaugh et al. 1997, Ping, Sun et al. 2014), but can be found in the 
cytoplasm in some malignant cells, for example in AML (Barbieri, Tzelepis et al. 2017), 
and breast cancer (Alarcón, Lee et al. 2015).  
METTL3 has been shown to be essential for a wide range of biological processes, 
including yeast meiosis and sporulation (Clancy, Shambaugh et al. 2002), 
differentiation of murine embryonic stem cells (Batista, Molinie et al. 2014, Geula, 
Moshitch-Moshkovitz et al. 2015), sex determination in fruit flies (Haussmann, Bodi 
et al. 2016) and spermatogenesis (Xu, Yang et al. 2017). In addition, METTL3 is 
known to respond to stress, for example heat shock results in radical re-localisation 
of Mettl3 to heat-shock genes, where it acts together with Dgcr8 to co-
transcriptionally mark mRNAs for subsequent RNA degradation, ultimately 
ensuring rapid clearance of heat shock transcripts (Knuckles, Carl et al. 2017). 
Similarly, UV radiation causes rapid re-localisation of the heterodimer 
METTL3/METTL14 to areas of damage, and subsequently increased m6A at these 
sites. This m6A is required for effective recruitment of the enzyme DNA polymerase 
kappa, ultimately facilitating DNA repair (Xiang, Laurent et al. 2017).  
Within the cytoplasm, METTL3 may function as a reader, thereby promoting 
translation. For example, in lung cancer cells, the interaction between METTL3 and 
EIF3 (which is overexpressed in many cancers) results in the increased translation of 
transcripts bound to the 3’UTR of METTL3 (Lin, Choe et al. 2016).  
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Although the majority of m6A mRNA methylation is installed by the METTL3-METTL14 
complex, METTL16 has recently been identified as the methyltransferase which 
modifies U6 spliceosomal RNA (Pendleton, Chen et al. 2017, Warda, Kretschmer et 
al. 2017). In addition, METTL16 is also responsible for the regulation of MAT2A, the 
human gene encoding S-adenosylmethionine (SAM)-synthetase. In this way, 
METTL16 controls the production of SAM, an essential methyl donor for numerous 
biological processes. METTL16 may function as an m6A reader, directing alternative 
splicing of MAT2A in response to low SAM levels (Pendleton, Chen et al. 2017), or 
may regulate MAT2A mRNA stability through YTHDC1 mediated m6A mRNA 
degradation (Shima, Matsumoto et al. 2017).  
 
1.3.2.2 m6A erasers 
To date, two m6A mRNA demethylases have been identified; fat mass and obesity-
associated protein (FTO) and ALKBH5, both of which are members of the α-
ketoglutarate (αKG)-dependent dioxygenase enzyme family.  
FTO was the first m6A mRNA demethylase discovered (Jia, Fu et al. 2011). 
Subsequently, the same group showed that FTO oxidation of m6A occurs in a 
stepwise manner, from m6A to N6-hydroxymethyladenosine (hm6A), and then to f6A. 
In doing so, they demonstrated that FTO can bind hm6A as well as m6A substrates 
(Fu, Jia et al. 2013). Subsequent to this, Mauer et al. showed that FMO selectively 
demethylates the first encoded nucleotide adjacent to the 7-methylguanosine cap in 
mRNA, termed N6,2'-O-dimethyladenosine (m6Am). These authors showed that FTO 
preferentially demethylates m6Am rather than m6A. Most recently, however, Wei et al. 
used cross linking immunoprecipitation sequencing (CLIP-Seq) to investigate the 
spectrum of FTO substrates, and concluded that FTO exhibits effective demethylation 
activity toward m1A in specific tRNAs, m6Am in some snRNAs, and internal m6A and 
cap-m6Am in mRNA (Wei, Liu et al. 2018). These authors also showed that FTO 
mediates mRNA m6A and cap-m6Am demethylation in the cytoplasm, but mainly 
mRNA m6A demethylation in the nucleus. Although FTO was initially reported as a 
nuclear protein, Wei et al. showed that in some AML cell lines a large amount of FTO 
is located within the cytoplasm, and consequently, up to 40% of mRNA m6A is 
subjected to demethylation by FTO (in contrast to common cell lines such as HeLa 
and HEK, where FTO is largely nuclear, therefore only 5-10% of mRNA m6A is subject 
to its demethylation activity) (Wei, Liu et al. 2018). Roles of FTO reported to date 
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include response to heat shock (Zhou, Wan et al. 2015), cardiac remodelling and 
repair (Mathiyalagan, Adamiak et al. 2019), stress related psychiatric disorders (Engel 
and Chen 2018), adipogenesis (Wu, Liu et al. 2018) and cancer (Tan, Dang et al. 
2015, Li, Weng et al. 2017, Yang, Wei et al. 2019).  
ALKBH5 was the second demethylase of m6A to be discovered (Zheng, Dahl et al. 
2013). Zheng et al. reported that the demethylation activity of ALKBH5 affects mRNA 
export and RNA metabolism, as well as the assembly of mRNA processing factors in 
nuclear speckles. These authors showed that Alkbh5 is widely expressed in mouse 
tissues, with particularly high expression levels in the testes. They went on to show 
that targeted deletion of Alkbh5 results in male specific infertility in mice, due to 
apoptosis affecting meiotic metaphase-stage spermatocytes (Zheng, Dahl et al. 
2013).  
1.3.2.3 m6A readers 
 
Several families of reader proteins for m6A have been identified, which bind m6A 
modified mRNA through different mechanisms. The YT521-B homology (YTH) 
domain containing family of proteins bind m6A mRNA directly via the highly conserved 
YTH domain (Xu, Wang et al. 2014), whereas heterogeneous nuclear 
ribonucleoproteins (HNRNPs) rely upon the ‘structural switch’ induced by m6A 
modification to access and bind specific RNA (Liu, Dai et al. 2015). Most recently, 
insulin-like growth factor 2 mRNA binding proteins (IGF2BPs; including 
IGF2BP1/2/3) have been identified as a third class of m6A mRNA binding proteins 
(Huang, Weng et al. 2018), through an as yet unknown mechanism. A summary of 
m6A readers and their functions is listed in Table 1.3.2.3.   
 
m6A reader Functional role 
YTHDF1 Promotes translation of target transcripts by recruitment of translation initiation factors 
(Wang, Zhao et al. 2015) 
YTHDF2 Targets m6A mRNA for decay, partially by recruitment of the CCR4-NOT deadenylase 
complex (Du, Zhao et al. 2016) 
YTHDF3 Promotes translation and decay of m6A mRNA (Shi, Wang et al. 2017) 
YTHDC1 Regulates mRNA splicing (Xiao, Adhikari et al. 2016), mRNA export (Roundtree, Luo 
et al. 2017), decay of selected mRNA transcripts (Shima, Matsumoto et al. 2017), and 
function of XIST, a long non coding RNA involved in X-chromosome inactivation (Patil, 
Chen et al. 2016) 
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YTHDC2 Facilitates the switch from mitosis to meiosis in male and female gametogenesis 
(Bailey, Batista et al. 2017, Hsu, Zhu et al. 2017, Wojtas, Pandey et al. 2017, Jain, 
Puno et al. 2018) 
HNRNPC/G 
HNRNPA2B1 
Regulate alternative splicing or processing of target transcripts (Alarcón, Goodarzi et 
al. 2015, Liu, Dai et al. 2015, Liu, Zhou et al. 2017, Wu, Su et al. 2018)  
IGF2BPs Promote stability and storage of target m6A mRNAs (Huang, Weng et al. 2018) 
Proline rich coiled-coil 
2A (Prrc2a) 
Recently discovered, reported to stabilise a critical m6A modified transcript required for 
myelination (Wu, Li et al. 2019) 
Fragile X mental 
retardation 1 (FMR1) 
Affects RNA translation and RNA stability likely through interplay with YTHDF1 and 
YTHDF2 (Edupuganti, Geiger et al. 2017, Zhang, Kang et al. 2018)  
Eukaryotic initiation 
factor 3 (eIF3) 
Participates in translation initiation, and allows for cap-independent translation of 
mRNAs with m6A modified 5′ UTR (Meyer, Patil et al. 2015) 
 
Table 1.3.2.3 m6A readers and their functions.  
 
In humans, the YTH domain family of proteins includes five members; cytoplasmic 
YTHDF1, YTHDF2, YTHDF3 and YTHDC2, and nuclear YTHDC1. Although 
YTHDF1, YTHDF2 and YTHDF3 have been shown to have their own unique target 
mRNAs, there is also a set of common mRNA targets which they share (Wang, Zhao 
et al. 2015, Shi, Wang et al. 2017). YTHDF1 has been shown to promote mRNA 
translation, by delivering more cellular mRNAs to translation machinery, and also by 
increasing mRNA translation efficiency (Wang, Zhao et al. 2015). In contrast, 
YTHDF2 has been shown to affect the stability of m6A-modified mRNAs by localising 
them to mRNA decay sites, such as processing bodies (Wang, Lu et al. 2014). The 
opposing roles of YTHDF1 and YTHDF2, and the overlap of their mRNA targets, 
indicate a degree of complexity in the overall function of m6A on mRNA. Interestingly, 
Wang et al. reported that shared mRNA targets are first bound by YTHDF1, and 
subsequently by YTHDF2, and proposed that the two reader proteins might be playing 
complementary roles to provide a tight level of control (i.e. a rapid but short-lived 
response of sufficient magnitude) of gene expression at the post transcriptional level 
(Wang, Zhao et al. 2015).  
 
Further complexity is evident in the opposing roles of YTHDF2 and IGFBP2 on m6A 
mRNA stability. In 2016, Du et al. showed that YTHDF2 recruits the CCR4-NOT 
complex by a direct interaction between the YTHDF2 N terminus and the SH domain 
of the CNOT1 subunit, thereby targeting m6A containing mRNAs for deadenylation by 
CAF1 and CCR4, and subsequent degradation (Du, Zhao et al. 2016). In contrast, 
Huang et al. showed in 2018 that IGF2BPs promote the stability and storage of their 
target mRNAs (for example, MYC) in an m6A dependent manner under normal and 
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stress conditions. One explanation for the differential outcome following m6A mRNA 
binding by YTHDF2 and IGF2BPs is their differential binding sites on mRNA; whilst 
YTHDF2 favours the 3’ UTR, IGFBPs preferentially bind to the coding sequence 
(Huang, Weng et al. 2018). 
Very recently, Ries et al. published a study showing that the cytosolic m6A-binding 
proteins YTHDF1, YTHDF2 and YTHDF3 undergo liquid-liquid phase separation in 
vitro and in cells (Ries, Zaccara et al. 2019). These authors showed that 
polymethylated mRNAs act as a multivalent scaffold for the binding of the low 
complexity domain YTHDF proteins, ultimately resulting in phase separated 
YTHDF–m6A–mRNA complexes in cells. As a result, the number and location of m6A 
sites on mRNA (which varies according to disease state and cell type) determines 
the composition of the phase separated transcriptome, which in turn influences 
partitioning into intracellular compartments for example P-bodies, stress granules, 
or neuronal granules. Thus, the pattern of m6A mRNA methylation is important in 
determining phase separation and therefore the outcome of m6A mRNA 
modification (Ries, Zaccara et al. 2019).   
1.3.3 YTHDF2 
 
The YTHDF2 gene (located on chromosome 1) encodes a 579-residue protein, which 
is identified in the Swiss-Prot database with the accession number Q9Y5A9. 
Synonyms for YTHDF2 include High-Glucose-Regulated Protein 8, Renal Carcinoma 
Antigen NY-REN-2, and CLL-Associated Antigen KW-14. BLAST analysis has shown 
that the YTHDF2 gene spans 32 kilobases and consists of 5 exons (Cardelli, 
Marchegiani et al. 2006). The YTHDF2 protein is highly conserved across vertebrates, 
with a stretch of 546 residues in the human protein which are 99.7% identical to that 
of the mouse, and a stretch of 518 residues which show significant similarity (89.8%) 
to that of the zebrafish (Cardelli, Marchegiani et al. 2006).  
 
The YTHDF2 C-terminal YTH domain is responsible for specifically binding m6A 
containing mRNA, with a preference for transcripts containing a consensus motif of 
G(m6A)C (Wang, Lu et al. 2014). The crystal structure of YTHDF2 has been reported 
by two groups, revealing the mechanism for recognition of m6A (Li, Zhao et al. 2014, 
Zhu, Roundtree et al. 2014). Zhu et al. reported that YTH domains are highly 
conserved across YTH-domain containing proteins (YTHDF1-3, YTHDC1-2) and 
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species, implying an important function. Through fluorescence polarization assays 
and electrophoretic mobility shift assays, they showed that YTHDF2 binds m6A RNA 
with a significantly higher affinity than unmodified RNA. Crystal structure analysis of 
YTHDF2 revealed a globular fold with a central core of 4-stranded b-sheets 
surrounded by 4 a helices and flanking regions on two sides. Subsequently, these 
authors showed the basic residues K416 and R527 on the surface of YTHDF2 are 
involved in binding to the RNA backbone, whilst the residues W432 and W486 within 
an adjacent hydrophobic pocket contribute to the specific recognition of m6A (Zhu, 
Roundtree et al. 2014). Similarly, Li et al. also showed that YTHDF2 binds m6A via a 
hydrophobic pocket, and went on to show that the m6A mononucleotide is positioned 
in an aromatic cage of three aromatic amino acids, of which Trp486 from β4-β5 
loop forms the base, and Trp432 from β2 strand and Trp491 from β4-β5 loop form 
the walls (Li, Zhao et al. 2014).  
 
In the mouse, Ythdf2 is highly expressed in a wide range of tissues, including testis, 
ovary, spleen, liver, thymus (Ivanova, Much et al. 2017). In a study from 2017, 
YTHDF2 deletion in mice was reported to be partially permissive, with approximately 
half of expected Ythdf2 knock out mice observed at weaning. Viable Ythdf2 knock out 
mice in that study were outwardly indistinguishable from their wild type or 
heterozygous litter mates, but females were sterile. Through a maternal conditional 
deletion strategy, this sterility was shown to be due to a lack of Ythdf2 within the 
germline, resulting in failure of maternal RNA degradation and stalled oocyte 
development (Ivanova, Much et al. 2017). In contrast, a study from 2018 used a 
different knock out mouse strain in which Ythdf2 deletion was found to be embryonic 
lethal, with the majority of lethality occurring between E14.5 and E18.5 (Li, Zhao et al. 
2018). Analysis of dissected knock out and heterozygous embryos (the latter showed 
semi-lethality) revealed abnormal cortical development in the absence of Ythdf2. 
Mechanistically, the authors attributed this to reduced degradation of neuron 
differentiation-related m6A-containing mRNAs in Ythdf2 deficient embryos (Li, Zhao 
et al. 2018).   
  
It has been shown that YTHDF2 can relocate from the cytoplasm to the nucleus in 
response to stress, for example following heat shock (Zhou, Wan et al. 2015). In this 
study, the authors showed that YTHDF2 competes with FTO in the nucleus to prevent 
5’UTR demethylation of heat shock response genes. The increased 5’UTR 
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methylation enables cap-independent translation initiation, providing a mechanism for 
selective mRNA translation under heat shock stress. 
 
A polymorphism of YTHDF2 located in an Alu-Rich Genomic Domain is known to be 
associated with human longevity (Cardelli, Marchegiani et al. 2006), and YTHDF2 has 
been described as a novel RUNX1 translocation partner gene in human AML 
(Nguyen, Ma et al. 2006).  
 
1.3.4 Roles of m6A 
 
Given the wide range of m6A reader functions (1.3.2.3), it is not surprising that m6A 
has been shown to play a critical role in almost all major biological processes, many 
of which have been presented already, in the context of m6A regulators (see 1.3.2.1-
3).  
 
m6A has also been shown to regulate the pace of circadian RNA processing, and 
therefore control circadian clock speed (Fustin, Doi et al. 2013). Fustin et al. initially 
showed that a non-specific inhibitor of methylation, 3-deazaadenosine (DAA), 
lengthens the circadian period in cultured cell lines and in mice. High throughput 
sequencing and m6A immunoprecipitation revealed a number of circadian RNAs 
marked by m6A and downregulated by DAA. Fustin et al. subsequently showed that 
siRNA Mettl3 inhibition extended the duration of the circadian period, and delayed the 
nuclear exit of mature Per2 and Bmal1 (Arntl) circadian clock gene mRNA (Fustin, 
Doi et al. 2013).  
 
A recurring theme in the reported roles of m6A mRNA methylation is its ability to 
regulate the transition between cell states. For example, early work by Geula et al. 
showed that m6A-dependent regulation of the transcript stability of pluripotency 
regulators determines the transition between naïve pluripotency and differentiation in 
mouse embryonic stem cells (Geula, Moshitch-Moshkovitz et al. 2015). More recently, 
a study by Zhao et al. highlighted the role of m6A in maternal-to-zygotic transition in 
zebrafish (Zhao, Wang et al. 2017). In this study, Zhao et al. crossed Ythdf2-deficient 
female zebrafish to wild type males, creating offspring lacking maternal Ythdf2. Loss 
of maternal Ythdf2 slowed the rate of decay of maternal mRNAs, impeding zygotic 
genome activation. Similarly, the loss of Ythdf2 has been reported to inhibit oocyte 
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development (Ivanova, Much et al. 2017) and cortical development in mice (Li, Zhao 
et al. 2018). In both cases, failure of transition was attributed to persistence of mRNAs 
associated with the existing cell state.   
 
1.3.5 m6A in cancer 
 
Given the critical role that m6A plays in both self-renewal and differentiation in cells, it 
is not surprising that m6A also plays a regulatory role in the context of cancer. 
Investigations into the effect of dysregulated m6A methylation machinery (writers, 
erasers or readers) show that m6A regulators can act as tumour suppressors or 
oncogenes, depending on the context. A summary of these studies is shown in Table 
1.3.5.  
 





MEK/ERK (Zhong, Liao et al. 2019) 
YTHDF2 Oncogene miR145 (Yang, Li et al. 2017) 
METTL3 Oncogene SOCS2 (Chen, Wei et al. 2018) 
METTL14 Tumour 
suppressor 
miR126 (Ma, Yang et al. 2017) 
Glioblastoma ALKBH5 Oncogene FOXM1 (Zhang, Zhao et al. 2017) 
METTL3/14 Tumour 
suppressors 
ADAM19, EPHA3, KLF4 (Cui, Shi et al. 2017) 
METLL3 Oncogene SOCS2 (Visvanathan, Patil et al. 
2018) 
Endometrial cancer METTL3/14 Tumour 
suppressors 
AKT (Liu, Eckert et al. 2018) 
Breast cancer ALKBH5 Oncogene NANOG (Zhang, Samanta et al. 
2016) 
Cervical cancer FTO Oncogene Unknown  (Wang, Li et al. 2017) 





(Chen, Sun et al. 2017) 
Gastric cancer METTL3 Oncogene AKT/ p70S6K/CyclinD1 
 
(Lin, Liu et al. 2019) 
YTHDF2 Oncogene Unknown (Zhang, Pi et al. 2017) 
Lung adenocarcinoma METTL3 Oncogene miR-33-a (Lin, Choe et al. 2016) 
Prostate cancer YTHDF2 Oncogene Unknown (Li, Meng et al. 2018) 
Acute myeloid 
leukaemia 
METTL3 Oncogene CEBPZ, c-MYC, SP1, SP2 (Barbieri, Tzelepis et al. 
2017) 
METTL3 Oncogene c-MYC, BCL2, PTEN (Vu, Pickering et al. 2017) 
METTL3 Oncogene MYB, MYC (Weng, Huang et al. 2018) 
METTL14 Oncogene MYB, MYC (Weng, Huang et al. 2018) 
FTO Oncogene ASB2, RARA (Li, Weng et al. 2017) 
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FTO Oncogene MYC/CEBPA (Su, Dong et al. 2018) 
IGF2BP Oncogene MYC (Huang, Weng et al. 2018) 
 
Table 1.3.5 The role of m6A regulators in cancer. Adapted (and modified) from 
Fitzimmons and Batista (Fitzsimmons and Batista 2018). 
 
The role of m6A in hepatocellular carcinoma (HCC) is controversial. In 2017, Yang et 
al. reported that YTHDF2 levels are increased in HCC, and are negatively correlated 
with prognosis. They also showed that microRNA (miR)-145 levels are decreased in 
HCC, and that overexpression of miR-145 decreases YTHDF2 expression at both the 
mRNA and protein levels, by targeting the 3’ UTR of YTHDF2 mRNA (Yang, Li et al. 
2017). Whilst this study indicated an oncogenic role for YTHDF2 in HCC, a recent 
study proposed that YTHDF2 acts as a tumour suppressor in this tumour instead 
(Zhong, Liao et al. 2019). Zhong et al. reported that YTHDF2 is specifically induced 
by hypoxia in HCC, and suppresses cell proliferation, tumour growth, and activation 
of MEK and ERK in HCC cells. Mechanistically, the authors showed that m6A-
dependent YTHDF2 binding to the 3’UTR of EGFR mRNA results in degradation of 
EGFR mRNA in HCC cells, and therefore suppression of cell proliferation and growth.  
 
In contrast, a study into the role of METTL3 in HCC showed that m6A-dependent 
YTHDF2-mediated mRNA degradation promotes tumour progression (Chen, Wei et 
al. 2018). Chen et al. showed that METTL3 levels and m6A methylation levels are 
increased in HCC and are correlated with a negative prognosis. These authors 
demonstrated decreased HCC tumorigenicity and lung metastasis in vivo following 
METTL3 knock out, and conversely, increased HCC growth in vitro and in vivo in 
response to METTL3 overexpression. Mechanistically, they identified suppressor of 
cytokine signalling 2 (SOCS2) as a target of METTL3 m6A modification, and showed 
that m6A targets SOCS2 mRNA for degradation via YTHDF2 (Chen, Wei et al. 2018). 
The findings of Chen et al. were surprising in view of earlier work by Ma et al., who 
reported decreased m6A methylation levels in HCC, alongside a reduction in 
METTL14 expression (Ma, Yang et al. 2017). These authors reported that METTL14 
suppresses the metastatic potential of hepatocellular carcinoma by modulating m6A-
dependent primary microRNA processing. Specifically, they identified miR-126 as a 
critical target of METTL14 in metastatic HCC, and showed that depletion of METTL14 
decreased miR-126 expression by modulating binding of the microprocessor protein 
DGCR8 to primary miR126 in an m6A dependent manner (Ma, Yang et al. 2017).  
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In glioblastoma, as in HCC, the role of m6A methylation is a subject of debate. In 2017, 
Zhang et al. showed that ALKBH5 is highly expressed in glioblastoma stem cells 
(GSCs), and is associated with a poor prognosis. Mechanistically, increased ALKBH5 
expression was reported to increase demethylation of FOXM1 mRNA, and therefore 
decrease m6A-mediated FOXM1 mRNA degradation, ultimately increasing FOXM1 
levels (Zhang, Zhao et al. 2017). In the same year, Cui et al. reported that knockdown 
of METTL3 or METTL14 dramatically promotes GSC growth, self-renewal and 
tumorigenesis, whilst METTL3 overexpression, or inhibition of FTO suppresses GSC 
growth and self-renewal. Mechanistically, Cui et al. showed that these effects 
depended on m6A mRNA modification of target oncogenes including ADAM19, 
EPHA3, and KLF4 (Cui, Shi et al. 2017). More recently however, Visvanathan et al. 
reported an opposing role for METTL3 in glioblastoma. These authors showed that 
m6A modification is increased in GSCs and that METTL3-dependent m6A modification 
is crucial for GSC maintenance. Mechanistically, they identified SOX2 mRNA as a 
downstream target of METTL3, whose stability is increased following m6A 
modification in a Human antigen R-dependent fashion (Visvanathan, Patil et al. 2018).  
In tumours of female reproductive organs, m6A methylation has repeatedly been 
associated with tumour suppression. Liu et al. reported that up to 70% of endometrial 
tumours have decreased m6A methylation compared to matched normal endometrial 
tissue, due to a hotspot R298P mutation in METTL14, or a reduction in METTL3 
expression (Liu, Eckert et al. 2018). Mechanistically, these authors showed that 
reductions in m6A methylation lead to decreased expression of the negative AKT 
regulator PHLPP2 and increased expression of the positive AKT regulator mTORC2, 
ultimately increasing proliferation and tumorigenicity of endometrial cancer cells (Liu, 
Eckert et al. 2018). Reductions in m6A methylation have also been implicated in breast 
cancer pathogenesis. Zhang et al. reported that hypoxia stimulates hypoxia-inducible 
factor (HIF)-1α- and HIF-2α-dependent expression of ALKBH5 in breast cancer cells. 
This increased ALKBH5 expression decreases m6A methylation of NANOG mRNA, 
which increases NANOG levels, and the breast cancer stem cell phenotype (Zhang, 
Samanta et al. 2016).  Finally, decreased m6A methylation is also reported to drive 
cervical cancer progression. Wang et al. reported decreased m6A methylation in 
cervical cancer cells compared to adjacent normal tissue, and showed that increased 
m6A methylation (through knockdown of FTO/ALKBH5 demethylases, or 
overexpression of METTL3/METTL14 methyltransferases) suppressed cervical 
tumour development in vitro and in vivo (Wang, Li et al. 2017).  
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m6A regulators have also been implicated in tumours of the gastrointestinal tract, 
pancreas and lungs. Increased YTHDF2 expression in pancreatic cancer has been 
reported to promote proliferation, whilst inhibiting migration and invasion (so called 
‘migration proliferation dichotomy’) (Chen, Sun et al. 2017). In gastric cancer, both 
METTL3 and YTHDF2 have been reported to act as oncogenes (Zhang, Pi et al. 2017, 
Lin, Liu et al. 2019), and in pulmonary adenocarcinoma, METTL3 promotes tumour 
growth, survival and invasion through enhanced translation of certain mRNAs, 
including TAZ and EGFR (Lin, Choe et al. 2016).  
In addition to its role in solid tumours, m6A modification is known to play a critical role 
in haematological malignancies, in particular AML. Analysis of datasets from the 
Cancer Genome Atlas Research Network (TCGA) revealed that mutations or copy 
number variations of m6A regulatory genes are strongly associated with TP53 
mutations in AML, and predict a poorer prognosis in these patients (Kwok, Marshall 
et al. 2017). Studies in mice and human cells have shown an essential requirement 
for the methyltransferases METTL3 and METTL14 (Barbieri, Tzelepis et al. 2017, Li, 
Weng et al. 2017, Vu, Pickering et al. 2017, Weng, Huang et al. 2018) and the 
demethylase FTO (Li, Weng et al. 2017) in AML. However, the role of the YTH-family 
of m6A readers in AML, including that of YTHDF2, has not been investigated 
previously.  
1.4 Hypothesis and aims 
 
Given the critical role that m6A plays in both self-renewal and differentiation in cells, 
and the rapidly accumulating evidence of its function in cancer, we hypothesized that 
the m6A reader YTHDF2 would play a significant role in normal and malignant 
haematopoiesis.  
 
The aims of this thesis were therefore to establish the requirement for YTHDF2 in 
normal haematopoiesis and in the context of AML. By characterizing the role of 
YTHDF2 in HSC fate decisions, we hoped to identify potential novel therapies with 
which to eliminate leukaemic stem cells in AML, and therefore improve the prognosis 
























Chapter 2: Methods 
 
2.1 Mouse strains 
All mice were on the C57BL/6 genetic background. Ythdf2fl/fl transgenic mice were 
generated by Ivanova et al. (Ivanova, Much et al. 2017). Vav-iCre (de Boer, Williams 
et al. 2003) and Mx1-Cre (Kuhn, Schwenk et al. 1995) mice were purchased from the 
Jackson Laboratory. Conditional knock out mice were generated by crossing Ythdf2fl/fl 
mice with Vav-iCre mice. Inducible knock out mice were generated by crossing 
Ythdf2fl/fl mice with Mx1-Cre mice. All transgenic and knockout mice were CD45.2+. 
Congenic recipient mice were CD45.1+/CD45.2+. 
2.2 Mouse husbandry 
All experiments were performed with Home Office approval, under the project licence 
70/8417 and the personal licence I9FC1E63F. Mice were housed in a dedicated 
specific pathogen free facility, and every effort was made to comply with the 3Rs 
principles in the course of their use. Mice were used for breeding from 6-8 weeks of 
age, and were housed as pairs or triplets. Pups were weaned at 3 weeks of age, at 
which time they were ear notched for identification purposes. The tissue obtained 
during the notching process was used for subsequent genotyping.  Stock mice were 
caged in sex-matched groups of £ 6 mice.  
2.3 Genotyping 
 
Polymerase chain reaction (PCR) was used to genotype all transgenic mice. PCR is 
a method which uses thermal cycling for exponential amplification of small amounts 
of DNA. The process involves 20-40 cycles of three basic steps: denaturation of 
double-stranded DNA into single strands, annealing of specific primers, and DNA 
replication by DNA polymerase.  
 
2.3.1 DNA extraction 
 
Genomic DNA was extracted from ear notching tissue or haematopoietic cells using 
the PCR Direct Genotyping Kit (Cat. B40015-BIT, Bimake) according to the 
manufacturer’s instructions. Samples were placed into 1.5 ml centrifuge tubes. In a 
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separate tube, a protease mixture was prepared using Buffer L (100 µl per sample) 
and Protease Plus (2 µl per sample). The mixture was added to the sample tubes and 
incubated for 15 minutes at 55°C. The digested samples were incubated for a further 
5 minutes at 95°C, after which the lysates were ready for use as a PCR template.   
 
2.3.2 PCR primers and programmes  
A PCR Mix was prepared using PCR Super Master MixÔ (Cat. B46018, Bimake) or 
Mango MixÔ (Cat. BIO-25033, Bioline), each of which contained DNA Polymerase, 
MgCl2 and dNTPs. Water, primers and extracted genomic DNA were added to this 
mix, as detailed below. All primers were made up at 100 µM.  
2.3.2.1 Vav-iCre PCR 
 
Vav-iCre PCR Mix 
2 µl DNA DNA 
0.1 µl CCGAGGGGCCAAGTGAGAGG  
0.1 µl GGAGGGCAGGCAGGTTTTGGTG 
10 µl  PCR Super Master MixÔ 
7.8 µl  Nuclease free H20 
 
The PCR programme consisted of 5 minutes at 95°C (initialisation); 30 cycles of 94°C 
for 30 seconds, 64°C for 40 seconds, 72°C for 30 seconds (denaturation, primer 
annealing and elongation); then 72°C for 5 minutes (final elongation), and finally the 
samples were held at 10°C. The expected band (Cre) was 400 bp. 
 
2.3.2.2 Mx1-Cre PCR 
 
Mx1-Cre PCR Mix 
2 µl  DNA 
0.1 µl CGTTTTCTGAGCATACCTGGA 
0.1 µl ATTCTCCCACCGTCAGTACG 
10 µl  PCR Super Master MixÔ 
7.8 µl  Nuclease free H20 
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The PCR programme consisted of 5 minutes at 95°C (initialisation); 39 cycles of 95°C 
for 30 seconds, 67°C for 45 seconds, 72°C for 1 minute (denaturation, primer 
annealing and elongation); then 72°C for 5 minutes (final elongation), and finally the 
samples were held at 10°C. The expected band (Cre) was 400 bp. 
 
2.3.2.3 Ythdf2 flox PCR 
 
YTHDF2 flox PCR Mix 
2 µl  DNA 
0.1 µl GGGGAAAGGACCTTTCCGAA  
0.1 µl CAGTGTATTGGCTCCTTCGAA  
10 µl  PCR Super Master MixÔ 
7.8 µl  Nuclease free H20 
 
The PCR programme consisted of 5 minutes at 95°C (initialisation); 34 cycles of 95°C 
for 30 seconds, 60°C for 1 minute, 72°C for 40 seconds (denaturation, primer 
annealing and elongation); then 72°C for 5 minutes (final elongation), and finally the 
samples were held at 10°C. The expected bands were: Wild Type (294 bp) and Flox 
(340 bp).  
 
2.3.2.4 Sexing PCR 
 
Sexing PCR Mix 
2 µl  DNA 
0.1 µl AATAAATGTTTTACAACTCCTGATTCC 
0.1 µl TGCATAGACGTGTAAAACCTGC 
0.1 µl GAGAGCATGGAGGGCCAT 
0.1 µl CCACTCCTCTGTGACACT 
10 µl  PCR Super Master MixÔ 
7.6 µl  Nuclease free H20 
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The PCR programme consisted of 3 minutes at 95°C (initialisation); 34 cycles of 95°C 
for 30 seconds, 60°C for 30 seconds, 72°C for 30 seconds (denaturation, primer 
annealing and elongation); then 72°C for 2 minutes (final elongation), and finally the 
samples were held at 12°C. The expected bands were: 195 bp (X) and 266 bp (Y).  
 
2.3.3 Gel electrophoresis 
 
PCR products were separated according to molecular size using gel electrophoresis. 
Agarose gels were prepared by dissolving agarose (Cat. AG500, Thistle) in 1X TAE 
buffer (40 mM Tris acetate, pH 8.3, 1 mM EDTA) (Cat. 161-0773, Biorad) and SybrÔ 
Safe DNA Gel Stain (Cat. S33102, Life Technologies), which is a less hazardous 
alternative to ethidium bromide for visualisation of DNA in agarose gels, was added 
at 0.0001X. Gels were run at 90 V in 1X TAE buffer, and DNA band length was 
measured against a standard ladder (Easy Ladder I, Cat. BIO-33046, Bioline). The 
agarose percentage of the gel and the running time were tailored to achieve optimal 
resolution of PCR products (see Table 2.3.3).  
 
PCR Agarose (%) Gel running time (minutes) 
Vav-iCre 2 40 
Mx1-Cre 2 40 
Ythdf2 flox 2.5 120 
Sexing PCR 2 40 
 
Table 2.3.3 Gel electrophoresis resolution of specific PCR products. 
 
2.4 Cell lines and primary murine cells 
 
Two packaging cell lines were used for virus production, one for lentiviral production 
(HEK 293T) and one for retroviral production (Platinum E). 
 
2.4.1 HEK 293/HEK 293T - HEK 293 cells are a packaging cell line established from 
primary embryonic human kidney transformed with sheared human adenovirus type 
5 DNA. These cells are straightforward to grow in culture and highly transfectable by 
various techniques, including the calcium phosphate method. A variant of this cell line 
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is HEK 293T, which additionally contain the SV40 Large T-antigen that allows for 
episomal replication of transfected plasmids containing the SV40 origin of replication. 
   
2.4.2 Platinum-E (Plat-E) - these cells are a retrovirus packaging cell line based on 
the HEK 293T cell line. These cells express gag, pol and env genes under the control 
of an EF1α promoter, allowing for retroviral packaging with a single plasmid 
transfection, and ensuring longer stability and high-yield structural protein expression. 
An IRES (internal ribosome entry site) potentiates expression of blasticidin and 
puromycin selection markers.  
 
2.4.3 NIH3T3 - murine fibroblast cell line used for testing virus.   
 
2.4.4 Primary murine cells - pre-leukaemic stem cells (pre-LSCs) were generated 
by retroviral transformation of foetal liver (FL) haematopoietic stem and progenitor 
cells (HSPCs) followed by serial re-plating (see section 2.13). Leukaemic stem cells 
(LSCs) were harvested from the bone marrow of leukaemic recipient mice.  
 
2.5 Cell culture 
 
Pre-LSCs and LSCs were cultured in Iscove's Modified Dulbecco's Medium (IMDM) 
(Cat. 12440061, Life Technologies) with 10% foetal bovine serum (FBS), 2.0 mM L-
glutamine, 1% penicillin/streptomycin (100 Units/ml penicillin and 100 mg/ml 
streptomycin) and cytokines favouring myeloid differentiation: IL-3 20 ng/ml, IL-6 20 
ng/ml, and SCF 40 ng/ml (IL-3 Cat. 575506; IL-6 Cat. 575706; SCF Cat. 579708, all 
from Biolegend). Cells were cultured in an incubator at 5% CO2 and 37°C. Cells were 
passaged every 2-3 days at 200 000 cells/ml.  
 
HEK293, Plat-E and NIH3T3 cells were all cultured in Dulbecco's Modified Eagle 
Medium (DMEM) (Cat. 41965062, Life Technologies) supplemented with 10% FBS, 
2.0 mM L-glutamine and 1% penicillin/streptomycin (100 Units/ml penicillin and 100 
mg/ml streptomycin). Cells were cultured in an incubator at 5% CO2 and 37°C. Cells 
were passaged in a 1:10 split ratio once they reached 80% confluency, which was 
approximately every 3-4 days.    
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The number and viability of cells in culture was determined by staining a 10 µl aliquot 
of cell suspension with Trypan Blue (Cat. T8154, Sigma Aldrich), and counting live 
(unstained) versus dead (stained blue) cells with a haemocytometer. 
2.5.1 Freezing cells 
 
To freeze harvested cells (either cell lines or primary murine cells), cells in the 
exponential phase of cell growth were centrifuged (500 g for 5 minutes) and the pellet 
was re-suspended in cold freezing mix (i.e. FBS containing 10% DMSO (Sigma)) and 
aliquoted to pre-chilled 1.8 ml cryovials. Each vial contained approximately 0.5-3 x 
106 cells. These cryovials were transferred to a freezer box (Cat 5100-0001, Thermo 
Fisher Scientific, allows slow cooling at the rate of - 1°C/min) and placed into the -
80°C freezer overnight. The cells were then moved to liquid nitrogen for long-term 
preservation. In order to culture cells from liquid nitrogen, cells in the cryovials were 
thawed in a water bath at 37°C and swiftly transferred into a conical tube containing 
10 ml of standard culture media (containing 10% FBS), pre-warmed at 37°C. The cells 
were centrifuged (300 g for 3 minutes) and then cultured as described above. 
 
2.6 Blood sampling 
Peripheral blood samples were obtained from the tail vein for haematopoietic 
multilineage assessment. Mice were warmed in a heat box at 38°C to induce 
vasodilation. Individual mice were then identified based on ear notches, and placed 
into a restraining tube. Blood samples were collected from the lateral tail vein by 
puncturing the vein with a needle (25g 5/8 inch) before applying the tip of an EDTA 
collection tube (MicrovetteÒ CB 300 K2E, Cat. 16.444, Sarstedt) and allowing blood 
to enter via capillary action. A maximum of 200 µl of blood was collected per sampling, 
although typically the volume of blood collected was less than 50 µl.  
For preparation of blood samples, 12µl of EDTA anti-coagulated blood was added to 
600 µl of NH4Cl and mixed thoroughly. The samples were incubated at room 
temperature for 10 minutes, then centrifuged at 400 g for 8 minutes. The supernatant 
was removed, and the cells were resuspended in pre-prepared antibody mix (see 
section 2.8).  
 
 85 
2.7 Preparation of bone marrow, spleen, thymus and foetal liver cell 
suspensions 
 
To retrieve BM, tibias and femurs of both hind legs were taken from 8-12-week-old 
adult mice and crushed with a pestle and mortar to achieve a homogeneous cell 
suspension. BM cells were collected in PBS 2% FBS and filtered through a 70 µm 
nylon strainer (Cat. 22363548, Fisherbrand). Spleen, thymus and FL cell suspensions 
were all generated by mashing of the tissue with a 5 ml syringe plunger, and flushing 
through a 70 µm nylon strainer with PBS 2% FBS. Cell counts were obtained using 
an automatic cell counter (Celltac α MEK-6500K, Nihon Kohden) for use in 
subsequent assays.  
 
2.8 Immunophenotypic characterisation of white blood cells (WBCs) 
HSC staining: 12 x 106 BM or FL cells were centrifuged (500 g for 5 minutes) and 
resuspended in 50 µl of CD16/CD32 antibody (Fc Block) in cold phosphate-buffered 
saline (PBS, Sigma) supplemented with 2% heat-inactivated foetal bovine serum 
(PBS 2% FBS), then incubated at 4°C in the dark for 5 minutes. Next, 50 µl of 2X 
antibody mix containing Sca-1, c-Kit, CD48, CD150 and a biotin conjugated lineage 
cocktail (see Table 2.8.1) was added, and the sample was incubated for 30 minutes 
in the dark at 4°C. The cells were then washed in cold PBS 2% FBS, centrifuged (500 
g for 5 minutes) and the pellet was resuspended in 100 µl of Streptavidin conjugated 
antibody. After 15 minutes of incubation in the dark at 4°C, the cells were washed in 
cold PBS 2% FBS, centrifuged (500 g for 5 minutes), resuspended in 500 µl cold PBS 
2% FBS and filtered through 35 µm mesh into capped FACS tubes.  
Myeloid progenitor cell staining (Pronk and Bryder 2011): 8 x 106 BM cells were 
centrifuged (500 g for 5 minutes) and resuspended in 100 µl of antibody mix 
containing Sca-1, c-Kit, CD150, CD16/32, CD41, CD105 and a biotin conjugated 
lineage cocktail (BM GMP lineage cocktail, see Table 2.8.1). The cells were incubated 
for 30 minutes in the dark at 4°C. The cells were then washed in cold PBS 2% FBS, 
centrifuged (500 g for 5 minutes) and the pellet was resuspended in 100 µl of 
Streptavidin conjugated antibody. After 15 minutes of incubation in the dark at 4°C, 
the cells were washed in cold PBS 2% FBS, centrifuged (500 g for 5 minutes), 
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resuspended in 500 µl cold PBS 2% FBS and filtered through 35 µm mesh into capped 
FACS tubes. 
 
Lineage cocktail Antibodies 
FL SLAM lineage cocktail CD4, CD5, CD8a, B220, Ter119, Gr-1 
BM SLAM lineage cocktail  CD4, CD5, CD8a, B220, Ter119, Gr-1, CD11b 
BM GMP lineage cocktail CD4, CD5, CD8a, B220, Gr-1, CD11b 
 
Table 2.8.1 Biotin-conjugated lineage antibody cocktails 
 
Lineages staining: 2 x 105 cells (BM, spleen or thymus) were incubated for 20 
minutes in the dark at 4°C with antibody mix as follows: myeloid cells (Gr-1+, CD11b+), 
B cells (B220+, CD19+), T cells (CD4+, CD8+), erythroid cells (Ter119+, CD71+). The 
cells were then centrifuged (500 g for 5 minutes), resuspended in 200 µl PBS 2% FBS 
and filtered through 35 µm mesh into capped FACS tubes.  
 
Leukaemic cell staining: 2 x 105 BM cells were incubated for 20 minutes in the dark 
at 4°C with antibody mix as follows: CD45 markers (CD45.1, CD45.2), myeloid cells 
(Gr-1, CD11b), and c-Kit cells. The cells were then centrifuged (500 g for 5 minutes), 
resuspended in 200 µl PBS 2% FBS and filtered through 35 µm mesh into capped 
FACS tubes.  
 
Antibody Conjugate Concentration  Cat #  Clone Manufacturer 
Anti-Mouse CD4 Biotin 0.3125 μg/mL 553649 H129.19 BD 
Biosciences 
Anti-Mouse CD5 Biotin 0.625 μg/mL 553019 53-7.3 BD 
Biosciences 
Anti-Mouse CD8a Biotin 0.625 μg/mL 553029 53-6.7 BD 
Biosciences 




Biotin 2.5 μg/mL 553086 RA3-6B2 BD 
Biosciences 




Biotin 5 μg/mL 553125 RB6-8C5 BD 
Biosciences 
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Anti-Mouse c-Kit/CD117 APC-Cy7 1 μg/mL 105826 2B8 Biolegend 
Anti-Mouse c-Kit/CD117 APC 1 μg/mL 105812 2B8 Biolegend 
Anti-Mouse Sca-1 PB 2.5 μg/mL 122520 E13-
161.7 
Biolegend 
Anti-Mouse Sca-1 APC-Cy7 1 μg/mL 122513 E13-
161.7 
Biolegend 
Anti-Mouse CD48 PE 0.25 μg/mL 103406 HM48-1 Biolegend 
Anti-Mouse CD150 PE-Cy7 1 μg/mL 115914 12F12.2 Biolegend 
Anti-Mouse 
CD45R/B220 
PerCP 0.4 μg/mL 103236 RA3-6B2 Biolegend 
Anti-Mouse CD19 APC-Cy7 0.2 μg/mL 6D5 115530 Biolegend 
Anti-Mouse CD11b PB 0.5 μg/mL M1/70 101224 Biolegend 
Anti-Mouse CD11b PE 0.2 μg/mL M1/70 101208 Biolegend 
Anti-Mouse CD11b APC 0.2 μg/mL  M1/70 101212 Biolegend 
Anti-Mouse Gr-1/Ly-
6G/C 
PE-Cy7 0.1 μg/mL RB6-
8C5 
108416 Biolegend 
Anti-Mouse CD8a APC 0.2 μg/mL 53-6.7 100712 Biolegend 
Anti-Mouse CD8a PE 0.2 μg/mL 53-6.7 100708 Biolegend 
Anti-Mouse CD4 PE 0.05 μg/mL H129.19 130310 Biolegend 
Anti-Mouse CD45.1 BV711 0.4 μg/mL A20 110739 Biolegend 
Anti-Mouse CD45.2 PB 0.5 μg/mL 104 109820 Biolegend 
Anti-Mouse Ter119 APC 0.2 μg/mL TER-119 17-5921 eBiosciences 
Anti-Mouse 
CD120b/TNFRII 
PE 1 μg/mL TR75-89 113405 Biolegend 
Annexin-V (PE 
conjugated) 
PE 1/100 dilution - 556421 BD 
Biosciences 
Streptavidin PerCP 1.3 μg/mL - 405213 Biolegend 
Fc Block None 10 μg/mL 2.4G2 553142 BD 
Biosciences 
  
Table 2.8.2 Flow cytometry antibodies 
 
For all analyses, cells were acquired on a FACS Fortessa (BD). Data were acquired 
through BD FACS Diva (BD Biosciences) and analysed by Flowjo software (Tree Star 
Inc., USA). TO-PROÔ-3 Iodide (Cat. T3605, Life Technologies) or DAPI (4’ ,6-
Diamidino-2-Phenylindole, Dihydrochloride) (Cat. D1306, Life Technologies) were 
used for dead cell exclusion.  
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2.9 Transformation and maxiprep of plasmid DNA 
Bacteria (α-Select Chemically Competent Cells, Cat. BIO-85027, Bioline) were 
transformed with plasmids. For this, 1.5 µl of plasmid was mixed with 20 µl of 
competent bacteria in a 1.5 ml centrifuge tube. After 5 minutes of incubation on ice, 
the tube was placed in a water bath at 42°C for 30 seconds followed by 2 minutes of 
incubation on ice. The mix was streaked onto a Lysogeny Broth (LB) agar plate 
containing 100 µg/ml of ampicillin and incubated overnight at 37°C. An individual 
colony from the LB agar plate was selected and cultured in 5 ml of LB broth (starter 
culture) with ampicillin (100 µg/ml) for 6 hours at 37°C in the bacterial shaker.  
Maxiprep of plasmids was carried out using the HiSpeed Plasmid Maxi Kit (Cat. 
12663, Qiagen), according to the manufacturer’s instructions. Briefly, the starter 
culture was added to 250 mL of LB broth and incubated in a shaker overnight at 37°C. 
The following day the bacteria were harvested by centrifugation at 6000 g for 15 
minutes at 4°C. The resultant bacterial pellet was re-suspended in 10 ml of Buffer P1 
(lysis step). Following addition of 10 ml Buffer P2, the mixture was incubated at room 
temperature for 5 minutes. 10 ml of pre-chilled Buffer P3 were then added and the 
lysate was transferred into the QIAfilter Cartridge and incubated at room temperature 
for 10 minutes. The lysate was then filtered through the QIAfilter Cartridge outlet 
nozzle into the equilibrated HiSpeed tip and left to enter the resin by gravity flow. The 
HiSpeed tip was then washed with 60 ml of Buffer QC and DNA was eluted with 15 
ml of Buffer QF. DNA was precipitated by adding 10.5 ml isopropanol, and then 
isolated by filtering the mixture through a QIAprecipitator Module. Following a 70% 
ethanol wash, DNA was eluted from the QIAprecipitator Module in a final volume of 
0.4 ml of nuclease free water. The concentration of the eluted DNA was measured by 
nanodrop spectrometer (Nanodrop ND1000 Spectrophotometer; Labtech 
International Ltd, East Sussex, UK). The DNA purity was assessed through the ratio 
of absorbance at 260 nm and 280 nm. DNA with an A260/A280 ratio of 1.7 - 1.9 was 
considered pure.  
2.10 Retrovirus/lentivirus production 
 
Both lentiviral and retroviral vectors were used during this project. In contrast to y-
retroviruses, which can only infect mitotically active cell types, lentiviruses (a subtype 
of retrovirus) are able to infect non-diving and actively dividing cell types. Retroviruses 
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were therefore used to deliver oncogenes to transform HSPCs (e.g. Meis1/Hoxa9), 
and lentiviruses were used as vectors during rescue experiments for shRNA delivery 
(Tnfrsf1b knock-down).  
 
The constructs used in the respective systems are listed below, and illustrated in 
Figure 2.10. In both cases, a transfer plasmid is used to deliver the transgene, 
sgRNA, or shRNA of interest. The transgene sequence is flanked by long terminal 
repeat sequences (LTRs), which facilitate integration of the plasmid sequences into 
the host genome. 
 
 
Figure 2.10 Lentiviral production schematic. Retrovirus was produced in the same 
way, but without the packaging vector. Adapted from https://www.addgene.org/viral-
vectors/lentivirus/lenti-guide/. 
For lentiviral production, a second-generation system was used (see Figure 2.10), 
consisting of 3 plasmids; the lentiviral transfer plasmid encoding the insert of interest, 
the envelope plasmid VSV-G, and the packaging plasmid psPAX2, which encodes 
the gag, pol, rev, and tat genes. Since retrovirus was produced in Plat-E cells, which 
express gag, pol and env genes, only the transfer plasmid was required in that case. 
Nevertheless, the pantropic envelope plasmid VSVG was also added because Plat-
E cells express an ecotropic envelope protein (able to infect only mouse and rat cells), 
which is less stable when compared to VSVG pseudotyped virus. 
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2.10.1 Lentiviral constructs 
 
pLKO.1 puro - third generation transfer plasmid (HIV-based). This is a recommended 
vector for cloning and expressing new shRNA sequences, and is being used by the 
RNAi Consortium to produce their shRNA library 
(https://portals.broadinstitute.org/gpp/public/). This plasmid was used to package 
shRNA for knockdown of Tnfrsf1b (see section 2.17). Selection is based on puromycin 
resistance.   
psPAX2 - lentiviral packaging plasmid encoding the rev, pol, gag and tat genes, and 
therefore suitable for both second and third generation lentiviral systems. Viral 
structural proteins are encoded by gag (group specific antigen) and pol (DNA 
polymerase), whereas essential regulatory elements are encoded by rev (regulator of 
expression of virion proteins) and tat (HIV trans-activator).  
• Gag is the major strutural protein of retroviruses, contributing to the matrix, 
capsid and nucleocapsid.  
• Pol is a precursor protein to reverse transcriptase, integrase and protease 
viral enzymes. 
• Tat facilitates the activation of transcription from the LTR promoter. 
• Rev binds to the Rev response element in order to facilitate nuclear export.  
VSV-G - Vesicular stomatitis virus G glycoprotein is an envelope plasmid encoding 
the env gene. VSV-G is commonly used in lentiviral particle production because it 
confers broad tropism over a range of species and cell types. 
 
2.10.2 Retroviral constructs 
 
MSCV – Murine Stem Cell Virus transfer plasmid used for retroviral packaging. This 
plasmid is optimized for introducing and expressing target genes in pluripotent cells, 
including murine haematopoietic cells.  
PGK – the phosphoglycerate kinase (PGK) promoter drives the expression of 
antibiotic resistance genes thus enabling selection of infected cells on the basis of 
antibiotic resistance.  
 91 
MSCV-Meis1-puro – Mouse Meis1a cDNA cloned into the EcoRI and HpaI site of the 
MSCV- PGK-PAC retroviral vector. The LTR region controls the expression of the 
Meis1 gene and the PGK promoter drives the puromycin resistance cassette (Kroon, 
Krosl et al. 1998).  
MSCV-HoxA9-neo – Mouse HoxA9 cDNA inserted in the BamHI-XhoI site of the 
pMSCVneo vector (neomycin (G418) resistance) (Kroon, Krosl et al. 1998). The LTR 
region controls the expression of the HoxA9 gene and the PGK promoter drives the 
neomycin resistance cassette.  
MSCV-MOZ-TIF2-GFP – This plasmid was a gift from Brian Huntly (Deguchi, Ayton 
et al. 2003). To construct the expression vector MOZ-TIF2, the breakpoint region was 
PCR amplified from patient cDNA (Carapeti, Aguiar et al. 1998) and ligated to 5 MOZ 
fragment obtained from pBS-MOZ (kindly provided by J. Borrow) and 3 TIF2 fragment 
obtained from pSG5-TIF2 (kindly provided by H. Gronemeyer) by two step ligation. 
The full-length cDNA was subcloned from pcDNA to MSCV2.2 GFP into the XhoI- 
EcoRI sites.  
MSCV-PML-RARA-neo – This plasmid was a gift from Eric So (Esposito, Zhao et al. 
2015). The LTR region controls the expression of the PML-RARA gene and the PGK 
promoter drives the neomycin resistance cassette.   
MSCV-Mll-AF9 GFP – This plasmid was a gift from Neil Rodrigues. Selection is based 
on GFP fluorescence (Krivtsov, Twomey et al. 2006).   
2.10.3 Packaging virus 
Plat-E cells and HEK 293T cells were used to package MSCV constructs and lentiviral 
vectors respectively. Transfection was carried out using the calcium phosphate 
method, which relies upon formation of a calcium phosphate-DNA precipitate to 
facilitate DNA binding to the cell surface, and ultimately entry of DNA to the cell by 
(Kingston, Chen et al. 2003).      
For viral production, 10 cm tissue culture dishes were coated with 0.1% sterile gelatin 
for 20 minutes at room temperature. HEK 293T or Plat-E cells were trypsinised with 
care to obtain a single cell suspension, and 2 x 106 cells in 8 ml of supplemented 
DMEM (see section 2.5) were plated as evenly as possible into each dish, then 
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incubated at 37°C and 5% CO2 overnight. The following morning dishes suitable for 
transfection were selected based on the degree of cell confluency and evenness of 
plating. Culture media was removed from these dishes and replaced with DMEM 
supplemented with 10% FBS and 2.0 mM L-glutamine. 25 µM chloroquine (Cat. 
C6628-25G, Sigma) was added to increase transfection efficiency through 
preservation of transfected DNA integrity (Luthman and Magnusson 1983).  
 
For transfection (quantities given per 10 cm dish), 12.5 µg of plasmid DNA, 4 µg of 
VSV-G envelope plasmid, 6 µg HIV packaging plasmid (lentiviral production only) and 
62.5 µl 2M CaCl2 were diluted in sterile H20 to a total volume of 500 µl in a 2 ml Bijou 
tube (mixture henceforth referred to as ‘DNA mix’). In a separate Bijou tube, 500 µl of 
Hank’s Balanced Salt Solution (HBSS, Cat. H6648, Sigma) was bubbled continuously 
using a 5 ml pipette, and the DNA mix was then added dropwise to the HBSS solution. 
The transfection mixture (total 1 ml) was incubated at room temperature for 20 
minutes, then added dropwise to the pre-prepared dish of HEK 293T/Plat-E cells. The 
dishes were incubated for 6 hours at 37°C and 5% CO2, then washed 4 times with 8 
ml un-supplemented DMEM, to remove calcium phosphate crystals which might 
inhibit cell growth. The media was replaced with fully supplemented DMEM, and the 
cells were incubated once again. Supernatant (containing viral particles) was 
collected 12 and 24 hours after this media change, filtered through a 0.45 µm non-
protein binding filter (Merck) and snap frozen in dry ice in 1 ml aliquots, which were 
then stored at -80°C for future use.  
In order to test virus efficiency, NIH3T3 cells were plated in 6-well plates (1 x 105 cells 
per well) and incubated with virus for 12 hours. The efficacy of infection was assessed 
by comparing the number of live infected and non-infected cells after antibiotic 
selection or based on the fluorescence signal determined by flow cytometry. 
2.11 Isolation of murine foetal liver HSPCs 
 
Cells were extracted from FL as described in section 2.7. The cells were pelleted by 
centrifugation (500 g for 5 minutes) and resuspended in 100 µl PBS 2% FBS 
containing 5 µl of CD117 MicroBeads (Cat. 130-091-224, Miltenyi Biotec). The cells 
were incubated at 4°C in the dark for 20 minutes, then washed in PBS 2% FBS, 
centrifuged (500 g for 5 minutes), and resuspended in 3 ml of PBS 2% FBS. Cells 
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bound to magnetic CD117 MicroBeads were obtained by positive selection using LS 
Columns (Cat. 130-042-401, Miltenyi Biotec) positioned in the magnetic field of a 
QuadroMACSÔ Separator (Cat. 130-090-976, Miltenyi Biotec). A filter was placed 
into the top of each column and the system was primed with 3 ml PBS 2% FBS. The 
cell suspension was loaded into the column, and magnetically labelled cells were 
subsequently retained, whilst unlabelled cells passed through. The column was 
washed three times with 3 ml PBS 2% FBS, then removed from the separator and the 
magnetically retained CD117+ cells were eluted with the aid of a plunger in 8 ml PBS 
2% FBS (5 ml then 3 ml). The eluted cells were centrifuged (500 g for 5 minutes) and 
resuspended at a concentration of 200,000 cells/ml in IMDM supplemented with 
cytokines favouring myeloid differentiation (IL-3, IL-6 and SCF, see section 2.5).  
 
2.12 Transduction of murine HSPCs 
Murine HSPCs were transduced using the RetroNectinÒ (Cat. T100A, TaKaRa) 
bound virus method (Figure 2.12). RetroNectinÒ reagent is a 63 kD recombinant 
human fibronectin fragment (rFN-CH-296) composed of three functional domains: the 
cell-binding domain (C-domain), the heparin-binding domain (H-domain), and the CS-
1 sequence. RetroNectinÒ enhances gene transduction by potentiating co-
localisation of target cells and virions (Hanenberg, Xiao et al. 1996). Virus particles 
interact with the H-domain, whilst target cells bind through interaction of cell surface 
integrin receptor VLA-5 and VLA-4 with the fibronectin C-domain and CS-1 site, 
respectively.  
For transduction of one sample, 200 µl of RetroNectinÒ was placed into one well of a 
48-well non-tissue culture treated plate, and incubated at 4°C for 12 hours, or at 20°C 
for 2 hours. The RetroNectinÒ was removed (and frozen at -20°C for subsequent re-
use) and 1 ml viral supernatant (produced as described in section 2.10.3) was placed 
into the well. The plate was then centrifuged at high speed (2000 g) for 90 minutes at 
32°C. The viral supernatant was carefully removed and replaced by 200,000 HSPCs 
in 1 ml of supplemented IMDM (see section 2.5). The plate was centrifuged a second 
time, at 300 g for 3 minutes, to settle the cells at the bottom of the well. The plate was 
then incubated overnight at 37°C and 5% CO2. The whole process was repeated 3 
times in total, with a 12-hour gap between each cycle. After the final round of 
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transduction, the cells were incubated for 24 hours, and then selected based on 




Figure 2.12 The hypothesized mechanism of RetroNectinÒ mediated 
transduction. From the TaKaRa RetroNectinÒ Product Manual. The cell binds to the 
CS-1 site via VLA-4 and the C-domain via VLA-5. The viral particle can bind to the H-
domain of RetroNectinÒ. The interactions increase the localised concentrations of 
cells and viral particles, ultimately enhancing gene transduction. 
 
Transfer plasmid Selection  
MSCV-Meis1 Puromycin 1.5 µg/ml 
MSCV-Hoxa9 Neomycin 1 mg/ml 
MSCV-Mll-AF9 GFP 
MSCV-PML-RARA Neomycin 1 mg/ml 
3
RetroNectin® 





RetroNectin reagent is a recombinant human fibronectin fragment (rFN-CH-296) composed of three 
functional domains: the cell-binding domain (C-domain), heparin-binding domain (H-domain), 
and CS-1 sequence. The fragment enhances retroviral-mediated gene transduction by aiding the 
co-localization of target cells and virions. Specifically, virus particles bind RetroNectin reagent via 
interaction with the H-domain, and target cells bind mainly through the interaction of cell surface 
integrin receptor VLA-5 and VLA-4 with the fibronectin C-domain and CS-1 site, respectively.  
By facilitating close proximity, RetroNectin reagent can enhance retroviral-mediated gene transfer 
to target cells expressing integrin receptors VLA-4 and/or VLA-5.*1
There are two RetroNectin-mediated infection protocols: the supernatant (SN) infection method 
and the RetroNectin-bound virus (RBV) infection method.5),*2 With the SN infection method, cells 
are mixed with virus supernatant and loaded on a RetroNectin-coated plate. In the RBV method, 
the retrovirus is first bound to the RetroNectin-coated plate, and cells are added after removing the 
retrovirus supernatant. Removal of the supernatant reduces inhibitory molecules (e.g., molecules 
secreted from the producer cells such as proteoglycans and/or viral envelope proteins) that can 
reduce the efficiency of viral-mediated gene transduction. 
*1 RetroNectin can also enhance lentiviral-mediated gene transfer.
*2 Both methods can be used for efficient gene transduction. Although the RBV infection method 
is widely applicable, some modification might be required depending on the target cells, 
vectors, and/or target genes.
Figure 1.  The hypothesized mechanism of RetroNectin-mediated transduction.  
The cell binds to the CS-1 site via VLA-4, and to the C-domain via VLA-5. The 
viral particle can bind to the H-domain of RetroNectin. These interactions 
increase the localized concentrations of cells and viral particles, an effect that is 































pLKO.1 Puromycin 2 µg/ml 
 
Table 2.12 Selection markers for transfer plasmids used during viral 
production.  
 
2.13 Colony forming assay 
 
2.13.1 Methylcellulose preparation  
3231 methylcellulose was prepared by combining 20 ml IMDM, 80 ml MethoCultÔ 
M3231 (Cat. 3231, STEMCELL Technologies), 1 ml penicillin/streptomycin (100 
Units/ml penicillin and 100 mg/ml streptomycin) and cytokines favouring myeloid 
differentiation: 20 ng/ml SCF, 10 ng/ml IL-3, 10 ng/ml IL-6 and 10 ng/ml GM-CSF 
(GM-CSF Cat. 576306, Biolegend). The methylcellulose was vortexed and allowed to 
settle, then dispensed in 2.25 ml aliquots into 15 ml conical tubes. The aliquots were 
frozen at -20°C and defrosted as required.  
3434 methylcellulose (MethoCult™ GF M3434, Cat. 03434, STEMCELL 
Technologies) was dispensed in 2.25 ml aliquots into 15 ml conical tubes. The 
aliquots were frozen at -20°C and defrosted as required.  
 
2.13.2 Colony culture assays in 3231 methylcellulose 
 
Leukaemic colony forming assays were carried out using MethoCultÔ 3231 
methylcellulose medium. Selected cells were suspended in fresh IMDM at a 
concentration of 8,000 cells/ml (Meis1/Hoxa9 transformed cells) or 20,000 cells/ml 
(Mll-AF9, PML-RARA and MOZ-TIF2 transformed cells), and added to the prepared 
aliquots (see section 2.13.1) of methylcellulose (2.25 ml each) at a ratio of 1: 9 (i.e. 
250 µl was added to each methylcellulose aliquot, therefore 2,000 (Meis1/Hoxa9) or 
5,000 (Mll-AF9 PML-RARA and MOZ-TIF2) cells per plate). Where applicable, 
selection of transformed cells was continued during the colony forming assay, through 
addition of antibiotics (Meis1/Hoxa9 transformed cells: neomycin (1 mg/ml) and 
puromycin (1.5 µg/ml); PML-RARA transformed cells: neomycin (1 mg/ml) pLKO.1 
transduced cells puromycin (2 µg/ml)), in which case the concentration of the cell 
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suspension was adjusted accordingly to maintain the total volume of 2.5 ml. The 
methylcellulose samples were vortexed and allowed to settle, then divided equally 
into the two central wells of a 6-well plate using an 18 g needle and a 2.5 ml syringe. 
The outer four wells were filled with PBS in order to minimise evaporation of the semi-
solid medium, and the plate was incubated at 37°C and 5% CO2. After 4-5 days 
(Meis1/Hoxa9 transformed cells) or 6-7 days (Mll-AF9, PML-RARA and MOZ-TIF2 
transformed cells) the primary colonies (CFC1) were counted, and re-plated to 
secondary colonies (CFC2). For this, 5 ml of IMDM was drawn into a syringe and 2.5 
ml was dispensed onto the surface of each colony-containing well. The media and 
methylcellulose were syringed up and down to resuspend the colonies, and the 
resultant mixture was combined in a 15 ml conical tube. The process was repeated 
with a second 5 ml syringe of IMDM. The IMDM/cell/methylcellulose suspension was 
centrifuged at 500 g for 10 minutes. The supernatant was removed, and the cells were 
resuspended in 1 ml IMDM, counted, and plated into secondary colonies as for CFC1.  
 
2.13.3 Colony culture assays in 3434 methylcellulose 
 
Non leukaemic CFC assays were carried out using MethoCultÔ M3434 
methylcellulose medium. Selected cells were suspended in fresh IMDM at a 
concentration of 100,000 cells/ml and added to the prepared aliquots of 
methylcellulose (2.25 ml each) at a ratio of 1: 9 i.e. 25,000 cells per plate. The 
methylcellulose samples were vortexed and allowed to settle, then divided equally 
into the two central wells of a 6-well plate using an 18 g needle and a 2.5 ml syringe. 
The outer four wells were filled with PBS in order to minimise evaporation of the semi-
solid medium, and the plate was incubated at 37°C and 5% CO2. After 10 days the 
primary colonies (CFC1) were counted. 
In order to test virus efficiency, NIH3T3 cells were plated in 6-well plates (1 x 105 cells 
per well) and incubated with virus for 12 hours. The efficacy of infection was assessed 
by comparing the number of live infected and non-infected cells after antibiotic 
selection or based on the fluorescence signal determined by flow cytometry. 
2.14 Cell sorting 
Cells were isolated from the BM and FL as described in 2.7. Isolated BM or FL cells 
were enriched for HSPCs (c-Kit+ cells) using magnetic beads and LS columns, as 
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described in section 2.11, and antibody staining was carried out as described in 
section 2.8. Cell sorting was performed using a BD FACS Aria (BD Biosciences). 
2.15 Transplantation assays 
 
2.15.1 Non-leukaemic transplantation assays 
Irradiation details: 8-12-week-old mice (minimum bodyweight 20 g) were subjected to 
whole body gamma irradiation (Gammacell 40 Executor unit, Serial number 59R (Best 
Theratronics); source: Cesium 137). A total dose of 11 Gy (lethal irradiation) was 
delivered in two separate doses of 5.5 Gy each using a 33% attenuator (0.59 Gy/min). 
A 4-hour break was applied between irradiations. Where possible female mice were 
used for long term assays, as the chance of needing to cull mice due to fighting was 
significantly smaller. All animal experiments were authorized by the UK Home Office.   
Primary transplants: Lethally irradiated (11 Gy) CD45.1+/CD45.2+ syngeneic recipient 
mice were transplanted with 100 (FL) or 200 (BM) CD45.2+ HSCs (Lin-c-Kit+Sca-
1+CD48-CD150+) together with 200 000 unfractionated WT BM support cells 
(CD45.1+) via the tail vein in a total volume of 200 µl. The HSCs were obtained by 
sorting E14.5 dpc FL, or BM of 8-12-week-old adult mice, as previously described 
(see section 2.14). Monitoring of transplanted mice was carried out as described in 
section 2.15.3. All recipient mice were culled and analyzed 16-20 weeks post-
transplantation.  
 
Secondary transplants: Lethally irradiated (11 Gy) CD45.1+/CD45.2+ syngeneic 
recipient mice were transplanted with 2,000 (secondary from FL) or 3,000 (secondary 
from BM) CD45.2+ LSKs (Lin-c-Kit+Sca-1+) together with 200,000 unfractionated WT 
BM support cells (CD45.1+) via the tail vein in a total volume of 200 µl. The LSKs were 
obtained by sorting BM of primary recipient mice (see section 2.14) 4 months after 
transplantation. Monitoring of transplanted mice was carried out as described in 
section 2.15.3. All recipient mice were culled and analyzed 16-20 weeks post-
transplantation.  
 
Tertiary transplants: Lethally irradiated (11 Gy) CD45.1+/CD45.2+ syngeneic recipient 
mice were transplanted with 4M unfractionated CD45.2+ BM cells via the tail vein in a 
total volume of 200 µl. The CD45.2+ BM cells were obtained from secondary recipient 
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mice 4 months after transplantation. Monitoring of transplanted mice was carried out 
as described in section 2.15.3. All recipient mice were culled and analyzed 16-20 
weeks post-transplantation.  
 
2.15.2 Leukaemic transplantation assays 
 
For primary transplantation, knock-out and wild type pre-LSCs from CFC3 (see 
section 2.13.2) were harvested and counted. 100,000 live pre-LSCs (CD45.2+) were 
mixed with 200,000 support bone marrow cells (CD45.1+) and injected into the tail 
vein of lethally irradiated (11 Gy) syngeneic recipient mice (CD45.1+/CD45.2+) in a 
total volume of 200 µl. Leukaemic development was monitored as described in section 
2.15.4. 
 
For secondary transplantation, knock-out and wild type LSCs from culled leukaemic 
primary recipient mice were defrosted, passaged through one CFC (see section 
2.13.2), harvested and counted. 10,000-50,000 live LSCs (CD45.2+) were mixed with 
200,000 support bone marrow cells (CD45.1+) and injected into the tail vein of lethally 
irradiated (11 Gy) syngeneic recipient mice (CD45.1+/CD45.2+) in a total volume of 
200 µl. Leukaemic development was monitored as described in section 2.15.4. 
 
2.15.3 Monitoring of mice transplanted with non-leukaemic haematopoietic 
cells 
 
Engraftment of transplanted cells was followed by tracking CD45.2+ cell chimerism in 
the peripheral blood (Figure 2.15.3.1). Mice were bled every 4 weeks from the tail 
vein, and WBCs were stained for flow cytometry: CD45.1+ (WT support/competitor 
total bone marrow cells), CD45.2+ (cells under study) and CD45.1+/CD45.2+ (recipient 
BM cells remaining following irradiation). Engraftment was evaluated based on the 
proportion of CD45.2+ cells within the total transplanted cell population 
(CD45.2+/(CD45.1+ + CD45.2+). In addition, differentiation of transplanted cells was 
evaluated by staining for myeloid cells (Gr1+, CD11b+), B cells (CD19+) and T cells 
(CD4+, CD8+). The contribution of each differentiated cell type to the total CD45.2+ 
cell population was calculated, as was the proportion of CD45.2+ cells within each 
differentiated cell type (e.g. CD45.2+ B cells/CD45.1+ B cells + CD45.2+ B cells) 





Figure 2.15.3.1 Syngeneic model that allows tracking of transplanted 
haematopoietic cells (normal or leukaemic) in recipient mice. Peripheral blood 
samples are stained with antibodies against CD45.1 and CD45.2, and evaluated by 
flow cytometry. Populations are CD45.1+ (WT support/competitor total bone marrow 
cells), CD45.2+ (donor cells under study) and CD45.1+/CD45.2+ (recipient BM cells 





Figure 2.15.3.2 Two methods of evaluating engraftment of CD45.2+ donor cells 
within recipient mice. The contribution of each differentiated cell type to the total 
CD45.2+ cell population is calculated, as is the proportion of CD45.2+ cells within each 
differentiated cell type (e.g. CD45.2+ B cells/CD45.1+ B cells + CD45.2+ B cells). 
 
2.15.4 Leukaemic monitoring 
 
For all leukaemic mice models, AML development was followed by tracking CD45.2+ 
cell chimerism in the peripheral blood (Figure 2.15.3.1). Mice were bled every 2-4 
weeks from the tail vein, and WBCs were stained for flow cytometry: CD45.1+ (WT 
support/competitor total bone marrow cells), CD45.2+ (cells under study) and 
CD45.1+/CD45.2+ (recipient BM cells remaining following irradiation). Leukaemic 
engraftment was evaluated based on the proportion of CD45.2+ cells within the total 
transplanted cell population (CD45.2+/(CD45.1+ + CD45.2+) (Figure 2.15.3.1). In 
addition, immunophenotypic characterisation of the developing leukaemia was 
carried out by staining for myeloid cells (Gr1+, CD11b+), HSPCs (c-Kit+), and in the 
case of the Mll-AF9 knock in model, also B cells (CD19+) and T cells (CD4+, CD8+). 
Mice were weighed weekly and monitored daily. Upon developing clinical signs of 
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leukaemia (for example: loss of weight, reduced movement, hunched posture, staring 
coat, pale paws and tachypnoea indicative of anaemia) the mice were culled. One 
hind leg (tibia and femur) and the spleen were harvested and processed as described 
in section 2.7. Bone marrow WBCs were stained for flow cytometry as described 
above for leukaemic monitoring, and additional BM samples were frozen at -80°C for 
future use. Spleens were photographed and weighed. WBC counts were obtained 
from peripheral blood, or from harvested BM and spleen using an automatic cell 
counter (Celltac α MEK-6500K, Nihon Kohden).  
 
2.16 Preparation and administration of polyinosinic-polycytidylic acid 
(Poly(I:C)) 
 
Polyinosinic-polycytidylic acid (Poly(I:C)) (Cat. 27-4732-01, GE Healthcare) was used 
to induce gene deletion in the Mx1-Cre system. Poly(I:C) is a synthetic double 
stranded RNA which acts as a natural stimulant of Toll-like receptor 3 (TLR3) 
(Matsumoto and Seya 2008), and therefore induces type I interferon (IFN) 
inflammatory cytokine/chemokine production. Since the Mx1-Cre promotor is 
activated in an interferon dependent manner, administration of poly(I:C) ultimately 
results in Mx-1Cre induction, and deletion of the floxed allele in Mx1-Cre mice (Kuhn, 
Schwenk et al. 1995). 
 
To prepare 1 mg/ml of poly(I:C) solution, 100 ml of sterile PBS was added to 265 mg 
of lyophilised poly(I:C) and dissolved at 50°C for 2-3 hours. 165 ml of pre-warmed 
PBS was added to the poly(I:C) solution to make the volume up to 265 ml. The 
solution was placed at 50°C for one additional hour until the poly(I:C) had fully 
dissolved. The solution was allowed to cool overnight at room temperature and 2-5 
ml aliquots of 1 mg/ml concentration were prepared and stored at -20°C.  
To induce Mx1-Cre mediated gene deletion, 200-300 µl poly(I:C) (1 µg/µl) was 
administered to transplanted mice by intra-peritoneal injection once every other day 




2.17 shRNA-mediated Tnfrsf1b knockdown 
 
Meis1/Hoxa9 transformed Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-LSCs were transduced 
with lentiviruses expressing shRNA for Tnfrsf1b (shRNA1-3), or control shRNA 
(shRNA CTL) (Table 2.17) as described in section 2.12. Transduced pre-LSCs were 
selected by culture in the presence of 2 µg/ml puromycin.  
 
 TRC number Clone ID Manufacturer 
shRNA 1 TRCn0000012320 NM_011610.1-264s1c1 Sigma 
shRNA 2 TRCn0000012321 NM_011610.1-929s1c1 Sigma 
shRNA 3 TRCn0000012322 NM_011610.1-814s1c1 Sigma 
shRNA 
CTL 
 Custom cloned  
 
Table 2.17 shRNA for Tnfrsf1b knockdown 
   
2.18 RNA extraction for Affymetrix and m6A meRIP-Seq (TRIzol™ Method) 
 
Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-LSCs intended for RNA Extraction were pelleted 
by centrifugation (500 g for 5 minutes) and resuspended in TRIzolÔ Reagent (Cat. 
15596026, Life Technologies) in 1.5 ml EppendorfÒ DNA LoBind tubes (Cat. 
30108051, Sigma). A minimum of 0.75 ml TRIzolÔ was used per 5 x 106 cells, as per 
manufacturer’s instructions. Samples were briefly vortexed to ensure 
homogenization, and then snap frozen in dry ice and stored at -80°C for future use.  
 
When ready to proceed, the samples were allowed to defrost at room temperature, 
then incubated for a further 5 minutes at room temperature. Chloroform (25:24:1 
Phenol-Chloroform-Isoamyl Alchohol Mix for DNA Extraction Cat. 77617, Sigma) was 
then added at a ratio of 200 µl chloroform per 1 ml TRIzolÔ and the sample tubes 
were shaken vigorously by hand for 15 seconds, then incubated at room temperature 
for 2-3 minutes. The samples were centrifuged at 12000 g for 15 minutes at 4°C, and 
then the clear upper aqueous layer (containing RNA) was carefully transferred to a 
new 1.5 ml EppendorfÒ DNA LoBind tube. Then 10 µg (stock: 5 mg/ml; 10 µg = 2 µl) 
of linear acrylamide was then added to each sample to aid recovery of nucleic acids 
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during alcohol precipitation, after which 500 µl of isopropanol was added to precipitate 
RNA and samples were mixed by multiple (5 x) inversion. The samples were 
incubated at room temperature for 10 minutes, then centrifuged at 12000 g for 10 
minutes at 4°C. The supernatant was removed and 1 ml of 70% ethanol was added 
in order to clean the RNA precipitate and remove the remaining isopropanol. 
Following a brief vortex, the samples were centrifuged at 7500 g for 5 minutes at 4°C. 
The supernatant was removed and the RNA pellet was resuspended in 20 µl of 
nuclease-free water. RNA yield was determined using a nanodrop spectrometer 




RNA was prepared by Jasmin Paris (see section 2.18), further steps were carried 
out by Marcos Morgan. Total RNA (4 million cells per sample) was used to 
synthesize biotinylated cDNA with the Ambion WT Expression kit (Cat. 4491974, 
Ambion). cDNA was fragmented and labelled with the Affymetrix, WT Terminal and 
Control Kits (Cat. 901524, Affymetrix) and then hybridized for 16 hours at 45°C on a 
GeneChip Mouse Gene 2.0 ST Array. The chip was later washed and stained with 
the Affymetrix Fluidics Station 450. Data were processed and analyzed as described 
in section 2.24. 
  
2.20 m6A meRIP-Seq 
 
RNA was prepared by Jasmin Paris (see section 2.18), further steps were carried out 
by Marcos Morgan and Juhno Choe in collaboration with Richard Gregory. m6A 
meRIP-Seq library preparation was performed as previously described (Lin, Choe et 
al. 2016) from Ythdf2fl/fl pre-leukaemic cells (50 million cells per sample). Three 
biological replicates for each condition were used. Data were processed and analyzed 




First, the SLAMseq Explorer Kit – Cell Viability Titration Module (Cat. No. 059, 
Lexogen) was used to carry out an initial titration series of experiments of 4-
Thiouridine (S4U) to assess cytoxicity and therefore identify the optimal concentration 
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of S4U for further experiments.  The SLAMseq Kinetics Kit – Catabolic Kinetics 
Module (Cat. No. 062, Lexogen) was subsequently used to prepare samples for 
SLAM Seq, according to the manufacturer’s instructions. This kit is designed for S4U 
labelling of RNA in cultured cells followed by treatment of cells with unlabelled uridine. 
In this way, existing RNA is labelled with S4U while newly synthesized RNA is 
unlabelled.  
2.21.1 S4U cytotoxicity assay 
 
Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-LSC cells were incubated with a  dilution series of 
S4U containing media in order to determine the optimal concentration for the catabolic 
kinetics experiment. Cells were seeded at 400,000 cells/ml in 0.5 ml of standard 
culture media (see section 2.5) in a 24-well plate. Three biological replicates of both 
Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-LSCs were plated into 12 wells each. Using the 
same culture media and a stock concentration of 100 mM S4U, a 2X concentrated 
dilution series was generated starting with 8,000 µM (tube 1) and decreasing twofold 
for 10 dilutions (tubes 2-11). A control dilution (tube 12) was generated with H20 in 
place of S4U. Subsequently, 0.5 ml of each S4U dilution was added to the wells, 
giving 200,000 cells/ml, at S4U concentrations ranging from 4,000 µM to 0 µM (Table 
2.21.1).  
 
Cell dilution Concentration (µM) Concentration (log2 [µM]) 
1 4000 11.966 
2 2000 10.966 
3 1000 9.966 
4 500 8.966 
5 250 7.966 
6 125 6.966 
7 62.5 5.966 
8 31.25 4.966 
9 15.625 3.966 
10 7.8125 2.966 
11 3.90625 1.966 
12 0 0 
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Table 2.21.1 S4U dilution series used for cytotoxicity assay.  
 
S4U incorporation rates are enhanced when fresh S4U-containing media is added 
during cell culture. Therefore, after 9 hours, 0.5 ml of media was carefully removed 
from the surface of each well, and replaced with 0.5 ml of S4U-containing media at 
the same dilution.  
 
After a further 15 hours (total of 24 hours; the cytotoxicity assay duration should be 
twice the duration of labelling used for the catabolic kinetics assay), cells were 
harvested, washed in PBS 2% FBS, and resuspended in 100 µl PBS 2% FBS. DAPI 
(1:1,000) was added and the percentage of DAPI positive and negative cells was 
analysed by FACS, as a measure of dead and live cells respectively.  
 
Note: S4U is highly light sensitive and can cross link (Herzog, Reichholf et al. 2017). 
Tubes and plates with S4U-containing media were therefore wrapped in tin foil, and 
exposure to light during cell culture was minimised. 
 
In GraphPad Prism, the percentage of dead cells was plotted against S4U 
concentration (log2 [µM]) to obtain inhibition versus S4U concentration curves for 
Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-LSC cells (Figure 2.21.1). Using these curves, 
the half-maximal inhibitory concentration (IC50) and experimental working 
concentration (IC10) were calculated for both pre-LSC cell types (Table 2.21.2) 
 
  


















Figure 2.21.1 S4U cytotoxicity curves for (A) Ythdf2fl/fl and (B) Ythdf2fl/fl;Vav-iCre 
pre-LSC cells.  
 
 IC10 IC50 
Ythdf2fl/fl 2.91 6.69 
Ythdf2fl/fl;Vav-iCre 3.77 12.48 
 
Table 2.21.2 S4U half-maximal inhibitory concentration (IC50) and experimental 
working concentration (IC10) in Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-LSC cells. 
 
2.21.2 S4U catabolic kinetics assay 
 
Three biological replicates of both Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-LSCs were 
studied. Initially, 4 million cells were seeded into T75 flasks in a total volume of 18 ml 
standard culture media (see section 2.5). After 6 hours, 2 ml of 10X concentrated S4U 
containing media was added, giving a total volume of 20 ml (200,000 cells/ml), with 
an S4U concentration of 2.91 µM (the limiting IC10, as determined in the cytotoxicity 
assay). Since S4U is highly light sensitive, tubes and plates with S4U-containing 
media were wrapped in tin foil, and exposure to light during cell culture was minimised. 
 
After 9 hours, 10 ml of media was carefully removed from the surface of each flask 
and replaced with 10 ml fresh 1X S4U media. After a further 3 hours, the cells were 
centrifuged at 500 g for 5 minutes, and resuspended in 20 ml PBS 2% FBS.  An 
aliquot of 1.4 ml (280 000 cells) was taken into an EppendorfÒ DNA LoBind tube (time 
0). The remainder of the cells were centrifuged as before, washed in a further 20 ml 
PBS 2% FBS, centrifuged again, and resuspended in media containing a 100X 
excess of uridine relative to the original S4U media i.e. 291 µM uridine. Further 1.4 
ml (280 000 cells) aliquots were taken from each flask 1 hour (time 1), 3 hours (time 
3) and 9 hours (time 9) after addition of uridine media.  
 
All aliquots (time 0, time 1, time 3, time 9) were processed immediately upon 
collection. In each case the samples were centrifuged at 500 g for 5 minutes at 4°C. 
The supernatant was removed and the samples were resuspended in 1 ml TRIzolÔ 
Reagent, snap frozen in dry ice, and stored at -80°C.  
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Further steps were carried out by Marcos Morgan (MRC Centre for Regenerative 
Medicine, University of Edinburgh). In brief, SLAM-seq libraries were prepared using 
the Lexogen catabolic kit (Cat. 062.24) and the Lexogen QuantSeq 3′ mRNA-Seq 
Library Prep Kit FWD for Illumina (Cat. no. 015.24) in both cases following 
manufacturers' instructions. Libraries were sequenced using an Illumina HiSeq 
platform in a 50 bp single-end mode. Biological triplicates for both Ythdf2fl/fl and 
Ythdf2fl/fl;Vav-iCre pre-leukaemic cells were used to generate the different libraries 




Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-LSC cells were seeded at 200,000 cells/ml in 10 
ml of supplemented IMDM in a T75 flask (2 million cells per sample), and incubated 
overnight at 37°C 5% CO2. The following day the contents of each flask was 
transferred to a 15 ml conical tube and centrifuged (5 minutes at 500 g). The 
supernatant was removed and the cells were washed with ice cold PBS (2 ml), 
centrifuged as above, and the supernatant removed. The cells were resuspended in 
cold PBS (1.4 ml) a second time, transferred to a 1.5 ml EppendorfÒ DNA LoBind tube 
and centrifuged for 2 minutes at 6,000 RPM at 4°C. The supernatant was discarded, 
and the cell pellet was resuspended in 300 µl of ice-cold lysis buffer containing 1% 
NP-40, 200 mM KOAc, 25 mM K-HEPES pH 7.2, 10 mM MgCl and 4 mM CaCl2. The 
cells were incubated on ice for 5 minutes, then centrifuged for 5 minutes at 9,000 
RPM at 4°C. The supernatant was collected, taking care not to disturb the pellet. An 
aliquot of 60 µl (termed ‘No nuclease sample’) was placed into a 1.5 ml 
EppendorfÒ DNA LoBind tube and lysed with 1 ml TRIzolÔ Reagent, then snap frozen 
in dry ice. The remaining 200 µl were placed into another 1.5 ml EppendorfÒ DNA 
LoBind tube and diluted with 200 µl water to lower the KOAc concentration to 100 
mM. Micrococcal nuclease (MNase) was then added to each sample (from a 2 mg/ml 
stock in 50% glycerol, 1 mM EDTA pH 7, 10 mM Tris pH 8, 50 mM NaCl) (Cat. 
10107921001, Roche Appiled Science) to a final concentration of 10 µg/ml. The 
samples were incubated for 30 minutes at 37°C, then divided equally (100 µl each) 
between four 1.5 ml EppendorfÒ DNA LoBind tubes, lysed with 1 ml TRIzolÔ, then 
snap frozen.  
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The remainder of the preparation was carried out by Marcos Morgan, following 
a previously described protocol (Reid, Shenolikar et al. 2015). Briefly, digested RNA 
was extracted with TRIzolÔ and later treated with PNK (Cat. M0201S, New England 
Biolabs) for 30 minutes at 37°C. To isolate ribosome-protected mRNA fragments 
(RPFs), the PNK-treated RNA was resolved on a 15% Novex TBE-Urea Gel (Cat. 
EC6885BOX, Thermo Fisher Scientific), and RPFs 25 to 40 nucleotides long were 
excised and purified. Libraries were then prepared using the NEBNextÒ Multiplex 
Small RNA Library Prep Set for Illumina following manufacturer’s instructions. For 
input controls, total RNA was extracted from the pre-leukaemic cell lysates before 
MNase digestion using TRIzolÔ. Samples were then depleted of ribosomal RNA 
using the Epicentre Ribo-zero kit (Cat. MRZH116, Illumina), and libraries were 
generated using the SENSE Total RNA-Seq Library Prep Kit (Cat. 009.08, Illumina) 
following manufacturer's instructions. Libraries were sequenced with the Illumina 
HiSeq platform in a 50 bp single-end mode. Biological triplicates were used to 
generate libraries for both Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-leukaemic cells. Data 
were processed and analyzed as described in section 2.24. 
 
2.23 Generation of Figure 5.4.6B.  
 
These analyses were carried out by Marcos Morgan. To generate Figure 5.4.6B 
the following publicly available datasets were used: GSE10358, GSE52891, 
GSE61804, GSE68833, GSE12417, GSE13159, GSE15061, GSE15434, 
GSE16015, GSE19577, and GSE22845 (Metzeler, Hummel et al. 2008, Tomasson, 
Xiang et al. 2008, Haferlach, Mecucci et al. 2009, Klein, Ruckert et al. 2009, Mills, 
Kohlmann et al. 2009, Haferlach, Kohlmann et al. 2010, Pigazzi, Masetti et al. 2011, 
Taskesen, Bullinger et al. 2011, Bachas, Schuurhuis et al. 2015, Metzelder, Michel et 
al. 2015). Exclusion criteria included datasets with less than 20 samples, samples 
with undefined tissue of origin, cell type and karyotype, in addition to RAEB samples. 
A total of 1732 samples were retained for further analysis. The Simpleaffy package 
from Bioconductor was used to extract quality measurement of microarrays 
(Gentleman, Carey et al. 2004, Wilson and Miller 2005). RNA degradation was 
assessed based on 3’ to 5’ ratio of GAPDH and ACTNB genes. Samples with NUSE 
< 1.05 and relative log expression (RLE) < 0.15 were excluded from further analysis 
(McCall, Murakami et al. 2011). The retained samples were assessed for their 
homogeneity using the Bioconductor arrayQualityMetrics package (Kauffmann, 
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Gentleman et al. 2009). Low quality RNA and outlier samples were excluded, while 
high quality samples retained after quality control were background corrected and 
normalized using RMAexpress software (http://rmaexpress.bmbolstad.com/). 
Pairwise comparisons between each karyotype and control were performed using 
student t-test.  
 
2.24 Statistical analyses 
 
For cell culture and mouse experimental work, statistical analyses were performed 
using GraphPad Prism 6 software (GraphPad Software, Inc.). Depending on whether 
data assumed a normal distribution or not, P values were calculated using a two-tailed 
unpaired t-test, or a Mann–Whitney U test respectively. Kaplan-Meier survival curve 
statistics were determined using the Log-rank (Mantel Cox) test. For mouse analyses 
or transplantation experiments, I selected group sizes that confer 80-97% power to 
detect inter-group differences of 50% in a measured parameter whose standard 
deviation (SD) was approx. 20%, assuming random normal data and a type I error rate 
of 5%. If initial experiments showed smaller differences than 50%, subtle ~25% inter-
group differences (assuming SD of 20%) were assessed using appropriate group sizes 
of animals to achieve >80% power.   
 
For Affymetrix, data were processed and analyzed using the Bioconductor Limma 
Package (Ritchie, Phipson et al. 2015). Samples were normalized using the rma 
function and differential expression was assessed using linear modelling. Log2-fold-
changes and moderated t-statistics were calculated using the contrasts.fit function.  
 
For m6A meRIP-Seq, reads were aligned to the mouse or human reference genome 
using HISAT2 (Kim, Langmead et al. 2015) and peaks were called using 
MACS2 (Zhang, Liu et al. 2008). To analyze the distribution of peaks along the 
transcripts, bedgraph files were converted to bigWig format and used as input for the 
computeMatrix function of the deepTools package (Ramírez, Dündar et al. 2014). 
Motif enrichment was done using HOMER selecting a motif length of 6 nucleotides. 
Background regions were generated by shuffling peaks along the transcriptome using 
the shuffleBed tool from the BEDtools suite (Quinlan and Hall 2010). Network analysis 
was performed using the ConsensusPathDB (CPDB) software (Kamburov, Stelzl et 
al. 2012). For gene set enrichment analysis (GSEA), the GSE76008 dataset (Ng, 
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Mitchell et al. 2016) was used to rank genes according to the engraftment potential of 
pre-leukemic cells. The GVIZ bioconductor package was used for peak 
visualization (Hahne and Ivanek 2016). Correlation with YTHDF2 was measured to 
determine robust YTHDF2 targets after the knockout (Mansson, Tsapogas et al. 
2004). Briefly, Pearson correlation between YTHDF2 and the identified YTHDF2 
targets was calculated using the 1732 AML samples described in section 2.23. 
Correlation significance was measured using parametric test with length (genes)-2 
degrees of freedom (cor.test function, stats package, R project, http://www.R-
project.org/), and adjusted for multiple comparisons using Benjamini & Hochberg 
method (Benjamini and Hochberg 1995). Genes with negative coefficients and 
adjusted p-value < 0.05 were considered strong targets of YTHDF2.  
 
For SLAM-Seq, libraries were analysed as previously described (Herzog, Reichholf 
et al. 2017). Briefly, T to C conversion rates were obtained using the SlamDunk 
pipeline. Conversion rates across different time points were normalised to time 0 for 
each gene and were used to fit a first order decay reaction with the R stats package 
nls function.  
 
For Ribo-Seq analysis, Kallisto (Bray, Pimentel et al. 2016) was used to obtain read 
counts per gene for the RPF and mRNA libraries. Read counts were then used to 
calculate the differential translational efficiency between Ythdf2fl/fl and Ythdf2fl/fl;Vav-
iCre pre-leukaemic cells with Xtail (Xiao, Zou et al. 2016). To estimate the relative 
translational efficiency for genes in each condition, we compared RPF and mRNA 
read counts using DESeq2 (Love, Huber et al. 2014).   
 
2.25 Accession  
 
Affymetrix, m6A meRIP-Seq, RIBO-seq and SLAM-seq datasets were deposited in 
ArrayExpress under the following accession numbers: E-MTAB-6783, E-MTAB-7782, 
E-MTAB-6791, E-MTAB-7783, E-MTAB-7785 and E-MTAB-7784. Data from human 
cell lines was obtained from previously published work with the following accession 
number: GSE87190 (NOMO-1, MA9.3ITD).  
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3.1.1. The role of RNA N6-methyladenosine in normal haematopoiesis    
 
In recent years, RNA N6-methyladenosine has emerged as a critical regulator of the 
transition between cell states. For example, m6A has been shown to affect the 
transcript stability of pluripotency regulators, facilitating the transition between naïve 
pluripotency and differentiation in mouse embryonic stem cells. Whilst embryonic 
stem cells lacking m6A remain pluripotent in spite of differentiation signals (Batista, 
Molinie et al. 2014, Geula, Moshitch-Moshkovitz et al. 2015), depletion of m6A in more 
differentiated cells results in increased and abnormal differentiation, suggesting that 
the effect of m6A is also both cell type and stage specific (Geula, Moshitch-Moshkovitz 
et al. 2015).  
 
Considering the role of m6A in regulating cell fates, several recent studies have 
focused on m6A in the haematopoietic system. A summary of these studies is 







mettl3 Zebrafish Morpholino 
Knock out 
Failure of endothelial to haematopoietic 
transition (EHT) in the AGM, decreased 
HSPC emergence, reduction all blood 
lineages. Mechanism through reduced 
notch1a and rhoca mRNA degradation.   
(Zhang, Chen 
et al. 2017) 
Mettl3 Mouse Conditional 
knock out 
(Vec-Cre) 
Failure of EHT in the AGM. Mechanism 
through reduced Ythdf2-mediated m6A-
dependent notch1a mRNA degradation. 
(Lv, Zhang et 
al. 2018) 
METTL3 Human shRNA 
CD34+ 
HSPCs 
Decreased proliferation and increased 
myeloid differentiation in vitro.  
(Vu, Pickering 
et al. 2017) 
METTL14 Human shRNA 
CD34+ 
HSPCs 
Increased myeloid differentiation in 
vitro, via a mechanism independent of 
YTHDF1-3.  
(Weng, Huang 
et al. 2018) 
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Mettl3 Mouse Conditional 
knock out 
(CD4-Cre) 
Disruption of T cell homeostasis and 
differentiation. 
(Li, Tong et al. 
2017) 
Mettl3 Mouse Conditional 
knock out 
(FoxP3-Cre) 
Severe autoimmune disease due to 
inability of Mettl3-deficient regulatory T 
cells to suppress naïve T cell 
proliferation. 
(Tong, Cao et 
al. 2018) 
Ythdf1 Mouse Knock out Increased capacity of Ythdf1-deficient 
dendritic cells to cross-prime CD8+ T 
cells, resulting in slower growth of B16-
OVA tumours.  
(Han, Liu et al. 
2019) 
Mettl3 Mouse Conditional 
knock out 
(Lysm-Cre) 







Large increase in HSCs following 
Mettl3 deletion, poor at reconstituting 
irradiated recipients upon 
transplantation. Increased cell cycling 
and reduced expression of HSC 
quiescence genes in Mettl3-deficient 
HSCs. 
(Yao, Sang et 
al. 2018) 
Mettl3 Mouse Inducible 




Increased HSCs and HPC-2s, as a 
result of decreased differentiation.  















Marked increase in ST-HSC and LT-
HSC. Improved LT-HSC engraftment 
upon transplantation (no change in 
multilineage reconstitution capacity). 
Expansion and increase in function of 
hUCB HSCs.  









Increased numbers of LT-HSCs and 
ST-HSCs, MPPs. Improved LT-HSC 
engraftment upon transplantation (no 
change in multilineage reconstitution 
capacity). 
5-FU treatment or repeated ionising 
radiation increased numbers and 
(Wang, Zuo et 
al. 2018) 
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function of LT-HSCs in Ythdf2fl/fl;Mx1-
Cre mice compared to controls. 
 
Table 3.1.1 Summary of studies targeting m6A regulators in haematopoiesis.   
 
Initial studies addressed the role of m6A in the emergence of definitive haematopoeitic 
stem and progenitor cells (HSPCs) during embryogenesis. In this context, the Liu 
group showed first in zebrafish (Zhang, Chen et al. 2017), and then in mice (Lv, Zhang 
et al. 2018), that m6A modulates haematopoietic stem and progenitor cell 
specification. Zhang et al. published that depletion of the m6A writer Mettl3 by mettl3 
morpholino knockdown in zebrafish resulted in a blockage of endothelial-to-
haematopoeitic transition (EHT) in the AGM, resulting in decreased HSPC emergence 
and a reduction of all blood lineages. Endothelial cells in mettl3 morphant zebrafish 
retained endothelial identity and expression of arterial markers deltaC, tbx20, hey2, 
and ephrin B2a. The authors subsequently generated ythdf2 morphants, which 
showed a similar phenotype to mettl3 morphants. They then mutated the binding sites 
for m6A on zebrafish Ythdf2, thereby showing that the function of Ythdf2 in HSPC 
development is dependent on its ability to bind m6A. Finally, the authors used a 
combination of RNA-Seq, m6A-Seq and miCLIP to identify notch1a as a target of 
Mettl3 and Ythdf2, and concluded that reduced Ythdf2-mediated mRNA decay of the 
arterial genes notch1a and rhoca contributes to the blocked EHT in mettl3 morphant 
zebrafish (Zhang, Chen et al. 2017). In a follow up report, Lv et al. used Mettl3fl/fl;Vec-
Cre endothelial specific conditional knock out mice to show that METTL3 is also 
essential for murine definitive haematopoiesis, and that this too is dependent on 
Notch1. The authors showed that in the absence of METTL3, Notch1 mRNA is not 
methylated and therefore NOTCH activity remains high, inhibiting EHT. Finally, they 
showed that YTHDF2 recognises the m6A peak near the stop codon of Notch1 mRNA, 
suggesting that YTHDF2-mediated Notch1 mRNA decay is responsible for the 
phenotype observed (Lv, Zhang et al. 2018). In conclusion therefore, the group 
showed using both zebrafish and mouse models that METTL3 regulates EHT through 
Notch1, whose expression depends upon m6A-directed YTHDF2-mediated mRNA 
decay. 
 
m6A has also been shown to regulate human stem and progenitor cells. A study of 
METTL3 in normal and malignant haematopoiesis showed that shRNA-mediated 
depletion of METTL3 in cord-blood derived CD34+ HSPCs decreased m6A levels, 
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decreased proliferation and increased myeloid differentiation in vitro (Vu, Pickering et 
al. 2017). Another study showed that shRNA-mediated depletion of METTL14 from 
human CD34+ HSPCs also increased their myeloid differentiation (Weng, Huang et 
al. 2018). However, these authors showed no consistent pattern for any YTHDF gene 
(YTHDF1-3) during differentiation of normal HSPCs, and were unable to demonstrate 
any effect of YTHDF knockdown on the METTL14 targets, MYB and MYC, which they 
had identified. The authors argued therefore that the effect of METTL14 on mRNA 
stability and translation of its target genes was unlikely to be mediated by YTHDF 
proteins in this instance.  
In contrast to early development, the role of m6A in differentiated adult 
haematopoiesis is less well defined. Functional studies have been carried out in T 
cells (Li, Tong et al. 2017, Tong, Cao et al. 2018), dendritic cells (Han, Liu et al. 2019), 
and to a lesser extent also myeloid cells (Lee, Bao et al. 2019). 
Two studies have shown that m6A modification plays an important role in T cell 
mediated pathogenesis. In the first, the authors demonstrated that deletion of the m6A 
‘writer’ Mettl3 in Mettl3fl/fl;CD4-Cre conditional knock out mice disrupts T cell 
homeostasis and differentiation (Li, Tong et al. 2017). Although no differences were 
observed in cell type or numbers at the level of the thymus, the number of naïve T 
cells in the spleen and lymph nodes of knock out mice was significantly increased 
compared to wild type mice. Furthermore, in a lymphopenic mouse adoptive transfer 
model (Rag2-/- mice), naïve Mettl3-deficient CD4+ T cells failed to undergo 
homeostatic expansion and remained in the naïve state for up to 12 weeks, thereby 
preventing colitis. In a follow up paper, the same group showed that deletion of Mettl3 
in Mettl3fl/fl; FoxP3-Cre conditional knock out mice resulted in severe autoimmune 
disease resulting from an inability of Mettl3-deficient regulatory T cells to suppress 
naïve T cell proliferation (Tong, Cao et al. 2018). In both cases, the mechanism was 
attributed to increased SOCS family activity, secondary to reduced m6A-mediated 
decay of Socs mRNAs. Upregulation of Socs family genes resulted in inhibition of IL-
7 signalling in CD4+ T cells, and the IL2-STAT5 pathway in FoxP3+ T cells, inhibiting 
activation and suppressive capacity respectively (Li, Tong et al. 2017, Tong, Cao et 
al. 2018). 
In terms of dendritic cells (DCs), Han et al. showed in a melanoma murine tumour 
model that neoantigen specific immunity is regulated by mRNA m6A methylation 
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through the m6A binding protein YTHDF1 (Han, Liu et al. 2019). In this paper, the 
authors observed slower growth of B16-OVA tumours and prolonged survival in 
Ythdf1-deficient mice and subsequently attributed this to an increased capacity of 
Ythdf1-deficient DCs to cross-prime CD8+ T cells. They also showed enhanced cross-
presentation ability by Mettl14-deficient DCs compared to wild type DCs, supporting 
a more general dependence on RNA m6A methylation. 
Most recently, Lee et al. conditionally deleted Mettl3 in myeloid cells by generating 
Mettl3fl/fl;Lysm-Cre mice, as part of a wider study investigating differentiation defects 
in Mettl3-deficient HSCs (described below) (Lee, Bao et al. 2019). They found no 
difference in the number of myeloid cells in the peripheral blood, BM or spleens of 6-
8 week old Mettl3fl/fl;Lysm-Cre mice compared with controls. Furthermore, 
macrophages derived from BM of Mettl3fl/fl;Lysm-Cre mice showed normal 
upregulation of inflammatory cytokines (Tnfα, Il1b, Il6) and normal engulfing activity 
compared to controls, suggesting that Mettl3 is not required for the maintenance or 
function of mature myeloid cells (Lee, Bao et al. 2019).  
In the last year, concurrent with the work outlined in the results section below, several 
publications have emerged supporting a requirement for m6A in haematopoietic stem 
and progenitor cell function and maintenance.  
Multiple studies have documented that expression of Mettl3 and Mettl14 is higher in 
HSPCs compared with differentiated cells in mouse bone marrow, suggesting a 
potential role in controlling the most primitive haematopoietic compartments (Weng, 
Huang et al. 2018, Yao, Sang et al. 2018, Lee, Bao et al. 2019). To investigate this 
possibility, Yao et al. generated inducible Mx1-Cre-mediated conditional knock out 
models to delete Mettl3, Mettl14 or both Mettl3 and Mettl14 in mice. The authors 
treated these mice at 6 weeks of age with pIpC to induce gene deletion, and analysed 
bone marrow compartments 6 weeks later. As expected, there was a reduction of 
m6A, although this was greater with Mettl3 deletion than with Mettl14 deletion. Notably 
there was also a large (10 fold) increase in HSCs following deletion of Mettl3. In 
contrast, deletion of Mettl14, either in isolation or together with Mettl3, had no 
discernible effect on HSPC compartments. Primary and secondary transplantation of 
BM from Mettl3 deleted mice showed reduced engraftment and multilineage 
reconstitution potential of Mettl3-deficient HSCs compared to wild type HSCs. The 
authors went on to show increased cell cycling and reduced expression of genes 
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which maintain HSC quiescence in Mettl3-deficient HSCs (Nr4a2, p21, Bmi-1, 
Prdm16). They concluded that METTL3 is a pivotal regulator of HSC self-renewal in 
adult BM, which functions by promoting the expression of genes which maintain HSC 
quiescence (Yao, Sang et al. 2018).  
 
The publication by Yao et al. was closely followed by another study evaluating the 
effect of Mettl3 deletion (Lee, Bao et al. 2019).  Lee et al. generated inducible Mx1-
Cre-mediated and Rosa26-CreERT2-mediated conditional knock out models to 
delete Mettl3 from mice. They reported a sustained significant increase in HSCs and 
HPC2 cells following Mettl3 deletion, a modest increase in HPC1 cells, and no 
significant difference in MPPs. Changes were also observed in committed progenitor 
cells (decreases in GMPs and increases in Pre-MegEs and MkPs) and differentiated 
cells (decreases in platelets, neutrophils and lymphocytes). Based on the results of 
BrdU incorporation assays, methylcellulose colony forming assays, 5-FU 
myeloablation treatment of mice, and competitive BM and HSC transplantation 
assays, the authors concluded that the increase in HSCs following Mettl3 deletion 
was a result of reduced differentiation, as opposed to increased self-renewal. They 
went on to use a combination of meRIP-Seq and RNA-Seq to demonstrate that Mettl3 
deletion decreased m6A modification of HSC differentiation genes, including Myc, 
Junb and Tet2. Interestingly RNA-Seq showed little difference in the transcriptome of 
control versus Mettl3-deleted HSCs, and the authors subsequently showed that the 
effect of m6A was predominantly on mRNA translation in this case. Lee et al. 
discussed the discrepancy between their findings and those of Vu et al. and Wang et 
al. ((Vu, Pickering et al. 2017, Weng, Huang et al. 2018), both of whom reported 
increases in differentiation following Mettl deletion in HSPCs. However, in those cases 
a mixed population of human cord blood CD34+ cells was used, arguably clouding the 
interpretation, particularly in light of the cell specific effects reported by Lee at al on 
HSCs versus progenitor cells following Mettl3 deletion (minimal effect on progenitor 
cells, marked effect on HSCs) (Lee, Bao et al. 2019).  
 
The requirement for YTHDF2 in haematopoietic stem and progenitor cell function and 
maintenance has also been reported in two recent publications (Li, Qian et al. 2018, 
Wang, Zuo et al. 2018).  
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Li et al. used an inducible Mx1-Cre-mediated conditional knock out model to delete 
Ythdf2 in mice. Four weeks after pIpC-mediated Ythdf2 deletion, the authors observed 
increased numbers of long-term HSCs (LT-HSCs) and short-term (ST-HSCs), without 
any change in progenitor or committed lineage cells, in the BM of Ythdf2-deleted mice 
compared to controls. Primary and secondary transplantation of total BM from Ythdf2-
deleted and control mice showed improved overall engraftment, without any alteration 
in multilineage reconstitution capacity or likelihood of malignant transformation, for 
Ythdf2-deleted cells. This study also reported that shRNA-mediated depletion of 
YTHDF2 led to an ex-vivo expansion of human umbilical cord blood (hUCB) HSCs 
and an increase in HSC functionality, as measured in a limiting dilution transplantation 
assay. The authors showed that in Ythdf2 KO HSPCs and YTHDF2 KD hUCB HSCs, 
there was an increase in methylated mRNAs encoding transcription factors essential 
for stem cell renewal, and attributed this to reduced YTHDF2-mediated decay of m6A 
modified transcripts (Li, Qian et al. 2018).  
Wang et al. used 3 conditional knock out models (Mx1-Cre, ERT-Cre and Vav-iCre) 
to delete Ythdf2 in mice (Wang, Zuo et al. 2018). They reported increased numbers 
of LT-HSCs and ST-HSCs, MPPs and LSK cells in pIpC treated Ythdf2fl/fl;Mx1-Cre 
mice compared to controls, without any changes in progenitor cell compartments 
(CMP, CLP, GMP, MEP), or differentiated cells (myeloid cells, B lymphocytes, T 
lymphocytes). Increased LT-HSCs numbers were also observed in Ythdf2fl/fl;Vav-iCre 
mice compared to controls. Transplantation of LT-HSCs from pIpC treated 
Ythdf2fl/fl;Mx1-Cre and control mice showed increased engraftment by Ythdf2-
deficient cells. Application of haematopoietic stressors, in the form of 5-FU treatment 
or repeated ionising radiation, resulted in increased numbers and function (based on 
in-vitro colony formation) of LT-HSC in Ythdf2fl/fl;Mx1-Cre mice compared to controls. 
Mechanistically, the authors used a combination of RNA-Seq, m6A-RIP-qPCR and 
actinomycin-D treatment to show upregulation of genes in the Wnt signalling pathway, 
including downstream targets Myc and Axin2, the mRNAs of which were significantly 
more methylated in Ythdf2-deficient HPSCs, and were also increased following 
actinomycin-D treatment. Administration of the small-molecule Wnt/β-catenin inhibitor 
ICG-001 to pIpC treated Ythdf2fl/fl;Mx1-Cre and control mice partially rescued the 
proliferation and phenotypic expansion of HSCs. The authors concluded that the 
expression of Ythdf2 in HSCs facilitates decay of the m6A-modified mRNAs of Wnt 
target genes, contributing to the repression of Wnt signalling in the steady state, whilst 
YTHDF2 deficiency simultaneously prevents the degradation of mRNAs of both Wnt 
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target genes and survival-related genes during hematopoietic stresses (Wang, Zuo 
et al. 2018).  
In summary, the combined data described above supports an important role for m6A 
in normal haematopoiesis, and provides the context for the results presented in this 
chapter.    
3.2 Aims 
 
Based on the evidence presented in this introduction, we hypothesised that YTHDF2 
would play an important role in haematopoiesis.  
 
The aims of the project were therefore to investigate the requirement for YTHDF2 at 
different stages of haematopoiesis and to identify molecular mechanisms by which 
YTHDF2 functions during these processes.  
 
3.3 Outline of experiments described in Chapter 3 
 
To study the functional role of YTHDF2 in haematopoiesis, we made use of the 
conditional and reporter Ythdf2fl mouse allele, in which exon 2 of Ythdf2 is flanked by 
LoxP sites, and eGFP is inserted into exon 1, generating a fully functional 
endogenously expressed eGFP-YTHDF2 fusion protein (Ivanova, Much et al. 2017). 
We analysed eGFP-YTHDF2 expression within the HSPC compartments of 8-12-
week old adult Ythdf2fl/fl mice, and E14.5 dpc (embryonic 14.5 days post coitum) 
embryos. We then crossed Ythdf2fl/fl mice with Vav-iCre mice (de Boer, Williams et al. 
2003), in order to delete the gene specifically within the haematopoietic system, and 
studied the effect of this on HSPC compartments in adult BM and foetal liver (FL), as 
well as peripheral blood and lymphoid organs of 8-12-week-old adult mice. Finally, to 
study the function of YTHDF2 in haematopoiesis, we carried out serial transplantation 










3.4.1 Expression of Ythdf2 in the HSPC compartment 
To study the role of YTHDF2 in haematopoiesis, we employed a mouse kindly provided 
by Ivanova et al., in which exon 2 of Ythdf2 is flanked by LoxP sites, and eGFP-
PreScission-His6-Flag-HA2 tag is inserted after the start codon of Ythdf2 within exon 
1 (Figure 3.4.1 A) (Ivanova, Much et al. 2017). According to these authors., N-terminal 
tagging of YTHDF2 with GFP-His6-FLAG-HA does not affect the expression (as 
examined by western blotting) or function of the protein (mice homozygous for Ythdf2fl 
are viable and fertile, with no outward abnormalities in contrast to Ythdf2-deficient 
mice, which display female specific infertility, see section 1.1.3). Furthermore, c-Kit+ 
stem and progenitor cells from Ythdf2fl/fl and Ythdf2+/+ mice express equal levels of 
YTHDF2 protein, and Ythdf2fl/fl and Ythdf2+/+ mice display identical numbers of HSCs 
and downstream progeny (unpublished data from the Kranc lab in London). In this 
mouse, here referred to as the Ythdf2fl/fl mouse, eGFP fluorescence reports YTHDF2 
protein levels. For convenience, eGFP will hereafter be referred to as GFP in this text.  
In their paper, Ivanova et al. examined HA-YTHDF2 protein levels in tissues of Ythdf2fl/fl 
mice by western blotting. They showed that the HA-YTHDF2 protein was expressed in 
all tissues analysed, specifically testis, ovaries, liver, spleen, thymus, kidney brain, 
heart, and lung. Notably, respective tissues expressed differential amounts of YTHDF2, 
with the highest expression in the testis, ovaries, spleen and thymus (Ivanova, Much et 
al. 2017).  
To investigate Ythdf2 expression in the HSPC compartment, we evaluated GFP 
expression in the FL (the major site of definitive haematopoiesis during development) 
of E14.5 dpc Ythdf2fl/fl embryos and BM of 8-12-week-old adult Ythdf2fl/fl mice. FL and 
BM were harvested, stained with antibodies against LSK SLAM markers, and 
analysed on an LSRFortessaÔ (BD) as described in sections 2.7 and 2.8.   
HSPC populations were gated according to the expression of the following surface 
makers: LK (Lin-Sca-1-c-Kit+); LSK (Lin-Sca-1+c-Kit+); haematopoietic stem cells 
(HSCs: LSK CD48-CD150+); multipotent progenitors (MPPs: LSK CD48-CD150-); 
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haematopoietic progenitor cells-1 (HPC-1: LSK CD48+CD150-); haematopoietic 
progenitor cells-2 (HPC-2: LSK CD48+CD150+), as shown in Figure 3.4.1 B.  
All hematopoietic cells from the FL and adult BM expressed GFP-YTHDF2 (Figures 
3.4.1 C-D). Notably, YTHDF2 was highly expressed in Lin-Sca-1+c-Kit+ (LSK) cells, 
LSK CD48-CD150+ HSCs, LSK CD48-CD150- multipotent progenitors (MPPs), 
primitive hematopoietic progenitor cells (i.e. LSK CD48+CD150-HPC-1 and LSK 
CD48+CD150+ HPC-2 populations), and Lin-Sca-1-c-Kit+ (LK) myeloid progenitors, 
and its expression was decreased in differentiated Lin+ cells (Figures 3.4.1 C-D). The 
correlation of YTHDF2 expression with primitive cell compartments suggested that it 
may be involved in maintenance of cells at the top of the haematopoietic hierarchy.  
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Figure 3.4.1 Ythdf2 expression within the haematopoietic system. (A) The 
sequences encoding the eGFP-PreScission-His6-Flag-HA2 epitope tag were inserted 
into exon 1 of the Ythdf2 locus, and exon 2 was flanked by LoxP sites (Ivanova, Much 
et al. 2017). For simplicity, this allele is referred to as Ythdf2fl and codes for eGFP-
PreScission-His6-Flag-HA2-YTHDF2 fusion protein (referred to as GFP-YTHDF2 
protein). (B) LSK SLAM population flow cytometry gating strategy. (C) GFP 
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expression in the indicated FL cell populations from Ythdf2fl/fl 14.5 dpc embryos. 
YTHDF2 is uniformly expressed in FL LSK cells, LSKCD48−CD150+ HSCs, 
LSKCD48−CD150− multipotent progenitors (MPPs), primitive haematopoietic 
progenitor cells (i.e. LSKCD48+CD150− HPC-1 and LSKCD48+CD150+ HPC-2 
populations), and Lin−Sca-1−c-Kit+ (LK) myeloid progenitors, and its expression is 
decreased in differentiated Lin+ cells. The data represent mean fluorescence intensity 
(MFI) ± SD (n = 3-4 mice per genotype). GFP levels are significantly lower in Lin+ 
compartment compared to all HSPC compartments (p<0.05 for MPP, and p<0.0001 
for all other comparisons, Unpaired t-test). (D) GFP expression in the indicated BM 
cell populations from 8-12-week-old mice. YTHDF2 is expressed at higher levels in 
HSC/progenitor cells compared to mature cells and its expression is decreased in the 
more differentiated Lin+ cell compartment. The data represent MFI ± SD (n = 3-4 mice 
per genotype). GFP levels are significantly lower in Lin+ compartment compared to all 
HSPC compartments (p<0.0001 for each comparison, Unpaired t-test). 
3.4.2 Generation and validation of Ythdf2fl/fl;Vav-iCre mice 
 
To reveal the role of YTHDF2 in haematopoiesis, we crossed Ythdf2fl/fl mice with Vav-
iCre mice (de Boer, Williams et al. 2003) to generate Ythdf2fl/fl;Vav-iCre mice, in which 
Ythdf2 is specifically ablated within the hematopoietic system shortly after the 
emergence of definitive HSCs (Figures 3.4.2 A-C). In these mice, the vav promoter 
elements direct Cre mediated recombination in all cells of the haematopoietic system, 
and mammalian codon usage is applied to Cre-recombinase (termed Codon-
improved Cre-recombinase, or iCre) for improved Cre expression, and reduced 
susceptibility to epigenetic silencing (Shimshek, Kim et al. 2002). This Cre mouse line 
has been used extensively by multiple groups including our own (Guitart, Subramani 
et al. 2013, Vukovic, Sepulveda et al. 2016) to delete floxed genes specifically from 
the haematopoietic system.  
Analysis of GFP-YTHDF2 expression by flow cytometry in LSKs derived from 
Ythdf2fl/fl;Vav-iCre embryos confirmed loss of GFP, and thereby efficient Ythdf2 
deletion (Figure 3.4.2 B-C). Ythdf2fl/fl;Vav-iCre mice were subsequently established 
as a breeding colony. Cre recombinase activity has been reported in the testes of 
Vav-iCre mice (de Boer, Williams et al. 2003, Croker, Metcalf et al. 2004), potentially 
resulting in germline deletion in some offspring. For this reason, we exclusively mated 
Cre+ females with Cre- males. Upon weaning at 3 weeks of age offspring were ear 
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notched, and the tissue was used for genotyping PCRs (Ythdf2 flox and Vav-iCre), as 
described in section 2.3 and as shown in Figure 3.4.2 D.  We found that Ythdf2fl/fl;Vav-
iCre mice were born at normal Mendelian ratios (Ythdf2fl/fl X Ythdf2fl/fl;Vav-
iCre matings resulted in 65 Ythdf2fl/fl and 47 Ythdf2fl/fl;Vav-iCre mice at weaning, P = 
0.29, Two-tailed T test Figure 3.4.2 E), and matured to adulthood without any 






Figure 3.4.2 Generation and validation of Ythdf2fl/fl;Vav-iCre mice. (A) Deletion of 
Ythdf2 from the haematopoietic system using Vav-iCre. FL cells from control E14.5 
dpc Ythdf2fl/fl embryos produce normal GFP-YTHDF2 protein. In the presence of iCre, 
exon 2 is deleted resulting in a frameshift mutation and a complete loss of the GFP-
YTHDF2 protein. (B) A representative histogram showing GFP-YTHDF2 protein 
expression in Ythdf2fl/fl FL LSK cells and the lack of GFP-YTHDF2 expression in 
Ythdf2fl/fl;Vav-iCre FL LSK cells. (C) Percentage of GFP-positive cells in the E14.5 
dpc FL LSK cell population from FLs of Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre embryos. Data 
are mean ± s.e.m. (n = 5 per genotype). (D) Representative gel showing PCR 
genotyping products for Ythdf2 flox and Vav-iCre. (E) Proportion of Ythdf2fl/fl and 
Ythdf2fl/fl;Vav-iCre weaned pups resulting from Ythdf2fl/fl X Ythdf2fl/fl;Vav-iCre breeding 
crosses (n = 112 pups from 20 crosses) P = 0.29, Two-tailed T test.  
3.4.3 Ablation of Ythdf2 affects cell distribution within stem and progenitor cell 
compartments  
Given the elevated levels of YTHDF2 in HSCs and progenitor cells compared to 
differentiated cells (Figures 3.4.1 C-D), we investigated the impact of Ythdf2 deletion 
on these cell populations.  
Haematopoietic stem cells and direct progeny were investigated in FL and BM of 
Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre E14.5 dpc embryos and adult mice respectively. 
There was no significant difference in the total WBC count between Ythdf2fl/fl and 
Ythdf2fl/fl;Vav-iCre genotypes in the FL (Figure 3.4.3 A) or BM (counts provided per 
one hind leg i.e. tibia plus femur) (Figure 3.4.3 B). The number of Lin-Sca-1-c-Kit+ 
(LK) cells was also unchanged between Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre genotypes, 
both in the FL (Figure 3.4.3 C) and in the adult BM (Figure 3.4.3 D). However, there 
was a significant expansion in both the frequency and the absolute number of LSK 
stem and progenitor cells in Ythdf2fl/fl;Vav-iCre FL (Figures 3.4.3 E-F) and adult BM 
(Figures 3.4.3 G-H) when compared to Ythdf2fl/fl controls. LSK, HSC and primitive 
progenitor (HPC-1 and HPC-2) compartments were all expanded. In adult BM, 
multipotent progenitor (MPP) numbers were reduced in Ythdf2fl/fl;Vav-iCre mice 
compared to Ythdf2fl/fl controls, however this difference was not observed in FL 




Figure 3.4.3 Ablation of Ythdf2 affects cell distribution within stem and 
progenitor cell compartments. (A-B) Total WBC counts in FL (A) and BM (B) from 
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Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre E14.5 dpc embryos and 8-12 week old adult mice 
respectively. BM counts are given per one hind leg i.e. tibia plus femur. (C-D) Total 
LK numbers in FL (C) and BM (D) from Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre E14.5 dpc 
embryos and 8-12 week old adult mice respectively. (E-F) Frequencies (E) and total 
numbers (F) of LSK, HSC, MPP, HPC-1 and HPC-2 cell populations in FLs from 
Ythdf2fl/fl (control, CTL) and Ythdf2fl/fl;Vav-iCre (conditional knock out, cKO) embryos. 
(G-H) Frequencies (G) and total numbers (H) in BM from Ythdf2fl/fl and Ythdf2fl/fl;Vav-
iCre 8-12 week old mice.  
Data are mean ± s.e.m. n = 10 (FL) or 7-8 (BM) per genotype. *, P < 0.05; **, P < 
0.01, ***, P < 0.001, ****, P < 0.0001, Mann-Whitney U test.  
 
Overall, the SLAM LSK staining data obtained for both adult BM and embryonic FL 
showed an expansion of HSCs and primitive progenitor cells (HPC-1 and HPC-2) and 
in the case of adult BM, also a reduction in multipotent progenitor cells.  
3.4.4 Ythdf2 loss affects myeloerythroid progenitor numbers, but not in vitro 
differentiation capacity 
In an attempt to further resolve the alterations in the HSPC compartments, 
myeloerythroid progenitor cell staining and flow cytometry was carried out (see 
section 2.8), based on a protocol described by Pronk et al (Pronk and Bryder 2011). 
This method allows for the identification of immature myeloerythroid progenitor 
subsets in murine bone marrow, including early bipotent progenitors for the 
erythroid/megakaryocyte lineages (pre-MegE), early monopotent erythroid (pre-CFU-
E and CFU-E) and megakaryocyte progenitors (MkP), and primitive 
granulocyte/macrophage progenitors (pre-GM and GMP) (Figure 3.4.4 A). To 
facilitate separation of these populations from the LK compartment, Pronk relied upon 
the detection of signalling lymphocytic activation molecule family member 1 
(Slamf1/CD150), Endoglin (Eng/CD105) and Integrin alpha 2b (Itga2b/CD41), in 
addition to CD16/32FCRII/IIII (Figure 3.4.4 B).   
Making use of this staining to analyse BM of Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre adult 
mice (8-12-weeks old), we found lower numbers of pre-GMP cells, and increased 
numbers of pre-MegE, pre-CFU-E and MkP cells in Ythdf2fl/fl;Vav-iCre mice compared 
to Ythdf2fl/fl controls (Figure 3.4.4 C). Nevertheless, lineage restricted progenitors of 
granulocytes and monocytes (GMP) and also erythroid cells (CFU-E) appeared 
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unaffected by loss of Ythdf2 (Figure 3.4.4 C), suggesting that the changes were 
successfully compensated at more differentiated stages. To further characterise the 
progenitor cell compartment, it would be useful to carry out additional antibody 
staining for lymphoid primed MPP (LMPP), common lymphoid progenitor (CLP), and 
common myeloid progenitor (CMP) cell populations, as described by Akashi and 
colleagues (Kondo, Weissman et al. 1997, Akashi, Traver et al. 2000). This staining 
was unfortunately not carried out earlier due to challenges faced when optimising a 
non-FITC conjugated CD34 antibody for use in the protocol (as opposed to the FITC 
conjugated CD34 antibody specified, which cannot be used in combination with GFP-
YTHDF2 mice).    
To investigate how the changes in HSPC compartments in Ythdf2fl/fl;Vav-iCre mice 
relate to self-renewal and differentiation potential in vitro, 25 000 FL cells isolated from 
E14.5 dpc Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre embryos were plated into 3434 
methylcellulose (MethoCult™ GF M3434), as described in section 2.13.2. This is a 
semi-solid growth medium, optimized for the growth and enumeration of 
hematopoietic progenitor cells in colony-forming unit assays of mouse bone marrow, 
spleen, peripheral blood, and foetal liver cells. The medium is formulated to support 
growth of primitive erythroid progenitor cells (CFU-Red), granulocyte-macrophage 
progenitor cells (CFU-GM, CFU-G and CFU-M), and multi-potential granulocyte, 
erythroid, macrophage, megakaryocyte progenitor cells (CFU-GEMM) (Miller and Lai 
2005). Enumeration of colonies after 10 days revealed no significant difference in the 
total colony number or multilineage differentiation potential of Ythdf2fl/fl;Vav-iCre cells 
compared to Ythdf2fl/fl controls (Figure 3.4.4 D-E).  
 
In summary, the combined results of in vitro 3434 methylcellulose colony assays and 
in vivo myeloerythroid progenitor cell staining suggested that the changes observed 
in the HSPC LSK SLAM compartments of Ythdf2-deficient mice are largely 











Figure 3.4.4 Ythdf2 loss affects myeloerythroid progenitor numbers, but not in 
vitro differentiation capacity. (A) Schematic overview of the first developmental 
stages in the differentiation from multipotent HSC to progeny possessing oligo and 
unilineage differentiation potentials. Adapted from Pronk et al. 2011 (Pronk and 
Bryder 2011). HSC haematopoietic stem cell, MPP multipotent progenitor, LMPP 
lymphoid primed MPP, CLP common lymphoid progenitor, CMP common myeloid 
progenitor, Pre-GM pre-granulocyte/macrophage progenitor, Pre-MegE pre-
megakaryocyte/erythrocyte, Pre-CFU-E pre-colony forming unit – erythrocytes, MkP 
megakaryocyte progenitor. (B) Flow cytometry-based strategy for multiparameter 
fractionation of murine myeloerythroid precursors according to the Pronk protocol. (C) 
Total numbers of committed progenitor cells in the BM of Ythdf2fl/fl and Ythdf2fl/fl;Vav-
iCre mice. Data are mean ± s.e.m. (n = 5-6 mice per genotype). *, P<0.05; ****, P < 
0.0001, Unpaired t-test. (D) CFU assays performed with BM cells from 8–10-wk-old 
mice. CFU-Red, CFU-erythroid and/or megakaryocyte; CFU-G, CFU-granulocyte; 
CFU-M, CFU-monocyte/macrophage; CFU-GM, CFU–granulocyte and 
monocyte/macrophage; CFU-Mix, at least three of the following: granulocyte, 
erythroid, monocyte/macrophage, and megakaryocyte. CFU-GEMM, all of the 
following: granulocyte, erythroid, monocyte/macrophage, and megakaryocyte. Data 
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are mean ± s.e.m. (n = 4 per genotype). (E) Representative images of CFU-Red, 
CFU-GM and CFU-GEMM colonies presented in (D). OLYMPUS IX50, 10X 
magnification.   
 
3.4.5 Ythdf2 loss affects T lymphocyte cell homeostasis 
 
Having shown that Ythdf2 loss expands the HSC compartment in the BM and FL of 
Ythdf2fl/fl;Vav-iCre adult mice and E14.5 dpc embryos, we next characterised 
differentiated haematopoietic cells in the peripheral blood and lymphoid organs. To 
do so, we harvested peripheral blood, BM, thymus and spleen from a cohort of 8-10 
week old Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre mice for cell counts, antibody staining and 
flow cytometry (see sections 2.6, 2.7, 2.8).  
 
As shown in Table 3.4.5, loss of Ythdf2 resulted in several significant alterations in 
the peripheral blood. Mild decreases were seen in white blood cells (WBCs), red blood 
cells (RBCs), CD8+ T lymphocytes (CD8+ T cells) and B lymphocytes (B cells), and a 
mild increase was observed in platelets (PLTs). However, with the exception of CD8+ 
T cell lymphocytes, where the reduction was approximately 2-fold, the peripheral 
blood changes observed as a result of Ythdf2 loss were all relatively small. 
 
Analysis of spleens from Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre mice revealed a significant 
reduction in CD8+ T lymphocytes, but no other abnormalities (Figures 3.4.5 A-B). In 
contrast, at the level of the thymus there was a small increase in overall WBC count 
and CD4+ T lymphocytes, but no difference in the number of CD8+ or CD4+CD8+ 
(double positive) T lymphocytes (Figures 3.4.5 C-D). The significance of these 
findings is unclear. Given that the naive T cell pool in mice is almost exclusively 
sustained by thymic output (den Braber, Mugwagwa et al. 2012), it may be that the 
reduction in CD8+ T lymphocytes within the peripheral blood and spleen of Ythdf2 
deficient cells is the result of peripheral expansion and/or loss. Nevertheless, there 
are several caveats to this conclusion, which are discussed further below (see 3.5 
Discussion).   
 
In summary, analysis of adult Ythdf2-deficient and control mice revealed small 
changes in red and white blood cell parameters, of which the most significant was a 
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reduction of CD8+ T lymphocytes in the peripheral blood and spleen. Nevertheless, in 
the unchallenged state, these changes did not appear to be clinically significant.  
 
 
 Ythdf2fl/fl Ythdf2fl/fl;Vav-iCre P value  
 
WBC (/µl) 9767 ± 935 
 




RBC (x104/µl)  1178 ± 23.61 
 




Hb (g/dl) 16.91 ± 0.3513 
 




HCT (%) 52.12 ± 0.9812 
 




MCV (fl) 44.26 ± 0.2271 
 




MCH (pg) 14.37 ± 0.1082 
 




PLT (x104/µl) 80.78 ± 3.896 
 




CD4+ T cells (/µl) 1459 ± 176.7 1161 ± 168.2 0.1135 
CD8+ T cells (/µl) 1102 ± 178.6 
 
530.5 ± 92.22 
 
0.0206 
B cells (/µl)  
(CD19+) 
 
5226 ± 575.6 
 






2112 ± 458.5 
 














Table 3.4.5 Peripheral blood counts of 8-10 week old Ythdf2fl/fl and Ythdf2fl/fl;Vav-
iCre mice. Data are mean ± s.e.m. (n = 8-9 mice per genotype). P values are 







Figure 3.4.5 Ythdf2 loss results in altered T cell homeostasis. (A) Total WBC in 
spleens of 8-10 week old Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre mice. (B) Total numbers of 
T cells, B cells, granulocytes, monocytes and erythroid cells in spleens from 8-10 
week old Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre mice. (C) Total WBC in the thymus of 8-10 
week old Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre mice. (D) Total numbers of CD4+, CD8+ and 
CD4+CD8+ T cells in the thymus of 8-10 week old Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre 
mice.  
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Data are mean ± s.e.m. (n = 5-6 mice per genotype). *, P < 0.05, Mann-Whitney U 
test. 
 
3.4.6 Ablation of Ythdf2 enhances HSC function – FL HSC transplantation 
 
Having demonstrated that Ythdf2fl/fl;Vav-iCre mice have increased numbers of FL and 
BM HSCs compared to Ythdf2fl/fl mice, we next sought to establish the functional 
status of these cells. To do so, we used a serial transplantation assay.  
 
We sorted HSCs from E14.5 dpc FL, and transplanted them into irradiated recipient 
mice, as described in section 2.15.1, and as shown in Figure 3.4.6 A.  
 
Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre LSKCD48-CD150+ HSCs were sorted, and 100 
CD45.2+ HSCs were transplanted via the tail vein into lethally irradiated (11 Gy) 
recipient mice (CD45.1+ CD45.2+), together with 200 000 unfractionated bone marrow 
support cells (CD45.1+). Haematopoietic monitoring was carried out as described in 
section 2.15.3, with CD45.1 and CD45.2 staining used to monitor engraftment and 
differentiation of study HSCs against the background of recipient and support bone 
marrow cells.  
Serial peripheral blood analysis of primary transplanted mice showed no significant 
difference in the engraftment of Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre FL HSCs for at least 
16 weeks after transplantation (Figure 3.4.6 B). HSCs lacking Ythdf2 gave equal 
overall reconstitution compared to control HSCs. Furthermore, whilst Ythdf2-deficient 
HSCs were capable of differentiating into all lineages (Figure 3.4.6 B), a skewing was 
observed, whereby Ythdf2-deficient HSCs had enhanced early myeloid lineage 
reconstitution capacity and compromised T-cell lineage reconstitution capacity when 
compared to control HSCs (Figure 3.4.6 B).  
After 16 weeks the mice were culled, and bone marrow was harvested for analysis 
(see sections 2.7 and 2.8). Strikingly, Ythdf2-deficient HSCs displayed a significantly 
increased capacity to contribute to the bone marrow LSK, HSC, and HPC-2 
compartments (Figure 3.4.6 C) of the recipient mice compared to control HSCs. 
When analysing contribution to BM differentiated cell compartments, there was no 
difference between recipients transplanted with Ythdf2-deficient or control HSCs 
(Figure 3.4.6 D). Based on these findings we concluded that Ythdf2-deficient FL 
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HSCs are at least as good as, and in some cases superior to, control FL HSCs in 
terms of reconstituting stem and progenitor cell compartments in transplanted mice, 
and are able to contribute to all lineages, albeit with a bias favouring myeloid over T 
cell differentiation.  
 
Next, we carried out secondary transplantation. For this, we sorted CD45.2+ LSK (Lin-
Sca-1+c-Kit+) cells from the BM of culled primary recipient mice and transplanted them 
into irradiated recipient mice, as described in sections 2.14 and 2.15.1, and as shown 
in Figure 3.4.6 A.  
 
Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre CD45.2+ LSKs were sorted, and 2000 CD45.2+ LSKs 
were transplanted via the tail vein into lethally irradiated (11 Gy) recipient mice 
(CD45.1+ CD45.2+), together with 200 000 unfractionated bone marrow support cells 
(CD45.1+). Haematopoietic monitoring was carried out as described in section 2.15.3, 
with CD45.1 and CD45.2 staining used to monitor engraftment and differentiation of 
study HSCs against the background of recipient and support bone marrow cells.   
Serial peripheral blood analysis of primary transplanted mice showed no significant 
difference in the engraftment of Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre HSCs for at least 16 
weeks after transplantation (Figure 3.4.6 E). HSCs lacking Ythdf2 gave equal overall 
reconstitution compared to control HSCs. Furthermore, whilst Ythdf2-deficient HSCs 
were capable of differentiating into all lineages, Ythdf2-deficient HSCs had enhanced 
myeloid lineage reconstitution capacity and compromised T-cell lineage reconstitution 
capacity when compared to control HSCs (Figure 3.4.6 E), replicating the pattern 
observed in primary recipients.  
After 16 weeks the mice were culled, and bone marrow was harvested for analysis 
(see sections 2.7 and 2.8). Strikingly, Ythdf2-deficient HSCs displayed a significantly 
increased capacity to contribute to the bone marrow LSK, HSC, MPP, HPC-1, HPC-
2, LK, Lin- and Lin+ compartments (Figure 3.4.6 F) and myeloid differentiated cell 
compartments (Figure 3.4.6 G) of the recipient mice compared to control HSCs. 
Based on these findings we concluded that Ythdf2-deficient FL HSCs are able to 
outcompete control HSCs and display enhanced myeloid reconstitution capacity in 
secondary recipients.  
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Finally, we carried out tertiary transplantation. For this, we harvested BM from 
secondary recipients and transplanted 4 million unfractionated and unsorted cells to 
lethally irradiated tertiary recipients, with no additional BM support. In an ideal world, 
this tertiary transplantation would have been carried out using a set number (2000-
3000) of CD45.2+ LSK cells together with CD45.1+ BM support, however the level of 
engraftment in the secondary recipients was too low for this to be feasible. To 
standardise the transplanted BM as much as possible, BM with similar levels of 
CD45.2+ chimerism was selected for transplantation.  
Serial peripheral blood analysis of tertiary transplanted mice showed a significantly 
higher engraftment in recipients of Ythdf2fl/fl;Vav-iCre HSCs compared with control 
Ythdf2fl/fl HSCs for at least 16 weeks following transplantation (Figure 3.4.6 H). The 
superior reconstitution capacity of Ythdf2fl/fl;Vav-iCre HSCs compared with Ythdf2fl/fl 
HSCs was also apparent within all differentiated cell lineages (granulocytic, 
monocytic, B lymphocyte), with the exception of T lymphocytes (Figure 3.4.6 H), once 
again mirroring the pattern in primary and secondary transplantation experiments. 
However, when the tertiary recipients were culled at 16 weeks, BM analysis revealed 
a very low donor derived cell chimerism at the level of the BM, with CD45.2+ cells 
comprising less than 1% of the total population in all but one mouse (Figure 3.4.6 I). 












Figure 3.4.6 Ablation of Ythdf2 enhances the function of FL HSCs. (A) Schematic 
of primary, secondary and tertiary transplantation of HSCs from FL. 100 FL HSCs 
(from Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre embryos) were transplanted into lethally 
irradiated 8-10 week old syngeneic CD45.1+/CD45.2+ recipient mice (n = 18-27 mice 
per genotype) together with 2 x 105 CD45.1+ competitor BM cells. After 16 weeks 
primary recipient mice were culled, and 2,000 CD45.2+ BM LSK cells from primary 
recipients were transplanted into lethally irradiated 8-10-week-old syngeneic 
CD45.1+/CD45.2+ secondary recipient mice (n = 10 mice per genotype) together with 
2 x 105 CD45.1+ competitor BM cells. After a further 16 weeks, secondary recipient 
mice were culled, and 4 million (4M) unfractionated BM cells were transplanted into 
lethally irradiated 8-10-week-old syngeneic CD45.1+/CD45.2+ tertiary recipient mice 
(n = 10 mice per genotype). Peripheral blood was obtained on a monthly basis from 
all recipient mice up to 4 months, at which stage recipients were culled for BM 
analysis. (B) Percentage of CD45.2+ cells overall in the peripheral blood (PB) and in 
the monocyte, granulocyte, B cell and T cell compartments of the PB of primary 
recipients. Data are mean ± s.e.m. *, P<0.05; **, P<0.01, Mann-Whitney U test. (C-D) 
Percentage of CD45.2+ cells in the LSK, HSC, MPP, HPC-1, HPC-2, LK, Lin- and Lin+ 
(C) and differentiated (D) cell compartments in the BM of primary recipient mice. Data 
are mean ± s.e.m. *, P<0.05; **, P<0.01, Mann-Whitney U test. (E) Percentage of 
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CD45.2+ cells overall in the peripheral blood (PB) and in the monocyte, granulocyte, 
B cell and T cell compartments of the PB of secondary recipients. Data are mean ± 
s.e.m. *, P<0.05; **, P<0.01; ****, P < 0.0001, Mann-Whitney U test. (F-G) Percentage 
of CD45.2+ cells in the LSK, HSC, MPP, HPC-1, HPC-2, LK, Lin- and Lin+ (F) and 
differentiated (G) cell compartments in the BM of secondary recipient mice. Data are 
mean ± s.e.m. *, P<0.05; **, P<0.01, Mann-Whitney U test. (H) Percentage of CD45.2+ 
cells overall in the peripheral blood (PB) and in the monocyte, granulocyte, B cell and 
T cell compartments of the PB of tertiary recipients. Data are mean ± s.e.m. *, P<0.05; 
**, P<0.01; ***, P < 0.001; ****, P < 0.0001, Mann-Whitney U test. (I) Percentage of 
CD45.2+ cells overall in the BM of tertiary recipients. Data are mean ± s.e.m.  
 
3.4.7 Ablation of Ythdf2 enhances HSC function – BM HSC transplantation 
 
Next, we sought to corroborate the findings obtained using FL HSCs with BM HSCs. 
We therefore carried out primary and secondary transplantation assays, as shown in 
schematic Figure 3.4.7 A.  
 
For the primary transplantation, Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre LSKCD48-CD150+ 
HSCs were sorted, and 200 CD45.2+ HSCs were transplanted via the tail vein into 
lethally irradiated (11 Gy) recipient mice (CD45.1+ CD45.2+), together with 200 000 
unfractionated bone marrow support cells (CD45.1+) (Figure 3.4.7 A). Monitoring was 
carried out as described previously.  
Serial peripheral blood analysis of primary transplanted mice showed a slower initial 
engraftment of Ythdf2-deficient HSCs (Figure 3.4.7 B week 2), but thereafter no 
significant difference in the engraftment of Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre FL HSCs 
for at least 18 weeks after transplantation (Figure 3.4.7 B). Furthermore, whilst 
Ythdf2-deficient HSCs were capable of differentiating into all lineages (Figure 3.4.7 
B), a skewing was observed, whereby Ythdf2-deficient HSCs had enhanced myeloid 
lineage reconstitution capacity and compromised T-cell lineage reconstitution 
capacity when compared to control HSCs (Figure 3.4.7 B).  
After 18 weeks the mice were culled, and bone marrow and spleens were harvested 
for analysis (see sections 2.7 and 2.8). Strikingly, Ythdf2-deficient HSCs displayed a 
significantly increased capacity to contribute to the bone marrow LSK, HSC, MPP, 
HPC-1, HPC-2, LK and Lin+ compartments (Figure 3.4.7 C) of the recipient mice 
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compared to control HSCs. When analysing contribution to BM differentiated cell 
compartments, Ythdf2-deficient HSCs had enhanced myeloerythroid lineage 
reconstitution capacity and compromised T-cell lineage reconstitution capacity when 
compared to control HSCs (Figure 3.4.7 D). Based on these findings we concluded 
that Ythdf2-deficient BM HSCs are able to outcompete control HSCs and display 
enhanced myeloid reconstitution capacity in primary recipients. The findings mirrored 
those obtained using FL HSCs.  
 
To further characterise the reconstitution capacity of Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre 
BM HSCs we examined the contribution of individual HSPC compartments to the 
engrafted CD45.2+ cell population as a whole (Figure 3.4.7 E). The results showed 
that Ythdf2-deficient LSK cells formed a greater proportion of CD45.2+ cells compared 
to control LSK cells, which was the result of greater HPC-1 and HPC-2 contributions 
to the CD45.2+ cell population as a whole for Ythdf2-deficient cells.  
 
We also looked at the contribution of CD45.2+ cells to the differentiated lineages in 
the spleen of primary recipients (Figure 3.4.7 F). This revealed a significant reduction 
in the donor derived chimerism within the CD8+ T cell population for recipients of 
Ythdf2-deficient cells (Figure 3.4.7 F). No other significant differences were observed 
in the spleens of Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre recipients.  
 
Next we carried out secondary transplantation. For this, we sorted CD45.2+ LSK (Lin-
Sca-1+c-Kit+) cells from the BM of culled primary recipient mice and transplanted them 
into irradiated recipient mice, as described in sections 2.14 and 2.15.1, and as shown 
in Figure 3.4.7 A.  
 
Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre CD45.2+ LSKs were sorted, and 3000 CD45.2+ LSKs 
were transplanted via the tail vein into irradiated recipient mice (CD45.1+ CD45.2+), 
together with 200 000 unfractionated bone marrow support cells (CD45.1+). However, 
at the time this experiment was carried out, a reduced irradiation dose had been 
implemented (two doses of 4.6 Gy four hours apart, as opposed to two doses of 5.5 
Gy four hours apart) in agreement with the Home Office, as an interim response to 
several unexplained post irradiation mouse deaths in the unit. Unfortunately, the 
irradiation provided was therefore sub-lethal, resulting in reduced engraftment of 
transplanted cells.      
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As a result, serial peripheral blood analysis of these secondary transplanted mice 
showed limited overall and lineage specific engraftment initially, and a collapse to 
negligible levels over the 16 weeks of observation (Figure 3.4.7 G). No significant 
difference was observed for mice transplanted with Ythdf2fl/fl or Ythdf2fl/fl;Vav-iCre 
LSKs. After 16 weeks the transplanted mice were culled and bone marrow was 
analysed, as described previously. In accordance with peripheral blood data, bone 
marrow engraftment, and contribution to HSPC compartments, was low, and there 
were no significant differences between Ythdf2-deficient and control cells (Figures 






Figure 3.4.7 Ablation of Ythdf2 enhances the function of BM HSCs. (A) 
Schematic of primary and secondary transplantation of HSCs from BM. 200 BM HSCs 
(from Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre mice) were transplanted into lethally irradiated 
8-10 week old syngeneic CD45.1+/CD45.2+ recipient mice (n = 11-13 mice per 
genotype) together with 2 x 105 CD45.1+ competitor BM cells. After 18 weeks primary 
recipient mice were culled, and 3,000 CD45.2+ BM LSK cells from primary recipients 
were transplanted into lethally irradiated 8-10-week-old syngeneic CD45.1+/CD45.2+ 
secondary recipient mice (n = 6-14 mice per genotype) together with 2 x 105 CD45.1+ 
competitor BM cells. After a further 16 weeks, secondary recipient mice were culled. 
Peripheral blood was obtained on a monthly basis from all recipient mice up to 4 
months, at which stage recipients were culled for BM analysis. (B) Percentage of 
CD45.2+ cells overall in the peripheral blood (PB) and in the monocyte, granulocyte, 
B cell and T cell compartments of the PB of primary recipients. Data are mean ± s.e.m. 
*, P<0.05; **, P<0.01, Mann-Whitney U test. (C-D) Percentage of CD45.2+ cells in the 
LSK, HSC, MPP, HPC-1, HPC-2, LK, Lin- and Lin+ (C) and differentiated (D) cell 
compartments in the BM of primary recipient mice. Data are mean ± s.e.m. *, P<0.05; 
**, P<0.01; ***, P < 0.001; ****, P < 0.0001, Mann-Whitney U test. (E) Percentage of 
LSK, MPP, HSC, HPC-1 and HPC-2 cells within the CD45.2+ cell compartment of BM 
of primary recipient mice. Data are mean ± s.e.m. ***, P < 0.001; ****, P < 0.0001, 
Mann-Whitney U test. (F) Percentage of CD45.2+ cells overall in the monocyte, 
granulocyte, B lymphocyte, erythroid, CD4+ T lymphocyte and CD8+ T lymphocyte 
compartments of the spleen of primary recipients. Data are mean ± s.e.m. *, P<0.05, 
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Mann-Whitney U test. (G) Percentage of CD45.2+ cells overall in the peripheral blood 
(PB) and in the monocyte, granulocyte, B cell and T cell compartments of the PB of 
secondary recipients. Data are mean ± s.e.m. (H) Percentage of CD45.2+ cells overall 
in the BM of secondary recipients. Data are mean ± s.e.m. (I) Percentage of CD45.2+ 
cells in the LSK, LK, Lin- and Lin+ in the BM of secondary recipient mice. Data are 
mean ± s.e.m.  
3.5 Discussion 
The results presented in this chapter demonstrate the important role that YTHDF2 
plays in normal haematopoiesis. Using the Ythdf2fl/fl mouse, in which GFP 
fluorescence reports YTHDF2 protein levels, we first showed that YTHDF2 is highly 
expressed by cells at the top of the haematopoietic differentiation hierarchy, suggesting 
it may play a role in their maintenance. Next, we used Ythdf2fl/fl; Vav-iCre conditional 
knock out mice to show that haematopoiesis-specific Ythdf2 deletion results in an 
expansion of HSPCs in both FL and adult BM, and a reduction in peripheral CD8+ T 
cells in adult mice. Finally, we used serial transplantation experiments of both FL and 
adult BM HSCs to demonstrate that Ythdf2-deficient HSCs engraft at least as well, if 
not better than, control HSCs, and retain multilineage differentiation capacity, albeit 
with a bias towards myeloid lineages and away from T lymphocyte cells.  
Our findings correlate well with previous publications about the importance of m6A in 
haematopoiesis. In particular, two recent studies have also reported an expansion of 
HSCs following Ythdf2 deletion in the mouse (Li, Qian et al. 2018, Wang, Zuo et al. 
2018). In both cases, the authors used an Mx1-Cre inducible mouse model to acutely 
delete Ythdf2 through pIpC administration, and subsequently observed increases in 
LT-HSCs and ST-HSCs. However, in both cases there was no lineage skewing, either 
in the baseline state or following BM transplantation. In contrast, we observed 
reduced peripheral CD8+ T lymphocytes in Ythdf2-deficient mice and a bias towards 
myeloid differentiation and away from T cell differentiation, by transplanted Ythdf2-
deficient HSCs. The cause of this discrepancy is unclear, but may reflect the 
differences in methodology between the three groups.  
Both Li et al. and Wang et al. used a Mx1-Cre inducible mouse model to acutely delete 
Ythdf2 through pIpC administration, followed by BM analysis (4 weeks later in the 
case of Li et al., unspecified in the case of Wang et al.) (Li, Qian et al. 2018, Wang, 
 145 
Zuo et al. 2018). In contrast, we used Vav-iCre mice, in which Ythdf2 is deleted 
specifically from the haematopoietic system shortly after the emergence of definitive 
HSCs (de Boer, Williams et al. 2003), and analysed adult mice at 8-10 weeks of age. 
Given that the Mx-1 Cre is activated in many tissues (including the liver, heart, kidney 
and spleen) upon pIpC treatment  (Kuhn, Schwenk et al. 1995), it is possible that 
Ythdf2-deletion in other cell types, for example the stromal cells of the haematopoietic 
niche (Morrison and Scadden 2014), may have influenced the phenotype observed 
by Li et al. and Wang et al. Wang et al. did also report increased LT-HSC in Ythdf2fl/fl; 
Vav-iCre mice, but no mention of multilineage differentiation, or BM transplantation 
was made in that case.  
It is also interesting to note that when Li et al. analysed their mice 5 months after pIpC 
administration, they detected only a modest increase in LT-HSCs, although they 
reported persistently greater HSC function in Ythdf2-deleted cells (Li, Qian et al. 
2018). They did not comment on the presence or absence of lineage skewing 5 
months post pIpC. 
In agreement with our findings, both Li et al. and Wang et al. reported increased 
engraftment of Ythdf2-deficient cells in BM transplantation experiments, albeit without 
lineage skewing. Once again however, there were variations in methodology between 
the groups. Given the differences in baseline HSC numbers between Ythdf2fl/fl and 
Ythdf2fl/fl;Vav-iCre mice, we elected to sort HSCs for primary transplantation (100 FL 
HSCs, 200 BM HSCs), in order to compare Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre HSC 
function in an objective manner. In contrast, Li et al. transplanted unfractionated total 
bone marrow in both primary and secondary transplantations (Li, Qian et al. 2018), 
whilst Wang also used unfractionated total bone marrow for secondary 
transplantations (Wang, Zuo et al. 2018).  
Although Li et al. did not report any lineage skewing following acute Ythdf2 deletion, 
other publications do suggest that m6A plays a role in haematopoietic multilineage 
differentiation. An increase in myeloid differentiation has been reported following 
shRNA-mediated depletion of METTL3 (Vu, Pickering et al. 2017) or METTL14 
(Weng, Huang et al. 2018) in human HSPCs. Furthermore, multiple papers suggest 
that m6A impacts upon the homeostasis of peripheral white blood cell subsets. 
Deletion of Mettl3 has been shown to maintain CD4+ T cells in a naïve state (Li, Tong 
et al. 2017), and to inhibit the suppressor capacity of FoxP3+ T cells (Tong, Cao et al. 
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2018), whilst deletion of Ythdf1 from dendritic cells improves their capacity for CD8+ 
T cell priming (Han, Liu et al. 2019).  
Deletion of Mettl3 in CD4+ T cells was reported to control T cell homeostasis by 
targeting the IL-7/STAT5/SOCS pathways (Li, Tong et al. 2017). This is interesting in 
the context of our own observations, since it is known that Interleukin-7 (IL-7) also 
mediates the homeostasis of naïve and memory CD8+ T cells (Schluns, Kieper et al. 
2000). It is therefore possible that the decreased peripheral CD8+ T cells we observe 
in Ythdf2fl/fl;Vav-iCre mice may also reflect alterations in IL-7 levels brought about by 
defective m6A dependent processes.  
Either way, it is clear that this area deserves further work, particularly when the 
caveats of our immune cell analyses are considered. For example, the Ythdf2fl/fl;Vav-
iCre and Ythdf2fl/fl mice were analysed at 8-10 weeks of age. It is known that the 
cellularity of the mouse thymus expands rapidly after birth, reaching a plateau at 4-
6 weeks of age, after which the thymus starts to involute (Gray, Seach et al. 2006). 
For this reason, studies of the mouse thymus generally use 4-6-week-old mice 
(Bornstein, Nevo et al. 2018). Furthermore, in our experience thymic involution and 
surrounding fat deposition makes accurate harvesting of the intact thymus challenging 
in older mice, whilst lower thymic cell counts potentially limit the power of any 
subsequent conclusions. Finally, CD4 and CD8 antibody staining is only a small 
component of complete immunophenotypic thymic evaluation, which could also 
include staining for CD25, CD44, B220, TCR β, CD5 and CD69 (Biosciences and 
Jose 2012). In summary therefore, the role of Ythdf2 in T lymphocyte biology is an 
intruiging subject and warrants further study.  
In this chapter, haematopoietic evaluation of both FL and adult BM is presented. The 
repopulation potential of foetal liver HSCs in mice has been reported to exceed that 
of their adult BM counterparts (Rebel, Miller et al. 1996). Consistent with this, we 
observed a greater engraftment of transplanted FL HSCs (53-57% at 4 months) 
compared to BM HSCs (21-23% at 4 months) in primary recipient mice. Nevertheless, 
in contrast to some studies, which have reported opposing results in FL and adult BM 
studies (Kim, Saunders et al. 2007), the general pattern of our results was very similar 
i.e. increased number and function of HSCs in Ythdf2-deficient embryos/adult mice, 
with a myeloid bias upon transplantation.  
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In addition to the increase in HSCs we observed in Ythdf2-deficient mice, there were 
also increases in the HPC-1 and HPC-2 compartments. In contrast, MPP cells were 
either unchanged in number (BM), or decreased (FL) in number. Li et al. also reported 
increases in LT-HSCs and ST-HSCs, but no change in MPPs, in Ythdf2-deficient mice 
(Li, Qian et al. 2018). The reason for this is unclear, but could reflect a blockage at 
the HPC stage of differentiation.  
 
HSC transplantation of irradiated primary recipient mice resulted in an equal overall 
engraftment of Ythdf2-deficient cells compared to control cells, with the exception of 
week 2 for adult BM, when engraftment of Ythdf2-deficient HSC engraftment lagged 
behind that of control HSC engraftment (Figure 3.4.7 B). Reduced early engraftment 
might suggest a homing defect (Szilvassy, Meyerrose et al. 2001, Lapidot, Dar et al. 
2005, Liang, Van Zant et al. 2005). However, both Li et al. and Weng et al. found no 
evidence for homing defects in Ythdf2-deficient HSCs (Li, Qian et al. 2018, Wang, 
Zuo et al. 2018). Furthermore, multiple publications suggest that HSCs with homing 
defects fail to achieve efficient long-term reconstitution (Ishikawa, Chang et al. 2013, 
Ruppert, Moser et al. 2015). Given that we demonstrated increased long-term 
reconstitution of the HSC compartment by Ythdf2-deficient HSCs, significant homing 
effects are considered unlikely.  
To further study the effects of Ythdf2 deletion, additional work is being carried out by 
our group, including acute deletion in the Mx1-Cre model and 5-FU injections to 
explore the ability of Ythdf2-deficient cells to respond to stress. In addition, Ythdf2fl/fl 
and Ythdf2fl/fl;Vav-iCre mice are being aged, in order to evaluate the effect of long 
term Ythdf2 deficiency on haematopoiesis and the potential for malignant 
transformation. 
In conclusion, the work presented in this chapter shows that deletion of Ythdf2 results 
in an expansion of HSCs which retain the capacity for multilineage reconstitution in 
serial transplantation assays. This suggests that targeting of YTHDF2, for example 
through the use of small molecule inhibitors (currently in production, personal 
communication), may provide a means by which to expand human HSCs in vitro, and 
potentially also in vivo, for therapeutic purposes. HSCT is regarded as the optimal 
treatment for a variety of diseases, including leukaemia, autoimmunity, bone marrow 
failure syndromes, and also in gene therapy settings (Copelan 2006) but is limited by 
a shortage of HSCs (see section 1.1.8 for a discussion of current expansion 
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strategies). In this context, our findings suggest that pharmacological targeting of 
YTHDF2 may be an exciting future therapeutic strategy for HSCT.   
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4.1.1 The role of m6A in acute myeloid leukaemia 
 
Having characterised the important role of YTHDF2 in normal haematopoiesis, 
namely in regulating HSC maintenance and myeloid differentiation, we next sought to 
establish the role of YTHDF2 in the context of malignant haematopoiesis, specifically 
acute myeloid leukaemia (AML).  
 
In the last few years, it has become clear that m6A plays a critical role in AML. 
However, the studies to date have focused only on m6A writers or erasers, whilst the 
role of m6A writers, YTHDF2 included, has not yet been investigated (Figure 4.1.1 
and Table 1.3.5).  
 
 
Figure 4.1.1 The role of m6A regulators in AML. Studies have revealed an essential 
requirement for the m6A writers METTL3 and METTL14, and for the m6A eraser FTO 
in AML (Barbieri, Tzelepis et al. 2017, Li, Weng et al. 2017, Vu, Pickering et al. 2017, 
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Su, Dong et al. 2018, Weng, Huang et al. 2018, Yao, Sang et al. 2018). Inhibition of 
these m6A regulators inhibits LSCs and AML. However, the role of m6A readers, 
including YTHDF2, remains unknown.  
Several studies have shown an essential requirement for m6A writers in acute myeloid 
leukaemia. According to the Caner Genome Atlas (TCGA; 
https://cancergenome.nih.gov/) members of the m6A writer complex, particularly 
METTL3, and RBM15, are highly expressed in AML compared to other cancer types 
(Cerami, Gao et al. 2012, Gao, Aksoy et al. 2013). High expression of METTL3 and 
METTL14 in both human and mouse AML cells has also been reported in several 
focused studies (Barbieri, Tzelepis et al. 2017, Vu, Pickering et al. 2017, Sorci, 
Ianniello et al. 2018, Weng, Huang et al. 2018). Furthermore, a genome wide CRISPR 
based screen to identify genes essential for cell survival using 14 human AML cell 
lines ranked all members of the writer complex, including METTL3, METTL14, WTAP 
and KIAA1429, amongst the top 10% in the list of essential genes (Vu, Pickering et 
al. 2017, Wang, Yu et al. 2017).  
Barbieri et al. reported similar findings in mouse AML cells (Barbieri, Tzelepis et al. 
2017). This study used two distinct genetic screens, both based on the CRISPR Cas9 
system (first a genome wide screen, second a focused screen with a custom domain-
focused guide RNA library) to identify Mettl3 as an essential gene for growth of AML 
cells. Results of both the CRISPR Cas9 screen and shRNA knockdown of Mettl3 
showed that downregulation of Mettl3 causes cell cycle arrest and differentiation of 
AML cells (increased expression of CD11b), and failure to establish leukaemia in 
immunodeficient mice. They went on to show that METTL3, independently of 
METTL14, associates with chromatin, and localises to the transcriptional start site 
(TSS) of active genes (most of which have CEBPZ protein present at the TSS, which 
is required for METTL3 recruitment). They reported that promoter bound METTL3 
induces m6A modification in the coding region of the associated mRNA and enhances 
its translation by relieving ribosome stalling. In contrast, depletion of Mettl3 had no 
effect on transcription of METTL3 bound genes (Barbieri, Tzelepis et al. 2017).  
 
The role of METTL3 has also been reported in human AML cells (Vu, Pickering et al. 
2017). Vu et al. showed that METTL3 mRNA and protein are expressed more 
abundantly in human AML cells versus healthy HSPCs or other tumour types. They 
also showed that shRNA mediated depletion of METTL3 in human AML cell lines 
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leads to apoptosis and differentiation, and delays leukaemogenesis in vivo.  Using 
single-nucleotide-resolution mapping of m6A coupled with ribosome profiling, they 
went on to show that m6A promotes the translation of c-MYC, BCL2 and PTEN 
mRNAs in the MOLM13 AML cell line. They reported that loss of METTL3 increases 
phosphorylated AKT, thereby contributing to differentiation (Vu, Pickering et al. 2017).  
 
METTL14 has also been shown to promote leukaemogenesis via mRNA m6A 
modification (Weng, Huang et al. 2018). Weng et al. reported impaired colony 
formation in vitro and delayed leukaemia initiation in vivo by Mettl14-deficient cells 
(using a murine Mll-AF9 model). Similar findings were observed in secondary 
recipients, suggesting that METTL14 is required for both initiation and maintenance 
of AML. The authors went on to show that METTL14 depletion also impairs survival 
and growth of human AML cells (in vitro and in vivo xenotransplantation assays), and 
promotes ATRA induced myeloid cell differentiation. Using a combination of RNA-Seq 
and m6A-Seq, the authors identified METTL14 targets (hypomethylated), including 
MYB and MYC. Notably, in the majority of targets, mRNA levels were downregulated 
upon METTL14 knockdown. They went on to show that METTL14 knockdown 
regulates MYB and MYC expression by modulating mRNA stability (experiments 
performed with the transcription inhibitor actinomycin D) and mRNA translation 
(polysome profiling experiments). Since the authors were unable to identify a 
consistent pattern for YTHDF genes during drug induced differentiation of AML cells, 
and knockdown of YTHDF genes had no effect on MYB and MYC, the authors 
concluded that the effect of METTL14 on mRNA stability and translation of its target 
genes was unlikely to be mediated by YTHDF proteins (Weng, Huang et al. 2018).  
 
In addition to METTL3 and METTL14, there is evidence that other components of the 
m6A writer complex also play a role in AML, specifically WTAP and RBM15. WTAP 
was first identified as an interactor of the Wilms Tumour-1 (WT-1) protein (Little, 
Hastie et al. 2000). A subsequent study showed that WTAP levels are increased in 
human AML samples when compared to mononuclear blood cells from healthy 
patients, with elevated WTAP expression reported in 32% of newly diagnosed AML 
patients. Knockdown of WTAP reduced proliferation and clonogenic survival in AML 
cell lines and primary human AML samples in vitro, and leukaemogenesis in vivo 
(tumour xenograft experiments in nude mice). In addition, knockdown of WTAP also 
promoted phorbol 12-myristate 13-acetate (PMA)-induced myeloid differentiation 
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(Bansal, Yihua et al. 2014). More recent work by Sorci et al. showed that METTL3 
levels are essential for WTAP protein homeostasis, with both knockdown and 
overexpression of METTL3 resulting in elevated WTAP protein levels (Sorci, Ianniello 
et al. 2018). Importantly, the authors also showed that upregulation of WTAP in the 
absence of METTL3 is not sufficient to promote cell proliferation, leading them to 
conclude that the oncogenic function of WTAP is strictly connected to a functional 
m6A methylation complex (Sorci, Ianniello et al. 2018).  
 
RBM15, another component of the m6A writer complex, has also been implicated in 
acute myeloid leukaemia. Chromosomal translocations of RMB15 with the MAL gene 
have been shown to mediate acute megakaryoblastic leukaemia (Gruber and 
Downing 2015). RBM15 is known to play important roles in controlling HSC 
quiescence and differentiation of megakaryoblastic leukaemic cells by regulating the 
splicing of key haematopoietic differentiation genes, including GATA1, RUNX1, TAL1 
and c-MPL (Zhang, Tran et al. 2015). Given that RBM15 is involved in m6A formation 
in the transcriptome, the oncogenic effects of RBM15 overexpression and RBM15-
MAL translocation might reflect abnormal m6A formation.  
 
In contrast to m6A writers, whose requirement in AML is undisputed, the role of m6A 
demethylases is currently unclear. An initial study by Li et al. in 2017 reported that 
FTO plays an oncogenic role in AML as an m6A demethylase (Li, Weng et al. 2017). 
These authors showed that FTO is highly expressed in AML, particularly in MLL-
rearranged AML, and reported that oncogenic transformation of murine bone marrow 
cells increases the levels of FTO, both at the RNA and protein level. Through in vitro 
overexpression and knockdown studies, they showed that FTO promoted cell 
transformation and proliferation and reduced apoptosis, whilst forced expression of 
FTO in vivo hastened development of MLL-induced leukaemia in recipient mice. 
Interestingly, when these authors performed m6A-Seq and RNA-Seq on control cell 
lines and those overexpressing FTO, they found that potential FTO targets (i.e. those 
whose methylation decreased upon FTO overexpression, for example ASB2 and 
RARA) appeared to be negatively regulated by FTO i.e. their mRNA levels decreased 
upon FTO overexpression. Since this finding was counter-intuitive to the idea of m6A 
directed YTHDF2-mediated degradation, the authors proposed that a separate, 
YTHDF2 independent mechanism, was responsible for the reduced stability of FTO 
targets (Li, Weng et al. 2017).  
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However, there are several caveats to the conclusions of this initial paper. Firstly, in 
a CRISPR-based screen designed to identify genes essential for cell survival, the 
depletion of FTO did not show a substantial effect on AML cell viability across most 
of the 14 AML cell lines studied (Wang, Yu et al. 2017). Secondly, although FTO was 
originally thought to demethylate m6A, it has since been shown to act primarily as a 
demethylase of m6Am (the N6 -2’-O-dimethyladenosine modification in mRNA 5’ caps) 
(Mauer, Luo et al. 2017). Thirdly, it has been pointed out that FTO is an 𝛼-
ketoglutarate (𝛼-KG)-dependent dioxygenase, and as such will be competitively 
inhibited by the structurally related metabolite D-2-hydorxyglutarate (D2-HG), which 
accumulates in isocitrate dehydrogenase 1 or 2 (IDH1/2)-mutant tumours, including 
20% of AMLs. For this reason, any effect of FTO has to be determined based on the 
IDH mutation status of an AML sample (Elkashef, Lin et al. 2017).  
 
Whilst the requirement for m6A demethylases in AML is less well defined at present 
than that of m6A writers, the role of m6A readers remains completely unexplored. With 
this in mind, and building on our findings in normal haematopoiesis (see Chapter 3) 
we examined the role of YTHDF2 in acute myeloid leukaemia. The results of this work 
are presented in this chapter.  
 
4.1.2 Leukaemia models  
 
In this chapter, a retroviral transduction/transformation assay (RTTA) was used to 
study the effect of Ythdf2 deficiency in acute myeloid leukaemia driven by the co-
expression of Meis1/Hoxa9 oncogenes, or by expression of an oncogenic fusion (Mll-
AF9, PML-RARA, MOZ-TIF2).  
 
In RTTA, HSPCs are transduced with oncogenes or oncogenic fusion proteins, and 
serially re-plated in cytokine-supplemented semi-solid media prior to selection and 
transplantation to irradiated recipient mice (Lavau, Szilvassy et al. 1997).  
RTTA has been used successfully for several decades to generate pathological AML 
from a variety of oncogenic drivers in mice (Lavau, Szilvassy et al. 1997, 
Thorsteinsdottir, Sauvageau et al. 1997, Kroon, Krosl et al. 1998, Lavau, Luo et al. 
2000, Kroon, Thorsteinsdottir et al. 2001). Advantages of the technique over 
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transgenic models include the ability to evaluate the action of an oncogene in a 
specific subset of murine HSPCs, to study leukaemic transformation using human 
HSPCs in xenograft models, or to evaluate multiple oncogenes in parallel experiments 
using HSPCs from one mouse strain of genetic interest. Furthermore, retrovirally 
transduced cells can be tracked based on expression of reporter markers (for 
example GFP), facilitating monitoring of AML development and propagation. 
Nevertheless, there are also limitations to RTTA, most notably the potential for 
uncontrolled and potentially supra-physiological levels of oncogene expression. This 
is an important consideration given that the transforming effects of cellular 
oncogenes, including MLL fusions, MYC, BCR-ABL and CEBPA, may differ 
significantly depending on their expression levels (Caslini, Serna et al. 2004, Ren 
2004, Chapiro, Russell et al. 2006, Chen, Kumar et al. 2008). Furthermore, limited 
control over the retroviral integration site during RTTA can lead to insertional 
mutagenesis, which means that the MSCV retroviral vector itself is associated with 
leukaemogenesis (Du, Jenkins et al. 2005).  
4.1.2.1 Meis1/Hoxa9 
 
The Meis1/Hoxa9 retroviral AML mouse model is well characterised and has been 
widely used in leukaemic studies (Kroon, Krosl et al. 1998, Thorsteinsdottir, Kroon et 
al. 2001, Lessard and Sauvageau 2003, Zeisig, Milne et al. 2004, Vukovic, Guitart et 
al. 2015, Guitart, Panagopoulou et al. 2017).  
 
Forced expression of Hoxa9 in murine HSPCs is sufficient to induce leukaemic 
transformation in murine HSPCs, albeit with a long latency (Thorsteinsdottir, Kroon et 
al. 2001). Whilst retroviral overexpression of Meis1 in murine HSPCs does not induce 
proliferation or leukaemic transformation in isolation, co-expression of Meis1 and 
Hoxa9 significantly reduces the latency of leukaemia induced by Hoxa9 alone 
(median survival 54 days Meis1/Hoxa9 versus 185 days Hoxa9 alone) (Kroon, Krosl 
et al. 1998, Thorsteinsdottir, Kroon et al. 2001). Affected mice succumb to a myeloid 
leukaemia composed of approximately 77% blast cells versus 23% more mature 
myeloid cells (consistent with FAB M2 classification), with infiltration of spleen, lymph 
nodes and thymus in addition to BM (Thorsteinsdottir, Kroon et al. 2001).  
 
Co-activation of MEIS1 and HOXA9 is a common feature of human AML of all 
subtypes except promyelocytic leukaemia (Lawrence, Rozenfeld et al. 1999) and is 
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associated with high-risk AML subtypes (Drabkin, Parsy et al. 2002). This, in 
combination with its high penetrance and short latency, makes the Meis1/Hoxa9 
retroviral AML mouse model an effective tool for studying AML in vivo.  
 
4.1.2.2 Mll-AF9 
MLL-AF9 has been successfully used in the RTTA in several publications (Krivtsov, 
Twomey et al. 2006, Somervaille and Cleary 2006, Chen, Kumar et al. 2008, Thiel, 
Blessington et al. 2010), and a high correlation of CFC activity with leukaemogenic 
potential has been reported in this model of AML (Somervaille and Cleary 2006). Mice 
transplanted with MLL-AF9 transduced cells develop AML at a high frequency (100% 
reported), with a median latency of 84.5 days (range 60-121) (Somervaille and Cleary 
2006). MLL-AF9 leukaemia has been shown to follow a stem cell model (Krivtsov, 
Twomey et al. 2006, Somervaille and Cleary 2006), in which the bulk of leukaemic 
cells are derived from a rare population of cells (LSCs) capable of the limitless self-
renewal necessary for cancer initiation and maintenance. It has been demonstrated 
that retroviral delivery of MLL-AF9 can be used to transform both early haematopoietic 
progenitors (Somervaille and Cleary 2006) and more committed haematopoietic 
progenitors (Krivtsov, Twomey et al. 2006), although this indiscriminate 
transformation capacity may simply be a gene dosage effect, given the supra-
physiological levels of MLL-AF9 expression in this model (Chen, Kumar et al. 2008). 
Transformation by MLL-AF9 induces aberrant expression of the MLL-AF9 target 
genes HOXA9 and MEIS1, whose continued expression is essential for maintaining 
MLL-fusion mediated immortalisation (Ayton and Cleary 2003, Zeisig, Milne et al. 
2004).   
4.1.2.3 PML-RARA 
Retroviral transduction of murine HSPCs with PML-RARA induces retinoic acid-
sensitive promyelocytic leukaemias at a high frequency (>80%) with a latency of 
approximately 4 months (Minucci, Monestiroli et al. 2002). Retroviral PML-RARA is 
believed to be a ‘multiple-hit’ murine AML model, in which the fusion protein causes 
a “preleukaemic” phase and leukaemia occurs after additional genetic lesions 
(Minucci, Monestiroli et al. 2002).  
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4.1.2.4 MOZ-TIF2 
Retroviral transduction of murine HSPCs with MOZ-TIF2 generates AML at a high 
frequency (100% penetrance), with a short latency of approximately 3 months 
(Deguchi, Ayton et al. 2003). MOZ-TIF2 has been identified as a leukaemia oncogene 
with the capacity to transform committed myeloid progenitor cells, which would 




Based on the evidence presented in this introduction, we hypothesised that YTHDF2 
might play a role in the development and maintenance of acute myeloid leukaemia.  
 
The aim of this chapter was therefore to investigate the requirement for YTHDF2 at 
different stages of leukaemic transformation.  
 
4.3 Outline of experiments described in Chapter 4 
 
To investigate the functional requirement for YTHDF2 in leukaemogenesis, a 
retroviral transduction and transformation assay was used to generate pre-leukaemic 
stem cells (pre-LSCs) transformed with Meis1/Hoxa9 oncogenes, or with an 
oncogenic fusion (Mll-AF9, PML-RARA or MOZ-TIF2), and these cells were 
transplanted to irradiated primary recipient mice. Upon development of leukaemia in 
these mice, leukaemic stem cells (LSCs) were harvested and transplanted to 
irradiated secondary recipient mice. The effect of Ythdf2 deficiency was studied using 
Ythdf2fl/fl;Vav-iCre conditional knock out mice, in which Ythdf2 is specifically ablated 
within the hematopoietic system shortly after the emergence of definitive HSCs (de 
Boer, Williams et al. 2003). The effect of acute Ythdf2 deletion was studied using 
Ythdf2fl/fl;Mx1-Cre inducible conditional knock out mice, in which Ythdf2 deletion is 
induced by polyinosinic:polycytidylic acid (pIpC) administration (Kuhn, Schwenk et al. 






4.4.1 Ythdf2 is required for leukaemic transformation in vitro 
 
In order to assess the effect of Ythdf2-deficiency on leukaemic transformation in vitro, 
a retroviral transduction and transformation assay (RTTA) was employed. The Vav-
iCre system was used to generate mice lacking Ythdf2 specifically within the 
haematopoietic system, as previously described (see section 3.4.2).   
 
HSPCs (c-Kit+ cells) were harvested from the FL of E14.5dpc Ythdf2fl/fl;Vav-iCre and 
Ythdf2fl/fl (control) embryos, and transduced with retroviruses co-expressing Meis1 
and Hoxa9 oncogenes, or expressing chromosomal translocations known to be 
involved in leukaemogenesis (Mll-AF9, MOZ-TIF2, PML-RARA), as described in 
sections 2.11 and 2.12. In the case of Mll-AF9 and MOZ-TIF2, whose vectors contain 
a GFP selection cassette, C57BL/6 HSPCs (which are GFP-) were transformed as 
controls in place of Ythdf2fl/fl HSPCs (which are GFP+), to facilitate FACS sorting of 
transformed (GFP+) cells.   
 
Transduced cells were serially re-plated using the colony forming assay (see section 
2.13.2) as an in-vitro measure of self-renewal capacity.   
Both Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre cells were able to form colonies after 
transduction with Meis1/Hoxa9, or with any one of the three oncogenic fusions studied 
(Mll-AF9, MOZ-TIF2, PML-RARA). However, Ythdf2fl/fl;Vav-iCre pre-LSCs generated 
significantly fewer colonies compared with Ythdf2fl/fl pre-LSCs in all cases (Figure 
4.4.1 A-D), although this effect was less marked in the case of Mll-AF9 (Figure 4.4.1 
C). Furthermore, there was a clear difference in the morphology of colonies derived 
from Ythdf2-deficient pre-LSCs, when compared to control pre-LSCs (Figure 4.4.1 E-
F). Control colonies were predominantly compact and dense, whereas Ythdf2-
deficient colonies were smaller, looser and less well defined. Colony morphology is 
reported to reflect cell differentiation status (Lavau, Szilvassy et al. 1997). Lavau et 
al. showed that HRX-ENL transformed cells generated three types of colonies in serial 
replating assays. Most (50–80%) were very compact and resembled colonies 
generated by primitive hematopoietic cells. A smaller subset (20–40%) had a compact 
centre with a diffuse halo of differentiating cells, and a third minor subset (15%) was 
comprised of large diffuse colonies. They went on to show that the compact colonies 
contained immature myeloid cells, whereas the diffuse colonies also included 
differentiated macrophages. Consistent with this observation, diffuse colonies had a 
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lower frequency of replating (only 1 in 5 diffuse colonies replated) compared with 
compact colonies (Lavau, Szilvassy et al. 1997). The colony morphology and replating 
capacity we observed in Ythdf2-deficient cells therefore suggested that pre-LSC 
differentiation might be increased in the absence of Ythdf2.  
Overall, our results indicated that Ythdf2 is required for leukaemic transformation in 






Figure 4.4.1 Ythdf2-deficient c-Kit+ cells show reduced transformation capacity 
in vitro. (A-D) Serial re-plating colony counts for HSPCs transformed with (A) 
Meis1/Hoxa9 (B) PML-RARA (C) Mll-AF9 (D) MOZ-TIF2. (E-F) Representative colony 
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images (10X magnification) for (E) Ythdf2fl/fl and (F) Ythdf2fl/fl;Vav-iCre HSPCs 
transformed with MOZ-TIF2. Data are mean ± s.e.m, n = 4-6. Unpaired t-test.  
 
4.4.2 Immunophenotypic characterisation of transformed colonies 
 
In order to further explore the reduced transformation capacity of Ythdf2-deficient cells 
compared to control cells, immunophenotypic characterisation of pre-LSCs was 
carried out. Meis1/Hoxa9 transformed pre-LSCs were harvested from CFC3 colonies 
and cultured in liquid media (see section 2.5) prior to evaluation. Cells were stained 
with antibodies against mature myeloid markers (Gr-1 and CD11b) and the immature 
cell marker c-Kit, then analysed by flow cytometry (see section 2.8). Both Ythdf2fl/fl 
and Ythdf2fl/fl;Vav-iCre pre-LSCs expressed c-Kit and the myeloid markers Gr-1 and 
CD11b (Figure 4.4.2). There was a trend towards reduced monocytic differentiation 
(Gr-1- CD11b+) and greater granulocytic differentiation (Gr-1+ CD11b+) in Ythdf2-
deficient pre-LSCs, but it was not statistically significant. No other differences were 






Figure 4.4.2 Immunophenotypic characterisation reveals no differences 
between Ythdf2-deficient and control Meis1/Hoxa9 transformed pre-LSCs. 
Percentage of (A) c-Kit+ cells (B) Gr-1+ CD11b+ cells (C) Gr-1+ CD11b+ c-Kit+ cells (D) 
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Gr-1- CD11b+ cells (E) Gr-1- CD11b+ c-Kit+ cells from Ythdf2-deficient and control 
Meis1/Hoxa9 transformed pre-LSCs. Data are mean ± s.e.m, n = 5. Mann-Whitney U 
test. 
 
4.4.3. Ythdf2 inactivation compromises development of Meis1/Hoxa9 leukaemia 
in vivo 
 
In order to assess the role of Ythdf2 in development of leukaemia in vivo, 
Meis1/Hoxa9 pre-LSCs generated by RTTA (see sections 2.11-2.13) were 
transplanted to irradiated recipient mice, as described in section 2.15.2, and as shown 
in Figure 4.4.3 A. HSPCs were harvested from FL of Ythdf2fl/fl (control), Ythdf2+/fl;Vav-
iCre (heterozygote) and Ythdf2fl/fl;Vav-iCre (Ythdf2-deficient) E14.5dpc embryos and 
transformed with Meis1/Hoxa9 prior to serial re-plating in vitro.  Pre-LSCs were 
harvested at CFC3 and 100 000 cells (CD45.2+) were transplanted via the tail vein 
into lethally irradiated (11 Gy) recipient mice (CD45.1+ CD45.2+), together with 200 
000 unfractionated bone marrow support (CD45.1+). Leukaemic monitoring was 
carried out as described in section 2.15.4, with CD45.1 and CD45.2 staining used to 
monitor engraftment of leukaemic cells against the background of recipient and 
support bone marrow cells.   
Serial peripheral blood analysis showed slower engraftment of leukaemic cells in 
recipients of Ythdf2-deficient pre-LSCs (Figure 4.4.3 B) compared to control cells. At 
20 days post transplantation, donor-derived chimerism in the peripheral blood was 
5% for recipients transplanted with Ythdf2-deficient pre-LSCs and 43% for those 
transplanted with control pre-LSCs. By 60 days, chimerism was 81% compared with 
2%, for Ythdf2-deficient pre-LSCs and control pre-LSCs respectively. Interestingly, 
engraftment in recipients of heterozygous (Ythdf2+/fl;Vav-iCre) pre-LSCs was midway 
between that of control and Ythdf2-deficient cells at all time points, consistent with a 
dose dependent phenotype.  
When recipient mice started to show signs of sickness, such as shortness of breath, 
hunched posture, pale paws, weight loss and reduced motion, they were culled and 
date of death was registered. Predictably, the slower engraftment of Ythdf2-deficient 
cells was reflected in the final Kaplan Meier survival curve (Figure 4.4.3 C), which 
showed a significantly longer median survival in recipients of Ythdf2-deficient pre-
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LSCs (147.5 days) compared to control pre-LSCs (68 days), and heterozygous pre-
LSCs (103 days).  
Since this initial pilot experiment was carried out with one biological replicate 
(transplanted to 6 recipients each) per genotype, a follow up experiment was 
performed, this time with 3 biological replicates (transplanted to 3-5 recipients each) 
for both Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre genotypes. This experiment confirmed the 
reproducibility of the preliminary result, with the Kaplan Meier survival curve showing 
a significantly longer survival for recipients of Ythdf2-deficient cells (97 days) 
compared with control cells (48 days) (Figure 4.4.3 D).  
Post mortem examination of culled leukaemic mice revealed pale bones and grossly 
enlarged spleens (Figure 4.4.3 E) compared to healthy mice. However, spleen weight 
did not differ between leukaemic mice transplanted with control or Ythdf2-deficient 
cells (Figure 4.4.3 F).   
Bone marrow of culled leukaemic mice was analysed by flow cytometry (see sections 
2.7 and 2.8). This showed a complete absence of GFP expression in Ythdf2fl/fl;Vav-
iCre LSCs, confirming continued lack of Ythdf2 expression in these cells (Figure 4.4.3 
G). Consistent with the clinical picture, the bone marrow was almost entirely effaced 
by CD45.2+ LSCs (Figure 4.4.3 H), the majority of which were Gr-1+ CD11b+ or Gr-1- 
CD11b+, consistent with myeloid leukaemia (Figure 4.4.3 I). A moderate proportion 
of LSCs was also c-Kit+ (Figure 4.4.3 J). Notably, in spite of the longer latency of 
Ythdf2-deficient leukaemia, and consistent with the findings in pre-LSC cells, there 








Figure 4.4.3 Ythdf2 inactivation compromises development of leukaemia in a 
Meis1/Hoxa9 murine AML model (A) Ythdf2fl/fl (control), Ythdf2+/fl;Vav-iCre 
(heterozygote) and Ythdf2fl/fl;Vav-iCre (Ythdf2-deficient) FL c-Kit+ cells were co-
transduced with Meis1 and Hoxa9 retroviruses and serially re-plated. 100,000 c-Kit+ 
pre-leukaemic cells were transplanted into lethally irradiated recipient mice (n = 6 per 
genotype) together with 200,000 BM support cells. (B) Percentage of CD45.2+ 
leukaemic cells in the peripheral blood of the recipient mice 20-60 days after 
transplantation. Data are mean ± s.e.m, n = 6. *, P < 0.05; **, P<0.01. Mann-Whitney 
U test. (C) Kaplan-Meier survival curve of the recipient mice (n = 6 per genotype), **, 
P<0.01; ***, P < 0.001. Log-rank (Mantel-Cox test). (D) Repeat experiment Kaplan 
Meier survival curve (n = 11-15 per genotype), ****, P < 0.0001 Log-rank (Mantel-Cox 
test). (E) Appearance of spleens from culled leukaemic mice, and a healthy control. 
(F) Speen weights from culled leukaemic mice transplanted with Ythdf2fl/fl and 
Ythdf2fl/fl;Vav-iCre cells. Data are mean ± s.e.m, n = 9-17 recipients per genotype. (G) 
Percentage of GFP-expressing cells as a measure of YTHDF2 expression in Ythdf2fl/fl 
and Ythdf2fl/fl;Vav-iCre leukaemic cells within the bone marrow of culled recipient 
mice, n = 5-6 per genotype. (H) Percentage of leukaemic (CD45.2+) cells within total 
bone marrow of culled recipient mice, n = 5-6 per genotype. (I-J) Percentage of (I) 
myeloid cells (CD11b+± Gr-1+) and (J) c-Kit+ cells within CD45.2+ leukaemic bone 
marrow cells of culled recipient mice, n = 5-6 per genotype.  
4.4.4. Ythdf2 inactivation may compromise development of Mll-AF9 leukaemia 
in vivo 
 
Having established that Ythdf2 inactivation compromises the development of 
Meis1/Hoxa9 leukaemia in a murine retroviral model in vivo, we next sought to 
corroborate this in another retroviral murine AML model. Initially, we attempted to do 
so using pre-LSCs generated through RTTA with MOZ-TIF2 retrovirus. However, due 
to the small numbers of Ythdf2-deficient colonies generated by serial replating in vitro 
(see section 4.4.1), it was only possible to transplant 10 000 CFC3 pre-LSCs per 
mouse (to 6 mice in total per genotype), despite the use of 3 biological replicates, 
each of which was plated in duplicate. Sequential peripheral blood analysis over the 
following 6 months showed no evidence of leukaemic engraftment by either control, 
or Ythdf2-deficient pre-LSCs, therefore this experiment was discontinued. Next, we 
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attempted to study the effect of Ythdf2 deficiency in a separate model of AML by using 
pre-LSCs generated through RTTA with Mll-AF9 retrovirus (see section 4.4.1). Mll-
AF9 transformed C57BL/6 and Ythdf2fl/fl;Vav-iCre pre-LSCs were harvested at CFC3, 
and 100 000 cells (CD45.2+) were transplanted via the tail vein into lethally irradiated 
(11 Gy) recipient mice (CD45.1+ CD45.2+), together with 200 000 unfractionated bone 
marrow support cells (CD45.1+). Leukaemic monitoring was carried out as previously 
described (see section 2.15.4). 
Analysis of the transplanted population showed no difference in surface marker 
expression between control and Ythdf2fl/fl;Vav-iCre pre-LSCs (Figure 4.4.4 A-B). Mll-
AF9 pre LSCs were mostly myeloid (CD11b+±Gr-1+) (Figure 4.4.4 A), and 
approximately 20% expressed c-Kit (Figure 4.4.4 B).  
Peripheral blood analysis 3 weeks after transplantation showed lower engraftment of 
leukaemic cells in recipients of Ythdf2-deficient pre-LSCs compared to control pre-
LSCs (Figure 4.4.4 C). Donor-derived chimerism in the peripheral blood was 3% for 
recipients transplanted with Ythdf2-deficient pre-LSCs and 11% for those 
transplanted with control pre-LSCs. However, this difference was no longer significant 
at 6 and 9 weeks (Figure 4.4.4 C), and the Kaplan Meir survival curves for recipients 
of Ythdf2-deficient and control pre-LSCs are also relatively similar to date (Figure 
4.4.4 D). The role of Ythdf2 in Mll-AF9 leukaemia is therefore still unclear. For further 
discussion, please see section 4.5.  
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Figure 4.4.4 Ythdf2 inactivation may compromise development of leukaemia in 
a Mll-AF9 murine AML model. Percentage of (A) myeloid cells (CD11b+± Gr-1+) and 
(B) c-Kit+ cells within CD45.2+ pre-LSC population at the time of transplantation. Data 
are mean ± s.e.m, n = 5. (C) Percentage of CD45.2+ leukemic cells in the peripheral 
blood of the recipient mice 3, 6 and 9 weeks after transplantation. Data are mean ± 
s.e.m, n = 10 per genotype. *, P < 0.05. Mann-Whitney U test. (D) Kaplan-Meier 
survival curve of the recipient mice (n = 10 per genotype). 
4.4.5 Acute deletion of Ythdf2 impairs LSC development and AML propagation 
in mice  
 
Having established that Ythdf2 is required for the development of Meis1/Hoxa9 
leukaemia using the Vav-iCre system, we next sought to establish the effect of acute 
Ythdf2 deletion using an inducible model. To do so, we made use of the Mx1-Cre 
model (Kuhn, Schwenk et al. 1995), which has been widely used in experimental 
haematology by numerous groups (Gao, Graves et al. 2009, Gozdecka, Meduri et al. 
2018) including our own (Kranc, Schepers et al. 2009, Guitart, Subramani et al. 2013, 
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Vukovic, Sepulveda et al. 2016, Guitart, Panagopoulou et al. 2017). The Mx dynamin-
like GTPase 1 (Mx1) promoter, which is part of the viral response to infection, is 
minimally active in healthy mice. However, the Mx1 promoter can be transiently 
activated to high levels of transcription in multiple tissues upon treatment with 
interferon α (IFN-α), interferon ß (IFN-ß), or pIpC (which induces interferon signalling) 
(Kuhn, Schwenk et al. 1995), thus activating Cre recombinase. Upon pIpC treatment 
of Mx1-Cre mice, Cre mediated “floxed” target gene deletion occurs in many tissues, 
but is particularly efficient in the liver and immune system, with 98% deletion reported 
after one dose of pIpC, and complete deletion after 3 doses (Kuhn, Schwenk et al. 
1995).  
 
For the purposes of our study, Ythdf2fl/fl mice were crossed with Mx1-Cre mice to 
generate Ythdf2fl/fl;Mx1-Cre and control Ythdf2fl/fl mice. Meis1/Hoxa9 transformed 
Ythdf2fl/fl and Ythdf2fl/fl;Mx1-Cre pre-LSCs were generated using RTTA as described 
previously (see sections 2.11-2.13). Pre-LSCs were harvested at CFC3 and GFP 
expression (which indicates YTHDF2 expression) was checked by flow cytometry, as 
a means of ruling out spontaneous activation of Mx1-Cre in-vitro. GFP expression 
was greater than 90% in all samples, and there was no significant difference in GFP 
expression between Ythdf2fl/fl and Ythdf2fl/fl;Mx1-Cre pre-LSCs, indicating comparable 
levels of YTHDF2 expression at this stage (Figure 4.4.5 A). Next, Ythdf2fl/fl and 
Ythdf2fl/fl;Mx1-Cre pre-LSCs were transplanted to irradiated primary recipient mice, as 
described previously (see section 2.15.2). Briefly, 50 000 pre-LSCs (CD45.2+) were 
transplanted via the tail vein into lethally irradiated (11 Gy) recipient mice (CD45.1+ 
CD45.2+), together with 200 000 unfractionated bone marrow support (CD45.1+). 
Three weeks after transplantation, peripheral blood was obtained from the tail vein 
and analysed by flow cytometry to establish leukaemic engraftment levels. The results 
showed a mean engraftment of 5% for both Ythdf2fl/fl and Ythdf2fl/fl;Mx1-Cre pre-LSCs 
(Figure 4.4.5 B). The mice were subsequently divided into two cohorts based on 
leukaemic engraftment levels (Figure 4.4.5 C).  
 
4.4.5.1 Acute deletion of Ythdf2 in pre-LSCs slows leukaemic engraftment 
 
The first cohort of mice (hence termed ‘Pre-LSC group’, all with engraftment < 6%) 
received 300 µg pIpC by intraperitoneal injection every other day for a total of 6 doses 
to induce Mx1-Cre mediated deletion of Ythdf2 from the transplanted pre-LSC 
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population. Peripheral blood analysis was carried out 3 days after the final pIpC 
injection (week 5) and every 3 weeks thereafter (Figures 4.4.5 D-E). This showed a 
dramatic and sustained drop in GFP expression by Ythdf2fl/fl;Mx1-Cre pre-LSCs 
following pIpC treatment, indicating effective deletion of Ythdf2 (Figure 4.4.5 D). 
Simultaneously, leukaemic engraftment was slower in recipients of Ythdf2fl/fl;Mx1-Cre 
pre-LSCs compared with recipients of control pre-LSCs, although the difference only 
achieved statistical significance at week 11 (Figure 4.4.5 E). The Kaplan Meier 
survival curve (Figure 4.4.5 F) showed a trend towards increased survival in 
recipients of Ythdf2fl/fl;Mx1-Cre pre-LSCs (median 104 days) compared with control 
pre-LSCs (median 93 days), although this did not achieve statistical significance.  
Bone marrow of culled leukaemic mice was analysed by flow cytometry (see section 
2.8). This showed almost complete absence of GFP expression in Ythdf2fl/fl;Mx1-Cre  
LSCs, confirming continued lack of Ythdf2 expression in these cells (Figure 4.4.5 G). 
Consistent with the clinical picture, the bone marrow was almost entirely effaced by 
CD45.2+ LSCs (Figure 4.4.5 H), the majority of which were Gr-1+ CD11b+ or Gr-1- 
CD11b+, consistent with myeloid leukaemia (Figure 4.4.5 I). Approximately 20% of 
LSCs were also c-Kit+ (Figure 4.4.5 J). Notably there was no significant difference in 
the immunophenotype of Ythdf2-deleted and control LSCs.  
4.4.5.2 Acute deletion of Ythdf2 in LSCs impairs maintenance and propagation 
of AML 
 
The second cohort of mice (hence termed ‘LSC group’) were left to develop leukaemia 
without pIpC treatment, but were monitored alongside the ‘Pre-LSC group’ by serial 
peripheral blood analysis during this time. Interestingly, at the 3 week analysis time 
point, a reduction in GFP expression, indicating spontaneous Ythdf2 deletion, was 
observed in the ‘LSC group’ Ythdf2fl/fl;Mx1-Cre recipient mice, despite the fact that 
they had received no pIpC treatment (Figure 4.4.5 K). This observation was 
consistent with spontaneous Mx1-Cre-activation (and thus “floxed” gene deletion), 
which has been reported previously at levels ranging from 2-3% (Kuhn, Schwenk et 
al. 1995), to 30-50% post transplantation (Velasco-Hernandez, Sawen et al. 2016).  
 
The ‘LSC group’ mice were culled when they showed clinical signs compatible with 
leukaemia, as described previously. CD45.2+ LSCs obtained from the BM of these 
mice were sorted for GFP+ cells (those without Ythdf2 deletion), and plated through 
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one round of CFC in preparation for transplantation. GFP expression at this stage 
was greater than 90% in all samples, and there was no significant difference between 
Ythdf2fl/fl and Ythdf2fl/fl;Mx1-Cre LSCs, indicating comparable levels of Ythdf2 
expression before secondary transplantation (Figure 4.4.5 L). Next, 50 000 
Ythdf2fl/fl and Ythdf2fl/fl;Mx1-Cre LSCs (CD45.2+) were transplanted via the tail vein 
into lethally irradiated (11 Gy) recipient mice (CD45.1+ CD45.2+), together with 200 
000 unfractionated bone marrow support (CD45.1+), as previously described (section 
2.15.2). Three weeks after transplantation, peripheral blood was obtained from the 
tail vein and analysed by flow cytometry to establish engraftment levels (Figure 4.4.5 
M). Whilst Ythdf2fl/fl GFP+ cells engrafted rapidly and caused aggressive AML upon 
transplantation to secondary recipients (Figure 4.4.5 N), Ythdf2fl/fl;Mx1-Cre GFP+ 
cells lost YTHDF2 expression (Figure 4.4.5 O), presumably due to spontaneous Mx1-
Cre activation upon LSC transplantation (Velasco-Hernandez, Sawen et al. 2016), 








Figure 4.4.5 Acute deletion of Ythdf2 impairs LSC development and AML 
propagation in mice. (A) Percentage of GFP-expressing cells as a measure of 
YTHDF2 expression in Ythdf2fl/fl and Ythdf2fl/fl;Mx1-Cre pre-LSCs prior to 
transplantation. Data are mean ± s.e.m, n = 3. (B) Percentage of CD45.2+ leukaemic 
cells in the peripheral blood of primary recipient mice 3 weeks after transplantation. 
Data are mean ± s.e.m, n = 9-17 recipients per genotype. (C) Schematic of Mx1-Cre 
experiments. Ythdf2fl/fl and Ythdf2fl/fl;Mx1-Cre FL c-Kit+ cells were co-transduced with 
Meis1 and Hoxa9 retroviruses, serially re-plated and transplanted into primary 
recipient mice, which were either treated with pIpC (Pre-LSC group) or left to develop 
AML (LSC group). GFP+ CD45.2+ cells sorted from LSC group leukemic primary 
recipients were re-transplanted into secondary recipient mice (n = 14-16 mice per 
genotype). (D) Percentage of CD45.2+ leukaemic cells in the peripheral blood of pIpC 
treated primary recipient mice 3-11 weeks after transplantation. Data are mean ± 
s.e.m, n = 6-14. *, P < 0.05. Mann-Whitney U test. (E) Percentage of GFP-expressing 
cells in the peripheral blood CD45.2+ cell compartment of pIpC treated primary 
recipient mice 3-11 weeks after transplantation. Data are mean ± s.e.m, n = 6-14. ***, 
P < 0.001; ****, P < 0.0001. Mann-Whitney U test. (F) Kaplan-Meier survival curve of 
primary recipient mice transplanted with Ythdf2fl/fl and Ythdf2fl/fl;Mx1-Cre pre-LSCs. 
Data are mean ± s.e.m, n = 6-14 per genotype. (G) Percentage of GFP-expressing 
cells as a measure of YTHDF2 expression in Ythdf2fl/fl and Ythdf2fl/fl;Mx1-Cre leukemic 
cells within the bone marrow of culled recipient mice, n = 5-6 per genotype. (H) 
Percentage of leukaemic (CD45.2+) cells within total bone marrow of culled recipient 
mice, n = 5-6 per genotype. (I-J) Percentage of (I) myeloid cells (CD11b+± Gr-1+) and 
(J) c-Kit+ cells within CD45.2+ leukaemic bone marrow cells of culled recipient mice, 
n = 5-6 per genotype. (K) Percentage of GFP-expressing cells in the peripheral blood 
CD45.2+ cell compartment of non pIpC treated (i.e. LSC group) primary recipient mice 
3 weeks after transplantation. (L) Percentage of GFP-expressing cells as a measure 
of YTHDF2 expression in Ythdf2fl/fl and Ythdf2fl/fl;Mx1-Cre leukaemic cells prior to 
secondary transplantation (M) Percentage of CD45.2+ leukaemic cells in the 
peripheral blood of the secondary recipient mice 3 weeks after transplantation (n = 
14-16 recipients per genotype). ****, P < 0.001. Mann-Whitney U test. (N) Kaplan-
Meier survival curve of mice transplanted with Ythdf2fl/fl and Ythdf2fl/fl;Mx1-Cre 
leukaemic cells. (n = 14-16 mice per genotype). ****, P<0.001 Log-rank (Mantel-Cox 
test). (O) Percentage of GFP-expressing cells in PB CD45.2+ cell compartment of 
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secondary recipient mice. Data are mean ± s.e.m.; ****, P < 0.001. Mann-Whitney U 
test. 
4.5 Discussion 
The work presented in this chapter demonstrates an important role for Ythdf2 in 
development and maintenance of AML. First, we demonstrated the requirement for 
Ythdf2 during in vitro leukaemic transformation with a variety of oncogenes and 
oncogenic fusions. Next, we showed that Meis1/Hoxa9 transformed Ythdf2-deficient 
pre-LSCs initiate leukaemia in vivo with a significant delay compared to their control 
counterparts. Finally, we used the inducible Mx1-Cre system to show that acute 
Ythdf2 deletion impairs LSC development and AML propagation in mice.  
The role of Ythdf2 has not previously been reported in AML. YTHDF2 has been 
studied in solid cancers of humans, including those affecting the stomach, pancreas, 
liver and prostate (Yang, Li et al. 2017, Zhang, Pi et al. 2017, Chen, Wei et al. 2018, 
Li, Meng et al. 2018, Zhong, Liao et al. 2019). However, the role of YTHDF2 in these 
tumours is controversial. In hepatocellular cancer, YTHDF2 has been reported to 
function as an oncogene (Yang, Li et al. 2017), and also as a tumour suppressor 
(Zhong, Liao et al. 2019). Similarly, in pancreatic cancer YTHDF2 has been shown to 
promote proliferation, whilst inhibiting migration and invasion (so called ‘migration 
proliferation dichotomy’) (Chen, Sun et al. 2017). Our study is the first to report the 
role of Ythdf2 in AML. Previously, multiple groups have shown an essential 
requirement for the m6A writers METTL3 and/or METTL14, as well the m6A eraser 
FTO, in AML development and maintenance (Barbieri, Tzelepis et al. 2017, Li, Weng 
et al. 2017, Vu, Pickering et al. 2017, Su, Dong et al. 2018, Weng, Huang et al. 2018). 
However, the proposed oncogenic mechanism has varied between studies. Some 
studies have reported decreased target mRNA stability upon loss of m6A (through 
inhibition of METTL14, or overexpression of FTO), suggesting a YTHDF2-
independent mechanism of oncogenesis (Li, Weng et al. 2017, Weng, Huang et al. 
2018). Others have identified an m6A dependent alteration in translation, as opposed 
to degradation, as the driving mechanism (Barbieri, Tzelepis et al. 2017, Vu, Pickering 
et al. 2017). Our work demonstrated that Ythdf2 is critically required for AML 
development and maintenance. Our studies to establish the mechanism for this are 
described in Chapter 5.  
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A high correlation of CFC activity with leukaemogenic potential has been reported 
using the RTTA model of AML (Lavau, Szilvassy et al. 1997, Somervaille and Cleary 
2006). Consistent with this, we observed a reduction in the number and size of 
colonies generated from Ythdf2-deficient pre-LSCs transformed with Meis1/Hoxa9, 
Mll-AF9, PML-RARA and MOZ-TIF2, and prolonged survival in mice transplanted with 
Ythdf2-deficient Meis1/Hoxa9 pre-LSCs. These findings are consistent with previous 
studies highlighting the importance of m6A modification in AML (Barbieri, Tzelepis et 
al. 2017, Li, Weng et al. 2017, Vu, Pickering et al. 2017, Weng, Huang et al. 2018).  
 
Although the survival curve has not been completed, the Mll-AF9 transplant results 
obtained thus far are less convincing than those of Meis1/Hoxa9, with no observable 
survival advantage for mice receiving Mll-AF9 Ythdf2-deficient pre-LSCs compared 
with Mll-AF9 control pre-LSCs. This result is surprising, given that Meis1 and Hoxa9 
are key targets of Mll-AF9, which mediate the effects of this oncogenic fusion in AML 
(Armstrong, Staunton et al. 2001, Ayton and Cleary 2003, Kumar, Hudson et al. 2004, 
Zeisig, Milne et al. 2004, Krivtsov, Twomey et al. 2006). There are several possible 
explanations for the discrepancy. Firstly, considering that gene dosage has been 
reported to influence the target cell specificity of Mll-AF9 (Chen, Kumar et al. 2008), 
it is possible that supra-physiological levels of Mll-AF9 expression are masking the 
effect of Ythdf2 deficiency in this retroviral model. To investigate this further, it would 
be useful to re-evaluate the effect of Ythdf2 deficiency in an transgenic Mll-AF9 model, 
for example in mice with doxycycline inducible Mll-AF9 transgene expression 
(Stavropoulou, Kaspar et al. 2016). Another approach would be to better characterise 
the pre-LSCs (control and Ythdf2-deficient) in the Mll-AF9 retroviral model, by 
performing a limiting dilution assay (Chen, Kumar et al. 2008, Hays 2009, Shlush, 
Zandi et al. 2014). Finally, given the heterogeneity of AML (Hays 2009, Meacham and 
Morrison 2013), it is perhaps not surprising that a range of mouse AML models may 
not all demonstrate the same genetic susceptibility (Velasco-Hernandez, Hyrenius-
Wittsten et al. 2014), which further supports our decision to evaluate multiple 
oncogenes and oncogenic fusions when studying the role of Ythdf2 in malignant 
haematopoiesis.  
 
The results of our Meis1/Hoxa9, MOZ-TIF2 and PML-RARA retroviral models 
suggested that YTHDF2 inhibition might be a therapeutic strategy in the treatment of 
human AML. For this to become a realistic proposition, we needed to establish 
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whether acute deletion of Ythdf2 in established AML would be sufficient to delay or 
abolish leukaemic progression. To do so, we made use of the inducible Mx1-Cre 
system, in which Cre is expressed upon treatment with pIpC (Kuhn, Schwenk et al. 
1995). We evaluated the effects of acute Ythdf2 deletion in pre-LSCs (primary 
recipients) and in LSCs (secondary recipients).  
 
In primary recipient mice, acute deletion of Ythdf2 from pre-LSCs resulted in 
significantly reduced leukaemic engraftment 11 weeks after transplantation (Figure 
4.4.5 E), and a trend towards a longer survival, although this did not reach statistical 
significance (Figure 4.4.5 F). However, it is worth noting that four mice had to be 
culled around the time of pIpC injections (all within a week of the last injection), owing 
to progressive anaemia, lethargy and weight loss. Antibody staining and flow 
cytometric BM analysis of these mice ruled out leukaemic progression as a cause of 
their clinical signs. Although mice were left to recover for 3 weeks following 
irradiation/transplantation prior to the initiation of pIpC injections, it is possible that this 
time period was insufficient. Following irradiation, transplanted animals undergo a 5 
to 10 day irradiation sickness period from which they generally recover within 14 days 
(Duran-Struuck and Dysko 2009), providing that donor and residual host HSCs rapidly 
enter the cell cycle and proliferate to repopulate the BM with progenitor cells. 
However, pIpC, a synthetic double stranded RNA used to mimic viral infections in 
vivo, acts through its receptor TLR3 (Matsumoto and Seya 2008) to stimulate an IFN 
dependent response, ultimately forcing quiescent HSCs into the cell cycle (Essers, 
Offner et al. 2009). Treatment with pIpC increases HSC cycling six- to seven-fold for 
up to 3 days, leading to the accumulation of reactive oxygen species and DNA 
damage in remaining HSCs (Walter, Lier et al. 2015). DNA damage itself induces type 
I IFN-mediated stem cell senescence (Yu, Katlinskaya et al. 2015). It is therefore 
possible that the combination of recent irradiation, and then repeated doses of pIpC 
(200-300 µl poly(I:C) (1 µg/µl) by intraperitoneal injection every 48 hours for 6 doses), 
exhausted the HSC repopulation capacity of some mice, ultimately leading to 
progressive anaemia. Unfortunately, the loss of these mice, together with the prior 
division of the cohort to also provide LSCs for the secondary experiment (Figure 4.4.5 
C) meant that this primary experiment may have been underpowered to detect a 
difference in survival following Ythdf2 deletion in pre-LSCs.  
 
 178 
In secondary recipient mice, spontaneous activation of Mx1-Cre occurred following 
transplantation, in the absence of pIpC treatment. As a result, Ythdf2fl/fl; Mx1-Cre 
LSCs lost Ythdf2 expression (Figure 4.4.5 O), and subsequently failed to initiate 
leukaemia in their recipient mice (Figure 4.4.5 N). Spontaneous activation of Mx1-
Cre has been reported previously, at levels of 2-10% under homeostatic conditions 
(Kuhn, Schwenk et al. 1995), and increasing to around 40% following BM 
transplantation (Velasco-Hernandez, Sawen et al. 2016). In our study, spontaneous 
Mx1-Cre activation occurred after transplantation of pre-LSCs to primary recipients 
(Figure 4.4.5 D week 3), but was more marked following transplantation of LSCs to 
secondary recipients (Figure 4.4.5 O). As a result, engraftment was only delayed in 
primary recipients (even after pIpC treatment), but was abolished in secondary 
recipients. The reason for the differential Mx1-Cre activation in pre-LSCs and LSCs 
is not clear, but could reflect a difference in the behaviour, or host response to, the 
stage of leukaemic cell transplanted. To further investigate this, pre-LSCs and LSCs 
could be transplanted to parallel cohorts of mice in one experiment, ensuring all other 
variables are kept constant, to determine whether the effect is dependent on cell type 
or other factors. To circumnavigate the problem of spontaneous Mx1-Cre activation, 
future experiments could involve one of the alternative models described in the 
literature for inducible gene deletion, such as Cre-ERT (Hayashi and McMahon 2002) 
or Ah-Cre/Mx1-Cre together with Cre-ERT (Kemp, Ireland et al. 2004).  
 
In summary, the results presented in this chapter show that Ythdf2 is required for the 
development and propagation of AML, making Ythdf2 inhibition an exciting potential 
novel therapeutic strategy for treatment of this aggressive disease. Investigations into 












5.1.1 Mechanisms of m6A machinery in AML 
 
Several studies have documented the important role of m6A in AML, and this has been 
discussed in Chapter 1 (including Table 1.3.5) and Chapter 4. Although ours is the 
first study to focus on the role of YTHDF2 in AML, other groups have reported a 
requirement for the writer METTL3, and for members of the complex it forms together 
with METTL14, WTAP, KIAA1429, and ZFP217. The m6A eraser FTO is also known 
to play an important role in AML. Three recent studies have identified the m6A RNA 
modifying enzymes METTL3 and METTL14 as critical regulators of differentiation in 
both normal haematopoiesis and AML pathogenesis (Barbieri, Tzelepis et al. 2017, 
Vu, Pickering et al. 2017, Weng, Huang et al. 2018).  
 
Vu et al., who showed that METTL3 controls myeloid differentiation of normal 
haematopoietic and leukaemia cells, used a combination of single nucleotide 
resolution mapping of m6A coupled with ribosome profiling to demonstrate that m6A 
promotes the translation of c-MYC, BCL2 and PTEN mRNAs, whilst loss of METTL3 
leads to increased phosphorylated AKT, which contributes to induction of 
differentiation (Vu, Pickering et al. 2017).  
 
Barbieri et al. also reported that METTL3 maintains myeloid leukaemia by m6A 
dependent translational control (Barbieri, Tzelepis et al. 2017). This study carried out 
anti-METTL3 ChIP-Seq (chromatin immunoprecipitation followed by next-generation 
sequencing) and found that METTL3 associates with chromatin and localises to the 
transcriptional start site (TSS) of active genes. They showed that most of these genes 
have CEBPZ protein present at the TSS, and confirmed that this is required for 
METTL3 recruitment. Using a combination of m6A meRIP-Seq and ribosome 
footprinting, they went on to show that promoter-bound METTL3 induces m6A 
modification in the coding region of the associated mRNA and enhances its translation 
by relieving ribosome stalling. They showed that METTL3 binds the promoters of the 
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transcription factors SP1 and SP2, which in turn bind the promoter of c-MYC. In 
support of this mechanistic pathway, overexpression of SP1 was able to rescue the 
effect of METTL3 knock down on the growth of a human AML cell line in vitro (Barbieri, 
Tzelepis et al. 2017).  
 
METTL14 has also been shown to promote leukaemogenesis via mRNA m6A 
modification (Weng, Huang et al. 2018). Using a combination of m6A meRIP-Seq, 
RNA-Seq and CLIP assays, Weng et al. identified METTL14 targets, including MYB 
and MYC. Using actinomycin D to inhibit transcription and elucidate mRNA decay 
kinetics, and polysome profiling to characterise the translating pool of mRNAs, they 
showed that METTL14 knock down affects both the half-lives and translation of MYC 
and MYB mRNAs. Interestingly, in this study, the majority of identified METTL14 
targets (m6A peaks with decreased abundance upon METTL14 knock down) were 
associated with decreased mRNA levels in knock down cells, suggesting an 
alternative, non-YTHDF2 based mechanism for decreased mRNA stability in this case 
(Weng, Huang et al. 2018).  
 
The demethylase FTO has also been shown to play an oncogenic role in AML (Li, 
Weng et al. 2017). Li et al. used a combination of RNA-Seq and m6A meRIP-Seq in 
control and FTO-overexpressing cell lines, to identify potential FTO targets, including 
ASB2 and RARA. Of note, the mRNA levels of these targets decreased upon FTO 
overexpression, once again suggesting the involvement of another, non-YTHDF2 
dependent mechanism in determining mRNA stability (Li, Weng et al. 2017).  
 
5.1.2 Molecular methods used to investigate the mechanism of YTHDF2 in AML 
 
In order to investigate the mechanism of YTHDF2 requirement in AML we employed 
a variety of molecular techniques to evaluate the transcriptome overall, mRNA 
methylation, and the intracellular dynamics of mRNA transcription, processing, 
translation and decay. 
 
5.1.2.1 RNA microarray 
 
Gene microarray technology depends on the ability to deposit large numbers of DNA 
sequences in an ordered fashion on a small surface, typically referred to as a ‘chip’. 
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DNA arrays are used to probe a solution of labelled nucleic acids, with the final 
hybridization pattern reflecting the relative concentrations of nucleic acid species 
present in the sample (Lockhart, Dong et al. 1996).  
 
For the purposes of our study, we used the GeneChip™ Mouse Gene 2.0 ST Array, 
which is a whole-transcript array that includes probes to measure both mRNA 
(>28,000 coding transcripts) and long intergenic non-coding RNA transcripts.  
 
5.1.2.2 m6A meRIP-Seq 
 
N(6)-methyladenosine-sequencing (m6A meRIP-Seq) is an immunocapturing 
approach for the unbiased transcriptome-wide localization of m6A in high resolution 
(Dominissini, Moshitch-Moshkovitz et al. 2013). The method relies upon antibody-
mediated enrichment of methylated RNA fragments followed by massively parallel 
sequencing. Subsequently, read densities are compared between 
immunoprecipitated RNA and untreated input control to identify methylated sites.  
 
5.1.2.3 SLAM-Seq 
Thiol (SH)-Linked Alkylation for the Metabolic Sequencing of RNA (SLAM-Seq) is an 
RNA sequencing technology that detects 4-thiouridine (S4U) incorporation in RNA 
species at single-nucleotide resolution (Herzog, Reichholf et al. 2017). Unlike 
standard RNA-Seq methods, which only measure RNA species at a single time point, 
SLAM-Seq can provide information about the intracellular dynamics of RNA 
transcription, processing and decay.  
The SLAM-Seq technique was developed from pre-existing protocols for metabolic 
labelling of RNA using S4U (Rabani, Levin et al. 2011). These protocols relied upon 
S4U incorporation into newly transcribed RNA in place of uridine, allowing 
quantification of RNA synthesis with no detrimental effect on cell growth and survival. 
S4U containing RNA was separated out on the basis of biotin binding, and hybridized 
to microarrays, or subjected to RNA sequencing technologies.  
The key distinguishing feature of the SLAM-Seq technique is an alkylation step after 
S4U labelling, during which iodoacetamide (IAA) covalently attaches a 
carboxyamidomethyl group to S4U by nucleophilic substitution (Figure 5.1.2.3). 
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During the subsequent cDNA library preparation step, the presence of a 
carboxyamidomethyl group causes reverse transcriptase to incorporate Guanine (G) 
instead of Adenine (A) in any position where a reduced S4U modified nucleotide is 
encountered. Analysis of T>C mutations can then be used to identify nascent RNA 
(Herzog, Reichholf et al. 2017). The technique has the advantage of enabling 
quantitative analysis of nascent and existing RNA in a single sample without the need 
for biochemical isolation (no biotin-dependent RNA pull-down required), thus reducing 
cost, labour, RNA input requirements and background noise.  
 
Figure 5.1.2.3 SLAM-Seq workflow. Cultured cells are treated with S4U to label 
nascent RNA (green), then total RNA is purified (sampling) and iodoacetamide (IAA) 
is added to induce alkylation of S4U. During reverse transcription (RT), the resulting 
carboxyamidomethyl group causes a G to be added instead of an A wherever a 
reduced S4U modified nucleotide is encountered. Second strand synthesis and PCR 
complete the protocol, and the presence of T>C mutations can then be used to identify 
nascent RNA. Taken from Lexogen SLAM-Seq kit protocol. 
In this chapter, we describe use of SLAM-Seq specifically to look at RNA turnover 
(catabolic kinetics). Because S4U uptake is variable depending on the cell type 
studied, it is critical to first assess toxicity in the cells of interest, and determine the 
optimal S4U concentration for further experiments. Based on the results of this 
optimisation assay (see 2.21.1), we used 2.91 µM S4U (the limiting IC10, as 
determined in the cytotoxicity assay) for SLAM-Seq. 
5.1.2.4 RIBO-Seq 
RIBO-Seq is a technique which relies on deep sequencing of ribosome-protected 
mRNA fragments (generated by treatment of polyribosomes with exogenous 
nucleases) to provide a transcriptome-wide assessment of mRNA translation (Ingolia, 
4 LEXOGEN · SLAMseq Explorer and Kinetics Kits · User Guide
1. Overview
This user guide outlines the protocol for Lexogen’s SLAMseq Kits, which contain four different 
Modules: 
 • The SLAMseq Explorer Kit - Cell Viability Titration Module (Cat. No. 059.24), is required for opti-
mizing reaction conditions for new cell lines.
 • The SLAMseq Explorer Kit - S4U Incorporation Module (Cat. No. 060.24) , for determining glob-
al S4U incorporation before alkylation.
 • The SLAMseq Kinetics Kit - Anabolic Kinetics Module (Cat. No. 061.24), measures RNA synthesis 
kinetics.
 • The SLAMseq Kinetics Kit - Catabolic Kinetics Module (Cat. No. 062.24), measures RNA degra-
dation kinetics.
The SLAMseq Kits are not next generation sequencing (NGS) library prep kits. They are used for 
S4U metabolic labeling and alkylation of RNA and are intended for use with cultured cells. The 
SLAMseq Kinetics Kits are designed to be used in conjunction with NGS library preparation for 
RNA sequencing. Lexogen highly recommends using the QuantSeq 3’ mRNA-Seq Library Prep 
Kits (Cat. No. 012, 015, 016). QuantSeq Flex Library Prep V2 Kits can also be used for targeted RNA 
sequencing approaches (Cat. No. 033, 034, 035).
Lexogen’s SLAMseq (Thiol (SH)-Linked Alkylation for Metabolic Sequencing) provides a rapid 
and scalable method to measure newly synthesized (nascent) and existing RNA levels in para-
lell. The core SLAMseq workflow involves metabolic labeling of RNA using 4-Thiouridine (S4U) 
and alkylation of incorporated S4U nucleotides (Fig. 1). In short, cell cultures are incubated with 
media containing S4U. S4U is taken up by the cells and becomes incorporated into newly syn-
thesized RNA instead of uridine, labeling nascent RNA transcripts. After an alkylation step, total 
RNA can be used for library preparation. Reverse transcriptase introduces a Guanine (G) instead 
of an Adenine (A) wherever a modified S4U nucleotide is encountere . Nascent transcripts can 
therefore be distinguish d from existing trans ripts in an NGS experiment by mapping to a refer-



































Figure 1. The SLAMseq workflow. Cultured cells are treated with 4-Thiouridine (S4U) for labeling of nascent RNA 
(green). Total RNA is purified (sampling), and alkylation of the 4-thiol group is induced by the addition of iodo-
acetamide (IAA). During library preparation, for example using the QuantSeq 3’ mRNA-Seq Library Prep Kit, the 
presence of the resulting carboxyamidomethyl-group causes reverse transcriptase to incorporate guanine (G, in 
red) instead of adenine (A, in black) at any position where an alkylated *S4U-modified nucleotide is encountered. 
Second s rand synthesis and PCR complete the preparation of a double-stranded library ready for sequencing. In 
this way, nascent RNA can be distinguished from existing RNA by the presence of T>C mutations in sequencing 
reads (see Appendix F, p.35). 
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Ghaemmaghami et al. 2009). For the purpose of our study, we employed a recently 
described ribosome profiling technique based on micrococcal nuclease (MNase) 
(Reid, Shenolikar et al. 2015). In contrast to previous ribosome profiling methods 
(which typically use RNAse1), this method avoids the need for ribosome purification 
prior to extraction of ribosome-protected mRNA fragments (RPFs). This is because 
MNase activity can be tightly controlled under the reaction conditions specified, 
avoiding significant rRNA degradation. The RPFs generated can then be purified by 
gel electrophoresis based on size selection alone (Reid, Shenolikar et al. 2015). 
5.2 Aims 
 
The aims of this chapter were to understand the mechanism by which Ythdf2 loss 
impedes the development and maintenance of acute myeloid leukaemia.  
 
5.3 Outline of experiments described in Chapter 5 
 
Experiments in this chapter were carried out jointly with colleagues. Samples were 
prepared and processed to the stage of RNA extraction (TRIzolÔ method) by Jasmin 
Paris for Affymetrix, m6A meRIP-Seq, SLAM-Seq and Ribo-Seq, and the remainder 
of these experiments, including data analyses, were performed by Marcos Morgan. 
Experiments in section 5.4.6 were carried out jointly with other collaborators (Joana 
Campos, Alena Shmakova, David Wotherspoon, Tim Sommervaille, Gary Spencer, 
Ivayla Ivanova, Junho Choe, Hannah Lawson & Richard Gregory) and are presented 
for completeness, and to explain the work carried out in section 5.4.7, which was 
completed solely by Jasmin Paris.  
 
This chapter describes the experiments carried out to investigate the mechanism by 
which Ythdf2 loss impedes the development and maintenance of acute myeloid 
leukaemia. A combination of transcriptome profiling (AffymetrixÔ) and m6A meRIP-
Seq were used to identify deregulated gene sets upon loss of Ythdf2, and their 
relationship with m6A occupancy. Subsequently, SLAM-Seq and RIBO-Seq were 
used to investigate how these changes might relate to a role for YTHDF2 in mRNA 
degradation and translation respectively. Finally, since combined data analyses 
identified Tnfrsf1b upregulation as a potential mechanism for impaired 
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leukaemogenesis in Ythdf2-deficient cells, an attempt to rescue the phenotype in vitro 




5.4.1 Loss of Ythdf2 results in deregulated gene expression 
 
YTHDF2 is known to target methylated transcripts for decay through deadenylation 
(Wang, Lu et al. 2014, Du, Zhao et al. 2016). We therefore hypothesised that Ythdf2 
loss might result in altered transcript levels, which could in turn explain the impaired 
leukaemogenesis observed. To investigate this we submitted Meis1/Hoxa9 
transformed Ythdf2fl/fl and  Ythdf2fl/fl;Vav-iCre pre-LSCs (n = 5 for each genotype) for 
transcriptome profiling using the GeneChipÔ Mouse Gene 2.0 ST Assay (see 
AffymetrixÔ, sections 2.18 and 2.19). This is a whole-transcript array that includes 
probes to measure both mRNA and long intergenic non-coding RNA transcripts. 
 
In order to minimise variability due to gender differences, pre-LSCs were generated 
from sex-matched (all female) HSPCs for this purpose (see section 2.3.2.4), as shown 
in Figure 5.4.1 A. The Affymetrix data are deposited under the accession number E-
MTAB-6783. 
 
As predicted, the microarray results showed deregulated gene expression upon loss 
of Ythdf2, with 754 upregulated and 582 downregulated genes respectively (P < 0.05), 
in Ythdf2fl/fl;Vav-iCre compared to Ythdf2fl/fl pre-leukaemic cells (Figure 5.4.1 B and 
Appendix 1).  
 
In order to functionally profile the up- and down-regulated genes, Gene Ontology (GO) 
term enrichment was performed (Ashburner, Ball et al. 2000). GO term enrichment is 
a computational technique for interpreting gene sets based on the Gene Ontology 
system of classification. The Gene Ontology Consortium began in 1998, as a joint 
project based on three model organisms Drosophila melanogaster (fruit fly), Mus 
musculus (mouse), and Saccharomyces cerevisiae (yeast) (Ashburner, Ball et al. 
2000). The number of different organisms represented in GO is now in the thousands 
(http://geneontology.org). The GO describes the current knowledge of biology with 
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respect to three aspects; molecular function, cellular component, and biological 
processes.  
 
GO term enrichment of deregulated genes in Ythdf2fl/fl;Vav-iCre pre-LSCs compared 
to Ythdf2fl/fl pre-LSCs revealed mostly generic metabolic processes in the upregulated 
genes and immune response processes in the down regulated genes (Figure 5.4.1 
C). Interestingly, the enrichment for metabolic processes is also found in upregulated 
genes in Ythdf2-deficient oocytes (Ivanova, Much et al. 2017). Furthermore, down-
regulation of immune response processes may be linked to the reduction in CD8+ T 
cells observed in the peripheral blood and spleens of Ythdf2fl/fl;Vav-iCre mice, and the 
compromised CD4+ and CD8+ T cell reconstitution by Ythdf2fl/fl;Vav-iCre deficient 






Figure 5.4.1 Loss of Ythdf2 results in deregulated gene expression in 
Ythdf2fl/fl;Vav-iCre pre-leukaemic cells. (A) Representative ‘Sexing PCR’ gel 
showing PCR amplification of genomic DNA from foetal liver c-Kit+ cells. Generated 
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genotypes were XX (female) or XY (male). (B) Transcript expression scatter plot from 
Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-leukaemic cells. Significantly upregulated or 
downregulated transcripts are highlighted in red (adjusted moderate t-student test, P 
< 0.05 corresponding to a fold change of ≧ 1.2). Five biological replicates were used 
for each condition. (C) Gene ontology analysis for the upregulated and downregulated 
genes in  Ythdf2fl/fl;Vav-iCre pre-leukaemic cells. The enrichment is presented as –
log10 (P-value).  
 
5.4.2 m6A methylated transcripts are upregulated in Ythdf2-deficient pre-
leukaemic cells 
 
Having identified up- and down-regulated genes associated with Ythdf2-deficiency, 
we next sought to understand which of the deregulated transcripts could be direct 
targets of YTHDF2. For this purpose, m6A meRIP-Seq was carried out to determine 
transcriptome-wide mRNA m6A in Ythdf2fl/fl;Vav-iCre compared to Ythdf2fl/fl pre-
leukaemic cells (see sections 2.18 and 2.20). This revealed the expected distribution 
of m6A within the transcriptome, with highest m6A peak occupancy around the stop 
codon in both genotypes (Figure 5.4.2 A). The consensus motif (Figure 5.4.2 B), and 
the overlap of m6A peaks with separate transcript regions (5'UTR; start codon; coding 
sequence; stop codon; 3'UTR) (Figure 5.4.2 C) was as expected based on previous 
studies (Meyer, Saletore et al. 2012, Dominissini, Moshitch-Moshkovitz et al. 2013). 
Importantly, Ythdf2 deficiency did not alter any of these parameters, and there was 
no significant difference in m6A methylation between control and Ythdf2-deficient pre-
LSCs. This finding was not unexpected, since Ythdf2 functions as a ‘reader’ of m6A, 
as opposed to a ‘writer’ or ‘eraser’ responsible for m6A deposition or removal 
respectively.  
 
Since YTHDF2 binds methylated transcripts and targets them for degradation, we 
predicted that loss of Ythdf2 would be significantly associated with an upregulation of 
methylated transcripts. Indeed, a comparison of mRNA microarray and m6A meRIP-
Seq results revealed a significant enrichment for m6A occupancy in the upregulated 
genes (P < 0.05, 754 genes) in Ythdf2fl/fl;Vav-iCre pre-LSCs compared to the 
corresponding unchanged or downregulated gene sets (Figure 5.4.2 D).  
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Reciprocally, we analysed the transcriptome based on RNA m6A modification, and 
found that methylated transcripts were more likely to be upregulated in Ythdf2fl/fl;Vav-
iCre pre-LSCs compared with Ythdf2fl/fl pre-LSCs (Figure 5.4.2 E). In fact, the level of 






Figure 5.4.2 m6A methylated transcripts are upregulated in Ythdf2-deficient pre-
leukaemic cells. (A) m6A peak occupancy along a transcript body model is shown 
for Ythdf2fl/fl (black) and Ythdf2fl/fl;Vav-iCre (red) pre-leukaemic cells. One 
representative sample of three biological replicates is shown for each genotype. 
Transcripts models were extended 400 nucleotides upstream and downstream of the 
start and stop codons, respectively. (B) m6A-seq motif enrichments and associated 
P-values are shown for each genotype. (C) m6A peaks overlaps with different 
transcript regions (5'UTR; start codon; coding sequence, CDS; stop codon; 3'UTR) 
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are shown for each condition. (D) m6A peak strength (-log10Q) in Ythdf2fl/fl pre-
leukaemic cells for transcripts grouped according to expression changes between 
Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-leukaemic cells is shown (down, genes 
significantly downregulated in Ythdf2fl/fl;Vav-iCre (P < 0.05); unchanged, genes not 
significantly changing in Ythdf2fl/fl;Vav-iCre; up, genes significantly upregulated in 
Ythdf2fl/fl;Vav-iCre (P < 0.05). ** indicates P < 0.01, Mann-Whitney, two-sided test). 
The upper and lower quartiles and the median are shown for each group. (E) Violin 
plots showing expression change between Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-
leukaemic cells for not methylated (no m6A), methylated (m6A, -log10Q ≤ 25) and 
highly methylated (m6A high, -log10Q > 25) transcripts (** indicates P < 0.01, Mann-
Whitney, two-sided test). The upper and lower quartiles and the median are indicated 
for each group. (F) Cumulative distributions of transcripts’ expression change in 
Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-leukaemic cells for not methylated, methylated 
and highly methylated transcripts as in E.  
 
5.4.3 m6A methylated transcripts in pre-leukaemic cells are also upregulated in 
Ythdf2-deficient leukaemic cells 
 
To understand whether the observations made in pre-leukaemic cells also extended 
to AML in vivo, we isolated LSCs from mice with Meis1/Hoxa9 AML derived from 
Ythdf2fl/fl and  Ythdf2fl/fl;Vav-iCre pre-LSCs (culled mice, section 2.15.4), and repeated 
the AffymetrixÔ gene expression analyses. As in pre-leukaemic cells, LSC microarray 
results showed deregulated gene expression upon loss of Ythdf2, with 381 
upregulated and 221 downregulated genes respectively (P < 0.05), in Ythdf2fl/fl;Vav-
iCre compared to Ythdf2fl/fl leukaemic cells (Figure 5.4.3 A). Furthermore, mirroring 
the observations made in pre-leukaemic cells, a significant enrichment for transcripts 
methylated in pre-LSCs was observed in upregulated genes of Ythdf2fl/fl;Vav-iCre 
LSCs compared to the corresponding unchanged or downregulated gene sets 
(Figure 5.4.3 B). When analysing the leukaemic cell transcriptome based on pre-LSC 
RNA m6A modification, we found that pre-LSC methylated transcripts were more likely 
to be upregulated in Ythdf2fl/fl;Vav-iCre LSCs compared with Ythdf2fl/fl LSCs (Figure 
5.4.3 C), and once again showed that methylation was correlated with degree of 
transcript upregulation (Figure 5.4.3 D).  
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Based on these results, we concluded that the relationship between m6A occupancy 
and increased transcript dosage was present in both pre-leukaemic and leukaemic 




Figure 5.4.3 m6A methylated transcripts in pre-leukaemic cells are also 
upregulated in Ythdf2-deficient leukaemic cells. (A) Transcript expression scatter 
plot from Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre leukaemic cells. Significantly upregulated or 
downregulated transcripts are highlighted in red (Adjusted moderate t-student test, P 
< 0.05). Four biological replicates were used for each condition. (B) m6A peak 
significance (-log10Q) in pre-leukaemic cells for transcripts grouped according to 
 191 
expression changes between Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre leukaemic cells is 
shown (down, genes significantly downregulated in Ythdf2fl/fl;Vav-iCre (P < 0.05); 
unchanged, genes not significantly changing in Ythdf2fl/fl;Vav-iCre; up, genes 
significantly upregulated in Ythdf2fl/fl;Vav-iCre (P < 0.05). ** indicates P < 0.01, Mann-
Whitney, two-sided test). The upper and lower quartiles and the median are shown 
for each group. (C) Violin plots showing expression change between Ythdf2fl/fl and 
Ythdf2fl/fl;Vav-iCre leukaemic cells for pre-leukaemic cells not methylated (no m6A), 
methylated (m6A, -log10Q ≤ 25) and highly methylated (m6A high, -log10Q > 25) 
transcripts (** indicates P < 0.01, Mann-Whitney, two-sided test). The upper and lower 
quartiles and the median are shown for each group. (D) Cumulative distribution of 
transcripts’ expression change in Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-leukaemic cells 
for not methylated, methylated and highly methylated transcripts as in C.  
 
5.4.4 Ythdf2 loss increases half-life of methylated transcripts 
 
Since YTHDF2 is responsible for targeting methylated transcripts for decay, we 
predicted that the upregulation of m6A-containing transcripts in the absence of Ythdf2 
was likely to be due to an increase in their half-life.  We therefore measured mRNA 
half-life transcriptome-wide in pre-leukaemic cells using SLAM-Seq (Herzog, 
Reichholf et al. 2017), as described in sections 2.21 and 5.1.2.3.  
 
SLAM-Seq revealed an overall modest increase in mRNA half-life in Ythdf2fl/fl;Vav-
iCre pre-LSCs (Figure 5.4.4 A) when compared to Ythdf2fl/fl pre-LSCs. Reassuringly, 
when evaluating Ythdf2fl/fl pre-LSCs, the half-lives of m6A-containing transcripts were 
shorter than the half-lives of transcripts not containing m6A (Figure 5.4.4 B), an 
observation which underscores the important role m6A plays in mRNA decay under 
normal circumstances. The loss of Ythdf2 extended the half-life of m6A containing 
transcripts but not that of unmethylated transcripts (Figure 5.4.4 C and D). These 
findings were consistent with the theory that transcript upregulation upon loss of 
Ythdf2 is through modulation of mRNA decay, specifically through an increased half-





Figure 5.4.4 Ythdf2 loss increases half-life of methylated transcripts. (A) Mode 
decay curves for Ythdf2fl/fl (black) and Ythdf2fl/fl;Vav-iCre (red) pre-leukaemic cell 
transcriptomes are shown. The shaded areas indicate the first and third quantile 
decay curves range for each genotype. Transcript decay was estimated by the 
normalized cDNA T to C conversion rate at 0, 60, 180 and 540 minutes after S4U 
removal. Transcripts half-life modes for each genotype are indicated with horizontal 
dotted lines and are also shown at the panel top. (B-C) Cumulative distributions of 
transcripts' half-life in (B) Ythdf2fl/fl and (C) Ythdf2fl/fl;Vav-iCre pre-leukaemic cells are 
shown for not methylated, methylated and highly methylated transcripts (as in Figure 
5.4.2 E). The half-life change significance between the methylated and not methylated 
transcripts are indicated (Mann-Whitney, two-sided test). (D) Cumulative distributions 
of relative stability change between Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-leukaemic 
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cells are shown for not methylated, methylated and highly methylated transcripts. The 
relative stability change significances between the methylated and not methylated 
transcripts are indicated (Mann-Whitney, two-sided test).  
 
5.4.5 Ythdf2 loss does not alter translational efficiency 
 
YTH domain family proteins (YTHDF1 and YTHDF3) are known to mediate m6A 
dependent changes in translational efficiency. Furthermore, the tumour promoting 
effects of METTL enzymes in AML have been largely ascribed to m6A dependent 
translational control (Barbieri, Tzelepis et al. 2017, Vu, Pickering et al. 2017). With 
this in mind, we sought to investigate whether the effect of Ythdf2-deficiency in this 
context might also be mediated in part by changes in translational efficiency. To do 
so, we employed RIBO-Seq (Reid, Shenolikar et al. 2015), as described in sections 
2.22 and 5.1.2.4.  
 
Our results indicated that loss of Ythdf2 does not affect translational efficiency. There 
was no gross difference in translational efficiency between Ythdf2fl/fl and  
Ythdf2fl/fl;Vav-iCre pre-LSCs (Figure 5.4.5 A). Based on a cut-off defined as a 
significant two-fold reduction in translational efficiency, approximately 19 of 9474 
analysed transcripts were less efficiently translated in Ythdf2fl/fl;Vav-iCre pre-LSCs 
compared to Ythdf2fl/fl pre-LSCs, but this did not correlate with the presence of 
absence of m6A. Indeed, the loss of Ythdf2 did not alter the translational efficiency of 
either m6A or non-m6A- containing transcripts (Figure 5.4.5 B), for either Ythdf2fl/fl or  
Ythdf2fl/fl;Vav-iCre pre-LSCs. 
 
The combination of results obtained by SLAM-Seq (section 5.4.4) and RIBO-Seq 
demonstrate that YTHDF2 regulates the leukaemic transcriptome through modulation 





Figure 5.4.5 Ythdf2 loss does not alter translational efficiency. (A) Volcano plot 
of translational efficiency change between Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-
leukaemic cells. Not methylated, methylated and highly methylated transcripts 
(defined as in Figure 6.4.2 E), are shown in black, green and red, respectively. The 
number of transcripts with a significant two-fold reduction in translational efficiency is 
indicated for each group. (B) Cumulative distributions of translational efficiency of not 
methylated (right panel), methylated (centre panel) and highly methylated transcripts 
(left panel) are shown for Ythdf2fl/fl (black) and Ythdf2fl/fl;Vav-iCre (red) pre-leukaemic 
cells.  
 
5.4.6 Interrogation of Ythdf2 molecular pathways 
 
The work described in this section was carried out in collaboration with colleagues 
(see 5.3), and is described for completeness, and in order to explain the experiments 
performed in section 5.4.7.  
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We next sought to understand if the m6A and Ythdf2-deregulated transcripts in our 
mouse AML model are also relevant to human AML. We found that the population of 
transcripts which were significantly upregulated in the Ythdf2fl/fl;Vav-iCre pre-
leukaemic cells were also preferentially methylated in the NOMO-1 and MA9.3ITD 
human AML cell lines (Figure 5.4.6 A). In order to focus our mechanistic studies, we 
defined selection criteria with which to group genes for further study. Upregulated 
genes in Ythdf2fl/fl;Vav-iCre pre-leukaemic cells, which were also highly methylated in 
Ythdf2fl/fl pre-leukaemic cells and methylated in human MA9.3ITD and NOMO-1 cells 
were selected for further study (Figure 5.4.6 B and Appendix 2). There were 754 
genes upregulated in Ythdf2fl/fl;Vav-iCre pre-leukaemic cells, and of these 344 genes 
were high in m6A, but only 292 genes were also methylated in MA9.3ITD and NOMO-
1 cells. These 292 genes were selected for further study.  
 
To understand the molecular pathways that these common mouse and human m6A 
transcripts underpin, we performed ConcensusPathDB (CPDB) network analysis. 
CPDB is a meta-database (human, mouse and yeast) which integrates a physical 
protein interactions, metabolic and signalling reactions, and gene regulatory 
interactions in a functional association network (Kamburov, Pentchev et al. 2010, 
Kamburov, Pentchev et al. 2011, Kamburov, Stelzl et al. 2012). The results of our 
CPDB network analysis showed enrichment for RNA processing, mitochondrial 
function, ubiquitination, and also TNF signalling (Figure 5.4.6 C). 
 
To understand why the loss of Ythdf2 is correlated with a weak leukaemogenic 
potential, we interrogated gene sets from human AML samples associated with 
different leukaemogenic potential upon xenotransplantation. The LSC signature gene 
set we employed was a 17-gene stemness score for rapid determination of risk in 
AML, published in Nature by Ng S., et al. (Ng, Mitchell et al. 2016). In this study Ng 
et al. used samples from 78 human patients to identify 17 genes associated with LSC 
activity in AML, and validated their findings by xenotransplantation. Using this LSC 
signature gene set to analyse the gene lists, we performed a Gene Set Enrichment 
Analysis (GSEA) study of genes positively or negatively correlated with YTHDF2 
across more than 1732 human AML samples (see 2.23). GSEA is an analytical 
method for interpreting gene expression data in order to determine biological 
relevance from genome-wide sequencing data. The method works by focusing on 
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gene sets i.e. groups of genes that share common biological function, chromosomal 
location, or regulation (Subramanian, Tamayo et al. 2005).  
 
The results of our GSEA are illustrated in the right panel of Figure 5.4.6 B and are 
listed in Appendix 3. We found that transcripts which negatively correlate with 
YTHDF2 expression are highly associated with the loss of leukaemogenic potential 
(Figure 5.4.6 D). In this way, when an AML sample expresses low amounts of 
YTHDF2, transcripts associated with the loss of leukaemogenic potential have greater 
expression.  In contrast, transcripts whose expression correlates with that of YTHDF2 
are depleted from the pool of transcripts associated with weak LSC activity (Figure 
5.4.6 B). In summary therefore, YTHDF2 negatively regulates transcripts whose 
expression limits LSC activity.  
 
Inspecting the genes that negatively correlate with YTHDF2 expression in human 
AML, contain m6A in both mouse and human AML, are upregulated in Ythdf2fl/fl;Vav-
iCre LSCs, and are associated with weak LSC function, we identified TNF receptor 2 
(TNFR2) encoded by the Tnfrsf1b (Tnfrsf2) gene (Figure 5.4.6 D). We focused our 
subsequent experiments on TNFR2 as TNF signalling was also identified as a node 
in the CPDB network analysis (Figure 5.4.6 C). Furthermore, TNFR2 together with 
TNFR1 has been shown previously to restrict the proliferation and survival of 
leukaemic cells (Hockendorf, Yabal et al. 2016). Notably, TNFRSF1B is highly 
methylated in both mouse pre-leukaemic cells and human AML cell lines (Figure 
5.4.6 E). Furthermore, TNFRSF1B expression is significantly decreased in AML 
patient samples compared to non-leukaemic controls (Figure 5.4.6 F), and its 
expression negatively correlates with LSC activity (Figure 5.4.6 G). In addition, RIP-
qPCR (carried out by David Wotherspoon, (Paris, Morgan et al. 2019)) revealed co-
precipitation of the Tnfrsf1b transcript with YTHDF2 in mouse pre-leukaemic cells 
(Figure 5.4.6 H). Finally, concurrent with the increased half-life of Tnfrsf1b transcript 
(Figure 5.4.6 I), the surface expression of TNFR2 is upregulated on mouse 
Ythdf2fl/fl;Vav-iCre pre-leukaemic cells (Figure 5.4.6 J). We therefore tested whether 
TNF stimulation had a differential impact on Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-
leukaemic cells. Indeed, the loss of Ythdf2 rendered cells more sensitive to TNF-
induced apoptosis (Figure 5.4.6 K). Based on these findings, we concluded that the 
TNFR2 pathway contributes at least one molecular mechanism by which the loss of 
Ythdf2 negatively impacts on AML. 
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Further work therefore focused on the TNFR2 pathway (Tnfrsf1b transcript) in 







Figure 5.4.6 TNFRSF1B gene expression is decreased in different AML 
subtypes and negatively correlates with LSC activity. (A) Violin plots of m6A peak 
strength (-log10Q) in MA9.3ITD and NOMO-1 cells for transcripts grouped according 
to expression changes between Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-leukaemic cells 
(defined as in Figure 5.4.2 E) are shown. (*, P < 0.05, **, P < 0.01, Mann-Whitney, 
two-sided test). The upper and lower quartiles and the median are indicated for each 
group. (B) Left, overview of gene selection criteria for this study. Upregulated genes 
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in Ythdf2fl/fl;Vav-iCre pre-leukaemic cells, highly methylated in Ythdf2fl/fl pre-leukaemic 
cells and methylated in human MA9.3ITD and NOMO-1 cells were further analyzed. 
Right, GSEA study of genes positively or negatively correlated with YTHDF2 across 
more than 1732 human AML samples. The LSC signature (Ng, Mitchell et al. 2016) 
gene set was used to analyze the gene lists. (C) CPDB analysis of genes significantly 
upregulated in Ythdf2fl/fl;Vav-iCre pre-leukaemic cells (P < 0.05) with high m6A levels 
(-log10Q > 25) in mouse pre-leukaemic cells and also methylated in human AML 
(MA9.3ITD and NOMO-1) cell lines. (D) GSEA using LSC signature gene set for 
genes defined in (C) and that negatively correlate with YTHDF2 expression in human 
AML samples (E) m6A IP read coverage (blue) from Ythdf2fl/fl pre-leukaemic cells 
along the Trnfrs1b genomic locus (upper panel) and m6A IP read coverage from 
NOMO-1, and MA9.3ITD cells along TNFRSF1B genomic locus (lower panels) are 
shown. Input coverage is shown in green. Gene models are depicted on top. (F) 
TNFRSF1B gene expression in control (CTL) and different cytogenetic subgroups of 
human AML bone marrow samples. Violin plots show the distribution of log2 
expression values. Horizontal line in the boxplots indicates median. **, P<0.01; ****, 
P<0.0001. CNG, cytologically normal with good prognosis; CNI, cytologically normal 
with intermediate prognosis; CAO, cytologically abnormal not otherwise specified. (G) 
TNFRSF1B gene expression in primitive AML cell compartments with (LSC+) and 
without (LSC−) leukaemic engraftment potential. ****, P<0.0001. (H) Tnfrsf1b 
enrichment in YTHDF2 immuno-precipitates from Ythdf2fl/fl pre-leukaemic cells is 
shown. Tnfrsf1b background levels were determined using Ythdf2fl/fl;Vav-iCre pre-
leukaemic cells. Data are mean ± s.e.m., n = 3. *, P < 0.05. (I) Decay curves for 
Trnfrs1b in Ythdf2fl/fl (top panel) and Ythdf2fl/fl;Vav-iCre (bottom panel) pre-leukaemic 
cells transcriptomes are shown. Transcript decay was estimated by the normalized 
cDNA T to C conversion rate at 0, 60, 180 and 540 minutes after S4U removal. The 
centre value and the error bars at each time point indicate the conversion rate mean 
and standard deviation, respectively. The conversion rates for each biological 
replicate are indicated with dots. For each genotype, the Trnfrs1b half-life is also 
shown. (J) Representative FACS plots showing the expression of TNFRSF1B on the 
cell surface of Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-leukaemic cells. The inner graph 
displays the quantification of TNFRSF1B expression. Data are mean ± s.e.m, n = 4 
per genotype. **, P < 0.01. (K) Percentage of Annexin V+DAPI− Ythdf2fl/fl and 
Ythdf2fl/fl;Vav-iCre pre-leukaemic cells treated with 10 ng/ml TNF-α at 0 and 6-hour 
timepoints are shown. Data are mean ± s.e.m., n = 3. *, P < 0.05. 
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5.4.7 Tnfrsf1b knockdown does not fully rescue impaired leukaemic 
transformation potential of Ythdf2-deficient cells in vitro, or delayed leukaemic 
development in vivo  
 
In order to test the hypothesis that TNFR2 upregulation contributes to the impaired 
leukaemic potential of Ythdf2fl/fl;Vav-iCre pre-LSCs, we attempted to rescue the 
phenotype through short hairpin RNA (shRNA) mediated knockdown of Tnfrsf1b. This 
is a method of RNA silencing based on expression of shRNAs from the RNA 
polymerase III promoter (Paddison, Caudy et al. 2002). In our case, we used the HIV-
based third generation transfer plasmid pLKO.1 puro for cloning and expressing the 
shRNA sequences with which to knockdown Tnfrsf1b (Stewart, Dykxhoorn et al. 
2003).  
 
Meis1/Hoxa9 transformed Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-LSCs were generated 
as previously described (see sections 2.11- 2.13). Control Ythdf2fl/fl pre-LSCs (n=2 
biological replicates) were then transduced with lentivirus carrying one of three 
Tnfrsf1b knockdown shRNAs (KD shRNA1-3), or control shRNA (CTL) (see sections 
2.12 and 2.17). Transduced cells were selected based on puromycin resistance, and 
subsequently stained with antibody against TNFR2 and analysed by flow cytometry 
(see section 2.8). When compared with CTL-transduced pre-LSCs (CTL pre-LSCs), 
surface expression of TNFR2 was significantly reduced following Tnfrsf1b knockdown 
with shRNA3, but not with shRNA1 and shRNA2 (Figure 5.4.7 A). Further 
experiments were therefore carried out with shRNA3 transduced cells only, hence 
referred to as ‘knockdown’ pre-LSCs (KD pre-LSCs).  
 
Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-LSCs (n = 5 biological replicates each) were 
transduced with lentivirus carrying Tnfrsf1b knockdown shRNA3 (validated as 
described above) or control shRNA (CTL). Transduced cells were selected based on 
puromycin resistance, and subsequently stained with antibody against TNFR2 and 
analysed by flow cytometry. As demonstrated previously (Figure 5.4.6 J), the surface 
expression of TNFR2 was upregulated on Ythdf2fl/fl;Vav-iCre pre-LSCs when 
compared with Ythdf2fl/fl pre-LSCs. (Figure 5.4.7 B). Following knockdown with 
shRNA3, surface expression of TNFR2 was reduced in Ythdf2fl/fl;Vav-iCre pre-LSCs, 
and although this reduction did not attain significance at this stage (CTL Ythdf2fl/fl;Vav-
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iCre pre-LSCs versus KD Ythdf2fl/fl;Vav-iCre pre-LSCs p = 0.0556), the difference 
between CTL Ythdf2fl/fl pre-LSCs and KD Ythdf2fl/fl;Vav-iCre pre-LSCs was no longer 
present (CTL Ythdf2fl/fl pre-LSCs versus CTL Ythdf2fl/fl;Vav-iCre pre-LSCs p = 0.0079, 
whereas CTL Ythdf2fl/fl pre-LSCs versus KD Ythdf2fl/fl;Vav-iCre pre-LSCs p = 0.0952 
(Figure 5.4.7 B).   
 
CTL and KD pre-LSCs (both Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre genotypes of each) were 
serially re-plated as described previously (see section 2.13.2) as an in vitro measure 
of self-renewal capacity. Colony counts at CFC1, CFC2 and CFC3 showed no 
significant differences between CTL and KD pre-LSCs for either Ythdf2fl/fl or 
Ythdf2fl/fl;Vav-iCre genotypes (Figure 5.4.7 C). There was a trend towards increased 
colony numbers at CFC3 in Ythdf2fl/fl;Vav-iCre pre-LSCs following Tnfrsf1b 
knockdown, but this was not significant. Repeated antibody staining and flow 
cytometric analysis of CFC3 pre-LSCs (Figure 5.4.7 D) showed a significant 
reduction of surface expression of TNFR2 in Ythdf2fl/fl;Vav-iCre pre-LSCs following 
shRNA-mediated Tnfrsf1b knockdown (CTL Ythdf2fl/fl;Vav-iCre pre-LSCs versus KD 
Ythdf2fl/fl;Vav-iCre pre-LSCs p = 0.0159), ruling out escape from knockdown as a 
cause of the failure to demonstrate a significant rescue effect.  
 
In order to investigate the effect of Tnfrsf1b knockdown in vivo, Meis1/Hoxa9 
transformed CTL and KD pre-LSCs (both Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre genotypes 
of each), were transplanted to irradiated primary recipients, exactly as described 
previously (see section 2.15.2).  
Serial peripheral blood analysis showed no difference in the engraftment of KD pre-
LSCs compared with their CTL counterpart, for both Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre 
genotypes (Figure 5.4.7 E), and subsequently no difference in the Kaplan Meier 
survival curve (Figure 5.4.7 F). As observed previously, there was a significant 
difference in both engraftment and overall survival between Ythdf2fl/fl and 
Ythdf2fl/fl;Vav-iCre pre-LSCs (Figures 5.4.7 E-F), which knock down of Tnfrsf1b failed 





Figure 5.4.7 The impact of Tnfrsf1b knockdown on Ythdf2-deficient pre-
leukaemic cell colony formation in vitro and engraftment in vivo. (A) TNFR2 cell 
surface protein expression in Meis1/Hoxa9-transduced pre-leukaemic cells co-
transduced with lentiviruses expressing scrambled shRNA (CTL) or shRNAs targeting 
Tnfrsf1b (KD shRNA1-3). Data are mean ± s.e.m., n = 2. (B) TNFR2 cell surface 
protein expression in Meis1/Hoxa9-transduced pre-leukaemic cells co-transduced 
with lentiviruses expressing scrambled shRNA (CTL) or shRNA targeting Tnfrsf1b 
(KD). Data are mean ± s.e.m., n = 5. *, P < 0.05; **, P<0.01. (C) Number of CFC1-3 
colonies generated by cells shown in panel B. (D) TNFR2 cell surface protein 
expression of CFC3 cells shown in panel C. Data are mean ± s.e.m., n = 5. *, P < 
0.05; **, P<0.01. (E) Pre-leukaemic cells shown in panels C-D were transplanted into 
recipient mice. The graphs show leukaemic engraftment 3, 5 and 14 weeks after 
transplantation. Data are mean ± s.e.m., n = 8 recipients per genotype. (F) In progress 
Kaplan-Meier survival curve of the recipient mice (n = 8 per genotype) (experiment 
still underway).  
5.5 Discussion 
 
This chapter describes the results of our mechanistic studies into the requirement for 
YTHDF2 in AML. Using a combination of transcriptome profiling and m6A meRIP-Seq, 
we identified YTHDF2 targets, including Tnfrsf1b. SLAM-Seq and RIBO-Seq were 
then carried out to investigate mRNA decay kinetics and translation respectively. 
Unlike results of studies into m6A dependent METTL enzyme functions in AML (Lin, 
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Choe et al. 2016, Barbieri, Tzelepis et al. 2017, Vu, Pickering et al. 2017, Weng, 
Huang et al. 2018), our RIBO-Seq results indicated that YTHDF2 does not 
significantly impact mRNA translation. In contrast, SLAM-Seq results showed that 
m6A-directed YTHDF2-mediated mRNA decay regulates the leukaemic 
transcriptome. 
 
Our results are consistent with those of Wang et al. who used a combination of 
ribosome profiling and RNA-Seq on YTHDF2 knock down and control cells to show 
that YTHDF2 is primarily involved in RNA degradation, not translation (Wang, Lu et 
al. 2014). In this study, Wang et al. used two independent methods (PAR-CLIP and 
RIP-Seq) to look at YTHDF2 binding sites, as well as m6A meRIP-Seq to determine 
transcriptome wide methylation. They identified over 3000 YTHDF2 targets, mostly 
mRNA (but also non coding RNAs) with a conserved core motif of G(m6A)C, 
predominantly around the stop codon and 3’UTR of mRNAs. The subsequently 
showed that the carboxy (C) terminal of YTHDF2 selectively binds methylated mRNA, 
whilst the amino (N) terminal localises the mRNA to RNA decay sites (Wang, Lu et al. 
2014), known as processing (P) bodies.  
 
Du et al. then reported that methylated mRNAs show accelerated YTHDF2-
dependent deadenylation, mediated by the CCR4-NOT complex (Du, Zhao et al. 
2016). They showed that YTHDF2 recruits the CCR4-NOT complex by a direct 
interaction between the YTHDF2 N terminus and the SH domain of the CNOT1 
subunit, which is essential for the deadenylation of m6A containing RNAs by CAF1 
and CCR4 (Du, Zhao et al. 2016). Deadenylation is the commonest pathway by which 
eukaryotic mRNA degradation occurs, initiated by shortening of the protective 3’ polyA 
tail (Garneau, Wilusz et al. 2007)  
 
Wang et al. and Du et al. used non leukaemic cell lines (HeLa) to show that YTHDF2 
regulates the stability of m6A modified mRNAs (Wang, Lu et al. 2014, Du, Zhao et al. 
2016). In our study, we confirmed that the same is true in the context of AML.  
 
Our microarray results identified a large number of deregulated genes in Ythdf2-
deficient pre-LSCs compared to wild type controls, including 754 upregulated and 528 
downregulated genes. Subsequently, m6A meRIP-Seq showed that methylated 
transcripts were more likely to be upregulated in Ythdf2fl/fl;Vav-iCre pre-LSCs 
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compared with Ythdf2fl/fl pre-LSCs. To direct our investigations towards the most 
promising of these candidate genes, we employed several techniques to stratify and 
refine our results. Firstly, although there were 754 genes upregulated in Ythdf2fl/fl;Vav-
iCre pre-leukaemic cells, only 344 of these genes were high in m6A, and only 292 
genes were also methylated in MA9.3ITD and NOMO-1 cells (human AML cell lines). 
These 292 genes were chosen for further study. CPDB network analysis showed 
enrichment for RNA processing, mitochondrial function, ubiquitination, and also TNF 
signalling. Next, GSEA was carried out as another means of interpreting gene 
expression data, using a 17 essential gene set signature derived from human AML 
cases to establish YTHDF2 target transcripts associated with weak LSC function. The 
combination of these analyses, and human AML data sets, identified TNF receptor 2 
(TNFR2) encoded by the Tnfrsf1b gene, as a strong YTHDF2 target in AML.  
TNF is a pleiotropic cytokine signals which plays an important role in immune and 
inflammatory responses (Sedger and McDermott 2014). TNF signals through two 
receptors, TNFRSF1A (TNFR1) and TNFRSF1B (TNFR2), which have been reported 
as having differing roles. TNFR1 has an intracellular death domain and is involved in 
apoptosis signalling, whilst TNFR2 is implicated in the promotion of cellular 
proliferation (Aggarwal 2003). However, given the documented cross talk, including 
ligand passing between the receptors (Tartaglia, Pennica et al. 1993), it is likely that 
some of the functions of TNF may be dependent on expression of both receptors 
simultaneously. 
TNF has been implicated previously in the control of both normal and malignant 
haematopoiesis. Several groups have shown that TNF has the ability to suppress 
mouse and human HSC maintenance in vitro (Broxmeyer, Williams et al. 1986, 
Zhang, Harada et al. 1995, Bryder, Ramsfjell et al. 2001, Dybedal, Bryder et al. 2001). 
More recently, Pronk et al. reported that both TNFR1 and TNFR2 restrict the self-
renewal capacity of healthy HSPCs in vivo (Pronk, Veiby et al. 2011). These authors 
showed that BM cells deficient for both TNFR1 (Tnfrsf1a-/-) and TNFR2 (Tnfrsf1b-/-) 
receptors, hereafter referred to as TNFR double KO (Tnfrsf1-dKO), exhibited a 
significant competitive advantage over control BM cells in their ability to reconstitute 
myeloid and lymphoid cell lineages in myeloablated wild type recipients. A less 
pronounced, but still significant, competitive advantage was also seen for BM cells 
deficient in either Tnfrsf1a or Tnfrsf1b (Pronk, Veiby et al. 2011).  
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However, other groups have shown contrasting effects of TNF on HSCs. In vitro, Caux 
et al. reported a stimulatory role for TNF-α on human HSPCs (Caux, Saeland et al. 
1990). In vivo, Rebel at al showed a fourfold decrease in the number of Tnfrsf1a-
deficient HSCs in a competitive repopulating assay, and impaired self-renewal ability 
of Tnfrsf1a-deficient HSCs in secondary BM transplantation experiments (Rebel, 
Hartnett et al. 1999). In this study, adult Tnfrsf1a-deficient mice had increased marrow 
cellularity and increased numbers of myeloid and erythroid colony forming progenitor 
cells, paralleled by elevated peripheral blood cell counts. In contrast to the increased 
myeloid compartment, pre-B CFCs were deficient in older Tnfrsf1a-deficient mice 
(Rebel, Hartnett et al. 1999). More recent work by Pearl-Yafe et al. also indicated a 
supportive role for TNFRs in murine HSPC function in the early stages of engraftment 
following BM transplantation (Pearl-Yafe, Mizrahi et al. 2010).  
Very recently, Yamashita and Passegué reported a complex role for TNF-α in 
haematopoietic regeneration (Yamashita and Passegué 2019). They showed that 
TNF-α has different effects on HSCs and progenitor cells, which facilitates 
haematopoietic clearance and regeneration in an inflammatory context. Their studies 
indicated that TNF-α induces myeloid progenitor cell apoptosis, but simultaneously 
promotes HSC survival and myeloid differentiation through a p65-NF-κB-dependent 
gene program (Yamashita and Passegué 2019).  
The role of TNF signalling in leukaemia is similarly complex. Constitutive NF-κB 
activity has been described as a contributor to leukaemic progression in mouse 
models of AML, and has been attributed to autocrine TNF-α secretion by leukaemia 
initiating cells (Kagoya, Yoshimi et al. 2014). A correlation between TNF-α and NF-
κB activity has also been documented in human AML samples (Kagoya, Yoshimi et 
al. 2014). In contrast, knock out of both Tnfrsf1a and Tnfrsf1b in a FLT3-ITD driven 
AML mouse model resulted in a strong increase in the overall leukaemic burden 
compared with wild type mice, which was attributed to a reduction in RIPK3-
dependent cell death and differentiation (Hockendorf, Yabal et al. 2016).  
We attempted to confirm the role of the YTHDF2-TNFR2 axis in AML through shRNA 
mediated knock down of Tnfrsf1b in Ythdf2fl/fl and Ythdf2fl/fl;Vav-iCre pre-LSCs. 
Despite achieving a significant level of knock down using one construct (Figure 5.4.7 
D), this did not translate to a survival advantage following transplantation to irradiated 
mice. There are several possible explanations for this. Firstly, it is unlikely that the 
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supporting role of Ythdf2 in development and propagation of AML is dependent on a 
single pathway. More probably, multiple interacting pathways are contributing. 
Secondly, it may be that in the context of TNF, knock down of both Tnfrsf1a and 
Tnfrsf1b would be preferable in order to rule out potential compenstation in the 
system, particularly as the two receptors have been shown to have a synergistic effect 
in mediating TNF signalling in HSPCs (Pronk, Veiby et al. 2011).  
In summary, our mechanistic studies showed that the critical role of Ythdf2 in AML 
development and propagation depends on m6A-directed Ythdf2-mediated mRNA 
decay, and we demonstrated that Tnfrsf1b upregulation represents one specific 








Chapter 6: Conclusions and future work 
 
The work presented in this thesis identifies YTHDF2 as a critical regulator of normal 
and malignant haematopoiesis. Previous studies of METTL3/14 methyltransferases, 
and the demethylase FTO, have shown a key role for m6A in AML pathogenesis 
(Barbieri, Tzelepis et al. 2017, Li, Weng et al. 2017, Weng, Huang et al. 2018). Whilst 
modification of mRNA with m6A can have multiple outcomes on the respective 
transcript (Zhao, Roundtree et al. 2017), we demonstrate here that the YTHDF2-
mediated m6A-dependent mRNA degradation pathway is essential for cancer stem 
cells in AML. Using mouse models, we find that deletion of Ythdf2 specifically 
compromises LSC development and propagation. Furthermore, consistent with 
recent findings in mouse and human HSCs (Li, Qian et al. 2018, Wang, Zuo et al. 
2018), we demonstrate that targeting Ythdf2 expands HSCs and enhances their 
myeloid reconstitution potential in lethally irradiated mice (Figure 6).  
 
These unique properties of YTHDF2 highlight the therapeutic potential of YTHDF2 
inhibition as a strategy for AML treatment. Such an intervention would have the dual 
benefits of eradicating malignant LSCs while bestowing a competitive advantage to 
normal HSCs. Standard AML therapies are non-specific, and are therefore associated 
with significant side effects. Whilst the survival of young people with AML has 
improved significantly in the last 30 years, the prognosis for older patients remains 
stubbornly poor (Döhner, Estey et al. 2017). Whilst this is partly due to older patients 
having higher cytogenetic risk disease, many of these patients are also unable to 
tolerate high intensity cytarabine/anthracycline therapy, or HSCT. At present, 
treatment options for these patients are limited, and are associated with a poor 
response. The median survival time for patients > 60 years is only 6-9 months. In this 
group of patients therefore, YTHDF2-inhibition would be a particularly promising 
treatment strategy. 
 
In a separate context, YTHDF2 inhibition might offer a novel strategy with which to 
expand HSCs in vitro for therapeutic purposes. Given their unique dual capacity for 
self-renewal and multipotency, HSCs are a valuable therapeutic commodity for the 
purposes of HSCT, which can be used to treat a variety of diseases, including cancer, 
congenital or acquired BM failure, immunodeficiency states, and autoimmunity 
(Copelan 2006). At present, HSCT is hampered by an inability to isolate HSCs in 
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sufficient quantities, and a failure to expand them in vitro (Dahlberg, Delaney et al. 
2011). HSC self-renewal, differentiation and quiescence is determined by signals from 
the microenvironment, as well as stem cell intrinsic regulators (Nakamura-Ishizu, 
Takizawa et al. 2014). The primary limiting factor for the use of HSCT is the limited 
number of HSCs that can be obtained from donors, and the poor efficacy of expanding 
these HSCs in vitro. For ex-vivo HSC expansion, approaches that potentiate HSC 
symmetrical division without further differentiation are required (Morrison and Kimble 
2006). However, cytokine cocktails currently used to potentiate HSC proliferation in 
vitro (such as SCF, Flt3, TPO, IL-3 and IL-6) may only regulate short term (4 day) 
HSC survival(Knapp, Hammond et al. 2017). More recently, high throughput screens 
have identified several new compounds with the potential to improve HSC expansion 
in vitro, but their efficacy in a clinical setting remains to be proven (Tajer, Pike-Overzet 
et al. 2019). Based on our findings, YTHDF2 inhibition is another candidate strategy 





Figure 6 The effect of targeting Ythdf2 on normal and malignant 
haematopoiesis. Ythdf2 inhibition inhibits degradation of m6A-modified mRNA, 
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resulting in an accumulation of m6A-modified transcripts. As a result, HSC expansion 
occurs, and AML initiation and propagation are compromised, in part through Tnfrsf2 
(Tnfrsf1b). Adapted from Paris, Morgan et al. 2019 (Paris, Morgan et al. 2019). 
 
Whilst undeniably positive, the reason for the differential outcomes of targeting Ythdf2 
in HSCs and LSCs is not clear. However, several previous studies have shown that 
the effect of m6A is context dependent, varying according to cell type and stage. For 
example, Geula et al. showed that depletion of Mettl3 in embryonic stem cells (ESCs) 
compromised their ability to transform into a primed epiblast state in vitro. However, 
upon examining a later stage of differentiation, the same group found that depletion 
of Mettl3 actually hastened differentiation. They concluded that the effect of Mettl3 
was stage dependent, probably reflecting the background switch between 
pluripotency and differentiation genes (Geula, Moshitch-Moshkovitz et al. 2015).  
There is evidence to suggest that Mettl3 may also have varying effects in normal and 
malignant haematopoiesis. Using two independent CRISPR genetic screens, Barbieri 
et al. showed that that METTL3 was essential for growth of AML cells, but was not 
required by primary haematopoietic cells (Barbieri, Tzelepis et al. 2017). 
Subsequently, Yao et al. and Lee et al. both used a Mx1-Cre conditional genetic 
deletion strategy to target Mettl3 in adult mice, and reported a large increase in HSCs, 
albeit lacking reconstitution capacity in transplantation experiments (Yao, Sang et al. 
2018, Lee, Bao et al. 2019). In contrast, METTL3 depletion in human AML samples 
has been shown to result in apoptosis and differentiation, and delayed leukaemia in 
vivo (Vu, Pickering et al. 2017). These findings suggest that m6A can have differing 
functions in haematopoietic cells under normal and malignant conditions, therefore 
supporting our own findings, that targeting Ythdf2 expands HSCs and compromises 
AML initiation and propagation.   
 
Although mechanistic investigations presented in this thesis only focused on LSCs, 
further work is underway by other members of the group to characterise the 
mechanism for YTHDF2 in a non-malignant context. It will be interesting to assess 
the similarities or differences between the two, when considering the contrasting 
phenotypes.   
 
Looking to the future as a group, we hope to develop small molecule inhibitors with 
which to target YTHDF2, initially in mouse models of AML, and later in human cell 
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lines and primary AML cells. If these results prove to be promising, we will work with 
collaborators to bring these treatments into the clinical field. Meanwhile, we will extend 
our murine studies to include a transgenic model of AML, to complement the RTTA 
transplantation studies conducted to date.  
 
With regards to YTHDF2 targeting in the context of non-malignant haematopoiesis, 
we plan to collaborate with groups working to expand HSCs in vitro for therapeutic 
purposes. Finally, I plan to look more closely at the immune system of the Ythdf2-
deficient mice, in particular the lymphocyte lineages which are compromised upon 
Ythdf2 deletion, to better characterise the phenotypic and functional effects of Ythdf2 
deficiency within the adaptive immune system.   
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Appendix: Supplementary tables relating to Chapter 5  
   
Symbol log2(FC) adj. P Value 
Csn2 5,51 0,00004099 
Sva 4,57 0,00000001 
Gm595 2,90 0,02040276 
Cpne2 2,55 0,00000048 
Mrgpra2a 1,92 0,00100306 
Dlk1 1,90 0,04005395 
Nrp2 1,88 0,01201683 
Il1rl2 1,85 0,00657882 
Laptm4b 1,83 0,04615550 
Scarf1 1,82 0,00227636 
Il1f9 1,81 0,02953698 
Lair1 1,68 0,00055642 
Gatm 1,64 0,01129324 
Pmp22 1,54 0,00978065 
Eng 1,39 0,01382162 
Npl 1,37 0,02225112 
Hspa1b 1,33 0,00715852 
Kcnk12 1,33 0,02697286 
Glyat 1,31 0,00267415 
Chst15 1,27 0,01082185 
0610040J01Rik 1,27 0,00648365 
Slc16a7 1,22 0,00892191 
Lrg1 1,20 0,00617104 
Slc40a1 1,19 0,01259119 
Cpne8 1,18 0,02930489 
Ccl6 1,15 0,04678231 
Ly6g5b 1,15 0,03334376 
Lpl 1,14 0,01277766 
Myo1e 1,12 0,02775427 
Afap1 1,11 0,00142512 
Rxra 1,10 0,00048341 
Rnf144b 1,08 0,00999466 
Mycn 1,08 0,01772719 
Plxna2 1,08 0,00393508 
Slc39a4 1,07 0,03829813 
Ak3 1,07 0,00108212 
Ces2g 1,06 0,00280342 
Pde2a 1,03 0,00165227 
Bai1 1,01 0,00417171 
Zmat3 1,00 0,00327908 
Cd55 0,98 0,00690838 
Cd79b 0,97 0,00722837 
Zfp943 0,93 0,00264831 
Pla2g5 0,92 0,00897905 
Adrbk2 0,91 0,01832420 
Fen1 0,90 0,03609294 
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Ptk7 0,90 0,00719714 
Pik3r5 0,90 0,00033087 
Dio2 0,90 0,00722837 
Hpgds 0,88 0,01028171 
1810011H11Rik 0,87 0,02127968 
Ecm1 0,84 0,01305287 
Ogdhl 0,84 0,04255846 
Nid2 0,83 0,02241511 
Plcg1 0,80 0,00424456 
NA 0,78 0,01407804 
Pik3r6 0,77 0,00955344 
Olfr56 0,75 0,00712944 
Tanc1 0,75 0,00293324 
Myo7a 0,74 0,01211048 
Ppap2b 0,73 0,02847224 
Dock9 0,72 0,03556259 
Wwc2 0,72 0,00711345 
Gpr84 0,72 0,00393508 
Gkap1 0,72 0,02625104 
Snx7 0,71 0,00995127 
H2afy2 0,71 0,00845127 
Gatsl2 0,71 0,00534147 
Nanp 0,71 0,01209590 
Gp9 0,70 0,04776381 
Vamp5 0,69 0,00374844 
Arsb 0,69 0,01368656 
Cbr1 0,69 0,02953698 
Mospd3 0,68 0,03257628 
Tusc1 0,68 0,00844962 
Tbc1d30 0,67 0,01186164 
Chd3 0,66 0,00401669 
Tmc7 0,66 0,01642187 
Lima1 0,66 0,00089937 
Trp53inp1 0,66 0,04946880 
Rab3il1 0,66 0,00293324 
Srxn1 0,65 0,00690838 
Tnfaip8l1 0,65 0,00621088 
Cpped1 0,65 0,00357674 
Dock10 0,65 0,02020948 
Ubash3a 0,65 0,01002245 
Gm364 0,64 0,02075986 
Mrpl46 0,64 0,00849760 
Ppfibp1 0,64 0,02102952 
Renbp 0,64 0,00074506 
2310028H24Rik 0,64 0,00293324 
Hebp1 0,64 0,00176940 
Als2 0,64 0,00231350 
Mrpl16 0,63 0,00074506 
Chchd10 0,63 0,00691575 
Plxna1 0,63 0,02190816 
Olfr51 0,62 0,03092340 
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Psd3 0,62 0,00844962 
Pgp 0,62 0,04580074 
Emid1 0,62 0,02374741 
Hnmt 0,62 0,02023394 
Irak1bp1 0,61 0,01034518 
Sh3tc1 0,61 0,00628337 
Nlgn2 0,61 0,02618829 
Exoc3l 0,61 0,03559810 
Ephx1 0,61 0,01129324 
Plscr3 0,61 0,03054057 
Clmn 0,61 0,00773601 
Emilin1 0,60 0,03107530 
Rpusd1 0,60 0,00143744 
Commd5 0,60 0,00185915 
Fam115a 0,60 0,04490563 
Batf 0,60 0,00534147 
Arl4a 0,60 0,00730580 
2810432D09Rik 0,60 0,02023394 
Pak1 0,59 0,00621088 
Csf3r 0,59 0,03364364 
Ubtd2 0,59 0,01481064 
Tbc1d16 0,59 0,00629381 
9030617O03Rik 0,59 0,01757521 
Kctd6 0,59 0,00231350 
Scamp5 0,58 0,01348771 
Abhd6 0,58 0,02068986 
Gmppb 0,58 0,02673716 
Btg2 0,58 0,02865139 
Extl3 0,58 0,01248263 
Cdc42bpb 0,58 0,00392058 
Plekha1 0,58 0,03062262 
Prodh 0,58 0,00231350 
Tacc2 0,58 0,01324153 
Klhl8 0,57 0,02775427 
Acy3 0,57 0,01089479 
Mfsd5 0,57 0,00064919 
BC003266 0,57 0,00374844 
Tanc2 0,57 0,02731743 
Mrpl51 0,57 0,00888400 
Ubtd1 0,56 0,00789830 
Abt1 0,56 0,00713144 
Tsku 0,56 0,00825478 
Hyal2 0,56 0,00709176 
Tmem53 0,56 0,02080605 
Mrpl43 0,56 0,00169303 
Als2cl 0,56 0,03221455 
Fam195a 0,56 0,00691575 
Spryd4 0,56 0,00393508 
Plekho1 0,55 0,04433043 
Wdr55 0,55 0,03121408 
Fam69a 0,55 0,00621088 
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E130012A19Rik 0,54 0,00282906 
Tysnd1 0,54 0,02787096 
H2-DMb1 0,54 0,01145623 
Pqlc2 0,54 0,02010105 
Tomm5 0,54 0,02043170 
Nfatc2 0,54 0,00641007 
Znhit2 0,54 0,02374741 
N6amt2 0,54 0,01950134 
Gnb1l 0,54 0,00940835 
Phlda3 0,54 0,00844962 
Trmt5 0,53 0,00296933 
Dusp9 0,53 0,00690838 
Siah1b 0,53 0,02403610 
Tk1 0,53 0,02526871 
Atg12 0,53 0,00148083 
Nlrx1 0,53 0,01563641 
Grwd1 0,53 0,00357270 
Irgm1 0,53 0,01090952 
Zbtb45 0,53 0,01797250 
Rab7l1 0,53 0,00721282 
Tuba4a 0,53 0,02977308 
Shroom4 0,53 0,01229685 
Frmd6 0,53 0,01234749 
Hfe 0,52 0,03283321 
D330045A20Rik 0,52 0,00789830 
Mpzl1 0,52 0,03852733 
Lpar5 0,52 0,00789830 
Kbtbd4 0,52 0,01279567 
Mrps7 0,52 0,01015088 
Ccdc23 0,52 0,02391575 
Chpf2 0,52 0,00995127 
Zcchc17 0,52 0,02149877 
Slc16a13 0,51 0,00888064 
Mrpl12 0,51 0,01002245 
Pik3c2b 0,51 0,01779216 
Dok4 0,51 0,01096282 
Fkrp 0,51 0,00293324 
Bmpr1a 0,51 0,01089479 
Cables2 0,51 0,00116418 
Nxt1 0,51 0,01348771 
Slc10a3 0,51 0,01642155 
6230427J02Rik 0,51 0,00407070 
Wdr81 0,50 0,00363305 
Nubp2 0,50 0,02177819 
Ece2 0,50 0,00325600 
Nav2 0,50 0,01715493 
Bcl9 0,50 0,00393508 
5031439G07Rik 0,50 0,01563641 
Cdk18 0,50 0,00371773 
Oas2 0,50 0,03790564 
Srl 0,50 0,04867220 
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Rbmxl1 0,50 0,01568725 
Sep-08 0,50 0,01514006 
Rps6ka3 0,50 0,01457843 
Pter 0,50 0,01421999 
Itpk1 0,50 0,00940978 
Slc35a4 0,50 0,02190816 
Slc28a2 0,50 0,01062891 
Med29 0,49 0,03801022 
Trim65 0,49 0,00845127 
2410017P09Rik 0,49 0,00730580 
Phospho1 0,49 0,00610476 
4933430I17Rik 0,49 0,02225940 
Ece1 0,49 0,02115083 
Scd4 0,48 0,01015088 
Rgs8 0,48 0,02587636 
Fam105b 0,48 0,01530697 
Zswim1 0,48 0,01404115 
Impdh1 0,48 0,02667670 
Slc46a1 0,47 0,00593388 
Tnf 0,47 0,01832420 
Wdr66 0,47 0,01019248 
Trappc3 0,47 0,00417171 
Ndufaf4 0,47 0,00712944 
Spn 0,47 0,01810627 
Elof1 0,47 0,03234970 
Nupl2 0,47 0,00540659 
Fastkd2 0,47 0,02377744 
Tle1 0,47 0,02618829 
Alad 0,47 0,01816129 
Hsd3b7 0,47 0,00958761 
Bbs7 0,47 0,03875079 
Ldlrap1 0,47 0,02190816 
Spr 0,47 0,00995127 
Gmpr 0,46 0,01014895 
Asb8 0,46 0,01283398 
Fam110a 0,46 0,00986858 
Ndufaf1 0,46 0,02046304 
Tulp4 0,46 0,01258700 
Agap2 0,46 0,01650406 
Mmp19 0,46 0,00280342 
Mical3 0,46 0,01722702 
Ppfibp2 0,46 0,01028171 
Fam69b 0,46 0,01563641 
Tprn 0,46 0,02547456 
Rbpms2 0,46 0,03109627 
Elmod3 0,46 0,00417171 
Smad1 0,46 0,02595223 
0610011L14Rik 0,45 0,01327013 
Urgcp 0,45 0,00988236 
Rbm19 0,45 0,01129324 
Gclm 0,45 0,00357674 
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Atp6v0a2 0,45 0,00200253 
Gltp 0,45 0,00657882 
2810453I06Rik 0,45 0,02010105 
C2cd2 0,45 0,00779129 
Vps18 0,45 0,01248263 
Ywhag 0,45 0,00789830 
Khk 0,45 0,01715493 
Neu1 0,45 0,02190816 
Smpd2 0,45 0,00424451 
Plekho2 0,44 0,02771148 
Map2k3 0,44 0,01463136 
Slc19a2 0,44 0,01898743 
2410022L05Rik 0,44 0,00921589 
Ttyh2 0,44 0,01607309 
Gjb3 0,44 0,01463136 
Acer3 0,44 0,02697286 
Bysl 0,44 0,01151293 
B4galt4 0,44 0,04887601 
Igsf6 0,44 0,00425725 
B3gnt1 0,44 0,00598630 
Mpv17l2 0,44 0,00690838 
Phospho2 0,44 0,00267113 
Agpat2 0,43 0,00779615 
Gm962 0,43 0,01832420 
Dip2c 0,43 0,03756514 
Omg 0,43 0,00921589 
Gtdc2 0,43 0,03093125 
B230120H23Rik 0,43 0,00162838 
Poln 0,43 0,00995127 
Otud3 0,43 0,01301677 
Nudt19 0,43 0,04226806 
Ywhah 0,43 0,01425066 
Rpusd2 0,43 0,02602277 
Ccng1 0,43 0,00921589 
Ppp2r5b 0,43 0,02119237 
Sf3b4 0,43 0,03801022 
Nme6 0,43 0,01283398 
Tesk1 0,43 0,01018596 
Ano6 0,43 0,01326052 
B3gnt8 0,43 0,02296086 
Rhod 0,43 0,04893778 
Pinx1 0,43 0,00621088 
Mrpl50 0,43 0,00548984 
App 0,43 0,01984757 
Dnase2a 0,43 0,00452959 
Xrcc6bp1 0,42 0,00845127 
Nop2 0,42 0,03340482 
Tex264 0,42 0,00238538 
Zw10 0,42 0,02195807 
Ccne1 0,42 0,02075986 
Tnfrsf1b 0,42 0,01867878 
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Suox 0,42 0,00545505 
Phactr2 0,42 0,03084616 
Mgat4b 0,42 0,00480937 
Mrps25 0,42 0,02662149 
Oas1a 0,42 0,01299779 
Panx1 0,42 0,00709176 
Tmem8 0,42 0,03623233 
Erf 0,42 0,01607410 
Cyth4 0,42 0,01299577 
Mad2l1bp 0,42 0,01347608 
Gpr160 0,42 0,01543779 
Mrps30 0,42 0,02697286 
Naa40 0,41 0,01010354 
Mrps2 0,41 0,00512495 
Rapgef5 0,41 0,04963493 
Rgnef 0,41 0,02402526 
Thg1l 0,41 0,00713144 
Sipa1 0,41 0,01945030 
Bax 0,41 0,03280118 
Chpt1 0,41 0,00711345 
Clp1 0,41 0,01421999 
Hspa13 0,41 0,01070472 
Dhrs4 0,41 0,00940978 
Gria3 0,41 0,03036671 
Dgcr14 0,41 0,02010105 
Steap3 0,41 0,04725833 
Mgmt 0,41 0,01466073 
Pcyox1 0,41 0,03437566 
Ccrl2 0,41 0,02325173 
Fhod1 0,41 0,04238165 
Psmd7 0,41 0,04087968 
St6galnac4 0,41 0,00713144 
Tlr3 0,41 0,04892498 
1810055G02Rik 0,41 0,03906522 
Narfl 0,41 0,00534650 
Brms1 0,40 0,02595223 
Snord4a 0,40 0,04561035 
Ralb 0,40 0,01904211 
Grpel1 0,40 0,02980247 
Gsn 0,40 0,03406618 
Gfm1 0,40 0,04369755 
Nup50 0,40 0,01832420 
1110012L19Rik 0,40 0,01923240 
Ssbp4 0,40 0,00779615 
Timm8a1 0,40 0,01005398 
Ccdc59 0,40 0,04949090 
Pop7 0,40 0,01548282 
2010321M09Rik 0,40 0,01201683 
Uap1l1 0,40 0,04751215 
Mrto4 0,40 0,02142457 
Ppp1r13b 0,40 0,03045546 
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D230037D09Rik 0,40 0,03588580 
Rnmtl1 0,39 0,02783163 
Bcl9l 0,39 0,02099877 
C230052I12Rik 0,39 0,01028171 
Metrn 0,39 0,02930489 
Inpp4b 0,39 0,01541556 
Jmjd4 0,39 0,02403610 
Pde12 0,39 0,01201683 
Ripk1 0,39 0,01603693 
Zbtb41 0,39 0,00690838 
Exo1 0,39 0,02611982 
Def8 0,39 0,02798783 
0610010K14Rik 0,39 0,03082667 
Galnt7 0,39 0,03836688 
Foxp4 0,39 0,01120179 
Ctns 0,39 0,00773601 
Orai1 0,39 0,00845127 
Ipo13 0,38 0,01670152 
Slc12a7 0,38 0,03970393 
Bdh1 0,38 0,00743313 
Trmt61a 0,38 0,02918481 
Sac3d1 0,38 0,01935250 
Nagpa 0,38 0,02697286 
Xylb 0,38 0,02080605 
Sap30bp 0,38 0,00621088 
Sssca1 0,38 0,03036671 
Snx33 0,38 0,01348771 
Stard8 0,38 0,02930489 
Eif2b1 0,38 0,04238165 
1810063B05Rik 0,38 0,03169648 
Klhdc4 0,38 0,04933377 
Ndst1 0,38 0,01352362 
Gm10495 0,38 0,04544722 
Brp44 0,37 0,00621088 
Gemin4 0,37 0,04186192 
Gpsm2 0,37 0,00713144 
Kif21a 0,37 0,04523665 
Nudt18 0,37 0,03356401 
Pgd 0,37 0,03670644 
Chst12 0,37 0,01779216 
Mrpl15 0,37 0,02225940 
1500001M20Rik 0,37 0,01326052 
Cables1 0,37 0,03283321 
Mrps23 0,37 0,02147747 
Polr3g 0,37 0,02941507 
Hmox2 0,37 0,02325173 
Fkbpl 0,37 0,01028171 
Mrpl55 0,37 0,03641255 
Eif2ak1 0,37 0,02847224 
Osbpl11 0,37 0,00690838 
Jagn1 0,37 0,03556259 
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Dnajc15 0,37 0,02114312 
Tmem184b 0,37 0,02149877 
Ssh3 0,37 0,01216521 
Zfp507 0,37 0,02697286 
Snx8 0,37 0,00921589 
Cdyl2 0,37 0,03713034 
Nfam1 0,37 0,03556259 
D1Ertd622e 0,37 0,04347554 
Plcb2 0,36 0,03765366 
Nif3l1 0,36 0,01234749 
Mcat 0,36 0,01372618 
Vamp8 0,36 0,02225940 
Rps19bp1 0,36 0,02999950 
Tspan4 0,36 0,00908657 
Letm1 0,36 0,02115083 
Fam20b 0,36 0,02639957 
Ptpn12 0,36 0,01096282 
Rragc 0,36 0,01305287 
Bpnt1 0,36 0,02773164 
Snx20 0,36 0,02753860 
Rab11fip1 0,36 0,00920791 
Fzd9 0,36 0,04483083 
Fnip2 0,36 0,03924987 
Ptp4a3 0,36 0,01779216 
C1galt1 0,36 0,02726428 
D8Ertd738e 0,36 0,02677388 
Wdr18 0,36 0,03233268 
S1pr2 0,36 0,01589189 
Utp15 0,36 0,02010105 
D330012F22Rik 0,36 0,02190816 
2210016L21Rik 0,36 0,00690838 
1300001I01Rik 0,36 0,04657515 
Elovl1 0,35 0,03569713 
Ccdc22 0,35 0,01650406 
Gstp1 0,35 0,02241511 
Zdhhc8 0,35 0,02582792 
Thap7 0,35 0,01182005 
Gng7 0,35 0,02081778 
1110038F14Rik 0,35 0,03479415 
Zfp36l2 0,35 0,01483949 
Comtd1 0,35 0,02767841 
Pdhx 0,35 0,00789830 
Cstf1 0,35 0,03755982 
Gcdh 0,35 0,01034518 
Baz1a 0,35 0,02753802 
Zfp771 0,35 0,01921388 
Aen 0,35 0,02049003 
Cyb561 0,35 0,04806947 
Ankrd40 0,35 0,02225940 
Tada2b 0,35 0,00691575 
Cgrrf1 0,35 0,02199502 
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Rogdi 0,35 0,04235515 
Cog8 0,35 0,03019283 
Ncor2 0,35 0,00964336 
Usp46 0,35 0,02479955 
Usp54 0,35 0,01556181 
9430016H08Rik 0,35 0,00921589 
Taf5l 0,35 0,00713144 
Pstpip1 0,35 0,02940043 
Depdc7 0,35 0,03641048 
Akr7a5 0,35 0,03609294 
Pip4k2b 0,35 0,01028171 
Tymp 0,35 0,03935789 
Cyp3a59 0,35 0,01585454 
Med21 0,35 0,01422985 
2310079F23Rik 0,35 0,04771581 
Gpr125 0,35 0,03364364 
Jtb 0,35 0,00844962 
1700123O20Rik 0,35 0,04946880 
Atp5e 0,35 0,02353486 
Ggct 0,35 0,01863124 
Nat15 0,34 0,00879460 
Lrrc14 0,34 0,04447683 
Nln 0,34 0,01547374 
Ccdc86 0,34 0,03641255 
Bzrap1 0,34 0,03469313 
Lsm10 0,34 0,01327013 
Txnl4a 0,34 0,01305287 
Ccnyl1 0,34 0,03342003 
Rhou 0,34 0,03107530 
Isg20l2 0,34 0,01898743 
4933403F05Rik 0,34 0,01233038 
Apeh 0,34 0,01040613 
Orai3 0,34 0,02183621 
Ftsjd1 0,34 0,02183621 
Ehd4 0,34 0,01151293 
9030625A04Rik 0,34 0,04238165 
Tmem115 0,34 0,02738620 
Puf60 0,34 0,02673716 
Setd6 0,34 0,01382338 
Mprip 0,34 0,00888400 
Nol6 0,34 0,04725833 
Pgpep1 0,34 0,03484916 
Crat 0,34 0,01351343 
Rai14 0,34 0,01485115 
Senp3 0,34 0,03394171 
Cops8 0,33 0,03878083 
Zfp282 0,33 0,02445213 
Rybp 0,33 0,02325173 
Rnpepl1 0,33 0,03556259 
Syngr1 0,33 0,01072270 
Hps4 0,33 0,01329059 
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E130218I03Rik 0,33 0,04054128 
9130401M01Rik 0,33 0,02190816 
Dtnbp1 0,33 0,02190816 
2510039O18Rik 0,33 0,04124861 
Ints5 0,33 0,04660266 
Fbxo6 0,33 0,01715493 
Rrp12 0,33 0,02119237 
Mrps17 0,33 0,03148539 
BC023829 0,33 0,03052097 
Mtmr10 0,33 0,02450124 
Hrh2 0,33 0,04976677 
Pdpr 0,33 0,01234749 
Mrpl36 0,33 0,04608961 
4930453N24Rik 0,33 0,02190816 
Olfr1360 0,33 0,01848341 
Tmem214 0,33 0,04893778 
LOC674846 0,33 0,04279566 
Pus1 0,33 0,03933416 
Supt7l 0,33 0,03257628 
Oxnad1 0,33 0,01670852 
1110008P14Rik 0,33 0,00964336 
Sdhaf2 0,33 0,01129324 
Dhx33 0,33 0,02400225 
Tm2d2 0,32 0,02359196 
Dbf4 0,32 0,03400765 
Cep68 0,32 0,03037567 
Bcl3 0,32 0,03641255 
Chrac1 0,32 0,02385398 
Nt5c 0,32 0,02278446 
Klhl12 0,32 0,03019283 
Zdhhc3 0,32 0,00956603 
Chaf1b 0,32 0,01348771 
Dtwd2 0,32 0,01881617 
Dnajc30 0,32 0,02885172 
Llph 0,32 0,03549780 
Max 0,32 0,04469221 
Slc35b4 0,32 0,03975578 
Ufsp1 0,32 0,01877036 
Il21r 0,32 0,04226806 
Srrd 0,32 0,00884534 
Tssc4 0,32 0,01326312 
Ccdc91 0,32 0,02834419 
Sphk2 0,32 0,01284027 
Sgsm3 0,32 0,04492646 
Uspl1 0,32 0,04925869 
Zfp746 0,32 0,03022302 
Efhd2 0,32 0,04948625 
Tram2 0,32 0,02353486 
Mesdc2 0,32 0,02804935 
Snap29 0,32 0,03938804 
Pikfyve 0,32 0,03623233 
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Tbc1d13 0,32 0,02190816 
Bag5 0,32 0,01642155 
Adap1 0,32 0,03926480 
Def6 0,32 0,01945030 
Fam118b 0,32 0,02088732 
Ccdc56 0,32 0,02206416 
Dpp7 0,32 0,04217340 
2510012J08Rik 0,32 0,04164029 
Rab35 0,32 0,03850942 
Bend3 0,32 0,03082667 
Zfp259 0,32 0,01822229 
2010012O05Rik 0,31 0,03556259 
Snx15 0,31 0,04434335 
Taf1c 0,31 0,01327013 
Anxa11 0,31 0,03267723 
Mrps18b 0,31 0,02582792 
Wrap53 0,31 0,01481064 
Rnf8 0,31 0,01904211 
9630033F20Rik 0,31 0,01348771 
Cox10 0,31 0,01348771 
Ythdf1 0,31 0,02658308 
Fanca 0,31 0,04890944 
Mrps34 0,31 0,02046304 
Lrr1 0,31 0,04648836 
Ifrd2 0,31 0,03069264 
Tnrc6c 0,31 0,03109627 
Acacb 0,31 0,04725833 
Hras1 0,31 0,03023608 
Ftsj2 0,31 0,03121408 
Zdhhc1 0,31 0,04027854 
Ptcd2 0,31 0,03935789 
Pip4k2a 0,31 0,01946451 
Mfn2 0,31 0,02074663 
Mms19 0,31 0,01242175 
Stx2 0,31 0,01327013 
Tnfrsf21 0,31 0,03667541 
Fut4 0,31 0,02625104 
Zscan22 0,31 0,03926480 
4930534B04Rik 0,31 0,03294780 
Bcr 0,31 0,01832420 
Lrrc41 0,30 0,02798783 
Rhobtb2 0,30 0,01466230 
Snap47 0,30 0,01360734 
Nit1 0,30 0,02742213 
Trappc5 0,30 0,01279567 
Tmco7 0,30 0,03979223 
Lonrf3 0,30 0,03221455 
2700078E11Rik 0,30 0,02636142 
Spsb3 0,30 0,04567470 
Zfp628 0,30 0,02677388 
Ube2f 0,30 0,02639957 
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Shq1 0,30 0,01696034 
Ext2 0,30 0,01283398 
Ptplb 0,30 0,02798783 
Mllt1 0,30 0,02440558 
Crtc1 0,30 0,04867220 
Txndc15 0,30 0,03125136 
Rpp14 0,30 0,04542172 
Btd 0,30 0,04544722 
Elac2 0,30 0,02296327 
Dtx4 0,30 0,03447792 
Mtf1 0,30 0,01867480 
Gm16517 0,30 0,04725833 
Tgfbrap1 0,30 0,01755408 
Thap11 0,30 0,02447607 
Ppip5k1 0,30 0,00964336 
Pdk2 0,30 0,04186192 
Gclc 0,29 0,03434549 
Clpp 0,29 0,03082667 
Serac1 0,29 0,04946880 
Ptrh2 0,29 0,02149877 
Tapt1 0,29 0,01002382 
Flad1 0,29 0,02751109 
Fam89b 0,29 0,01362013 
Sec14l1 0,29 0,03609294 
Agpat6 0,29 0,03280118 
Dcun1d2 0,29 0,03962952 
Traf6 0,29 0,00940978 
2410016O06Rik 0,29 0,03405626 
Ccdc32 0,29 0,02190816 
Gnptab 0,29 0,02646819 
Tpst2 0,29 0,03462218 
Cdh4 0,28 0,04186192 
Commd7 0,28 0,01372618 
Ehd1 0,28 0,02877450 
Traf3 0,28 0,02669824 
Herc2 0,28 0,04445136 
Yipf5 0,28 0,02931718 
Fam50a 0,28 0,04219583 
Ndufaf3 0,28 0,03862010 
Rela 0,28 0,03825770 
H6pd 0,28 0,03623233 
Ubox5 0,28 0,02190816 
Yars2 0,28 0,03233793 
Fem1b 0,28 0,03221455 
Ubiad1 0,28 0,03589848 
Tgfbr1 0,28 0,04976541 
Ccdc93 0,28 0,02088199 
Prmt10 0,28 0,01963059 
Rnf25 0,28 0,02325173 
Kctd1 0,28 0,03922586 
2310022A10Rik 0,27 0,03406618 
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Aste1 0,27 0,03882155 
Cln5 0,27 0,03875079 
Hes6 0,27 0,04725833 
Dot1l 0,27 0,01361750 
Suds3 0,27 0,02858574 
C1rl 0,27 0,03566335 
Dicer1 0,27 0,02667670 
Cln8 0,27 0,04170296 
Clcn4-2 0,27 0,03233268 
Tmem216 0,27 0,03609294 
Ppif 0,27 0,04951116 
Aak1 0,27 0,04280188 
Stk16 0,27 0,02183621 
Prl4a1 0,27 0,04678231 
Patz1 0,27 0,04849433 
Fbxw9 0,27 0,04893778 
Kdm2b 0,27 0,04751215 
Cdca4 0,27 0,02799211 
Fitm2 0,27 0,02595223 
Ttc1 0,26 0,02861142 
Bud31 0,26 0,02246936 
Csrp2bp 0,26 0,04326930 
Ltbr 0,26 0,04751215 
E130309D02Rik 0,26 0,01945030 
Gemin7 0,26 0,02190816 
Pi4kb 0,26 0,04130175 
Rsl24d1 0,26 0,02931718 
Npas3 0,26 0,04238165 
Cat 0,26 0,03623233 
Phf23 0,26 0,03452207 
Fes 0,26 0,02750440 
Ammecr1l 0,26 0,02475394 
Cela3b 0,26 0,03933416 
Jam3 0,26 0,03213064 
Map2k2 0,26 0,04238165 
Rbm28 0,26 0,04475580 
Scaf1 0,26 0,02695018 
C1qbp 0,26 0,04238165 
Chmp1a 0,26 0,02998360 
Nacc1 0,26 0,02263495 
Pcbp1 0,26 0,04893778 
Gng12 0,26 0,01444040 
Prep 0,26 0,02119237 
Cdk9 0,26 0,01305287 
Cog2 0,26 0,04544722 
Ctsz 0,26 0,04284466 
1110057K04Rik 0,26 0,04648836 
Naif1 0,26 0,03400765 
Rev1 0,26 0,03144574 
Mrps18a 0,26 0,04430945 
Eme2 0,25 0,03601115 
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Mpp1 0,25 0,02753860 
Extl2 0,25 0,03926480 
Gne 0,25 0,03641255 
Cmtm7 0,25 0,02783163 
Plekhm2 0,25 0,04235515 
AI317395 0,25 0,03636136 
Fam53b 0,25 0,03556259 
Dnajb14 0,25 0,02346214 
4831426I19Rik 0,25 0,04648836 
Acad9 0,25 0,04576472 
Slc48a1 0,25 0,03559810 
Rapgef1 0,25 0,04751215 
Stk11 0,25 0,02659283 
Slc25a45 0,24 0,02318130 
Vrk2 0,24 0,04161791 
Pigq 0,24 0,04940302 
Brap 0,24 0,03618319 
Rab13 0,24 0,03756514 
Mif4gd 0,24 0,04036948 
Mon1a 0,24 0,02436120 
Klhl26 0,24 0,02658308 
Prosc 0,24 0,02861142 
Kti12 0,24 0,03087063 
Sharpin 0,24 0,04238165 
Dcaf13 0,24 0,04648836 
Akap1 0,24 0,02917611 
Klhdc3 0,23 0,02064972 
Rps6kb2 0,23 0,04235515 
Muted 0,23 0,02582792 
4930471M23Rik 0,23 0,04939795 
Mettl8 0,23 0,04849433 
Ecd 0,23 0,04946880 
1700017B05Rik 0,23 0,04232360 
Cdk13 0,23 0,04946880 
Vat1 0,23 0,04430945 
Eci2 0,22 0,02392065 
Crkl 0,22 0,02930489 
Stx6 0,22 0,03588580 
Spin1 0,22 0,04445136 
Xrcc1 0,21 0,04935024 
Mrpl17 0,21 0,04129087 
Tfec 0,21 0,02667670 
Fiz1 0,21 0,03641255 
Klhl15 0,21 0,04959157 
Trim27 0,21 0,03850942 
 
Appendix 1 List of significantly upregulated genes (p<0.05) in Ythdf2fl/fl;Vav-iCre 
compared to Ythdf2fl/fl pre-leukaemic cells. Symbol, gene symbol; log2(FC), 




Symbol log2(FC) adj. P  Val  -log10(q) 
Rxra 1,10 0,0005 27,55 
Fen1 0,90 0,0361 31,16 
1810011H11Rik 0,87 0,0213 36,94 
Gpr84 0,72 0,0039 30,26 
Nanp 0,71 0,0121 52,65 
Srxn1 0,65 0,0069 41,52 
Tnfaip8l1 0,65 0,0062 55,03 
Mrpl46 0,64 0,0085 29,58 
Sh3tc1 0,61 0,0063 50,29 
Emilin1 0,60 0,0311 28,61 
Rpusd1 0,60 0,0014 30,27 
Commd5 0,60 0,0019 32,81 
Batf 0,60 0,0053 41,01 
Arl4a 0,60 0,0073 42,69 
Ubtd2 0,59 0,0148 32,08 
Kctd6 0,59 0,0023 33,13 
Gmppb 0,58 0,0267 44,13 
Extl3 0,58 0,0125 59,72 
Mfsd5 0,57 0,0006 48,33 
Ubtd1 0,56 0,0079 45,11 
Abt1 0,56 0,0071 41,13 
Hyal2 0,56 0,0071 36,51 
Mrpl43 0,56 0,0017 32,79 
Spryd4 0,56 0,0039 30,83 
Plekho1 0,55 0,0443 37,31 
Nfatc2 0,54 0,0064 37,97 
Znhit2 0,54 0,0237 52,25 
Gnb1l 0,54 0,0094 65,28 
Phlda3 0,54 0,0084 70,01 
Siah1b 0,53 0,0240 25,39 
Tk1 0,53 0,0253 43,34 
Nlrx1 0,53 0,0156 93,14 
Grwd1 0,53 0,0036 69,33 
Irgm1 0,53 0,0109 72,50 
Zbtb45 0,53 0,0180 53,28 
Kbtbd4 0,52 0,0128 31,50 
Mrps7 0,52 0,0101 27,72 
Chpf2 0,52 0,0099 70,54 
Zcchc17 0,52 0,0215 26,54 
Slc16a13 0,51 0,0089 38,17 
Fkrp 0,51 0,0029 66,09 
Bmpr1a 0,51 0,0109 34,22 
Cables2 0,51 0,0012 64,91 
Nxt1 0,51 0,0135 51,55 
Slc10a3 0,51 0,0164 32,69 
Wdr81 0,50 0,0036 65,61 
Bcl9 0,50 0,0039 42,20 
Itpk1 0,50 0,0094 93,49 
Slc35a4 0,50 0,0219 41,79 
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Trim65 0,49 0,0084 60,72 
Spn 0,47 0,0181 39,18 
Nupl2 0,47 0,0054 31,52 
Asb8 0,46 0,0128 51,33 
Fam110a 0,46 0,0099 65,89 
Tulp4 0,46 0,0126 35,07 
Agap2 0,46 0,0165 53,50 
Fam69b 0,46 0,0156 67,32 
Tprn 0,46 0,0255 35,14 
Elmod3 0,46 0,0042 47,28 
Urgcp 0,45 0,0099 98,09 
Rbm19 0,45 0,0113 37,25 
C2cd2 0,45 0,0078 48,63 
Vps18 0,45 0,0125 60,07 
Neu1 0,45 0,0219 29,59 
Plekho2 0,44 0,0277 37,65 
Map2k3 0,44 0,0146 41,39 
Bysl 0,44 0,0115 68,52 
B4galt4 0,44 0,0488 54,45 
Phospho2 0,44 0,0027 41,73 
Agpat2 0,43 0,0078 53,26 
Poln 0,43 0,0099 28,81 
Rpusd2 0,43 0,0260 63,97 
Sf3b4 0,43 0,0380 32,11 
Tesk1 0,43 0,0102 44,42 
B3gnt8 0,43 0,0229 43,13 
Tex264 0,42 0,0024 33,95 
Zw10 0,42 0,0219 25,33 
Tnfrsf1b 0,42 0,0187 63,53 
Phactr2 0,42 0,0308 26,69 
Mrps25 0,42 0,0266 30,01 
Panx1 0,42 0,0071 26,71 
Cyth4 0,42 0,0130 31,42 
Mad2l1bp 0,42 0,0135 35,19 
Gpr160 0,42 0,0154 47,65 
Mrps30 0,42 0,0270 27,55 
Naa40 0,41 0,0101 49,97 
Mrps2 0,41 0,0051 52,21 
Sipa1 0,41 0,0194 42,50 
Clp1 0,41 0,0142 35,96 
Hspa13 0,41 0,0107 45,76 
Dgcr14 0,41 0,0201 28,33 
Steap3 0,41 0,0472 27,08 
St6galnac4 0,41 0,0071 37,58 
1810055G02Rik 0,41 0,0390 48,60 
Narfl 0,41 0,0053 53,73 
Brms1 0,40 0,0259 31,33 
Ralb 0,40 0,0190 28,47 
Grpel1 0,40 0,0298 30,11 
Nup50 0,40 0,0183 41,11 
1110012L19Rik 0,40 0,0192 26,14 
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Timm8a1 0,40 0,0100 60,61 
Ccdc59 0,40 0,0495 39,19 
Pop7 0,40 0,0155 39,61 
Mrto4 0,40 0,0214 28,12 
Bcl9l 0,39 0,0210 37,83 
Jmjd4 0,39 0,0240 38,90 
Pde12 0,39 0,0120 25,26 
Ripk1 0,39 0,0160 34,90 
Exo1 0,39 0,0261 42,85 
Def8 0,39 0,0280 27,19 
Foxp4 0,39 0,0112 55,81 
Ctns 0,39 0,0077 54,59 
Ipo13 0,38 0,0167 35,31 
Bdh1 0,38 0,0074 42,87 
Trmt61a 0,38 0,0292 30,14 
Sac3d1 0,38 0,0193 66,51 
Sap30bp 0,38 0,0062 31,03 
Sssca1 0,38 0,0303 33,31 
Snx33 0,38 0,0135 66,34 
Eif2b1 0,38 0,0424 27,44 
Gemin4 0,37 0,0418 60,33 
Nudt18 0,37 0,0335 28,07 
Mrpl15 0,37 0,0222 74,61 
Cables1 0,37 0,0328 39,75 
Fkbpl 0,37 0,0103 71,23 
Eif2ak1 0,37 0,0285 35,44 
Osbpl11 0,37 0,0069 94,17 
Jagn1 0,37 0,0355 31,16 
Zfp507 0,37 0,0270 51,29 
D1Ertd622e 0,37 0,0434 57,59 
Nif3l1 0,36 0,0123 65,62 
Mcat 0,36 0,0137 70,10 
Rps19bp1 0,36 0,0300 71,66 
Fam20b 0,36 0,0264 50,28 
Ptpn12 0,36 0,0110 49,32 
Snx20 0,36 0,0275 103,10 
C1galt1 0,36 0,0272 56,42 
D8Ertd738e 0,36 0,0268 28,84 
S1pr2 0,36 0,0159 36,95 
2210016L21Rik 0,36 0,0069 32,46 
Zdhhc8 0,35 0,0258 30,62 
Thap7 0,35 0,0118 64,16 
Zfp36l2 0,35 0,0148 47,23 
Cstf1 0,35 0,0375 48,87 
Zfp771 0,35 0,0192 38,21 
Aen 0,35 0,0205 52,49 
Ankrd40 0,35 0,0222 74,23 
Tada2b 0,35 0,0069 55,46 
Cgrrf1 0,35 0,0220 55,66 
Cog8 0,35 0,0302 64,92 
Ncor2 0,35 0,0096 58,12 
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Taf5l 0,35 0,0071 52,89 
Akr7a5 0,35 0,0361 26,29 
Pip4k2b 0,35 0,0103 41,99 
Tymp 0,35 0,0393 63,24 
Lrrc14 0,34 0,0445 61,74 
Lsm10 0,34 0,0133 46,51 
Txnl4a 0,34 0,0130 55,40 
Rhou 0,34 0,0311 41,05 
Isg20l2 0,34 0,0190 40,47 
Orai3 0,34 0,0218 32,89 
Tmem115 0,34 0,0274 69,23 
Nol6 0,34 0,0472 48,75 
Pgpep1 0,34 0,0348 86,83 
Zfp282 0,33 0,0244 77,31 
Rybp 0,33 0,0232 26,19 
Rnpepl1 0,33 0,0355 45,23 
Hps4 0,33 0,0133 81,02 
2510039O18Rik 0,33 0,0412 48,99 
Ints5 0,33 0,0466 63,17 
Mtmr10 0,33 0,0245 62,41 
Pdpr 0,33 0,0123 49,47 
4930453N24Rik 0,33 0,0219 42,67 
Supt7l 0,33 0,0326 39,20 
Sdhaf2 0,33 0,0113 51,13 
Dhx33 0,33 0,0240 59,50 
Dbf4 0,32 0,0340 34,20 
Cep68 0,32 0,0304 46,90 
Chrac1 0,32 0,0238 38,12 
Zdhhc3 0,32 0,0096 35,85 
Chaf1b 0,32 0,0135 30,12 
Dnajc30 0,32 0,0288 53,28 
Max 0,32 0,0447 28,78 
Slc35b4 0,32 0,0397 41,18 
Il21r 0,32 0,0422 92,33 
Srrd 0,32 0,0088 60,78 
Sphk2 0,32 0,0128 36,92 
Uspl1 0,32 0,0492 53,08 
Zfp746 0,32 0,0302 68,12 
Pikfyve 0,32 0,0362 30,44 
Bag5 0,32 0,0164 27,62 
Adap1 0,32 0,0392 38,00 
Def6 0,32 0,0194 33,74 
Rab35 0,32 0,0385 43,49 
Bend3 0,32 0,0308 54,12 
Taf1c 0,31 0,0133 47,96 
Mrps18b 0,31 0,0258 26,11 
Rnf8 0,31 0,0190 49,03 
Cox10 0,31 0,0135 35,19 
Ythdf1 0,31 0,0266 26,27 
Mrps34 0,31 0,0204 39,27 
Lrr1 0,31 0,0465 27,32 
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Ifrd2 0,31 0,0307 32,69 
Tnrc6c 0,31 0,0311 59,22 
Pip4k2a 0,31 0,0194 51,00 
Mfn2 0,31 0,0207 34,94 
Tnfrsf21 0,31 0,0366 43,10 
Fut4 0,31 0,0262 38,09 
Zscan22 0,31 0,0392 63,99 
Bcr 0,31 0,0183 33,53 
Lrrc41 0,30 0,0280 29,20 
Rhobtb2 0,30 0,0146 38,73 
Snap47 0,30 0,0136 38,34 
Nit1 0,30 0,0274 38,83 
Trappc5 0,30 0,0128 46,45 
Spsb3 0,30 0,0456 60,87 
Zfp628 0,30 0,0268 30,90 
Shq1 0,30 0,0170 57,62 
Ext2 0,30 0,0128 34,78 
Mllt1 0,30 0,0244 59,26 
Txndc15 0,30 0,0312 44,55 
Btd 0,30 0,0454 76,41 
Dtx4 0,30 0,0344 33,01 
Mtf1 0,30 0,0187 54,48 
Tgfbrap1 0,30 0,0175 58,93 
Thap11 0,30 0,0245 35,59 
Serac1 0,29 0,0494 35,17 
Ptrh2 0,29 0,0215 41,29 
Tapt1 0,29 0,0100 49,44 
Dcun1d2 0,29 0,0396 72,24 
Traf6 0,29 0,0094 41,12 
Ccdc32 0,29 0,0219 47,74 
Gnptab 0,29 0,0264 42,27 
Tpst2 0,29 0,0346 57,97 
Traf3 0,28 0,0267 26,37 
Herc2 0,28 0,0444 84,51 
H6pd 0,28 0,0362 53,14 
Ubox5 0,28 0,0219 60,08 
Fem1b 0,28 0,0322 71,23 
Ubiad1 0,28 0,0359 28,66 
Ccdc93 0,28 0,0209 33,21 
Rnf25 0,28 0,0232 32,83 
Kctd1 0,28 0,0392 42,12 
2310022A10Rik 0,27 0,0340 46,76 
Aste1 0,27 0,0388 34,20 
Cln5 0,27 0,0387 38,70 
Hes6 0,27 0,0472 34,07 
Dot1l 0,27 0,0136 64,36 
Dicer1 0,27 0,0266 58,47 
Cln8 0,27 0,0417 62,95 
Tmem216 0,27 0,0361 64,51 
Aak1 0,27 0,0428 37,46 
Patz1 0,27 0,0485 76,12 
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Kdm2b 0,27 0,0475 31,53 
Cdca4 0,27 0,0280 39,06 
Fitm2 0,27 0,0259 35,40 
Ttc1 0,26 0,0286 30,80 
Ltbr 0,26 0,0475 56,10 
E130309D02Rik 0,26 0,0194 64,53 
Gemin7 0,26 0,0219 42,00 
Pi4kb 0,26 0,0413 31,60 
Phf23 0,26 0,0345 29,59 
Fes 0,26 0,0275 39,88 
Ammecr1l 0,26 0,0247 36,73 
Rbm28 0,26 0,0447 25,13 
Scaf1 0,26 0,0269 47,72 
Nacc1 0,26 0,0226 35,17 
Pcbp1 0,26 0,0489 46,38 
Cdk9 0,26 0,0130 39,91 
Ctsz 0,26 0,0428 28,95 
Naif1 0,26 0,0340 43,04 
Rev1 0,26 0,0314 67,80 
Eme2 0,25 0,0360 60,87 
Gne 0,25 0,0364 45,93 
Plekhm2 0,25 0,0423 55,24 
Fam53b 0,25 0,0355 73,98 
Stk11 0,25 0,0266 73,26 
Brap 0,24 0,0361 28,22 
Mif4gd 0,24 0,0403 31,14 
Mon1a 0,24 0,0243 28,36 
Klhl26 0,24 0,0266 82,66 
Sharpin 0,24 0,0424 34,88 
Akap1 0,24 0,0291 28,59 
Mettl8 0,23 0,0485 31,71 
Ecd 0,23 0,0494 27,67 
1700017B05Rik 0,23 0,0423 62,24 
Cdk13 0,23 0,0494 78,12 
Crkl 0,22 0,0293 78,36 
Stx6 0,22 0,0359 26,88 
Spin1 0,22 0,0444 35,19 
Fiz1 0,21 0,0364 33,08 
Trim27 0,21 0,0385 58,48 
 
Appendix 2 List of significantly upregulated genes (p<0.05) in Ythdf2fl/fl;Vav-iCre pre-
leukaemic cells that are highly methylated in Ythdf2fl/fl pre-leukaemic cells (-log10q>25) 
and methylated in MA9.3ITD and NOMO-1 cells. Symbol, gene symbol; log2(FC), 
expression fold change (log2); adj. P Value, moderated t-statistics adjusted P value 














































































































































































































































































































Appendix 3 Correlation with YTHDF2 expression levels across human AML samples 
for genes significantly upregulated (p<0.05) in Ythdf2fl/fl;Vav-iCre pre-leukaemic cells 
that are highly methylated in Ythdf2fl/fl pre-leukaemic cells (-log10q > 25) and 
methylated in MA9.3ITD and NOMO-1 cells. Symbol, gene symbol; Pearson coef., 
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